# WPC 2023

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Letter</td>
<td>3</td>
</tr>
<tr>
<td>Committee Members</td>
<td>6</td>
</tr>
<tr>
<td>Programa Español</td>
<td>8</td>
</tr>
<tr>
<td>General Information</td>
<td>8</td>
</tr>
<tr>
<td>Programa del Congreso</td>
<td>14</td>
</tr>
<tr>
<td>General Information</td>
<td>18</td>
</tr>
<tr>
<td>Wellness Way</td>
<td>22</td>
</tr>
<tr>
<td>WPC Art Walk</td>
<td>29</td>
</tr>
<tr>
<td>WPC Awards</td>
<td>30</td>
</tr>
<tr>
<td>WPC Clinical Research Village</td>
<td>31</td>
</tr>
<tr>
<td>Continuing Education</td>
<td>32</td>
</tr>
<tr>
<td>Travel Grants</td>
<td>33</td>
</tr>
<tr>
<td>Program-at-a-Glance</td>
<td>33</td>
</tr>
<tr>
<td>Congress Program</td>
<td>37</td>
</tr>
<tr>
<td>Posters and Poster Tours</td>
<td>67</td>
</tr>
<tr>
<td>Faculty List</td>
<td>126</td>
</tr>
<tr>
<td>Exhibitors &amp; Partners Table</td>
<td>130</td>
</tr>
<tr>
<td>Exhibit Floor Plan</td>
<td>131</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>132</td>
</tr>
<tr>
<td>Barcelona International Convention Center</td>
<td>141</td>
</tr>
<tr>
<td>PD Glossary</td>
<td>145</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>154</td>
</tr>
</tbody>
</table>
Dear friends:

On behalf of the WPC 2023 Steering Committee and the Board of Directors of the World Parkinson Coalition®, we welcome you to the 6th World Parkinson Congress and to Barcelona, Spain.

WPC 2023 will once again unite the global Parkinson community in a unique high-level scientific Congress where we will welcome registrants from more than 70 countries including neuroscientists, neurologists, nurses, rehabilitation specialists, Parkinson and Care Advocates and many others.

The World Parkinson Congress is the only global event that, while keeping scientific and clinical research and discovery at the heart of its program, brings together the entire Parkinson community. This includes not only dedicated researchers and health professionals who study the disease and care for those who live with it, but the people and care partners who live with Parkinson’s day in and day out – the real experts. We began in 2006 and since then our congresses have grown and still represent a unique opportunity for sharing and learning about this condition from all possible perspectives.

At the WPC you will have the opportunity to attend a wide variety of scientific presentations, geared to the diverse audience that makes WPC unique, given by top researchers and practitioners in the field, from Plenaries that make science accessible to non-specialists to highly technical, state of the art, presentations on the latest breakthroughs. Aligned with this is the exhibit area in which you can view the 800 plus scientific and living-with-Parkinson posters and sign up for evening poster tours where experts take you through a selection of the posters with their presenters. We encourage you also to visit our exhibitors, from around the world, representing both industry and non-profit organizations and to stop by the Clinical Research Village, where science meets advocacy and researchers and clinical trial participants will talk about clinical trials both ongoing and coming up.

Movement is paramount to maintaining wellness in Parkinson’s, so if you need a break from the science, visit the Renewal Room for a session on yoga, dance, boxing, or singing. Or visit the Mindfulness and Meditation room for a guided session to learn how this can be part of one’s wellness plan. For our care partners, we invite you to visit the Care Partner Lounge to connect, learn, and relax throughout the Congress. While Wellness Way rooms are geared towards people with Parkinson’s and care partners, the sessions are open to everyone including those who would not normally sample such opportunities.

Finally, be sure to check out the Art Walk and Film Room, showcasing art exhibits produced by people with Parkinson’s and Films about people with Parkinson’s, all of which highlight the power of creativity as part of a wellness plan and the talented community in which we live.

This is a meeting that bridges across from science to the individual with Parkinson’s and which caters to both those wanting to hear the latest scientific breakthroughs to those wanting to know more about how to better live with this condition. It is also a meeting of hope – a hope for better quality of life for those touched by Parkinson’s and one day a cure.

We look forward to meeting many of you during the Congress.

Sincerely,

Marie-Françoise Chesselet MD, PhD
WPC President

Roger Barker BA, MBBS, PhD, MRCP, FMedSci
WPC Vice President
Dear friends:

On behalf of the WPC 2023 Program Committee, we welcome you to the 6th World Parkinson Congress.

The process of creating this program that you are now holding in your hands started almost four years ago with the selection of 54 outstanding members of the Program Committee from 15 countries. They worked extensively to build this exceptional program that covers some of the most seminal topics today in Parkinson’s.

The program committee was broken into three subcommittees tasked with exploring and deciding on topics that fell under basic science, clinical science, and comprehensive care. In the committee meetings we had to decide what would and what would not make it into the program. It was not always easy making those decisions, but ultimately, we narrowed down the topics and crafted this final version in which you will find some incredible sessions.

Our goal, despite COVID delaying us one year, was to create a vibrant and comprehensive meeting that would appeal to our diverse audience. We did this by first selecting the most important and exciting topics being discussed and researched today and then by inviting experts from the global community to share their knowledge and experience on these very topics. We hope you are inspired by the research and where it will lead us, but also that you learn valuable information to take with you when you return home.

As at past Congresses, sessions are coded with icons by category (basic, clinical, care) and they each have a thermometer icon indicating the level of the talk. These icons are there to guide you in your selection of topics, so you find just what you are looking for each day.

The pre-congress day on July 4 offers six different ticketed courses followed by the opening ceremony and welcome reception. The next three days begin each morning with Hot Topics presentations at 8 AM highlighting just 12 of the more than 800 abstracts we accepted this year followed by morning plenaries which have been structured for maximum cross-fertilization of the diverse delegate body. We invite you to join us for these morning sessions to hear great talks, and to show your support for the six award recipients we’ll honor who have been serving the global PD community collectively for many years.

Please share what excites you most throughout the Congress on whatever social media channels you play on. Tag us using #WPC2023 when posting so we can see which topics and which speaker are having the biggest impact and please fill out the evaluations on the mobile app so we know which sessions really stood out with our audience. Your feedback will help us as we plan other programs in the coming years. Have fun learning this week! Thank you for joining us in the beautiful city of Barcelona.

Kind regards,

Marina Romero-Ramos, PhD
Chair, Program Committee

Andrew Singleton, PhD
Co-chair, Basic Science

David Standaert, MD, PhD
Co-chair, Clinical Science Subcommittee

Michael Okun, MD
Co-chair, Clinical Science Subcommittee

Alice Nieuwboer, PhD, PT
Co-chair, Comprehensive Care Subcommittee

Emily Henderson, PhD, MRCP
Co-chair, Comprehensive Care Subcommittee
Dear friends:

It has been almost 20 years since the first World Parkinson Congress was held in 2006 in Washington, D.C., and now here we are, welcoming you to the sixth iteration of this Congress. The WPC has grown in ways that we could not have predicted and has inspired community members to launch some incredible initiatives, organizations, mobile apps and more, many of which impact the global Parkinson’s community daily.

As WPC Parkinson Ambassadors and WPC Science Ambassadors, we represent a global community of people living with Parkinson’s and researching Parkinson’s. We were eager to fill the role of Ambassador to the WPC because we have all personally experienced the impact of the World Parkinson Congress. For those of us living with PD, the experience changed the trajectory of our lives and allowed us to find a unique community of people who inspire us daily. For those of us researching Parkinson’s, attending our first WPC changed the trajectory of how we look at, plan for, and execute our research and most of all how we communicate it to and relate with the people who deserve to know. We are committed to share the power of the WPC experience and look forward to hearing your stories about how the WPC changes you.

For those of you who are attending your first congress get ready because, if you embrace the WPC experience, you will leave the WPC with incredible connections and ideas. The contacts that you are about to make along with the friendships and the knowledge will go with you when you return home. The contacts will span the Parkinson’s community, so you will get to know people outside of your normal circles, which is what makes the WPC experience so rich.

At the close of the WPC you will be recognized as part of the WPC community and we invite you to share what you learn during and after the WPC. Tag us in any posts you make with #WPC2023. Also, be sure to visit the WPC Blog (www.WorldPDCongress.org) for information in the months and years between the Congresses and to stay on top of the research outcomes.

As WPC Ambassadors, we welcome you to Barcelona and the WPC 2023. We believe you will find this experience life changing and inspiring.

Sincerely,

WPC Parkinson Ambassadors
Alison Anderson (UK)
Miriam Bram (USA)
Geoff Constable (Australia)
Rui Couto (Portugal)
Richelle Flanagan, RD (Ireland)
Larry Gifford (Canada)
Christine Jeyachandran (Australia)
Heather Kennedy (USA)
Jon Pawelkop (USA)
Shanthipriya Siva, MD (India)
Omotola Thomas (UK/Nigeria)
A.C. Woolnough (USA)

WPC Science Ambassadors
Dayne Beccano-Kelly, PhD (UK)
Judith “Jude” Bek, PhD (Canada)
Xi Chen, PhD (USA)
Marie Fuzzati, PhD (France)
Richard Gordon, PhD (Australia)
Ariadna Laguna, PhD (Spain)
Ignacio “Nacho” Mata, PhD (USA)
Mattia Volta, PhD (Italy)
COMMITTEE MEMBERS

STEERING COMMITTEE
Co-chair: Marie-Françoise Chesselet, MD, PhD
Co-chair: Roger Barker, BA, MBBS, PhD, MRCP, FMedSci
Fulvio Capitanio
Francisco Cardoso, MD, PhD, FAAN
Emma Collin
Victor Fung, MD
Laura Morer Benages
Alice Nieuwboer, PhD, PT
Linda Olson, MD, FACR
Patricia Perez
Sara Riggare, PhD
Marina Romero-Ramos, PhD
Michael Schwarzschild, MD, PhD
David Standaert, MD, PhD
A Jon Stoessl, CM, MD, FRCPC
Ryosuke Takahashi, MD, PhD
Eduardo Tolosa, MD
Claudia Trenkwalder, MD
Miquel Vila, MD, PhD

PROGRAM COMMITTEE
Basic Science Subcommittee
Chair: Marina Romero-Ramos, PhD
Co-chair: Andrew Singleton, PhD
Veerle Baekelandt, PhD
Angela Cenci, MD, PhD
Michela Deleidi, MD, PhD
Céline Galvagnion, PhD
Ashley Harms, PhD
Kevin McFarthing, PhD
Darren Moore, PhD
Tiago Outiero, PhD
Coro Paison Ruiz, PhD
Ian Sargent, PhD
Leonidas Stefanis, MD
Jose Luis Venero, PhD
Miquel Vila, PhD
Amanda Woerman, PhD

Comprehensive Care Subcommittee
Co-chair: Emily Henderson, PhD, MRCP
Co-chair: Alice Nieuwboer, PhD, PT
Eline Boek, MSc, RSW
Nienke de Vries, PhD
Kat Hill, RN
Hanneke Kalf, SLP
Suketu Khandhar, MD
Victor McConvey, RN
Anat Mirelman, PT
Serené Paul, PhD
Elisa Pelosin, PhD
Daniel Peterson, PhD
Sue Thomas, RN
Lisa Warren, MHS
Julia Wood, MOT
Alison Yarnell, MD

Clinical Science Subcommittee
Co-chair: Michael Okun, MD
Co-chair: David Standaert, MD, PhD
Oscar Bernal, MD
Per Borghammer, MD, PhD
Nabila Dahodwala, MD
Susan Fox, PhD
Vanessa Milanese, MD, PhD
Benzi Kluger, MD
Daniel Martinez, MD
Joy Milne, RN
Jose Obeso, MD
Per Odin, MD, PhD
Genko Oyama, MD, PhD
Maria Cecilia Peralta, PhD
Mayela Rodriguez-Violante, MD
Susanne Schneider, MD
Maria Stamelou, MD
Jun Takahashi, MD, PhD
Eduardo Tolosa, MD
Daniel Weintraub, MD
Caroline Williams-Gray, MD

PARKINSON ADVOCATES COMMITTEE
Co-chair: Fulvio Capitanio
Co-chair: Sara Riggare, PhD
Artur Amich, MA
Francesca de Bartolomeis
Maria De Leon, MD
Karl Hill, RN
Soania Mathur, MD
Joy Milne, RN
Martin Taylor
Rune Vethe
Fred Woodleif, DDS

LEADERSHIP FORUM EXECUTIVE COMMITTEE
Co-chair: Emma Collin
Co-chair: Russell Patten
Maria Barretto, PhD
Andrew Bell
Jean Blake, MA
Fulvio Capitanio
Sohini Chowdhury
Polly Dawkins, MBA
Francesco de Renzis
Gaynor Edwards
Malcolm Irving
Rebecca Korduner
David Leventhal
Helen Mathews, MBA
Helena Mithiga
Jo-Anne Reeves

LOCAL ORGANIZING COMMITTEE
Co-chair: Eduardo Tolosa, MD
Co-chair: Miquel Vila, MD, PhD
Ernest Arenas, MD, PhD
Angel Bayes, MD
Ana Cámara, RN
Orial de Fábregas, MD
Isable Farías, PhD
Francisco Grandas, MD
Jaume Kuleskesvii, MD
Maria Jose Marti, MD
Pablo Mir, MD
Laura Morer Benages
Rose Roige
Angel Sesar, MD

PARKINSON AMBASSADORS
Alison Anderson (UK)
Alejandra Borunda (USA/Mexico)
Miriam Bram (USA)
Geoff Constable (Australia)
Rui Couto (Portugal)
Richelle Flanagan, RD (Ireland)
Larry Gifford (Canada)
Christine Jeyachandran (Australia)
Heather Kennedy (USA)
Jon Pawelkop (USA)
Werner Remmele (UK/Germany)
ShanthiPriya Siva, MD, (India)
Omotola Thomas (UK/Nigeria)
A.C. Woolnough (USA)

SCIENCE AMBASSADORS
Dayne Beccano-Kelly, PhD (UK)
Judith “Jude” Bek, PhD (Canada)
Xi Chen, PhD (USA)
Marie Fuzzati, PhD (France)
Richard Gordon, PhD (Australia)
Ariadna Laguna, PhD (Spain)
Ignacio “Nacho” Mata, PhD (USA)
Mattia Volta, PhD (Italy)

WPC STAFF
Elizabeth Pollard, Executive Director
Julie Winn, Outreach & Social Media Coordinator
Alina Vogel, Communications Coordinator
Helen Heyer-Wals, Project Coordinator
Judi Spencer, Choir Director
If you are living with Parkinson’s disease, medication isn’t your only option. To learn more about Deep Brain Stimulation (DBS) VISIT US AT BOOTH 1200.

This material is for informational Purposes only and not meant for medical diagnosis. This information does not constitute medical or legal advice, and Boston Scientific makes no representation regarding the medical benefits included in this information. Boston Scientific strongly recommends that you consult with your physician on all matters pertaining to your health.

US Indication for Use: The Boston Scientific Versico™ PC, Versico Gevia™, Versico Genus™ Deep Brain Stimulation Systems are indicated for use in:
- Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
- Bilateral stimulation of the internal globus pallidus (IGP) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
- Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medication alone and where the tremor constitutes a significant functional disability.

The Boston Scientific Versico Deep Brain Stimulation System is indicated for use in:
- Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications: The Boston Scientific Deep Brain Stimulation (DBS) Systems are not recommended for patients who will be exposed to the following procedures: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS). The safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established. Patients implanted with Boston Scientific DBS Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with the Versico Gevia or Versico Genus or Versico Genus Mixed System with MRI Adapter or Versico DBS Lead-Only System (before Stimulator is implanted) with ImageReady™ MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Boston Scientific DBS Systems are not recommended for patients who are unable to operate the system or are poor surgical candidates or who experience unsuccessful test stimulation.

Warnings: Unauthorized modification to the medical devices is prohibited. You should not be exposed to high stimulation levels. High level of stimulation may damage brain tissue. Patients implanted with a Boston Scientific DBS System may be at risk for intracranial hemorrhages (bleeding in the brain) during DBS lead placement. Strong electromagnetic fields, such as power generators, security screeners or theft detection systems, can potentially turn the stimulator off, or cause unpredictable changes in stimulation. The system should not be charged while sleeping. If you notice new onset or worsening depression, changes in mood or behavior or impulse control, or have thoughts of suicide contact your physician or emergency services immediately. Chemical burns may result if the Stimulator housing is ruptured or pierced. The Boston Scientific DBS Systems may interfere with the operation of implanted stimulation devices, such as cardiac pacemakers, implanted cardioverter defibrillators, or medication delivery pumps. Patients should operate motorized vehicles or potentially dangerous machinery with caution. It is unknown if the device may hurt an unborn baby. Your doctor may be able to provide additional information on the Boston Scientific DBS Systems. For complete indications for use, contraindications, warnings, precautions, and side effects, see DBSandME.com or call 833-327-4636. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician. OUS Indications for Use: CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

©2023 Copyright Boston Scientific Corporation or its affiliates. All rights reserved. MM-7991506-AA
INFORMACIÓN GENERAL

La World Parkinson Coalition es la organización detrás de los Congresos Mundiales trienales de Parkinson y ha sido un líder en la comunidad de Parkinson desde su lanzamiento en 2004. Desde el primer día, la WPC ha sido una organización líder reconocida por conectar a toda la comunidad de Parkinson, miembros de las comunidades científicas, clínicas y de defensoría del Parkinson que no habían interactuado previamente entre sí.

Cada Congreso Mundial de Parkinson ofrece un foro internacional para la discusión acerca de los últimos descubrimientos científicos, prácticas médicas e iniciativas de atención y cuidado relacionadas con la enfermedad de Parkinson. Cada Congreso reúne a especialistas en trastornos del movimiento, médicos, neurocientíficos, neurólogos, enfermeras, especialistas en rehabilitación, cuidadores o aliados de cuidado, familiares y personas con Parkinson, juntos bajo un mismo techo, para llevar un diálogo interesante para ayudar a acelerar el descubrimiento de una cura e identificar las mejores prácticas de tratamiento para esta enfermedad devastadora.

Cualquier persona que investigue el Parkinson, ya sea en ciencia básica o ciencia clínica, médicos que están tratando a personas que viven con la EP, promotores del Parkinson y promotores de la atención y el cuidado que están colaborando con organizaciones, empresas y profesionales para lograr avances en nuestra comprensión del Parkinson. La WPC es una reunión “inclusiva de promotores”. Los promotores del Parkinson y los promotores de la atención y el cuidado ayudaron a diseñar el programa y asistirán a la reunión como partes interesadas clave que están ayudando a impulsar nuestra comprensión de la enfermedad.

El idioma oficial del Congreso Mundial de Parkinson es el inglés. Se ofrecerá una interpretación simultánea limitada del inglés al español y el programa también incluirá una pista especial en español todos los días. Los ciudadanos de TODOS los países son bienvenidos a participar en el WPC 2023.

La exposición ofrece a los delegados del Congreso Mundial de Parkinson la oportunidad de aprender acerca de los últimos avances en suministros y equipos médicos, productos farmacéuticos y publicaciones médicas.

Los expositores del Congreso incluirán suministros o equipos médicos, productos farmacéuticos, equipos o instrumentos de laboratorio, software médico, kits y reactivos de biología, editores de libros y revistas médicas, sistemas de entrega alternativos (atención domiciliaria, hospicio), centros de investigación de Parkinson, asociaciones sin fines de lucro centradas en el Parkinson y otros grupos de promotores.

Los carteles se mostrarán a lo largo de las fechas del congreso en la exposición. Las sesiones oficiales de los carteles están programadas para el miércoles y jueves de 11:30 AM a 1:30 PM, momento en el que los presentadores de los carteles estarán ubicados junto a su cartel para hablar con los delegados. Consulte el programa de sesiones de carteles para obtener más información sobre cuándo se presentarán los carteles. La hora de colocación de carteles es el martes de 8:00 AM a 5:00 PM y el miércoles de 8:00 AM a 10:30 AM. Todos los carteles deben ser retirados antes de las 3:00 PM del viernes.

Las visitas de carteles se llevarán a cabo de 5:15 a 6:30 PM la tarde del miércoles y jueves, el 5 y 6 de julio, horarios en los que se presentará un número selecto de carteles. Insíbase para las visitas en la Sala de Exposiciones, en la mesa cerca de la primera fila de carteles en la parte posterior de la sala.
INFORMACIÓN GENERAL

Esta sala estará abierta todos los días de 9:00 AM a 6:00 PM para ofrecer un espacio tranquilo de descanso o simplemente para sentarse tranquilamente en meditación o oración. Cada día se ofrecerá una sesión guiada durante el almuerzo.

En el vestíbulo del AC Marriott Forum:

<table>
<thead>
<tr>
<th>Día</th>
<th>Horario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domingo 2 de julio</td>
<td>10:00 AM – 8:00 PM</td>
</tr>
<tr>
<td>Lunes 3 de julio</td>
<td>8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

En el vestíbulo del Centro de Convenciones Internacional de Barcelona (CCIB):

<table>
<thead>
<tr>
<th>Día</th>
<th>Horario</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martes 4 de julio</td>
<td>7:00 AM – 8:00 PM</td>
</tr>
<tr>
<td>Miércoles 5 de julio</td>
<td>7:00 AM – 6:30 PM</td>
</tr>
<tr>
<td>Jueves 6 de julio</td>
<td>7:00 AM – 6:30 PM</td>
</tr>
<tr>
<td>Viernes 7 de julio</td>
<td>7:00 AM – 3:30 PM</td>
</tr>
</tbody>
</table>

REDES SOCIALES

Conéctese con otros delegados y organizadores del Congreso a través de las redes sociales:

- Regálenos un Like en Facebook @World Parkinson Congress.
- Siga a la World Parkinson Coalition en LinkedIn.
- Síganos en Twitter @WorldPDCongress. El hashtag es #wpc2023.
- Consulte la comunidad WPC en Instagram@worldpdccongress. Únase a nuestro feed de fotos usando el hashtag #wpc2023.
- El canal de YouTube del WPC es WorldPDCongress.
- Mire el WPC en Tik Tok.
- Siga a la World Parkinson Coalition en LinkedIn.
- Consulte la comunidad WPC en Instagram@worldpdcongress. Únase a nuestro feed de fotos usando el hashtag #wpc2023.
- Mire el WPC en Tik Tok.

PARKY

El mapache “nació” en el verano de 2012, cuando Bob Kuhn, un embajador del WPC 2013, viajó por el mundo con una figura de cartón de Parky, que utilizó para iniciar conversaciones con personas con Parkinson que no hablaban inglés. Todo el mundo tenía curiosidad por este animal único, autóctono de Norteamérica, pero prácticamente desconocido para el resto del mundo. Parky es la mascota oficial del WPC 2016. Puede seguir el viaje de Parky en su sitio web aquí whereisparky.org.

ESTILO DE BIENESTAR

Ofreciendo un oasis lejos del ajetreo y bullicio del WPC, el área de Estilo de Bienestar ofrece salas donde los delegados pueden descansar de la ciencia y observar de primera mano el poder del ejercicio y la atención plena.

SALA DE RENOVACIÓN

La Sala de Renovación contará con un amplio programa lleno de sesiones interactivas como yoga, danza, canto, tambores y otras actividades musicales. El ejercicio es fundamental para vivir bien, por lo que esta sala destacará una variedad de modalidades de ejercicio para mantener a los delegados sintiéndose bien e introducir nuevos regímenes posibles de ejercicio en sus rutinas diarias.

SALÓN PARA CUIDADORES

El Salón para Cuidadores es un espacio seguro para que los promotores de la atención y el cuidado se reúnan y conozcan entre sí y se utilizará como un espacio de grupo de apoyo y tendrá una agenda formal programada todos los días, orientada a las personas que cuidan a alguien con Parkinson.
**RESUMEN DEL PROGRAMA**

<table>
<thead>
<tr>
<th>MARTES 4 DE JULIO</th>
<th>MIÉRCOLES 5 DE JULIO</th>
<th>JUEVES 6 DE JULIO</th>
<th>VIERNES 7 DE JULIO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8:00 AM</strong></td>
<td><strong>9:00 AM</strong></td>
<td><strong>Temas destacados</strong></td>
<td><strong>Temas destacados</strong></td>
</tr>
<tr>
<td><strong>9:00 AM</strong></td>
<td><strong>9:15 AM</strong></td>
<td><strong>Premio WPC</strong></td>
<td><strong>Premio WPC</strong></td>
</tr>
<tr>
<td><strong>9:30 AM</strong></td>
<td><strong>11:30 AM</strong></td>
<td><strong>Plenaria de la mañana</strong></td>
<td><strong>Plenaria de la mañana</strong></td>
</tr>
<tr>
<td><strong>11:30 AM</strong></td>
<td><strong>1:30 PM</strong></td>
<td><strong>Sesión de cartel</strong></td>
<td><strong>Sesión de cartel</strong></td>
</tr>
<tr>
<td><strong>1:30 PM</strong></td>
<td><strong>3:00 PM</strong></td>
<td><strong>Conferencia James Parkinson</strong></td>
<td><strong>Conferencias especiales</strong></td>
</tr>
<tr>
<td><strong>3:00 PM</strong></td>
<td><strong>3:30 PM</strong></td>
<td><strong>Almuerzo</strong></td>
<td><strong>Almuerzo</strong></td>
</tr>
<tr>
<td><strong>3:30 PM</strong></td>
<td><strong>5:00 PM</strong></td>
<td><strong>Sesiones y talleres paralelos</strong></td>
<td><strong>Sesiones y talleres paralelos</strong></td>
</tr>
<tr>
<td><strong>5:00 PM</strong></td>
<td><strong>5:15 PM</strong></td>
<td><strong>DESCANSO/REFRIGERIO</strong></td>
<td><strong>DESCANSO/REFRIGERIO</strong></td>
</tr>
<tr>
<td><strong>5:15 PM</strong></td>
<td><strong>6:30 PM</strong></td>
<td><strong>Exposición (11:00 AM - 6:45 PM)</strong></td>
<td><strong>Exposición (11:00 AM - 2:30 PM)</strong></td>
</tr>
<tr>
<td><strong>6:30 PM</strong></td>
<td><strong>9:00 PM</strong></td>
<td><strong>Ceremonia de inauguración (6:00 — 7:15 PM)</strong></td>
<td><strong>Cierre diario</strong></td>
</tr>
<tr>
<td><strong>9:00 PM</strong></td>
<td></td>
<td><strong>Encuentro y bienvenida de Amigos (4:00 — 5:30PM)</strong></td>
<td><strong>Comentarios de cierre y sorteo (6:00 — 7:00 PM)</strong></td>
</tr>
<tr>
<td><strong>9:00 PM</strong></td>
<td></td>
<td><strong>Sesiones y talleres paralelos</strong></td>
<td><strong>Cierre diario</strong></td>
</tr>
<tr>
<td><strong>9:15 AM</strong></td>
<td></td>
<td><strong>Visitas a carteles, cierre diario y sorteo</strong></td>
<td><strong>Eventos de networking:</strong> enfermeras revalidadas, fisioterapeutas, Terapeutas ocupacionales, terpeudes del lenguaje y el habla, trabajadores sociales, nutricionistas (6:30 — 8:00 PM)**</td>
</tr>
</tbody>
</table>

**CURSOS PRE-CONGRESO**

- **11:30 AM** — **1:30 PM**: Encuentro y bienvenida de Amigos (4:00 — 5:30PM)
- **3:00 PM** — **5:00 PM**: Ceremonia de inauguración (6:00 — 7:15PM)
- **6:30 PM** — **9:00 PM**: Recepción de bienvenida (7:15 — 9:00PM)
### PROGRAMA PRE-Congreso

Martes 4 de julio de 2023

#### CURSO III — FUNDAMENTALES DEL PARKINSON: EL RECORRIDO

<table>
<thead>
<tr>
<th>Horario</th>
<th>Tema</th>
<th>Orador y maestra de ceremonias:</th>
<th>Ponente:</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM – 5:15 PM</td>
<td>Bienvenida – ¿Por qué estamos aquí? Orador y maestra de ceremonias: Linda Olson (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>¿Qué es el Parkinson y cuáles son las características clínicas que vemos? Ponente:</td>
<td>Nabila Dahodwala (EE.UU.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>¿Cómo ha evolucionado el tratamiento médico y quirúrgico para la EP? Ponente: Vanessa</td>
<td>Milanese (Brazil)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preguntas y respuestas Moderador: Linda Olson (EE.UU.) Panelistas: Nabila Dahodwala</td>
<td>Adriana Gonzalez (EE.UU.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:25 AM ¡Vamos a movernos! Con: Pamela Quinn (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:30 PM DESCANSO/REFRIGERIO</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:00 AM ¿Qué hay de nuevo en la investigación? Ponente: Mark Cookson (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:25 AM ¿Qué nuevos tratamientos hay en el horizonte? Ponente: Roger Barker (Reino Unido)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:50 AM Preguntas y respuestas Moderator: Linda Olson (EE.UU.) Panelistas: Roger Barker (Reino Unido) Mark Cookson (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:10 PM ¡Vamos a movernos! Con: Selma Perváis Peláez (España)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:20 PM Antes de almorzar: ¿Qué hay de la nutrición? ¿Realmente importa? Ponente: Silke Appel-Cresswell (Canadá)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:00 PM ALMUERZO</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:45 PM Mantenerse resiliente como cuidador Ponente: Connie Carpenter Phinney (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:15 PM Cambios conductuales: ¿Cómo puedo hacer que los cambios se queden en mi rutina (____)? Ponente: Terry Ellis (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:50 PM Consejos y trucos para vivir con Parkinson más allá de la medicación Moderator: Terry Ellis (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1– Habla y deglución Panelistas: Darla Freeman (EE.UU.) Iracema Lerol (Irlanda) Adriana Gonzalez (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2– La ansiedad y la EP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3– La comunicación construye familias más fuertes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:50 PM PAUSA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:10 PM Creatividad y arte: ¿cómo impactan el cerebro y el Parkinson? Ponente: Anjan Chatterjee (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:40 PM Sacar el máximo partido al WPC 2023: Dos perspectivas Ponentes: Christine Jeychandran (Australia) Miriam Bram (EE.UU.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5:10 PM Comentarios de cierre</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Objetivos de aprendizaje:**
1. Obtener una comprensión básica del Parkinson, incluyendo la investigación de la(s) causa(s) de la enfermedad, los síntomas y las terapias actuales; 2. Ser capaz de explicar cómo cambiar los comportamientos para maximizar el impacto de un régimen de bienestar auto-mantenido; 3. Discutir el impacto de la creatividad estética en el cerebro; 4. Explicar cómo aprovechar al máximo la experiencia WPC.
Miércoles 5 de julio de 2023

**8:00 – 9:00 AM**

Temas de actualidad

Lugar: Salón principal de plenarias

Moderadora: David Standaert (EE.UU.)

Charla 1: Hallazgos genéticos del Estudio Internacional de Rostock sobre la Enfermedad de Parkinson (ROPAD)

Ponente: Ana Westenberger (Alemania)

Charla 2: Una pieza faltante en el rompecabezas del Parkinson: El papel fundamental del nutriólogo en el cuidado de las personas que viven con la enfermedad de Parkinson (EP)

Ponente: Richelle Flanagan (Irlanda)

Charla 3: Entendiendo los mecanismos de propagación y degradación de la a-sin: Papel de los nanotubos de túnel y de los lisosomas

Ponente: Chiara Zurzolo (Francia)

Charla 4: Caracterizando la frecuencia de variantes clínicamente reportables en los principales genes identificados en la enfermedad de Parkinson (EP) en una gran cohorte estadounidense

Ponente: Roy Alcalay (Israel)

---

**9:00 – 9:15 AM**

Ceremonia de premios WPC

Receptores del Premio Robin A Elliott del WPC al Servicio Destacado a la Comunidad

Galardonada: Lizzie Graham, premio entregado por Eli Pollard

Galardonada: Vincent “Enzo” Simone, premio póstumo entregado por Fulvio Capitanio

---

**9:30 – 11:30 AM**

Plenaria de la mañana

WP1 – Plenaria

Lugar: Salón principal de plenarias

¿Existen subtipos biológicos de la EP?

Moderadora: Leonidas Stefanis (Grecia)

Co-moderador: Kevin McFarthing (Reino Unido)

Charla 1: ¿Puede la genética de la EP y la DCL esporádicas ayudar en la definición del subtipo de la enfermedad? ¿Cuáles podrían ser las implicaciones terapéuticas?

Ponente: Sonja Scholz (EE.UU.)

Charla 2: Enfermedad de Parkinson primero en el cerebro o primero en el cuerpo

Ponente: Per Borghammer (Dinamarca)

Charla 3: Diferentes cepas de α-sinucleína en los cerebros de la enfermedad de Parkinson

Ponente: Markus Zweckstetter (Alemania)

Charla 4: ¿Qué significan los subtipos para las personas con Parkinson?

Ponente: Jonny Acheson (Reino Unido)


---

Niveles de sesión

- Crosstalk – conocimiento científico mínimo o no requerido
- Sesiones científicas de nivel moderado
- Sesiones científicas de alto nivel

Tipo de sesión

- Ciencia básica
- Ciencia clínica
- Atención integral

Idioma

- Interpretación simultánea de inglés a español
- Pista en español
**SESIÓN 1: COMIENZO Y PROGRESIÓN DEL PARKINSON**

**Lugar:** Sala 115  
Moderadores: Eduardo Tolosa (España) y Isabel Fariñas (España)

**Presentación #1: Rol de la sinucleína y cuerpos de Lewy**  
**Ponente:** Miquel Vila (España)

- Objetivos de aprendizaje: 1. Qué son los cuerpos de Lewy y la sinucleína y por qué son importantes para el Parkinson; 2. Identificar los síntomas precoces (prodrómicos) y las áreas del sistema nervioso implicadas.

**Presentación #2: Dónde y cuando empieza el Parkinson**  
**Ponente:** Francisco Grandas (España)

**Lugar:** Sala 112

**Mesa 2**  
La ciencia detrás de las diferencias entre sexos  
**Ponente:** Ariadna Laguna (España)

---

**SESIÓN 2: DIAGNÓSTICO Y SEGUIMIENTO DEL PARKINSON: NUEVAS HERRAMIENTAS**

**Lugar:** Sala 115  
Moderadores: Àngels Bayés (España) y Esther Cubo (España)

**Presentación #1: Nuevas herramientas diagnósticas: Parkinson típico y atípico**  
**Ponente:** Yaroslau Compta (España)

**Presentación #2: Monitorización del Parkinson: smartphones y otros dispositivos**  
**Ponente:** Cecilia Peralta (Argentina)

- Objetivos de aprendizaje: 1. Nuevas herramientas de laboratorio y radiológicas para el diagnóstico y pronóstico en el Parkinson y los parkinsonismos atípicos; 2. Utilidad de nuevos dispositivos para el diagnóstico y monitorización de los síntomas motores y no motores.

---

**WEoD - PANELES DE CIERRE DIARIO**

**Lugar:** Salon principal de plenarias  
**Moderadora:** Connie Marras (Canadá)  
**Co-moderador:** Omotola Thomas (Reino Unido)

**Panelistas:**  
Alice Nieuwboer (Bélgica)  
Claudia Trenkwalder (Alemania)  
Amanda Woerman (USA)  
Etienne Hirsch (Francia)
Lugar: Salón principal de plenarias
Moderadora: Marina Romero-Ramos (Dinamarca)

Charla 1: La asociación de todo el genoma identifica nuevas perspectivas etiológicas asociadas a la enfermedad de Parkinson en poblaciones africanas y de mezcla africana
Ponente: Oluwadamilola Ojo (Nigeria)

Charla 2: Abordaje del tratamiento de los problemas sexuales y de intimidad en personas con manifestaciones motoras y no motoras de la enfermedad de Parkinson
Ponente: Gila Bronner (Israel)

Charla 3: Exploración de la función de la flípsa lipídica lisosomal ATP10B en la vía dopaminérgica nigroestriatal en ratas
Ponente: Maria Sánchez Calvo (Bélgica)

Charla 4: Evaluación del potencial biomarcador del gen LRRK2 y la glucocerebrosidasa en monocitos de la enfermedad de Parkinson
Ponente: Laura Hughes (Australia)

Lugar: Salón principal de plenarias
Receptores del Premio a la Investigación Colaborativa Distinguida del WPC

Galardonada: Ignacio “Nacho” Mata, premio entregado por Malú Gámez Tansey
Galardonada: Marina Noordegraaf, premio póstumo entregado por Bastiaan Bloem

Lugar: Salón principal de plenarias

Monitoreo de la progresión de la enfermedad en el Parkinson: ¿Por qué y cómo?
Moderadora: Cecilia Peralta (Argentina)
Co-moderador: Linda Olson (EE.UU.)

Charla 1: ¿Por qué deberíamos monitorear la enfermedad de Parkinson?
Ponente: Bastiaan R. Bloem (Países Bajos)

Charla 2: ¿Cómo puede la imagenología monitorear la EP?
Ponente: Thilo van Eimeren (Alemania)

Charla 3: ¿Cómo podemos monitorear la EP utilizando biomarcadores basados en sangre y tejidos?
Ponente: David Standaert (EE.UU.)

Charla 4: Auto-monitoreo: ¿realizar o no realizar un monitoreo?
Ponente: Sara Riggare (Suecia)

Objetivos de aprendizaje: 1. Explicar lo que se entiende por “progresión” del Parkinson y dar dos razones por las que debemos monitorear la progresión; 2. Describir cómo la imagenología puede ser una herramienta para el monitoreo de la progresión y lo que se ha aprendido acerca de los biomarcadores basados en la imagenología; 3. Identificar biomarcadores de sangre y tejido como alfa-sinucleína y marcadores inmunitarios y explicar cómo éstos desempeñan un papel en el monitoreo de la progresión de la enfermedad; 4. Explicar cómo las personas con Parkinson pueden monitorear su propia enfermedad y recopilar datos significativos para ayudar en su propio plan de bienestar.

Niveles de sesión
Crosstalk – conocimiento científico mínimo o no requerido
Sesiones científicas de nivel moderado
Sesiones científicas de alto nivel

Tipo de sesión
Ciencia básica
Ciencia clínica
Atención integral

Idioma
Interpretación simultánea de inglés a español
Pista en español
### SESIÓN 3: FACTORES DE RIESGO EN EL PARKINSON

**Lugar:** Sala 115  
**Moderadores:** Ernesto Arenas (Suecia) y Ariadna Laguna (España)

| Presentación #1: Edad y género en el Parkinson  
**Ponente:** Mayela Rodríguez-Violante (México) | Presentación #2: Influencia de la genética en el desarrollo del Parkinson  
**Ponente:** Coro Paisan-Ruiz (EE.UU.) |

**Objetivos de aprendizaje:** Influencia de la edad, el sexo y la genética en el desarrollo y la progresión del Parkinson.

### SESIÓN 4: SÍNTOMAS NO MOTORES

**Lugar:** Sala 115  
**Moderadores:** Daniel Martínez-Ramírez (México) y Ana Cámara (España)

| Presentación #1: Apatía y alteraciones cognitivas  
**Ponente:** Jaime Kulisevsky (España) | Presentación #2: Disautonomía: estreñimiento y disfunción sexual  
**Ponente:** Dolores Vilas Rolán (España) |

**Objetivos de aprendizaje:** 1. Frecuencia e impacto de la apatía y los trastornos cognitivos en las distintas etapas del Parkinson; 2. Identificación y manejo de los trastornos gastrointestinales y disfunción sexual.

### SESIÓN DE CARTELES 2

**Lugar:** Sala de exhibiciones  
Vea los carteles y conozca a los autores.

### ALMUERZO

**11:30 AM - 1:30 PM**

### SESIÓN DE CARTELES 2

**Lugar:** Sala de exhibiciones  
Vea los carteles y conozca a los autores.

### TSL - CONFERENCIAS ESPECIALES

**12:00 - 1:15 PM**

**Lugar:** Salon principal de plenarias  
**Vivir bien con Parkinson**  
**Moderadora:** Linda Olson (EE.UU.)

| Panelistas: |  
| Shantipriya Siva (India)  
Geoffrey Constable (Australia)  
Sabela Avion (España)  
Chinyere Rachel Agwu (Nigeria)  
Richelle Flanagan (Irlanda) |

### TSP1 - PISTA EN ESPAÑOL

**1:30 - 3:00 PM**

**Lugar:** Sala 112  
**Mesa 2**  
Lo que toda mujer con Parkinson debería saber  
**Ponente:** Maria De Leon (EE.UU.)

**Mesa 4**  
Ansiedad y depresión en el Parkinson: Qué nos enseñan los modelos animales  
**Ponente:** Rosario Moratalla (España)

### TSP2 - PISTA EN ESPAÑOL

**3:30 - 5:00 PM**

**Lugar:** Sala 112  
**Mesa 5**  
Mitos y barreras en torno a la participación en la investigación  
**Ponente:** Coro Paisan-Ruiz (EE.UU.)

### TRT1 - MESAS REDONDAS

**1:30 AM - 1:30 PM**

### TRT2 - MESAS REDONDAS

**1:30 AM - 1:30 PM**

### TEO-D - PANELES DE CIERRE DIARIO

**Lugar:** Sala principal de plenarias  
**Moderadora:** Vanessa Milanese (Brasil)  
**Co-moderator:** Miquel Vila (España)

| Panelistas: |  
| Serge Przedborski (EE.UU.)  
Susan Fox (Canadá)  
Angela Cenci (Suecia)  
Marina Romero-Ramos (Dinamarca) |
### PROGRAMA ESPAÑOL
Viernes 7 de julio de 2023

#### 8:00 – 9:00 AM
**TEMAS DE ACTUALIDAD**

- **Lugar:** Salón principal de plenarias  
  **Moderadora:** Emily Henderson (Reino Unido)

  **Charla 1:** Descubriendo la interacción entre factores microbianos intestinales y mutaciones en el gen GBA1 en la patogénesis de la enfermedad de Parkinson  
  **Ponente:** Christin Weissleder (Alemania)

  **Charla 2:** Amplio conjunto de datos de encuestas realizadas a mujeres con Parkinson por mujeres con Parkinson  
  **Ponente:** Soania Mathur (Canadá)

- **Charla 3:** Modelo de la pigmentación del cerebro humano induce una patología similar al Parkinson y alteraciones transcriptómicas in vivo  
  **Ponente:** Nuria Peñuelas (España)

- **Charla 4:** NLX-112 ofrece seguridad, tolerabilidad y eficacia favorables contra la discinesia inducida por levodopa (DIL) en un estudio Ph2A aleatorizado, doble ciego, controlado con placebo y de prueba de concepto  
  **Ponente:** Adrian Newman-Tancredi (Francia)

#### 9:00 – 9:15 AM
**CEREMONIA DE PREMIOS WPC**

- **Lugar:** Salón principal de plenarias

  **Receptores del Premio Robin A Elliott del WPC al Servicio Destacado a la Comunidad**

  **Galardonada:** Kabugo Hannington, **premio entregado por** Omotola Thomas  
  **Galardonada:** Richelle Flanagan, **premio entregado por** Malú Gámez Tansey

#### 9:30 – 11:30 AM
**PLENARIA DE LA MAÑANA**

- **Lugar:** Salón principal de plenarias

  **FP3 – PLENARIA**

  **Moderadora:** Amanda Woerman (EE.UU.)  
  **Co-moderador:** Nicolas Dzamko (Australia)

  **Charla 1:** Prevalencia de copatologías en la enfermedad de Parkinson  
  **Ponente:** Lauren Walker (Reino Unido)

  **Charla 2:** El papel de la alfa-sinucleína y la co-patología en los síntomas cognitivos y no motores  
  **Ponente:** Georgina Aldridge (EE.UU.)

  **Charla 3:** Contribuciones de las co-patologías en la activación de la respuesta inmune en pacientes con la EP  
  **Ponente:** Ashley Harms (EE.UU.)

  **Charla 4:** Copatologías y Parkinson: ¿Qué significa todo esto para quienes viven con la EP?  
  **Ponente:** Soania Mathur (Canadá)

**Objetivos de aprendizaje:**
1. Conocimiento actual de las copatologías en la presentación clínica; 2. Comprensión actual de cómo interactúa la α-sinucleína con otras proteinopatías; 3. Discusión sobre cómo enfocar los esfuerzos de investigación para investigar las contribuciones de las co-patologías a la presentación clínica y la progresión de la enfermedad.

### Niveles de sesión
- **Crosstalk** – conocimiento científico mínimo o no requerido
- **Sesiones científicas de nivel moderado**
- **Sesiones científicas de alto nivel**
- **Tipo de sesión**
  - Ciencia básica
  - Ciencia clínica
  - Atención integral
- **Idioma**
  - Interpretación simultánea de inglés a español
  - Pista en español
**SESIÓN 5: ESTRATEGIAS EN EL MANEJO DEL PARKINSON (I)**

Lugar: Sala 115
Moderadores: Martilde Calopa (España) y Sabela Avion (EE.UU.)

<table>
<thead>
<tr>
<th>Presentación #1: Manejo del Parkinson inicial: medicación y estilo de vida</th>
<th>Presentación #2: Fluctuaciones clínicas y discinesias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ponente:</strong> María José Martí (España)</td>
<td><strong>Ponente:</strong> Oriol de Fàbregas-Boixar (España)</td>
</tr>
</tbody>
</table>

**Objetivos de aprendizaje:** 1. Conocer las estrategias terapéuticas en las etapas iniciales de la enfermedad; 2. Identificación y manejo de las complicaciones motoras. Descripción general de las terapias avanzadas (asistidas con dispositivos).

---

**SESIÓN 6: ESTRATEGIAS EN EL MANEJO DEL PARKINSON (II)**

Lugar: Sala 115
Moderadores: Angel Sesar (España) y Carlos M. Guerra Galicia (México)

<table>
<thead>
<tr>
<th>Presentación #1: Cirugía y otras estrategias terapéuticas complejas</th>
<th>Presentación #2: Ensayos clínicos en marcha: tratamientos sintomáticos y curativos</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ponente:</strong> Francesc Valideoriola (España)</td>
<td><strong>Ponente:</strong> Pablo Mir (España)</td>
</tr>
</tbody>
</table>

**Objetivos de aprendizaje:** 1. Reconocer la fase avanzada (compleja) del Parkinson y las estrategias terapéuticas actuales; 2. Tratamientos experimentales, líneas de investigación en intervenciones avanzadas y sus ventajas potenciales sobre los tratamientos actuales.

---

**FRT2 – MESA REDONDAS**

Lugar: Sala 112
Mesa 14

**Apatía y fatiga en la enfermedad de Parkinson**

**Ponente:** Mayela Rodríguez-Violante (México)

**Panelistas:**
- Coro Paisan-Ruiz (EE.UU.)
- Ryosuke Takahashi (Japón)
- Darren Moore (EE.UU.)
- Nabila Dahodwala (EE.UU.)

---

**FSP1 – PISTA EN ESPAÑOL**

**1:30 – 3:00 PM**

**FSP2 – PISTA EN ESPAÑOL**

**3:30 – 5:00 PM**

**FRT2 – MESA REDONDAS**

**5:15 – 6:00 PM**

**FEd – PANELES DE CIERRE DIARIO**

**6:00 – 7:00 PM**

**COMENTARIOS DE CLAUSURA Y RECEPCIÓN**

Lugar: Salon principal de plenarias

**Anfitriones:**
- Marina Romero-Ramos (Denmark)
- Roger Barker (Reino Unido)

---

**Niveles de sesión**

- Crosstalk – conocimiento científico mínimo o no requerido
- Sesiones científicas de nivel moderado
- Sesiones científicas de alto nivel

**Tipo de sesión**

- Ciencia básica
- Ciencia clínica
- Atención integral

**Idioma**

- Interpretación simultánea de inglés a español
- Pista en español
GENERAL INFORMATION

Delegates must wear their badge at all times in the Convention Center.

**BADGES & LANYARDS**

- BLUE: Health care providers & Researchers
- WHITE: Non-health care providers
- ORANGE: Exhibit Hall ONLY access

**MONEY, BANKS AND EXCHANGES**

**Bank opening hours**
Banks are usually only open from Monday to Friday from 8:00/8:30 AM to 1:30/2:00 PM.

**Currency exchange shops**
There are different ways to exchange money safely in Barcelona. These include ATMs and banks, prepaid cards, main hotels, and currency exchange shops. The currency exchange shops (look for the shops that say “Change” or “Cambio” in Spanish) are located mostly in the tourist areas, airport, and central railway station. Always check the exchange rates as they are constantly changing.

**Credit cards**
National and foreign credit cards as well as MasterCard, American Express and Visa are accepted in most of the shops, restaurants, and cafeterias.

**Withdraw cash at automatic cashiers (ATM)**
Many banks offer a cash card that functions both as a credit card and a cash withdrawal card. Bear in mind that you probably need to advise your bank that you wish to use your credit card in Spain during the travelling period. Some banks block the card for security reasons unless you advise your bank that issued the card before your trip.

There will be a fixed commission you need to pay every time you withdraw money. Ask your bank how much this commission is. Using your credit card/cash card to withdraw money also represents an easy way to get money in the foreign currency whenever you need it. There are auto banks situated all over the town so you will have not problems finding an ATM.

**Shopping and business hours**
Shopping hours are Monday to Saturday from 10:00 AM to 8:00 PM. Shops are closed on Sundays. Visitors from non-EU countries can ask for VAT refunds when purchasing goods.

**DISCLAIMER**
All best efforts will be made to present the program as printed. However, the Congress hosts, and secretariat reserve the right to alter or cancel, without prior notice, any arrangements, timetables, plans or other items relating directly or indirectly to the Congress, for any cause beyond its reasonable control. The Congress hosts, and secretariat are not liable for any loss or inconvenience caused because of such alteration. In the event of cancellation of the Congress all pre-paid fees will be refunded in full. However, the Congress hosts, and its agents are not liable for any loss or inconvenience caused as a result of such cancellation. Delegates are advised to take out their own travel insurance and to extend their policy to cover personal possessions as the Congress does not cover individuals against cancellation of bookings or theft or damage to belongings.

**DRESS CODE**
You may dress informally for the congress. The dress code for the social program and special events is also informal.

**ELECTRICITY**
The standard voltage in Barcelona is 230V/50Hz. Plugs are the continental style with two round pins. If you are traveling from a country that has a different plug from Spain, you will need to bring a converter to charge devices.
GENERAL INFORMATION

EMERGENCY TELEPHONE NUMBERS

European SOS number: 112

The SOS number 112 can be dialled to reach emergency services, medical, fire and police from anywhere in Europe. This European emergency number, can be called from any telephone (landline, pay phone or mobile cellular phone). Calls are free and can be used for any life-threatening situation, including serious medical problems (accident, unconscious person, severe injuries, chest pain, seizure), any type of fire (house, car) or life-threatening situations (crimes).

Medical emergency………. 061
Fire brigade……………… 080
City police………………… 092
City information…………. 010
Barcelona Tourist Office.. 933 689 700

EXHIBITION

Tuesday, July 4 7:00 PM – 9:00 PM
Wednesday, July 5 11:00 AM – 6:45 PM
Thursday, July 6 11:00 AM – 6:45 PM
Friday, July 7 11:00 AM – 2:00 PM

EXHIBIT HALL PASSPORT

The WPC Passport sponsors invite you to visit their booths to discover their products and services and to get your passport stamped for the drawing. Completed passport cards will be collected as people enter the Closing Ceremony on Friday, July 7 from 6 – 7 PM. Drawing will take place with one lucky winner receiving an iPad mini. Must be present to win.

CATERING

Daily boxed lunches as well as tea and coffee during the official afternoon breaks are included in your registration fee. There will be lunch tables set up at the International Barcelona Convention Center. Light food and drinks will be served during the Opening Reception on July 4 and the Closing Remarks on July 7.

ICONS

<table>
<thead>
<tr>
<th>Session Levels</th>
<th>Session Type</th>
<th>Language</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crosstalk – Minimal or no scientific background required</td>
<td>Basic Science</td>
<td>Simultaneous interpretation from English to Spanish Interpretación simultánea de inglés a español</td>
</tr>
<tr>
<td>Moderate-level scientific sessions</td>
<td>Clinical Science</td>
<td>Spanish track Pista española</td>
</tr>
<tr>
<td>High-level scientific sessions</td>
<td>Comprehensive Care</td>
<td>Ticketed event Evento con boleto</td>
</tr>
</tbody>
</table>

INTERNET ACCESS

Free Wi-Fi is offered at the Barcelona International Conference Center during the congress.

LANGUAGE

The official language of the World Parkinson Congress is English. Limited simultaneous interpretation from English to Spanish will be offered and the program will also include a special Spanish-language track daily.

Citizens of ALL countries are welcome to participate in the WPC 2023.
Did you know that we trained city members throughout Barcelona to welcome you to the city? We trained front of house staff, the convention center staff, airport staff, tour guides, police, fire brigade, and others to better understand Parkinson’s. This training has been done at every WPC since 2010 and is designed to help them prepare for welcoming you, but it’s also part of the WPC Legacy, leaving our mark behind well after we are gone by educating these community members to better understand Parkinson’s.

See back of program, pages 131–140.

The free World Parkinson Congress 2023 mobile app allows you to carry the WPC details on your smartphone or tablet, including the program, general information, side activities and list of participants. You will need this app to:
• Exchange messages with fellow delegates
• Submit questions to speakers during sessions

Download the application named World Parkinson Congress 2023.

Mobile phones must be switched off or muted in the session meeting rooms.

Photography and videotaping are not permitted in any of the oral or poster sessions without the express permission of the relevant oral presenter or poster authors.

An official photographer/videographer will be on site to capture the essence of the congress. These images may be used for promotion of the World Parkinson Coalition.

Posters will be displayed throughout the congress dates in the exhibition. Official poster sessions are scheduled on Wednesday and Thursday from 11:30 AM to 1:30 PM, at which time poster presenters will be stationed by their poster to discuss with delegates. See the poster session program for details on when posters will be hosted.

Poster tours will be held from 5:15 to 6:30 PM on Wednesday and Thursday evenings, July 5 and 6, at which times a select number of posters will be hosted. Sign up for tours in the Exhibit Hall, at the table near the first row of posters at the back of the hall.

In the lobby of Hotel Marriott AC Forum

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, July 2</td>
<td>1:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Monday, July 3</td>
<td>10:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

In the lobby of Barcelona International Conference Center (CCIB)

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, July 4</td>
<td>7:30 AM – 8:00 PM</td>
</tr>
<tr>
<td>Wednesday, July 5</td>
<td>7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Thursday, July 6</td>
<td>7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Friday, July 7</td>
<td>7:30 AM – 4:00 PM</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

SMOKING POLICY
Please do not smoke on streets and sidewalks. Only smoke in designated outdoor areas. All indoor areas of the Convention Center are non-smoking.

SOCIAL MEDIA
Connect with other delegates and Congress organizers using social media:
- Like us on Facebook @World Parkinson Congress.
- Follow us on Twitter @WorldPDCongress
  The hashtag is #wpc2023.
- The WPC YouTube channel is WorldPDCongress.
- Follow World Parkinson Coalition on LinkedIn.
- See the WPC community on Instagram@worldpdcongress. Join our photo feed by using hashtag #wpc2023.
- Watch the WPC on TikTok page @worldparkinsonconGRESS.

SPEAKER READY ROOM
All invited speakers can go to the Speaker Ready Room in room VIP Lounge where computers are available to invited speakers wishing to review or modify their presentation.

Speaker Ready Room Schedule

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, July 3</td>
<td>3:00 PM – 7:00 PM</td>
</tr>
<tr>
<td>Tuesday, July 4</td>
<td>7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Wednesday, July 5</td>
<td>7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Thursday, July 6</td>
<td>7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Friday, July 7</td>
<td>7:30 AM – 5:00 PM</td>
</tr>
</tbody>
</table>

TRANSPORTATION
The CCIB, venue of the WPC 2023, is well connected by public transport to all city areas and has taxi ranks and parking places nearby. It also has easy and quick access from the city centre. The nearest public transportation stops which will leave you just a few minutes’ walk away from the CCIB are:
- **Metro:** Line L4-Yellow, El Maresme-Forum station
- **Tram:** Line T4, Forum stop
- **Bus:** Routes H16 and 7

VOLUNTEERS
The WPC leadership thanks the many volunteers for their time to help welcome the thousands of delegates who traveled from around the world to attend the WPC 2023. More than 150 volunteers from 20 countries prepared to welcome and support you. Please thank a volunteer when you see them in their purple shirts. They improve the WPC experience!

WPC STORE
The WPC Store will be teaming up with our local Partner, the Catalan Parkinson Association to sell items from both our organizations. Stop by to pick up some WPC items or items from our Catalan friends. Items sell out, so don’t wait until the last day!

All items are limited. Once they are sold out, they will no longer be available for sale. Proceeds from the sale of Parky the Raccoon stuffed animals will go to the WPC 2026 Travel Grants program. Sale of all other items will go towards the WPC 2026 Planning Fund.
Wellness Way is made up of the areas at the Congress that focus on taking care of oneself. Whether a Parkinson Advocate, Care Advocate or Health Professional, we all need to engage in self-care to ensure we are living our best.

To help delegates achieve this goal, we offer spaces at the WPC where people can try a variety of exercises, networking and just resting peacefully. Be sure to make time during the WPC to visit these spaces so you are working your body as much as your mind! For more information and to view the schedule of each of these rooms visit our website at https://wpc2023.org/WellnessWay. Renewal Room sessions will be ticketed activities with tickets being given out 30 minutes before the sessions. One ticket per person.

Renewal Room
A place to get the blood moving, the space will offer a variety of classes to move the body, voice, and mind. Participate daily in a wide range of classes including: Yoga, Dance, Vocal training, Boxing and more!

Care Partner Lounge
Back by popular demand, this room offers a safe space for care partners to meet and greet each other. Care partners will enjoy special talks, support group space during lunch time and have a formal round table talk each day geared to care partners.

Support Group Leader Lounge
Made possible with support by PMD Alliance
A new space at the WPC, this lounge is designerd for support group leaders and those who want to learn about support groups and how to design and host them. A resource rich space, stop in to ask your questions, make connections, and learn about managing support groups globally.

Table Tennis Room
Made possible with support from International Table Tennis Federation and the Catalan Table Tennis Federation
Join us in the table tennis room for some exercise, wellness, and friendship. Table tennis helps with balance, mobility, reflexes and is just plain. Fun to do!

Meditation and Mindfulness Room
This room will be open daily to offer a place to spend time in quiet, reflection, contemplation, or prayer outside the hustle and bustle of all the other amazing activities and presentations. Guided mindfulness sessions will be provided within the space and showcase techniques you may find useful when you return home.

Film Room
Open to all, the films shown in this room will cover topics of humor, resiliency, overcoming challenges and highlight the importance of social connectedness. View the films and meet the artists behind them.
# RENEWAL ROOM SCHEDULE
Made possible with support by Boston Scientific and Supernus

**Location: Room 211**

A place to get the blood moving, the space will offer a variety of classes to move the body, voice, and mind. Participate daily in a wide range of classes including yoga, tai chi, laughter yoga, dance, vocal training, boxing and more!

## TIME

<table>
<thead>
<tr>
<th><strong>WEDNESDAY</strong></th>
<th><strong>THURSDAY</strong></th>
<th><strong>FRIDAY</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>July 5</strong></td>
<td><strong>July 6</strong></td>
<td><strong>July 7</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>TIME</strong></th>
<th><strong>WEDNESDAY</strong></th>
<th><strong>THURSDAY</strong></th>
<th><strong>FRIDAY</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 9:00 AM</td>
<td>Yoga for Strength and Healing</td>
<td>Keep Moving – Balance and Relaxation with Tai Chi</td>
<td>Chair Yoga for PD – Relax, Release, Renew</td>
</tr>
<tr>
<td></td>
<td>Presenter: Aminta St. Onge</td>
<td>Presenter: Mirko Lorenz</td>
<td>Presenter: Whitney Chapman</td>
</tr>
<tr>
<td>9:30 – 10:30 AM</td>
<td>Power for Parkinson’s Brain &amp; Body</td>
<td>Parkinson’s Specific Exercise: The Neuro Heroes Way!</td>
<td>Emotions in Motion</td>
</tr>
<tr>
<td></td>
<td>Presenter: Polly Caprio</td>
<td>Presenter: Laura Douglas</td>
<td>Presenter: Francesca De Bartolomeis</td>
</tr>
<tr>
<td>11:00 – 12:30 PM</td>
<td>Rock Steady Boxing</td>
<td>Dance for PD</td>
<td>Ronnie Gardiner Method: life is rhythm and rhythm is life</td>
</tr>
<tr>
<td></td>
<td>Presenters: Hans and Dini Lauwerse</td>
<td>Presenter: David Leventhal</td>
<td>Presenter: Maria Rosa Gutierrez Grau</td>
</tr>
<tr>
<td>1:00 – 2:00 PM</td>
<td>Laughter Yoga for Everyone!</td>
<td>Singing with Gusto! – Singing is Fun!</td>
<td>PD Warrior Play</td>
</tr>
<tr>
<td></td>
<td>Presenter: Brian Reedy</td>
<td>Presenters: Judi Spencer and Penny Stone</td>
<td>Presenter: Melissa McConelly</td>
</tr>
<tr>
<td>2:30 – 3:30 PM</td>
<td>Zumba Gold for Parkinson’s</td>
<td>PD Movement Lab</td>
<td>Alexander Technique</td>
</tr>
<tr>
<td></td>
<td>Presenter: Josefa Domingos</td>
<td>Presenter: Pamela Quinn</td>
<td>Presenter: Monica Gross</td>
</tr>
<tr>
<td>4:00 – 5:00 PM</td>
<td>Move &amp; Shout with Power for Parkinson’s</td>
<td>Get LOUD, Get BIG, Get Energized</td>
<td>Beat Parkinson’s with Reach Your Peak</td>
</tr>
<tr>
<td></td>
<td>Presenter: Nina Mosier</td>
<td>Presenter: Cynthia Fox</td>
<td>Presenters: Maria Lewis and Sally Tawhai</td>
</tr>
</tbody>
</table>

## Location: Room 211

A place to get the blood moving, the space will offer a variety of classes to move the body, voice, and mind. Participate daily in a wide range of classes including yoga, tai chi, laughter yoga, dance, vocal training, boxing and more!
This lounge is designed for Care Partners. Talks and sessions will address issues identified by care partners, giving participants support, tips, and tricks to address their needs as care partners along their journey.

**TIME** | **WEDNESDAY July 5** | **THURSDAY July 6** | **FRIDAY July 7**
---|---|---|---
9:30 – 10:30 AM | Discussion group: New Diagnosis: Where and how to begin  
*Hosts:* Allison Allen (USA)  
Sheryl Hague,  
Care Partner (Canada) | Discussion group: YOPD: keeping life on track  
*Hosts:* Elaine Book (Canada)  
Rebecca Gifford,  
Care Partner (Canada) | Discussion group: Mid stage PD: Staying Energized for the long haul  
*Host:* Lissa Kapust (USA)
11:00 AM – 12:00 PM | **Español**  
Charla: Aspectos neuropsiquiátricos y su impacto en los cuidadores (Neuropsych issues and impact on Care Partners)  
*Moderadora:* Adriana Gonzalez (USA)  
*Ponente:* Mayela Rodriguez-Violante (Mexico) | **Español**  
Charla: No apto para cardiacos (Caregiving is not for faint of heart)  
*Moderadora:* Adriana Gonzalez (USA)  
*Ponente:* Maria DeLeon (USA) | 12:00 – 1:30 PM  
The Poise Project: Partnering with Poise – Caring for Care Partners
12:30 – 1:30 PM | Lecture: Rewriting the care partner rule book  
*Host:* Connie Carpenter-Phinney (USA), Co-Founder, Davis Phinney Foundation | Discussion group: What’s on your mind? Open question period – nothing is off the table!  
*Host:* Allison Allen (USA) |  
Focus Group
2:00 – 3:00 PM | Lecture: Communication: it’s more than just about voice  
*Speaker:* Angela Roberts (Canada) | Lecture: Intimacy and the Care Partner experience  
*Speaker:* Gila Bronner (Israel) | Discussion group: Adios Barcelona ~ Going Home Hopeful  
*Moderator:* Anne Kosem
3:30 – 4:30 PM | Workshop: Finding your creativity  
*Host:* Sneha Mantri (Canada) | Workshop: Writing to cope & connect  
*Host:* Rebecca Gifford (Canada) |  

**Support Group Leader Lounge**  
Made possible with support by PMD Alliance

**Location:** 132

This lounge is a gathering place for current support group and wellness leaders, and anyone interested in becoming one. Join us to network, engage in discussions, learn activities to use in your group, and hear how other leaders are supporting the community in their corner of the world. Join us on Tuesday, 4 July 3-5:00 PM for a Meet & Greet.

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday, July 5</th>
<th>Thursday, July 6</th>
<th>Friday, July 7</th>
</tr>
</thead>
</table>
| 8:00 – 8:50 AM    | Lounge Open: Support Group/Grupo de apoyo  
*Host: Con P de Parkinson* | Lounge Open: Support Group/Grupo de apoyo  
*Host: Con P de Parkinson* | Lounge Open: Support Group/Grupo de apoyo  
*Host: Con P de Parkinson* |
*Host: David Leventhal (USA)* |
| 9:30 – 10:15 AM   | *Español – Actividad: Tranquilidad de espíritu  
*Anfitriona: Julie Worden (USA)* | Taller: El Sintomario: una herramienta de comunicación  
*Anfitriona: Laura Crawford (USA)* | Workshop: Support has many shapes and forms  
*Host: Larry Gifford (Canada)* |
| 10:30 – 11:15 AM  | Workshop: Building support groups around activities that foster connection  
*Hosts: Clara Kluge and Lori DePorter (USA)* | Activity: Creating Support Group Leader Meeting Makers  
*Hosts: PMD Alliance Staff and Ambassadors* | Discussion group: Support Groups with Global Impact  
*Host: Natasha Fothergill-Misbah (UK)* |
*Speaker: Indu Subramanian (USA)* | Discussion Group: Addressing Stigma as a Barrier to Support  
*Host: Maria Barretto (India)* | Coffee Connection: Networking (coffee in room)  
*Host: PMD Alliance Global Ambassador Team* |
| 12:30 – 1:15 PM   | Support Group: YOPD Women  
*Facilitator: Kristi LaMonica (USA)* | Workshop: Reaching Underserved Communities in Latin America  
*Host: Christine Jeya (Australia)* | Support Group: YOPD Men  
*Facilitator: Eric Aquino (USA)* |
| 2:00 – 2:45 PM    | Workshop: Responding to Emotional Aspects of Care Partner Support Group  
*Host: Greg Pontone (USA)* | Round Table: Support Groups from around the World  
*Hosts: Leaders from Kenya, Ghana, Nigeria, India, Spain and Norway* | *Español*  
Taller: Somos la Familia Parkinson  
*Anfitriona: Maria De Leon (USA)* |
| 3:00 – 3:45 PM    | Round Table: Impact of Social connection on Brain Health  
*Hosts: PMD Alliance and PD Avengers | Global Alliance to End Parkinson's Disease Assn* | Activity: Drumming Ice breaker  
*Host: Lori DePorter (USA)*  
FAREWELL |
| 4:00 – 4:45 PM    | Discussion group: Wellness-based Support Groups  
*Hosts: David Leventhal (USA) and Maria Portman Kelly (USA)* | Lounge open: Support Group/Grupo de apoyo  
*Host: Con P de Parkinson* | |

**Terminología en español:**

**Ubicación:** 132

Este es un lugar de reunión para los líderes de clases de movimiento y grupos de apoyo, y cualquier persona interesada en iniciar un grupo. Visítenos para relacionarse, conversar, aprender actividades grupales y escuchar cómo otros líderes están apoyando a su comunidad en su rincón del mundo. Martes 4 de julio, de 3 a 5:00 PM será la reunión de bienvenida.
**TABLE TENNIS ROOM (PING PONG)**

*Made possible with support from International Table Tennis Federation and the Catalan Table Tennis Federation*

**Location: 123**

Experience the benefits of table tennis for Parkinson’s disease and overall health. Exercise, assess yourself, meet the stars, improve your memory, challenge a robot! Table tennis enhances balance, coordination, calmness, movement, and social connections. Playing for 15-20 minutes reduces stiffness, improves timing, and reduces frustration. Results of one session last up to 2 days! *Come join us!*

<table>
<thead>
<tr>
<th>TIME</th>
<th>WEDNESDAY</th>
<th>THURSDAY</th>
<th>FRIDAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:30 AM</td>
<td>Warm up – Preparation</td>
<td>Warm up – Preparation</td>
<td>Presenting the results of the research</td>
</tr>
<tr>
<td>11:30 AM – 1:00 PM</td>
<td>Self-assessment to understand your level</td>
<td>Different exercises for health benefits</td>
<td>Compete against other players</td>
</tr>
<tr>
<td>1:00 – 1:30 PM</td>
<td>Meet the stars!</td>
<td></td>
<td>Meet the stars!</td>
</tr>
<tr>
<td>1:30 – 3:00 PM</td>
<td>Compete against other players</td>
<td></td>
<td>Compete against other players</td>
</tr>
<tr>
<td>3:00 – 4:30 PM</td>
<td>Different exercises for health benefits</td>
<td></td>
<td>Self-assessment to understand your level</td>
</tr>
<tr>
<td>4:30 – 6:00 PM</td>
<td>Research on benefits of table tennis for PD</td>
<td></td>
<td>Different exercises for health benefits</td>
</tr>
</tbody>
</table>

*Table Tennis teachers are all trilingual so come and join us in Spanish, Catalan, or English!*
MINDFULNESS & MEDITATION ROOM
Made possible by Boston Scientific and Supernus Pharmaceuticals

Location: 125
A place to spend time in quiet, reflection, contemplation, or prayer outside the hustle and bustle of all the other amazing activities and presentations. A few 20-minute guided mindfulness sessions will be provided within the keeping of the ambiance of this room to enhance refreshment and provide techniques you may choose to utilize in your daily lives.

JULIA WOOD, MOT, OTR/L
Join occupational therapist Julia Wood for her gentle, seated movement session. Utilizing the breath to move the body in a fluid and relaxing manner.

James is on the faculty of the Parkinson’s Foundation Team Training for Parkinson’s program, LSVT BIG certified and Training Faculty, and a member of the WPC 2023 Comprehensive Care Subcommittee.

JAMES BRASIC, MD, MPH
Join neurologist and child and adolescent psychiatrist, James Brasic, in guided imagery as you get ready for your day.

James has been practicing meditation, mindfulness, and yoga for decades, with specific practice and training in transcendental meditation and the Mindfulness Based Stress Reduction approach. He has utilized guided imagery for his patient’s experiencing anxiety.

WARREN SPENCER, JD, LLM
Join iRest meditation instructor and Unified Mindfulness meditation coach Warren Spencer, in guided mindfulness meditation techniques that provide time to refresh and calm the mind and body.

Warren has been practicing meditation over 20 years, beginning with the Vipassana tradition, later incorporating Yoga Nidra and the science of meditation. Warren is a Yoga Alliance certified yoga teacher, with specialized training in yoga for Parkinson’s Disease and has been a practicing attorney for more than 30 years.

Ubicación: 125
Un lugar para pasar tiempo en silencio, reflexión, contemplación u oración fuera del ajetreo de todas las demás actividades y presentaciones increíbles. Se ofrecerán algunas sesiones guiadas de atención plena de 20 minutos en el ambiente de esta sala para aumentar el descanso y proporcionar técnicas que puedan utilizar en su vida diaria.

<table>
<thead>
<tr>
<th>TIME</th>
<th>WEDNESDAY July 5</th>
<th>THURSDAY July 6</th>
<th>FRIDAY July 7</th>
</tr>
</thead>
</table>
| 7:45 – 8:05 AM  | Guided Imagery – Getting ready for the day  
                  Presenter: James Brasic | Guided Imagery – Getting ready for the day  
                  Presenter: James Brasic | Guided Imagery – Getting ready for the day  
                  Presenter: James Brasic or Warren Spencer |
| 12:30 – 12:50 PM| Meditation – Refresh for the afternoon  
                  Presenter: Warren Spencer | Meditation – Refresh for the afternoon  
                  Presenter: Warren Spencer | Moving Mindfully – Let your breath be the guide  
                  Presenter: Julia Wood |
| 5:15 – 5:35 PM  | Meditation – Calming the mind and body  
                  Presenter: Warren Spencer | Meditation – Calming the mind and body  
                  Presenter: Warren Spencer | |

#WPC2023 @worldpdcongress
This space is for the showing of films that were created by members of the Parkinson’s community or someone wishing to showcase someone in the community. Open to all, the films cover topics of humor, resiliency, overcoming challenges and the importance of social connectedness. View the films and meet the artists behind them.

**WPC FILM ROOM**

**Location: 127**

Este espacio está destinado a la proyección de películas creadas por miembros de la comunidad de Parkinson o por alguien que desee destacar a alguien de la comunidad. Abiertas a todos, las películas tratan temas como el humor, la resiliencia, la superación de retos y la importancia de la conexión social. Vea las películas y conozca a los artistas que las crearon.

**SALA DE CINE DEL WPC**

**Ubicación: 127**

<table>
<thead>
<tr>
<th>TIME</th>
<th>WEDNESDAY July 5</th>
<th>THURSDAY July 6</th>
<th>FRIDAY July 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM</td>
<td><em>Me to Play</em> – 71 min</td>
<td><em>Kinetics</em> – 47 min</td>
<td><em>Shaking hands with the devil</em> – 15 min</td>
</tr>
<tr>
<td></td>
<td><em>Director: Jim Bernfield (USA)</em></td>
<td><em>What a Load of Balls</em> – 12 min</td>
<td><em>Director: Natasha Fothergill-Misbah (UK)</em></td>
</tr>
<tr>
<td>1:45 PM</td>
<td><em>Hoje NÃO (Not Today)</em> – 50 min</td>
<td><em>Hal and Minter</em> – 30 min</td>
<td><em>Boys of Summer</em> – 53 min</td>
</tr>
<tr>
<td></td>
<td><em>(Portuguese without subtitles)</em></td>
<td><em>Actor: Minter Krotzer (USA)</em></td>
<td><em>Director &amp; Actor: Robert Cochrane (USA)</em></td>
</tr>
<tr>
<td></td>
<td><em>Producer: Joao Augusto Pedreira (Brazil)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td><em>Wear a light: The Future with Juvenile Parkinson’s Disease</em> – 39 min <em>(Japanese with English subtitles)</em> <em>Producer: Shun Coney (Japan)</em></td>
<td><em>Que Nos Traspase El Aire</em> – 53 min <em>(Spanish with English subtitles)</em> <em>Director: César Casares (Spain)</em></td>
<td><em>Would you sell your house to save your mother?</em> – 12 min <em>Director: Christine Jeyachandran (Australia)</em></td>
</tr>
<tr>
<td>4:30 PM</td>
<td><em>Todo Cambia – Everything Changes</em> – 30 min <em>(Japanese with English subtitles)</em> <em>Producer: Aki Kono (Japan)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WPC Research Spotlight**

Bringing the PD community together to increase understanding of, and support for Parkinson’s research.
WPC ART WALK

Four art installations will grace the halls, walls, and floor space of WPC 2023 showcasing creativity in Parkinson’s. We invite you to explore each exhibit and make time to meet two of the artists at designated “Meet & Greet” sessions to hear more about their artistic process and how creativity impacts them and their wellness.

PARKINSON’S TULIP GARDEN
Made possible with support from Supernus Pharmaceuticals
Location: Exhibit Hall

The Parkinson’s Tulip Garden is the culmination of the Parkinson’s Tulip Project, where thousands of images of people in the Parkinson’s community with tulips are brought together in one exhibit, paying homage to local Barcelona architect Antonin Gaudi, showcasing the diversity, creativity and strength of the Parkinson’s community, reminder us all we are connected from one part of the globe to another.

PARKINSON’S SYMPTOMS ART
Made possible with support from World Parkinson Coalition
Location: Foyer, near registration
Artist: Jonny Acheson, MD (UK)
Meet & Greet: Wednesday, July 5 from 12:00 – 1:00 PM

This collection of Parkinson’s artwork depicts Parkinson’s symptoms by drawing the letters that spell the symptom name. The surrounding cartoon and text portray what it may feel like for someone with PD. Powerful in their simplicity, each image draws the viewer in with humor and education around many of the most misunderstood symptoms that people with PD experience, sometimes many of them in one day.

I AM DANCE ~ PD DANCE PROJECT
Made possible with support from Supernus Pharmaceuticals
Location: Exhibit Hall, alongside The Tulip Garden
Coordinating Artist: Clara Kluge (USA)

I Am Dance – PD Dance Project was created by and for the Parkinson’s community-at-large. In association with the Mark Morris Dance Group, Dance for PD® Program, this project invited the global community to partake in a worldwide celebration and collaboration of dance. All dance artists were invited to express themselves by showing their own creative and unique dance piece(s). This project allows viewers to witness the dynamic values that exist for people who have Parkinson’s through choreography and dance. Research has shown that movement such as dance is vital to the well-being of a person living with PD.

PARKYLIFE
Made possible with support from Havas Media Group
Location: Foyer, near registration
Artist: Matt Eagles (UK) & Havas Media Group
Meet & Greet: Friday, July 7 from 12:00 – 1:00 PM

ParkyLife brings you The Art Wobble, the first art exhibition that both aids and inspires you, the Parkinson’s community. Each piece of artwork features a real Parkinson’s role model, positively brimming with attitude and life.

But instead of adorning the walls, our ‘Art Wobble’ can be found on the foyer floor, perfectly positioned to give you a wobbly walk through the exhibition, all at your own pace. So, please, do step on the art and enjoy.
The Prize was created to honor those whose efforts best embody the goals of the World Parkinson Congress. While those being honored with this award each served the Parkinson’s community differently, they have all made great impact beyond their corner of the globe. Whether it was: to expand collaboration on basic and clinical research that engaged patients; to create new and innovative treatment options; to inspire community building and engagement by people with Parkinson’s and care partners; or to engage in specific advocacy efforts to impact the Parkinson community.

WPC AWARD FOR DISTINGUISHED CONTRIBUTION TO THE PARKINSON COMMUNITY

LIZZIE GRAHAM (UK)

In 1989, Lizzie joined the UK Parkinson’s Disease Society (now Parkinson’s UK) where she worked full time as she helped to establish the European Parkinson’s Disease Association from 1990 to 2001. From 2001 onwards, Lizzie worked exclusively with the EPDA in various roles, most prominently as Secretary General and then as Executive Director from 2006 to 2018. Lizzie’s impact on Parkinson’s care continues today in the form of the Parkinson’s Disease Nurse Specialists program in the UK, a program that ensures thousands of people with PD in UK get access to trained Parkinson’s clinicians.

VINCENT “ENZO” SIMONE (USA)

Enzo made it his life’s mission to raise awareness and funds to find a cure for PD and Alzheimer’s, when his mother was diagnosed with Alzheimer’s in 2002 and in short succession his father-in-law found out he had Parkinson’s. He formed a group called ‘the regulars’ and climbed 10 mountains in 10 years leading to the creation of an award-winning film “10 mountains, 10 years” which has been screened globally. His passion and energy was infectious, his legacy continues to touch people today.

IGNACIO “NACHO” MATA (USA/Spain)

Ignacio helped launch an international effort to bring the Hispanic community to the forefront of genetic research in Parkinson’s disease (PD). He created a consortium comprised of doctors, researchers, patients and family members from more than 40 institutions in 14 countries across the Americas and the Caribbean that provides education about PD genetics/research and genetic testing for Latinos who have PD. His work has helped drive up the inclusion of under-represented Latino populations in research.

WPC AWARD FOR OUTSTANDING COMMUNITY SERVICE

RICHELLE FLANAGAN (Ireland)

Diagnosed with YOPD in 2017, Richelle wasted no time in becoming a Parkinson’s advocate. At the time of her diagnosis, she was working full-time as a dietitian, while raising two children with her husband. She attended the WPC 2019, and was inspired on her return home to: help educate others about the importance of diet and nutrition; raise money for PD causes; co-found My Moves Matter, a digital health app to the meet the specific needs of women living with PD and also co-found the Women and Parkinson’s Project to raise awareness of the research and care needs of women living with PD.

MARINA NOORDEGRAAF (Netherlands)

Marina was a patient researcher and accomplished visual artist living with Parkinson’s. Diagnosed with YOPD, her gift to the community and the world was her ability to improve and expand on the communication between people with PD and researchers, as she had an exceptional ability of translating between the lived expertise of PD and the learned expertise of PD that clinicians and researchers have.

KABUGO HANNINGTON TAMALE (Uganda)

In a country with limited resources and very few Parkinson’s trained clinicians, Hannington has created a community clinic, brought Parkinson’s identification and diagnostic training to health clinics and hospital staff members across Uganda and has elevated awareness of Parkinson’s in Uganda via the organization he runs, Parkinson Si Buko, (Parkinson’s is not witchcraft). Hannington works tirelessly to inform and educate Ugandans on the realities of Parkinson’s while working to eliminate the stigma around this condition.

IGNACIO “NACHO” MATA (USA/Spain)

Ignacio helped launch an international effort to bring the Hispanic community to the forefront of genetic research in Parkinson’s disease (PD). He created a consortium comprised of doctors, researchers, patients and family members from more than 40 institutions in 14 countries across the Americas and the Caribbean that provides education about PD genetics/research and genetic testing for Latinos who have PD. His work has helped drive up the inclusion of under-represented Latino populations in research.

WPC ROBIN A. ELLIOTT AWARD FOR OUTSTANDING COMMUNITY SERVICE

The Prize was created to honor the service of Robin A. Elliott who helped launch the World Parkinson Congresses in 2004. Robin’s 20 years of service to the community, as the head of the recently renamed Parkinson’s Foundation, and his commitment to supporting young researchers, clinicians, and people with Parkinson’s was evident in every decision he made. This award honors the work of individuals who aim to better the lives of people with PD with their daily service and support that impacted their region of the world and profoundly improved, and continues to improve, the lives of the individuals they serve.

ROBIN A. ELLIOTT (Ireland)

Robin’s 20 years of service to the community, as the head of the recently renamed Parkinson’s Foundation, and his commitment to supporting young researchers, clinicians, and people with Parkinson’s was evident in every decision he made. This award honors the work of individuals who aim to better the lives of people with PD with their daily service and support that impacted their region of the world and profoundly improved, and continues to improve, the lives of the individuals they serve.
## WPC CLINICAL RESEARCH VILLAGE

Location: Exhibit Hall – Clinical Research Village booth

<table>
<thead>
<tr>
<th>TIME</th>
<th>WEDNESDAY July 5</th>
<th>THURSDAY July 6</th>
<th>FRIDAY July 7</th>
</tr>
</thead>
</table>
| 11:40 AM   | Critical Path for Parkinson’s Working Session: A worldwide partnership to enable patient engagement in new and innovative ways  
• Worldwide partnerships and innovative patient engagement strategies  
• Connect globally with partners to engage in meaningful change  
• Empowering Parkinson’s patients through global partnerships and innovative engagement strategies | Critical Path for Parkinson’s Working Session: How to enable personalized medicine with the “right drug, right person, right time”  
• Impactful approaches to personalized medicine using the “right drug, right person, right time”  
• Unlocking personalized Parkinson’s medicine with “right drug, right person, right time” | Critical Path for Parkinson’s Working Session: Bringing data from around the world to inform clinical trials for the future  
• Strategic data collaboration to inform globally relevant clinical trials for the future  
• Transforming the future of clinical trials using global data and translational collaboration  
• Critical Path for Parkinson’s global collaboration and future innovations for data-driven Parkinson’s trials |
| 11:45 AM   | Panel Discussion: Patient Involvement and Engagement: The who, what, where, how and why | Panel Discussion: Involving Women in Parkinson’s Research | |
| 12:15 PM   | Panel Discussion: Clinical Research Across the Parkinson’s Disease Continuum: Engaging and involving people with Parkinson’s at all disease stages | Panel Discussion: Creating Opportunities for Research Engagement and Involvement for All: Experiences and strategies focused on people with Parkinson’s and care partners | Panel Discussion: Challenges, Considerations & Opportunities of Undertaking Research in Africa |
| 12:40 PM   | Presentation: Focused Patient and Public Involvement and Engagement (PPIE)  
Listening to the experience of participants on neurosurgical trials: Outcomes of the LEARN-GDNF and LEARN-Transeuro studies | Roundtable: Involving Young Onset Parkinson’s Disease (YOPD) Individuals in Research | |
| 1:15 PM    | 1:00 PM – Presentation: Focused Patient and Public Involvement and Engagement (PPIE)  
Towards a preliminary protocol for a multi-arm multi-stage trial of disease modify therapies in Parkinson’s disease: the EJS ACT-PD initiative | Presentation: Focused PPIE  
Building a coalition to advance engagement of black and African American communities in Parkinson’s disease (PD) research using best practices in diversity, equity and inclusion (DEI), and patient engagement: A multidisciplinary approach | Open Hours: Meet the Clinical Research Village Organizers – Share Feedback and Ideas |
| 1:30 PM    | UCB Roundtable: Patient Engagement Council for Parkinson’s Research: Demonstration of how the patient community is driving early involvement in research and development | 1:40 PM – Industry Roundtable: Patient Insights: What tools exist and what would be useful | |
| 5:15 PM    | 5:15 PM – PPIE Posters Tour | 6:00 PM – CRV Reception | |
CONTINUING EDUCATION

The 6th World Parkinson Congress will offer continuing education credits to medical doctors and nurses.

Certificates for continuing education credits will be emailed to delegates who pre-paid during registration. A survey link will be emailed out at the close of the WPC, this survey must be completed to collect credits. If you are using a travel agency to book your registration for the congress, be sure that they include your email address on the registration form. This avoids the confusion of having the certificate being sent to the travel agency.

If you wish to receive continuing education credits, and missed this application during registration, you may pay this fee at the registration desk during the WPC to ensure you will receive the survey post WPC. The fee for credits is $50 USD. If you miss this during the Congress and wish to collect the credits after the close of the WPC, the fee will be $100 USD for processing and handling after July 7.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and World Parkinson Coalition Inc. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

- Oakstone Publishing designates this live activity for a maximum of 32.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

- The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

- Oakstone Publishing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

- AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Each delegate, regardless of registration category, will receive a Certificate of Attendance via email post WPC. This is NOT the same as receiving continuing education credits.
TRAVEL GRANT RECIPIENTS

Amr Abdeen  
Veerle Aertsen  
Fatima Afaar  
Eduardo A. Albornoz  
Ghazi Alnajdi  
Jane Alty  
Miriam Amezcua  
Carla Ardau  
Kathleen Armstrong  
Yasunthara Balalle-Deo  
Benjamin Bement  
Monique Bosman  
Sheenagh Bottrell  
Samantha Bramich  
Shane Breslin  
Michele Callisaya  
Zuriel Ceja  
Jessica Chedid  
Hercules Cordova  
Sarah Davies  
Santiago Díaz Torres  
Paula Dodema  
Sue Edge  
Carlo Edwards  
Claudia Eyd  
Raymond Feeney  
Amali S. Fernando  
Luis García  
Roberto García Zarate  
Pei Ying Lee  
Susan Lopez-Payan  
Eirwen Malin  
Peter Masees  
Alice Masson  
Deepshikha Mathur  
Louis McCann  
Margaret McCormick  
Angus McNamara  
María Fernanda Medina Pérez  
Matthew Moore  
María Beatriz Navarro  
Ian O Brien  
Julia Obergasteiger  
Laura Olmos  
Graciela Lucia Orostizaga  
Isabel Margarita Palma Navarrete  
Nikolaos Papagiannakis  
Rebekah Parkinson  
Maria Teresa Pascual Cubos  
Laure Pauly  
Paulo Pelicioni  
Maria Jose Perez Jimenez  
Kirsti Peterson  
Tiwonge Elisa Phiri  
Lis Pilibeam  
Lesley Pretula  
Lydia Pyles  
Michael Quaglia  
Sandra Cristina Ramirez  
Jose Razquin  
Miguel E. Renteria  
Soheila Saboury  
Christian Schmidt-Heisch  
Varena Schmitt  
Bonnie Schwartz  
Youssef Soliman  
Andrea Spila  
Munal Subedi  
Christopher Sulphin  
Adam Tate  
Vasilios Theologidis  
Peter Tricario  
Olivier Uswihena  
Longfel Wang  
Xinyi Wang  
Lucia Wang  
Sophie Wardle  
Harrison Waters  
Fiona Weiss  
Kathrin Wersing  
David Williams  
Roberta Wilson-Garrett  
Zizheng Xian  
Madeleine Yule  
Apurva Zawar  
J. Diana Zhang  
Amr Abdeen  
Veerle Aertsen  
Fatima Afaar  
Eduardo A. Albornoz  
Ghazi Alnajdi  
Jane Alty  
Miriam Amezcua  
Carla Ardau  
Kathleen Armstrong  
Yasunthara Balalle-Deo  
Benjamin Bement  
Monique Bosman  
Sheenagh Bottrell  
Samantha Bramich  
Shane Breslin  
Michele Callisaya  
Zuriel Ceja  
Jessica Chedid  
Hercules Cordova  
Sarah Davies  
Santiago Díaz Torres  
Paula Dodema  
Sue Edge  
Carlo Edwards  
Claudia Eyd  
Raymond Feeney  
Amali S. Fernando  
Luis García  
Roberto García Zarate  
Pei Ying Lee  
Susan Lopez-Payan  
Eirwen Malin  
Peter Masees  
Alice Masson  
Deepshikha Mathur  
Louis McCann  
Margaret McCormick  
Angus McNamara  
María Fernanda Medina Pérez  
Matthew Moore  
María Beatriz Navarro  
Ian O Brien  
Julia Obergasteiger  
Laura Olmos  
Graciela Lucia Orostizaga  
Isabel Margarita Palma Navarrete  
Nikolaos Papagiannakis  
Rebekah Parkinson  
Maria Teresa Pascual Cubos  
Laure Pauly  
Paulo Pelicioni  
Maria Jose Perez Jimenez  
Kirsti Peterson  
Tiwonge Elisa Phiri  
Lis Pilibeam  
Lesley Pretula  
Lydia Pyles  
Michael Quaglia  
Sandra Cristina Ramirez  
Jose Razquin  
Miguel E. Renteria  
Soheila Saboury  
Christian Schmidt-Heisch  
Varena Schmitt  
Bonnie Schwartz  
Youssef Soliman  
Andrea Spila  
Munal Subedi  
Christopher Sulphin  
Adam Tate  
Vasilios Theologidis  
Peter Tricario  
Olivier Uswihena  
Longfel Wang  
Xinyi Wang  
Lucia Wang  
Sophie Wardle  
Harrison Waters  
Fiona Weiss  
Kathrin Wersing  
David Williams  
Roberta Wilson-Garrett  
Zizheng Xian  
Madeleine Yule  
Apurva Zawar  
J. Diana Zhang  
Amr Abdeen  
Veerle Aertsen  
Fatima Afaar  
Eduardo A. Albornoz  
Ghazi Alnajdi  
Jane Alty  
Miriam Amezcua  
Carla Ardau  
Kathleen Armstrong  
Yasunthara Balalle-Deo  
Benjamin Bement  
Monique Bosman  
Sheenagh Bottrell  
Samantha Bramich  
Shane Breslin  
Michele Callisaya  
Zuriel Ceja  
Jessica Chedid  
Hercules Cordova  
Sarah Davies  
Santiago Díaz Torres  
Paula Dodema  
Sue Edge  
Carlo Edwards  
Claudia Eyd  
Raymond Feeney  
Amali S. Fernando  
Luis García  
Roberto García Zarate  
Pei Ying Lee  
Susan Lopez-Payan  
Eirwen Malin  
Peter Masees  
Alice Masson  
Deepshikha Mathur  
Louis McCann  
Margaret McCormick  
Angus McNamara  
María Fernanda Medina Pérez  
Matthew Moore  
María Beatriz Navarro  
Ian O Brien  
Julia Obergasteiger  
Laura Olmos  
Graciela Lucia Orostizaga  
Isabel Margarita Palma Navarrete  
Nikolaos Papagiannakis  
Rebekah Parkinson  
Maria Teresa Pascual Cubos  
Laure Pauly  
Paulo Pelicioni  
Maria Jose Perez Jimenez  
Kirsti Peterson  
Tiwonge Elisa Phiri  
Lis Pilibeam  
Lesley Pretula  
Lydia Pyles  
Michael Quaglia  
Sandra Cristina Ramirez  
Jose Razquin  
Miguel E. Renteria  
Soheila Saboury  
Christian Schmidt-Heisch  
Varena Schmitt  
Bonnie Schwartz  
Youssef Soliman  
Andrea Spila  
Munal Subedi  
Christopher Sulphin  
Adam Tate  
Vasilios Theologidis  
Peter Tricario  
Olivier Uswihena  
Longfel Wang  
Xinyi Wang  
Lucia Wang  
Sophie Wardle  
Harrison Waters  
Fiona Weiss  
Kathrin Wersing  
David Williams  
Roberta Wilson-Garrett  
Zizheng Xian  
Madeleine Yule  
Apurva Zawar  
J. Diana Zhang

TRAVEL GRANT SPONSORS

WPC thanks the sponsors and donors who have made the WPC 2023 Travel Grants program possible:

Amr Abdeen  
Veerle Aertsen  
Fatima Afaar  
Eduardo A. Albornoz  
Ghazi Alnajdi  
Jane Alty  
Miriam Amezcua  
Carla Ardau  
Kathleen Armstrong  
Yasunthara Balalle-Deo  
Benjamin Bement  
Monique Bosman  
Sheenagh Bottrell  
Samantha Bramich  
Shane Breslin  
Michele Callisaya  
Zuriel Ceja  
Jessica Chedid  
Hercules Cordova  
Sarah Davies  
Santiago Díaz Torres  
Paula Dodema  
Sue Edge  
Carlo Edwards  
Claudia Eyd  
Raymond Feeney  
Amali S. Fernando  
Luis García  
Roberto García Zarate  
Pei Ying Lee  
Susan Lopez-Payan  
Eirwen Malin  
Peter Masees  
Alice Masson  
Deepshikha Mathur  
Louis McCann  
Margaret McCormick  
Angus McNamara  
María Fernanda Medina Pérez  
Matthew Moore  
María Beatriz Navarro  
Ian O Brien  
Julia Obergasteiger  
Laura Olmos  
Graciela Lucia Orostizaga  
Isabel Margarita Palma Navarrete  
Nikolaos Papagiannakis  
Rebekah Parkinson  
Maria Teresa Pascual Cubos  
Laure Pauly  
Paulo Pelicioni  
Maria Jose Perez Jimenez  
Kirsti Peterson  
Tiwonge Elisa Phiri  
Lis Pilibeam  
Lesley Pretula  
Lydia Pyles  
Michael Quaglia  
Sandra Cristina Ramirez  
Jose Razquin  
Miguel E. Renteria  
Soheila Saboury  
Christian Schmidt-Heisch  
Varena Schmitt  
Bonnie Schwartz  
Youssef Soliman  
Andrea Spila  
Munal Subedi  
Christopher Sulphin  
Adam Tate  
Vasilios Theologidis  
Peter Tricario  
Olivier Uswihena  
Longfel Wang  
Xinyi Wang  
Lucia Wang  
Sophie Wardle  
Harrison Waters  
Fiona Weiss  
Kathrin Wersing  
David Williams  
Roberta Wilson-Garrett  
Zizheng Xian  
Madeleine Yule  
Apurva Zawar  
J. Diana Zhang

Plus many anonymous donations from congress delegates.

Support the WPC Travel Grant Program
Change someone’s life!
# PROGRAM-AT-A-GLANCE

## Tuesday, July 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>9:00 AM Pre-Congress Courses</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:15 AM</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>11:30 AM</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>1:30 PM</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>3:00 PM</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>5:00 PM</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>6:30 PM</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>9:00 PM</td>
</tr>
</tbody>
</table>

**Opening Ceremony**
(6:00 — 7:15 PM)

**Welcome Reception**
(7:15 — 9:00 PM)

---

## Wednesday, July 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>9:00 AM</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>9:30 AM</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>11:30 AM</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>3:00 PM</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>5:00 PM</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>6:30 PM</td>
</tr>
<tr>
<td>6:30 PM</td>
<td>9:00 PM</td>
</tr>
</tbody>
</table>

**Hot Topics**

**WPC Award**

**Morning Plenary**

**Poster Session**

**James Parkinson Lecture**

**Lunch**

**Parallel Sessions & Workshops**

**Coffee Break**

**Parallel Sessions & Workshops**

**Poster Tours, Daily Wrap-Up & Raffle**

**Networking Events: RNs, PTs, OTs, SLPs, SWs, RD**
(6:30 — 8:00 PM)

**Renewal Room**
(7:45 AM — 5:30 PM)

**Care Partner Lounge**
(9:30 AM — 4:45 PM)
THURSDAY
JULY 6

8:00 AM - 9:00 AM
Hot Topics

9:00 AM - 9:15 AM
WPC Award

9:30 AM - 11:30 AM
Morning Plenary
Poster Session
Special Panel
Lunch

11:30 AM - 1:30 PM
Parallel Sessions & Workshops
Coffee Break

1:30 PM - 3:00 PM

3:30 PM - 5:00 PM
Parallel Sessions & Workshops

5:15 PM - 6:30 PM
Poster Tours, Daily Wrap-Up & Raffle

6:30 PM - 9:00 PM
Exhibition (11:00 AM - 6:45 PM)
Renewal Room (9:30 AM - 4:45 PM)
Care Partner Lounge (9:30 AM - 5:30 PM)

FRIDAY
JULY 7

9:00 AM - 9:15 AM
Hot Topics
WPC Award

9:30 AM - 11:30 AM
Morning Plenary
Special Presentations
Lunch

11:30 AM - 2:30 PM
Exhibition

1:30 PM - 3:00 PM
Parallel Sessions & Workshops

3:30 PM - 5:15 PM
Parallel Sessions & Workshops

5:15 PM - 6:30 PM
Daily Wrap-Up

6:30 PM - 9:00 PM
Closing Remarks & Raffle
(6:00 - 7:00 PM)

Simultaneous interpretation from English to Spanish
Ticketed event
SESSION DESCRIPTIONS

All sessions are open to all delegates. Some sessions require tickets at an additional fee.

**PRE-CONGRESS COURSES**
Tuesday
(Ticket required)

To take place on Tuesday, July 4, these day-long courses focusing on specific areas of Parkinson’s disease will allow unique access to some of the leaders in the community and will help introduce many topics to be covered in the main program giving participants a taste of what’s to come. They will require registration and a nominal fee to participate.

**HOT TOPICS**
Wednesday/Thursday/Friday
8:00 – 9:00 AM

Each morning, just before the opening plenary, four of the hottest topics from the poster abstracts will be selected for presentation to the broader audience. Oral presentations will be given on some of the most exciting, cutting-edge works happening today.

**PLENARY SESSIONS**
Wednesday/Thursday/Friday
9:30 – 11:30 AM

Designed to bring together all Congress attendees each morning, these will be held in a large auditorium each morning. Plenaries will offer very limited question and answer periods, but experts will be available in workshops or roundtables later each day to continue discussing the topics in more detail.

**PARALLEL SESSIONS**
Wednesday/Thursday/Friday
1:30 – 3:00 PM and 3:30 – 5:00 PM

Designed to offer in-depth sessions focused on specific research in the field of Parkinson’s. These sessions will appeal to those who want to understand the basic and clinical science underlying the research conducted to better understand the many facets of Parkinson’s disease. These will be set in larger lecture halls will offer question and answer periods.

**WORKSHOPS**
Wednesday/Thursday/Friday
1:30 – 3:00 PM and 3:30 – 5:00 PM

Designed for smaller groups of attendees of up to 150 people. Speakers will give an overview of the assigned topics then open to the audience to allow for more discourse and longer question and answer periods.

**ROUNDTABLES**
Wednesday/Thursday/Friday
1:30 – 3:00 PM and 3:30 – 5:00 PM

These popular and specially designed roundtable sessions will allow for delegates to sit down with an expert on a wide range of fields in a very small, intimate group, to get to the nitty-gritty with questions about the topics. Experts will give short talks and will then take questions. *(Limited seating. First come, first seated with 12 per table for 90-minute session.)*

**SPECIAL SESSIONS**
Wednesday/Thursday/Friday
12:15 – 1:15 PM

Special Lectures will be held during the WPC. Learn more about our special guests for these lectures by viewing the program in the following pages.

**DAILY WRAP-UP PANELS**
Wednesday/Thursday/Friday
5:15 – 6:30 PM

The wrap-up sessions are designed to bring together delegates at the end of each day to discuss the highlights of the day. Panelists will be leaders in the field who will have the tough task of preparing these talks each day. This is a great way to catch some key topics you may have missed.

**POSTER TOURS**
Wednesday/Thursday
5:15 – 6:30 PM

Tours to meet and greet young researchers and clinicians and hear about their work will be held on Wednesday and Thursday evenings from 5:15 – 6:30 PM. Be sure to stick around to meet these researchers and to thank them for their service to the Parkinson’s community. *(Limited place. Sign-up required.)*
8:00 – 9:30 AM | Past, current and future of infusion therapies for PD

Moderator: Raj Pahwa (USA)
Co-moderator: Michael Okun (USA)
Speakers: David Standaert (USA), Cecilia Peralta (Argentina), Victor Fung (Australia)

Learning objectives:
1. Explain how continuous enteral levodopa infusion has changed the treatment options for people with PD and how it is expected to change further in the future;
2. Summarize current understanding of apomorphine in treating Parkinson’s and how this may change in the future;
3. Outline two subcutaneous treatment options and how these are expected to evolve in the coming years.

9:45 – 11:15 AM | Neuroprotection: Are we closer to slowing disease progression?

Moderator: Malú Tansey (USA)
Co-moderator: A. Jon Stoessl (Canada)
Speakers: Miquel Vila (Spain), Eduardo Tolosa (Spain), Etienne Hirsch (France)

Learning objectives:
1. Explain how anti-synuclein therapies are getting us closer to slowing disease progression;
2. Summarize how LRRK2 inhibitors in slowing disease progression;
3. Outline the role of immunomodulatory approaches in slowing disease progression.

11:30 AM – 1:00 PM | Approaches to early diagnosis of Parkinson’s: How can we diagnose PD earlier?

Moderator: Victor Fung (Australia)
Speakers: John Hardy (UK), A. Jon Stoessl (Canada), Andrew Siderowf (USA)

Learning objectives:
1. Explain how geneticists can use pre-symptomatic genetic testing to diagnose or predict a PD diagnosis;
2. Summarize how imaging is being used in early diagnosis of PD;
3. Outline the current state research looking at abnormal synucleins to predict a PD diagnosis.

2:00 – 3:30 PM | Advances in Surgical therapies

Moderator: Roger Barker (UK)
Co-moderator: Binit Shah (USA)
Speakers: Vanessa Milanese (Brazil), Raul Martinez Fernandez (Spain), Agnete Kirkeby (Denmark)

Learning objectives:
1. Explain two advances that have been made in DBS over the last few years and how this impacts the patient;
2. Summarize the impact of focused ultrasound on Parkinson’s and barriers to bringing this option to everyone one;
3. Outline the current state of cell transplantation and what researchers are hopeful to see in the coming years with this technology.

3:30 – 4:00 PM | COFFEE BREAK

4:00 – 5:30 PM | Treatment of Non-Motor Symptoms

Moderator: Ryosuke Takahashi (Japan)
Co-moderator: Alison Anderson (UK)
Speakers: Daniel Weintraub (USA), Patricio Millar Vernetti (USA), Ira Leroi (Ireland)

Learning objectives:
1. Explain the cause of psychosis in PD and list one method of treatment when this symptom occurs;
2. Summarize how autonomic dysfunction impairs people with PD;
3. Detail the difference between depression and apathy and explain how the HCP can best address these symptoms.

5:30 PM | Closing Remarks
## COURSE II — INTERPROFESSIONAL CARE & PARKINSON’S

9:30 AM — 4:15 PM

**Target Audience:** Neurologists, physicians, nurses, rehab specialists, social workers, clinic coordinators, students.

**Goal:** To provide a forum for discussion of the evidence surrounding the impact of interdisciplinary care model and the realities of delivering care.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 AM</td>
<td>Welcome Remarks and Introduction to the program</td>
<td>Speaker: Suketu Khandhar (USA)</td>
</tr>
</tbody>
</table>
| 10:00 AM| Overcoming Cultural Barriers in Mexico to deliver Interdisciplinary Care | Speakers: Carlos Guerro (Mexico)                 
|        |                                                                         | Adriana Gonzalez-Aguinaga (Mexico)              |
| 10:45 AM| Q&A                                                                     |                                                 |
| 11:00 AM| Creating something out of nothing: A case from Cameroon                | Speakers: Esther Cubo (Spain)                    
|        |                                                                         | Jacques Doumbe (Cameroon)                        |
| 11:45 AM| Q&A                                                                     |                                                 |
| 12:00 PM| New kids on the block                                                  | Speaker: Suketu Khandhar (USA)                  |
| 12:30 PM| LUNCH                                                                   |                                                 |
| 1:30 PM| CASE STUDIES: YOPD vs Later life onset                                  | Moderator: Bastiaan Bloem (Netherlands)          |
| 1:30 PM| Case Presentation #1 – Medical Management: YOPD vs Later life onset    | Speakers: Nabila Dahodwala (USA)                
|        |                                                                         | Emily Henderson (UK)                             |
| 2:15 PM| Case Presentation #2 – Improving Quality of Life: Rehabilitation and Beyond | Speakers: Angela Roberts (Canada)                
|        |                                                                         | Natalie Allen (Australia)                        |
| 3:00 PM| COFFEE BREAK                                                            |                                                 |
| 3:30 PM| Case Presentation #3 – Communication/Cognition/ Psychiatric Management: YOPD vs Later life onset | Speakers: Kathy Dujardin (France)                
|        |                                                                         | Elaine Book (Canada)                             |
| 4:15 PM| Closing Remarks                                                         |                                                 |

**Learning objectives:**
1. Give three examples of approaches for maintaining quality of life across the continuum of ages of onset of PD;
2. Explain how self-efficacy and self-management can lead to self empowerment and explain how these play a role in the overall health of their patients;
3. Identify one way that they can empower their HCP colleagues on their team to make decisions in care of their patients that does not rotate solely around the physician on the team.
PRE-CONGRESS PROGRAM  Tuesday, July 4, 2023

NOTE: Course will be taught in English with simultaneous interpretation into Spanish

COURSE III — FUNDAMENTAL OF PARKINSON’S: THE JOURNEY

9:00 AM — 5:10 PM  |  Room 112

Target Audience: People with Parkinson’s, caregivers, people new to Parkinson’s care and new to the WPC.

Goal: Expose participants to key topics that will be elaborated on in the program. Give them a glimpse of what is to come and tools to get the most out of the meeting.

Learning objectives: 1. Gain a basic understanding of Parkinson’s, including the research into the cause(s) of the disease, symptoms, and current therapies; 2. Be able to explain how to change behaviors to better maximize the impact of a self-maintained wellness regimen; 3. To discuss the impact of aesthetic creativity on the brain; 4. Explain how to get the most out of the WPC experience.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker &amp; Emcee:</th>
<th>Moderator:</th>
<th>Panelists:</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>Welcome – Why are we here?</td>
<td>Linda Olson (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15 AM</td>
<td>What is Parkinson’s and what are the clinical features we see?</td>
<td>Nabila Dahodwala (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:40 AM</td>
<td>How Has Medical &amp; Surgical Treatment Evolved for PD?</td>
<td>Vanessa Milanese (Brazil)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05 AM</td>
<td>Q&amp;A</td>
<td>Linda Olson (USA)</td>
<td></td>
<td>Nabila Dahodwala (USA) Vanessa Milanese (Brazil)</td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Let’s Get Moving!</td>
<td>Pamela Quinn (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 PM</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>What’s New in Research?</td>
<td>Mark Cookson (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 AM</td>
<td>What new treatments are on the horizon?</td>
<td>Roger Barker (UK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Q&amp;A</td>
<td>Linda Olson (USA)</td>
<td></td>
<td>Roger Barker (UK) Mark Cookson (USA)</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>Let’s Get Moving!</td>
<td>Selma Pelaez Hervas (Spain)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 PM</td>
<td>Before we eat lunch: what about nutrition? Does it really matter?</td>
<td>Silke Appel-Cresswell (Canada)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>LUNCH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:45 PM</td>
<td>Staying resilient as a care partner</td>
<td>Connie Carpenter Phinney (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Behavior Change: How can I make the changes “stick” in my (____) routine?</td>
<td>Terry Ellis (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:50 PM</td>
<td>Tips &amp; Tricks for Living with Parkinson’s that Go Beyond Medication</td>
<td>Terry Ellis (USA)</td>
<td></td>
<td>Darla Freeman (USA) Iracema Leroi (Ireland) Adriana Gonzalez (USA)</td>
</tr>
<tr>
<td>3:50 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10 PM</td>
<td>Creativity and Art: How does it impact the brain and Parkinson</td>
<td>Anjan Chatterjee (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40 PM</td>
<td>Getting The Most Out of the WPC 2023: Two perspectives</td>
<td>Christine Jeychandran (Australia) Miriam Bram (USA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:10 PM</td>
<td>Closing Remarks</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OPENING CEREMONY > 6:00 - 7:15 PM

WELCOME RECEPTION > 7:15 - 9:00 PM
## COURSE IV — ADVOCACY AND ACTIVISM IN PD

**9:00 AM — 12:10 PM**

**Target Audience:** Parkinson and Care Advocates who are looking to elevate their level of engagement.

**Goal:** After attending, participants will: 1. Have a better understanding of the field of advocacy and activism in PD and other disease areas; 2. be better acquainted with other Parkinson advocates from all over the world; 3. develop a deeper understanding for the different advocacy roles that exist and determine what role they might want to play in Parkinson advocacy space; 4. have details of concrete models of advocacy in action and clearer understanding of what it would take to design and launch an initiative on their own.

### 9:00 – 9:05 AM
Welcome
Fulvio Capitanio (Spain)

### 9:05 – 9:30 AM
Patient advocacy and activism: How we got here and where we need to go
**Speaker:** Sara Riggare (Sweden)

### 9:30 – 10:15 AM
Breakout I (20 min presentation + 25 min Q&A) CHOOSE ONE room

<table>
<thead>
<tr>
<th>Room 113</th>
<th>Room 114</th>
<th>Room 115</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activism and Advocacy as the Self-care Expert, mentor, Communicator</td>
<td>Activism and Advocacy as the Academic, Patient researcher, Hacker, Activist, Tracker</td>
<td>Activism and Advocacy as the Healthcare Coordinator, the Healthcare Partner, the Innovator, the Entrepreneur</td>
</tr>
<tr>
<td><strong>Speakers:</strong> Sharon Krischer, mentor (USA) and Tim Hague, self-care expert (Canada)</td>
<td><strong>Speakers:</strong> Richelle Flanagan, academic (Ireland) and Larry Gifford, activist (Canada)</td>
<td><strong>Speakers:</strong> Maria De Leon, healthcare coordinator (USA) and Omotola Thomas, entrepreneur (UK)</td>
</tr>
</tbody>
</table>

### 10:15 – 10:30 AM
COFFEE BREAK

### 10:30 – 11:15 AM
Breakout II (20 min presentation + 25 min Q&A) CHOOSE ONE room

<table>
<thead>
<tr>
<th>Room 113</th>
<th>Room 114</th>
<th>Room 115</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activism and Advocacy as the Self-care Expert, mentor, Communicator</td>
<td>Activism and Advocacy as the Academic, Patient researcher, Hacker, Activist, Tracker</td>
<td>Activism and Advocacy as the Healthcare Coordinator, the Healthcare Partner, the Innovator, the Entrepreneur</td>
</tr>
<tr>
<td><strong>Speakers:</strong> Sharon Krischer, mentor (USA) and Tim Hague, self-care expert (Canada)</td>
<td><strong>Speakers:</strong> Richelle Flanagan, academic (Ireland) and Larry Gifford, activist (Canada)</td>
<td><strong>Speakers:</strong> Maria De Leon, healthcare coordinator (USA) and Omotola Thomas, entrepreneur (UK)</td>
</tr>
</tbody>
</table>

### 11:15 AM – 12:00 PM
Panel Discussion: How to be leaders, how to overcome challenges and barriers, how to advance the cause – Offering tips and lessons learned

**Moderator:** Sara Riggare (Sweden)
**Panelists:** Tim Hague (Canada), Sharon Krischer (USA), Richelle Flanagan (Ireland), Larry Gifford (Canada), Maria De Leon (USA), Omotola Thomas (UK)

### 12:00 – 12:10 PM
Closing Remarks — Wrap-up and next steps
**WPC Parkinson Advocate Committee Co-chairs:** Sara Riggare (Sweden) and Fulvio Capitanio (Spain)

### 12:10 – 1:00 PM
LUNCH

---

**OPENING CEREMONY > 6:00 – 7:15 PM**

**WELCOME RECEPTION > 7:15 – 9:00 PM**
# Pre- Congress Program

## Course V — Young Onset Parkinson’s Disease

**Target Audience:** People living with, or interested in learning about Young Onset Parkinson’s Disease.

**Goal:** To understand and explore topics that are directed towards living with YOPD, recognizing that the concerns and disease experience is different for those diagnosed early in life whether looking at the individual’s role in managing their PD, their relationships with others, and their medical care.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 1:15 PM</td>
<td>Welcome Remarks</td>
<td>Soania Mathur (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rune Vethe (Norway)</td>
</tr>
<tr>
<td>1:15 – 2:00 PM</td>
<td>Break out, presentation and Q&amp;A. Choose ONE room</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INDIVIDUAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exercise &amp; Wellness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Tim Hague (Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Miriam Rafferty (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>IN RELATION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parenting: How to Talk to Children</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Rebecca Gifford (Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Soania Mathur (Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MEDICAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Psychiatric and cognitive medication side effects in Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Becca Miller (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Dan Weintraub (USA)</td>
<td></td>
</tr>
<tr>
<td>2:00 – 2:15 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:15 – 3:00 PM</td>
<td>Break out, presentation and Q&amp;A. Choose ONE room</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INDIVIDUAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nutrition: Eat Well to Live Well with YOPD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Sabela Avion (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Richelle Flanagan (Ireland)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>IN RELATION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintaining Personal Relationships: Partner &amp; Social Circle</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Alison Anderson (UK)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Rune Vethe (Norway)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MEDICAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Challenges Specific to YOPD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Soania Mathur (Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: MJ Marti Domenech (Spain)</td>
<td></td>
</tr>
<tr>
<td>3:00 – 3:30 PM</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>3:30 – 4:15 PM</td>
<td>Break out, presentation and Q&amp;A. Choose ONE room</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>INDIVIDUAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coping with PD: Two perspectives</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Geoff Constable (Australia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speakers: Matt Eagles (UK) and Sree Sripathy (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>IN RELATION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Planning for the Future &amp; Disclosure of your diagnosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: A.C. Woolnough (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Sue Thomas (UK)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MEDICAL</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cognition &amp; Mental Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Becca Miller (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Greg Pontone (USA)</td>
<td></td>
</tr>
<tr>
<td>4:15 – 4:30 PM</td>
<td>Closing Remarks</td>
<td>Soania Mathur (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rune Vethe (Norway)</td>
</tr>
</tbody>
</table>

## Opening Ceremony

Opening Ceremony: 6:00 – 7:15 PM

## Welcome Reception

Welcome Reception: 7:15 – 9:00 PM
**PRE-CONGRESS PROGRAM**

**Tuesday, July 4, 2023**

**COURSE VI — WPC WORKING GROUPS**

**9:00 AM – 4:45 PM**

**Target Audience:** Community members, Industry members, and others who are interested in key issues impacting people with Parkinson’s and the Parkinson’s community.

**Goal:** Expose participants to key issues that WPC Working Groups have been learning about and working on since 2019.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Moderator(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 10:00 AM</td>
<td>Working Group: Young Onset Parkinson’s</td>
<td>Gaynor Edwards (UK)</td>
</tr>
<tr>
<td></td>
<td>Description: As Young Onset PD comes of age - we look at how it differs and potentially offers answers globally. The problem of misdiagnosis - and non-diagnosis and a hidden population. Divide and conquer - subgroups, rare types and genetics. Multi-disciplinary care - including the Netherlands model. The missing elements - moving from anecdotal to academic - epigenetics and beyond... just open your mind.</td>
<td></td>
</tr>
<tr>
<td>10:15 – 11:15 AM</td>
<td>Working Group: YOPD Women</td>
<td>Polly Dawkins (USA)</td>
</tr>
<tr>
<td></td>
<td>Description: Is it all in my head? Why do my Parkinson’s medications not work during one week of the month? Is it possible to get pregnant and breastfeed with Parkinson’s? Join us for a moderated panel discussion with YOPD women who have taken charge of their own diagnoses and want to teach, support, learn and share. Welcome to the supportive community of the YOPD sisterhood!</td>
<td></td>
</tr>
</tbody>
</table>
| 11:30 AM – 12:30 PM | Working Group: Anti-Stigma and Parkinson’s                            | Jean Blake (Canada)
                                      | Francesco de Renzis (Italy)          |
|               | Description: Stigma is a challenge people living with Parkinson’s face, to different degrees, all over the world, and among the top factors preventing people from seeking help from Parkinson’s organizations. We will present examples of communication/awareness initiatives on stigma developed by Parkinson’s organizations in different countries and propose a possible way forward for a world-wide campaign on the topic. |                                           |
| 12:30 PM      | LUNCH                                                                |                                           |
| 1:30 – 2:30 PM | Working Group: Building Global Alliances                              | Angela Halpern (USA)
                                      | Hellen Mwihiga (Kenya)                |
|               | Description: Are you interested in global relationships designed to enable more equitable access to information and resources for people with Parkinson’s and their families? If yes, please come to the presentation by the Building Global Alliance group. Learn about our pilot mentor/mentee program, other ongoing initiatives, and how you can participate. |                                           |
| 2:45 – 3:30 PM | Case Presentation – Kenya and India                                   | Maria Barretto (India)
                                      | Hellen Mwihiga (Kenya)                |
|               | Description: Reaching beyond boundaries – India to Kenya. Low- and middle-income countries (LMICs) across the world face similar challenges. We present findings from a pilot project to replicate a multidisciplinary model of care developed in India by PDMDS to the Kenyan context. In demonstrating the transferability and adaptability of the model, we look at lessons learned and explore further possibilities for collaboration. |                                           |
| 3:45 – 4:45 PM | Working Group: Technology and Parkinson’s                             | Fulvio Capitanio (Spain)
                                      | Malcolm Irving (Australia)            |
|               | Description: Providing a Parkinson’s Technology Community resource platform to centralize information on what is available, how it works and where you can find solutions to improve quality of life for people with PwP through technology. Available for ALL stakeholders in the Parkinson’s community: PwP, industry, physicians, allied health, PD organizations, and caregivers. |                                           |

**Note:** The Clinical Research Engagement Working Group will be meeting and discussing their work in the Clinical Research Village (CRV) from Tuesday at 7:30 PM through Friday at 2:30 PM in the exhibit hall. Visit the CRV booth for more info.
SCIENTIFIC PROGRAM

Wednesday, July 5, 2023

DAY 1

HOT TOPICS > 8:00 – 9:00 AM

Location: Main Plenary Hall
Moderator: David Standaert (USA)

Talk 1: Genetic findings of the Rostock International Parkinson’s Disease (ROPAD) Study
Speaker: Ana Westenberger (Germany)

Talk 2: A missing piece of the Parkinson’s puzzle:
The critical role of the dietitian in the care of people living with Parkinson’s disease (PD)
Speaker: Richelle Flanagan (Ireland)

Talk 3: Understanding the mechanisms of a-syn spreading and degradation: Role of tunneling nanotubes and lysosomes
Speaker: Chiara Zurzolo (France)

Talk 4: Characterizing the frequency of clinically reportable variants in major genes established in Parkinson’s disease (PD) in a large American cohort
Speaker: Roy Alcalay (Israel)

WPC AWARD CEREMONY > 9:00 – 9:15 AM

Location: Main Plenary Hall

Recipients for the WPC Robin A Elliott Award for Outstanding Community Service
Honoree: Lizzie Graham, award presented by Eli Pollard
Honoree: Vincent “Enzo” Simone, posthumous award presented by Fulvio Capitanio

MORNING PLENARY > 9:30 – 11:30 AM

WP1 – PLENARY
Location: Main Plenary Hall

Do biological subtypes of PD exist?

Moderator: Leonidas Stefanis (Greece)
Co-moderator: Kevin McFarthing (UK)

Talk 1: Can the genetics of sporadic PD and DLB help in disease subtyping?
What could be the therapeutic implications?
Speaker: Sonja Scholz (USA)

Talk 2: Brain-first or body-first Parkinson’s disease
Speaker: Per Borghammer (Denmark)

Talk 3: Different α-synuclein strains in Parkinson’s disease brains
Speaker: Markus Zweckstetter (Germany)

Talk 4: What do subtypes mean for people with Parkinson’s?
Speaker: Jonny Acheson (UK)

Learning Objectives:
1. Summarize the commonalities and differences between PD patients at the genetic, imaging and pathophysiological level;
2. Define how one size may not fit all in PD;
3. Explain how various aspects of PD-related research can be integrated;
4. List how subtypes can impact choices made by PwPs in their care plan.
## DAY 1

### LUNCH > 11:30 AM – 1:30 PM

<table>
<thead>
<tr>
<th>CARE PARTNER LOUNGE</th>
<th>CLINICAL RESEARCH VILLAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:30 – 1:30 PM</strong></td>
<td><strong>Location: Exhibit Hall – WPC Theater Stage</strong></td>
</tr>
</tbody>
</table>
| **Lecture:** Rewriting the care partner rule book  
**Speaker:** Connie Carpenter-Phinney (USA), Co-Founder, Davis Phinney Foundation | **11:45 AM – 12:15 PM**  
**Panel Discussion:** Patient Involvement and Engagement: The who, what, where, how and why |
| **Location:** 212 | **12:15 – 12:45 PM**  
**Panel Discussion:** Clinical Research Across the Parkinson’s Disease Continuum: Engaging and involving people with Parkinson’s at all disease stages |

### POSTER SESSION 1

<table>
<thead>
<tr>
<th><strong>11:30 AM – 1:30 PM</strong></th>
<th><strong>Location:</strong> Exhibit Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>View posters and meet authors.</strong></td>
<td><strong>Location:</strong> Exhibit Hall – Book Nook booth</td>
</tr>
</tbody>
</table>

### BOOK NOOK

<table>
<thead>
<tr>
<th><strong>11:30 AM – 1:30 PM</strong></th>
<th><strong>Location:</strong> Exhibit Hall</th>
</tr>
</thead>
</table>
| **Endng Parkinson’s Disease**  
**Meet the Authors:**  
Ray Dorsey (USA) and Michael Okun (USA) | **12:00 – 1:00 PM**  
**Gone: A Memoir of Love, Body, and Taking Back My Life**  
**Meet the Author:** Linda Olson (USA) |

### WSL – JAMES PARKINSON SPECIAL LECTURE

<table>
<thead>
<tr>
<th><strong>12:00 – 1:15 PM</strong></th>
<th><strong>Location:</strong> Main Plenary Hall</th>
</tr>
</thead>
</table>
| **Introduction:** Rosario Moratalla (Spain) | **Lecture 1:** Historical Perspective of the Function and dysfunction of the basal ganglia: Why it matters today  
**Speaker:** Jose Obeso (Spain) |
| | **Lecture 2:** Why we care about the Parkinson’s disease prodrome: From curious observations to therapeutic opportunities  
**Speaker:** Eduardo Tolosa (Spain) |

**Learning Objectives:** 1. Put in perspective “old ideas” versus new understanding of the changes in the brain; 2. Reflect upon the things we know and which ones are yet to be discovered, studied and researched; 3. Explain how early events in Parkinson’s disease research can improve understanding of the disease process.

### FILM ROOM

<table>
<thead>
<tr>
<th><strong>11:45 AM – 1:15 PM</strong></th>
<th><strong>Location:</strong> 127</th>
</tr>
</thead>
</table>
| **Film:** Me to Play – 71 min  
**Director Q&A:** Jim Bernfield (USA) | **12:00 – 12:40 PM**  
**Location:** Front Lobby – Art Walk Exhibit |
| **See page 28 for complete schedule.** | **Meet Jonny Acheson, artist, advocate, physician and more. Hear about his artistic process and how art impacts his PD, and how his PD impacts his art.** |
**WBP1 – SYNUCLEIN STRAIN AND SPREADING**  
*Location: Room 111*

Moderator: Veerle Baekelandt (Belgium)  
Co-moderator: Amanda Woerman (USA)

Talk 1: Pathogenic conformations of α-synuclein  
*Speaker: Hilal Lashuel (Switzerland)*

Talk 2: α-synuclein strain biology  
*Speaker: Anke Van der Perren (Belgium)*

Talk 3: The cellular environment in the α-syn aggregation  
*Speaker: Amanda Woerman (USA)*

*Learning Objectives:*  
1. Obtain new insights in the prion-like behavior of alpha-synuclein;  
2. Identify the similarities and differences between each alpha-synuclein strain;  
3. Define the structural source of biological differences between strains in vitro and in vivo;  
4. Explain the implications of strains on the heterogeneity of disease in synucleinopathy patients, and how different strains spread.

---

**WCP1 – ENVIRONMENTAL CONTRIBUTIONS TO PD**  
*Location: Room 113*

Moderator: Michael Okun (USA)  
Co-moderator: Per Odin (Sweden)

Talk 1: Contributions of pesticides to human PD  
*Speaker: Beate Ritz (USA)*

Talk 2: Chemical toxicant contribution to human PD  
*Speaker: Briana De Miranda (USA)*

Talk 3: Ending PD: Prevention in an industrialized world  
*Speaker: Ray Dorsey (USA)*

*Learning Objectives:*  
1. Outline the current understanding of role pesticides in PD;  
2. Update the current understanding of chemicals in PD;  
3. Discuss prevention of PD in the context of environmental exposure.

---

**WCCP1 – THE DIGITAL HORIZON FROM A PATIENT PERSPECTIVE: PROMISE AND PITFALLS**  
*Location: Room 114*

Moderator: Anat Mirelman (Israel)  
Co-moderator: Serene Paul (Australia)

Talk 1: Digital monitoring of mobility – why, when and how?  
*Speaker: Lynn Rochester (UK)*

Talk 2: Digital intervention  
*Speaker: Esther Cubo (Spain)*

Talk 3: Digital Evidence  
*Speaker: Jochen Klucken (Germany)*

*Learning Objectives:*  
1. Describe digital approaches to monitor mobility with a focus on what the future of mobility assessment could look like;  
2. Interventions, with a focus on telemedicine/e-health;  
3. Explain new patient centric evidence criteria for digital tools and medical devices.

---

**WSP1 – SESIÓN 1: COMIENZO Y PROGRESIÓN DEL PARKINSON**  
*Location: Room 115*

Moderadores: Esteban Muñoz (España) & Isabel Fariñas (España)

Presentación #1: Rol de la sinucleina y cuerpos de Lewy  
*Ponente: Miquel Vila (España)*

Presentación #2: Dónde y cuando empieza el Parkinson  
*Ponente: Francisco Grandas (España)*

*Objetivos generales de aprendizaje:*  
1. Qué son los cuerpos de Lewy y la sinucleina y porqué son importantes para el Parkinson;  
2. Identificar los síntomas prodrómicos y las áreas del sistema nervioso implicadas.
WORKSHOPS > 1:30 - 3:00 PM

**WWSB1 – NOVEL TECHNOLOGIES IN PARKINSON’S DISEASE**
*Location: Room 117*

**Moderator:** Serge Przedborski (USA)
**Co-moderator:** Etienne Hirsch (France)

**Talk 1:** Using iPSC to address non-neuronal cells in PD
*Speaker:* Mark Cookson (USA)

**Talk 2:** CRISPR genetic screenings to target converging mechanisms in neurodegeneration
*Speaker:* Aguzzi Adriano (Switzerland)

**Talk 3:** Using organoid culture systems to study Parkinson’s disease
*Speaker:* Hyunsoo Shawn Je (Singapore)

**Learning Objectives:**
1. Explain about novel stem cell-based models in the -OMIC era;
2. List two advantages and limitations of brain organoids for PD modeling;
3. Outline the current status and future development of regenerative medicine for PD based on in vivo cell reprogramming.

---

**WWSC1 – EMERGING THERAPIES FOR PARKINSON’S DISEASE**
*Location: Plenary Hall*

**Moderator:** Susan Fox (Canada)
**Co-moderator:** Markus Zweckstetter (Germany)

**Talk 1:** Drug repurposing for PD therapies
*Speaker:* Lorraine Kalia (Canada)

**Talk 2:** Development of PD drugs for genetic targets: α-synuclein, GBA, LRRK2 and beyond
*Speaker:* Jesse Cedarbaum (USA)

**Talk 3:** Emerging therapies targeting the immune system in PD
*Speaker:* Caroline Williams-Gray (UK)

**Learning Objectives:**
1. Explain the principles of Drug Repurposing;
2. Describe genetic targeting approaches to treat PD;
3. Name two neuroimmune or anti-inflammatory approaches to treat PD.

---

**WWSCC1 – SPARKING CREATIVITY: MAXIMIZING YOUR WELLBEING**
*Location: Room 116*

**Moderator:** Julia Wood (USA)
**Co-moderator:** Alison Anderson (UK)

**Talk 1:** Aesthetics, creativity, the brain, and Parkinson’s
*Speaker:* Anjan Chatterjee (USA)

**Panel:** How creativity impacts wellness
- **Art and wellness**
  *Panelist:* Jonny Acheson (UK)
- **Writing and wellness**
  *Panelist:* Rebecca Gifford (Canada)
- **Dancing and wellness**
  *Panelist:* Pamela Quinn (USA)
- **Music and wellness**
  *Panelist:* Tomás Gisby (UK)

**Learning Objectives:**
1. Explain the relevance of the connection between creativity and the brain for People with PD;
2. List three ways in which People with PD can engage in creative expression;
3. Describe a starting point to bring creative wellness into your community.

---

**WRT1**
*Location: Room 112*

**Table 1:** Aerobic exercise and PD
*Host:* Nienke de Vries (Netherlands)

**Table 2 (Español):** La ciencia detrás de las diferencias entre sexos
*Host:* Ariadna Laguna (España)

**Table 3:** Parkinson’s and writing to maintain wellness
*Host:* Kat Hill (USA)

**Table 4:** Subtyping in Parkinson’s: What are the therapeutic implications?
*Host:* Sonja Scholz (USA)

**Table 5:** Independent patient research – valuable contribution or uncontrolled data?
*Host:* Kevin McFarthing (UK)

**Table 6:** Understanding peripheral immune cells in the immune response in Parkinson’s
*Host:* Diana Mathеoud (Canada)

**Table 7:** Treatment for PD apathy and/or fatigue: Where should we be looking?
*Host:* Kathy Dujardin (France)

**Table 8:** Does non-invasive brain stimulation work for PD?
*Host:* Michael Simpson (Hong Kong)

**Table 9:** The role of microglia in PD pathology
*Host:* Žhenyu Yue (USA)

**Table 10:** Digital and/or wearable technology for monitoring of motor and non-motor function in PD
*Host:* Christopher Hess (USA)

**Table 11:** Reaching PD communities across Africa
*Host:* Omotola Thomas (UK)

**Table 12:** Occupational therapists can help people with PD live their best life
*Host:* Lisa Warren (USA)

**Table 13:** The role of the physical therapist in addressing non-motor symptoms
*Host:* Daniel Peterson (USA)

**Table 14:** Communicating well in person and virtually
*Host:* Walter Maetzler (Germany)

---

**COFFEE BREAK > 3:00 – 3:30 PM**
PARALLEL SESSIONS > 3:30 – 5:00 PM

WBS2 – EMERGING CONCEPTS AND PLAYERS OF IMMUNITY IN PARKINSON’S
Location: Room 111
Moderator: Ashley Harms (USA)
Co-moderator: Timothy Sampson (USA)
Talk 1: Bringing the immune system to Parkinson’s disease
Speaker: Malú Tansey (USA)
Talk 2: Peripheral immune cells in the immune response during Parkinson’s disease: T-cells
Speaker: Diana Matheoud (Canada)
Talk 3: Monocytes – The other peripheral immune cell in PD
Speaker: Caroline Williams-Gray (UK)

Learning Objectives:
1. Explain the role of the immune system as an early trigger of PD;
2. List common mechanisms between infectious/inflammatory diseases and PD;
3. Outline “neglected” immune cells in PD: T-cells, dendritic cells, and peripheral myeloid cells.

WCSP2 – APATHY AND FATIGUE: UNDERRECOGNIZED NON-MOTOR SYMPTOMS AND THEIR RELATION TO QUALITY OF LIFE IN PARKINSON’S
Location: Room 117
Moderator: Mayela Rodriguez-Violante (Mexico)
Co-moderator: Daniel Weintraub (USA)
Talk 1: Parkinson’s apathy: Why do we care?
Speaker: Dawn Bowers (USA)
Talk 2: Parkinson’s fatigue
Speaker: Graham Alec Glass (USA)
Talk 3: Treatment for PD apathy and fatigue: Where should we be looking?
Speaker: Kathy Dujardin (France)

Learning Objectives:
1. Identify and differentiate apathy and fatigue in persons with PD;
2. Appraise the association between apathy and fatigue and other PD non-motor symptoms;
3. Describe current and emerging treatment options for the management of apathy and fatigue.

WCCP2 – NOVEL INSIGHTS IN THE THERAPEUTIC BENEFITS OF EXERCISE-RELATED INTERVENTIONS
Location: Main Plenary Hall
Moderator: Nienke de Vries (Netherlands)
Co-moderator: Elisa Pelosin (Italy)
Talk 1: Exercise and physical therapy: Two sides of the same coin?
Speaker: Terry Ellis (USA)
Talk 2: Non-invasive brain stimulation and physiotherapy in PD
Speaker: Michael Simpson (Hong Kong)
Talk 3: Action observation and motor imagery: From neurophysiology to clinical practice
Speaker: Laura Avanzino (Italy)

Learning Objectives:
1. Explain the differences and overlap between the concepts exercise and physical activity based on the literature, and what this means for clinical practice;
2. Explain the underlying neurophysiological techniques and their potential use in the clinical practice;
3. Identify the gaps between research and clinical practice for non-pharmacological treatment targets.

SPANISH TRACK
3:30 – 5:00 PM

WSP2 – SESIÓN 2: DIAGNÓSTICO Y SEGUIMIENTO DEL PARKINSON: NUEVAS HERRAMIENTAS
Location: Room 115
Moderadores: Àngels Bayés (España) & Esther Cubo (España)
Presentación #1: Nuevas herramientas diagnósticas: Parkinson típico y atípico
Ponente: Yaroslau Compta (España)
Presentación #2: Monitorización del Parkinson: smartphones y otros dispositivos
Ponente: Cecilia Peralta (Argentina)

Objetivos generales de aprendizaje:
1. Nuevas herramientas de laboratorio y radiológicas para el diagnóstico y pronóstico en el Parkinson y los parkinsonismos atípicos; 2. Utilidad de nuevos dispositivos para el diagnóstico y monitorización de los síntomas motores y no motores.
Workshops > 3:30 – 5:00 PM

WWSB2 – THE MULTI-PLE FACETS OF MICROGLIA – FRIENDS OR FOES?
Location: Room 113
Moderator: Marina Romero-Ramos (Denmark)
Co-moderator: Joseph Mazzulli (USA)
Talk 1: Mitochondria at the interface between neurodegeneration and inflammation
Speaker: Anne Grünewald (Luxembourg)
Talk 2: The emerging role of mitochondrial dynamics in neuroinflammation
Speaker: Kim Tieu (USA)
Talk 3: Protective role of microglia in pathology
Speaker: Zhenyu Yue (USA)

Learning Objectives: 1. Explain the molecular signature of microglia and monocytes in PD; 2. Explain detrimental and protective microglia stated in PD; 3. Define single cell -omics for understanding of myeloid function and dysfunction in PD.

WWSC2 – CUTTING-EDGE TECHNOLOGY DRIVING AN ERA OF DIGITAL HEALTH FOR PD
Location: Room 114
Moderator: Genko Oyama (Japan)
Co-moderator: Alberto Espay (USA)
Talk 1: Digital and/or wearable technology for monitoring of motor and non-motor function in PD
Speaker: Christopher Hess (USA)
Talk 2: Should we be moving toward remote approaches to clinical trials?
Speaker: Ray Dorsey (USA)
Talk 3: Artificial intelligence meets Parkinson’s disease: How can AI help?
Speaker: Dina Katabi (USA)

Learning Objectives: 1. Explain the meaning of palliative care and the importance of implementing it early in the disease process; 2. Explain how people with PD and care partner can rewrite their future through integration of decision making with the healthcare team; 3. Outline the role of the palliative care physician and the team members necessary to facilitate the optimal quality of life for those living with PD.

WWWCC2 – REWRITING YOUR FUTURE – TAKING YOU ON A JOURNEY ALONG THE CONTINUUM OF CARE, FROM DIAGNOSIS TO END OF LIFE AND BEYOND
Location: Room 116
Moderator: Suketu Khandhar (USA)
Co-moderator: Lisa Warren (USA)
Talk 1: Palliative care begins at diagnosis
Speaker: Benzi Kluger (USA)
Talk 2: The palliative care team
Speaker: Ed Richfield (UK)
Talk 3: Rewriting your future – Together with your loved one(s)
Speakers: Larry Gifford & Rebecca Gifford (Canada)

Learning Objectives: 1. Explain the current technology of wearable and non-wearable devices for monitoring motor and non-motor aspects of PD; 2. Discuss the advantages and limitations of digital health technologies for assessing PD; 3. Give insight into the potential of artificial intelligence when used to analyze these data.

WRT2 –
Location: Room 112
Table 1: e-Health and PT
Host: Serene Paul (Australia)
Table 2: Engaging women in clinical research
Hosts: Richelle Flanagan (Ireland) & Indu Subramanian (USA)
Table 3: The many faces of PD – Prodromal and clinical subtypes
Host: Per Borghammer (Denmark)
Table 4: Enabling people with PD to exercise
Host: Natalie Allen (Australia)
Table 5: Which imaging biomarkers are useful to track disease progression in PD?
Host: Thilo van Eimeren (Germany)
Table 6: How PwPs can participate as consumer advisors in PD research programs
Host: Richard Gordon (Australia)
Table 7: The role of LRRK2 in gut inflammation/inflammatory bowel disease and PD
Host: Veerle Baekelandt (Belgium)
Table 8: Pesticides and Parkinson’s
Host: Beate Ritz (USA)
Table 9: Drug-repurposing: What are we really learning?
Host: Lorraine Kalia (Canada)
Table 10: Digital monitoring: Challenges we face and how to make it work for PD
Host: Lynn Rochester (UK)
Table 11: Clinical Trials: What is the evidence for the benefit of exercise in PD?
Host: Erwin van Wegen (Netherlands)
Table 12: Creativity, the brain, and Parkinson’s
Host: Anjan Chatterjee (USA)
Table 13: Constipation in Parkinson’s and how to address it
Host: Louise Ebenezer (UK)
Table 14: Better communication: Let us get started
Host: Angela Roberts (Canada)
### WPT - Poster Tour

**5:15 - 6:30 PM**

**Poster Tour 1:** Etiology, genetic and epidemiology  
*Host: Mike Nalls (USA)*

**Poster Tour 2:** Electrophysiology, brain physiology, dopamine receptors  
*Host: Nathalie Van Den Berge (Denmark)*

**Poster Tour 3:** Neuroprotection, cell death and protein misfolding  
*Host: Mark Cookson (USA)*

**Poster Tour 4:** Mitochondria, oxidative stress, inflammation, pathogenesis  
*Host: Kim Tieu (USA)*

**Poster Tour 5:** Self-management, empowerment and interprofessional teams  
*Host: Anjan Chatterjee (USA)*

**Poster Tour 6:** Rehabilitation sciences  
*Host: Indu Subramanian (USA)*

**Poster Tour 7:** Surgical therapy and Neuroimaging  
*Host: Daniel Martinez (Mexico)*

**Poster Tour 8:** Clinical trials: Design, outcomes  
*Host: Richard Gordon (Australia)*

**Poster Tour 9:** E-health, Progression, Cognition, and Sleep disorders  
*Host: Dawn Bowers (USA)*

**Poster Tour 10:** Advancing Research via collaboration and capacity building  
*Host: Dayne Beccano-Kelly (UK)*

**Location:** Exhibit Hall  
*See pages 120 to 125 for the list of posters included in each tour. Sign-up required.*

### WEoD - Daily Wrap-up Panels

**5:15 - 6:30 PM**

**Location:** Main Plenary Hall

**Moderator:** Connie Marras (Canada)  
**Co-moderator:** Omotola Thomas (UK)

**Panelists:** Alice Nieuwboer (Belgium)  
Claudia Trenkwalder (Germany)  
Veerle Baeklandt (Belgium)  
Etienne Hirsch (France)

### Book Nook

**5:15 - 6:30 PM**

**Location:** Exhibit Hall Stage

**Moderator:** Joy Milne (UK)  
**Topic:** Creativity and PD

**Panelists:** Torrance York (USA)  
Dianne Bramble (Canada)  
**Genes: The Continuing Adventures of the Accidental Superhero**
Claudine Naganuma (USA)  
**Peace About Life: Dancing with Parkinson’s**
Chantal Wolf (Canada)  
**Painted words, poetry art and Parkinson’s**

### Networking Reception

**> 6:30 PM - 8:30 PM**

**Location:** TBC  
*Made possible with support from American Parkinson Disease Association and Supernus Pharmaceuticals*

Networking Reception for non-MD clinicians (RN, PT, OT, SLP, SW, RD)
DAY 2
### HOT TOPICS > 8:00 – 9:00 AM

**Location:** Main Plenary Hall  
**Moderator:** Marina Romero-Ramos (Denmark)

| Talk 1: | Genome-wide association identifies novel etiological insights associated with Parkinson’s disease in African and African admixed populations  
*Speaker:* Oluwadamilola Ojo (Nigeria) |
|---|---|
| Talk 2: | Approach to the management of sexual and intimacy problems in people with motor and non-motor manifestations of Parkinson’s disease  
*Speaker:* Gila Bronner (Israel) |
| Talk 3: | Exploring the role of the lysosomal lipid flippase ATP10B in the nigrostriatal dopaminergic pathway of rats  
*Speaker:* Maria Sanchiz Calvo (Belgium) |
| Talk 4: | Assessing the biomarker potential of LRRK2 and GCase in Parkinson’s disease monocytes  
*Speaker:* Laura Hughes (Australia) |

### WPC AWARD CEREMONY > 9:00 – 9:15 AM

**Location:** Main Plenary Hall

**Recipients for the WPC Distinguished Collaborative Research Award**  
**Honoree:** Ignacio “Nacho” Mata, *award presented by Malú Gámez Tansey*  
**Honoree:** Marina Noordegraaf, *posthumous award presented by Bastiaan Bloem*

### MORNING PLENARY > 9:30 – 11:30 AM

**Location:** Main Plenary Hall

**Moderator:** Marina Romero-Ramos (Denmark)

| Talk 1: | Genome-wide association identifies novel etiological insights associated with Parkinson’s disease in African and African admixed populations  
*Speaker:* Oluwadamilola Ojo (Nigeria) |
|---|---|
| Talk 2: | Approach to the management of sexual and intimacy problems in people with motor and non-motor manifestations of Parkinson’s disease  
*Speaker:* Gila Bronner (Israel) |
| Talk 3: | Exploring the role of the lysosomal lipid flippase ATP10B in the nigrostriatal dopaminergic pathway of rats  
*Speaker:* Maria Sanchiz Calvo (Belgium) |
| Talk 4: | Assessing the biomarker potential of LRRK2 and GCase in Parkinson’s disease monocytes  
*Speaker:* Laura Hughes (Australia) |

### Learning Objectives:
1. Explain what is meant by ‘progression’ of Parkinson’s and give two reasons why we should track progression;  
2. Describe how imaging can be a tool in tracking progression and what have been learned about biomarkers based on imaging;  
3. Identify blood and tissue biomarkers such as alpha-synuclein and immune markers, and explain how these play a role in tracking disease progression;  
4. Explain how people with Parkinson’s can track their own disease and collect meaningful data to help in their own wellness plan.
### LUNCH > 11:30 AM – 1:30 PM

**Clinical Research Village**

**Location:** Exhibit Hall – WPC Theater Stage

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM</td>
<td><strong>Panel Discussion:</strong> Involving Women in Parkinson’s Research</td>
</tr>
<tr>
<td>12:15 PM</td>
<td><strong>Panel Discussion:</strong> Creating Opportunities for Research Engagement and Involvement for All: Experiences and strategies focused on people with Parkinson’s and care partners</td>
</tr>
</tbody>
</table>

### Poster Session 2

**Location:** Exhibit Hall

View posters and meet authors.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 11:30 AM – 1:30 PM | **Unraveling Parkinson’s Disease**  
Meet the Author: Janette Melo Franco (Brazil) |
|            | **Starve the Disease**  
Meet the Author: Vanessa Leschak (USA) |

### Book Nook

**Location:** Exhibit Hall – Book Nook booth

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 11:45 AM – 12:15 PM | **Unraveling Parkinson’s Disease**  
Meet the Author: Janette Melo Franco (Brazil) |
| 12:30 – 1:00 PM | **Starve the Disease**  
Meet the Author: Vanessa Leschak (USA) |

### TSL – Special Special Panel

Made possible with support from American Parkinson Disease Association

**Location:** Main Plenary Hall

- Living well with Parkinson’s
- **Moderator:** Linda Olson (USA)

- **Panelists:**
  - Shantipriya Siva (India)
  - Geoffrey Constable (Australia)
  - Sabela Avion (Spain)
  - Chinyere Rachel Agwu (Nigeria)
  - Richelle Flanagan (Ireland)

### Care Partner Lounge

**Location:** 212

- **Discussion Group:** What’s on your mind? Open question period – nothing is off the table!
- **Host:** Allison Allen (USA)

### Film Room

**Location:** 127

- **Director:** Sue Wylie (UK)
- **Films:**
  - **Kinetics** – 47 min
  - **What a Load of Balls** – 12 min

See page 28 for complete schedule.

---

**Session Levels**
- Crosstalk – Minimal or no scientific background required
- Moderate-level scientific sessions
- High-level scientific sessions

**Session Type**
- Basic Science
- Clinical Science
- Comprehensive Care

**Language**
- Simultaneous interpretation from English to Spanish (Interpretación simultánea de inglés a español)
- Spanish track (Pista española)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 3:00 PM</td>
<td>TBP1 – Glucocere-brosidase, disruptions in lipid metabolism, and Parkinson’s disease</td>
<td>TCP1 – Protein misfolding: next generation tests for diagnosing PD</td>
<td>TCCP1 – Proactivity across the Parkinson’s disease continuum</td>
</tr>
<tr>
<td>Location</td>
<td>Room 113</td>
<td>Room 114</td>
<td>Room 116</td>
</tr>
<tr>
<td>Moderator</td>
<td>Celine Galvagnion (Denmark)</td>
<td>David Standaert (USA)</td>
<td>Alison Yarnall (UK) &amp; Ariadna Laguna (España)</td>
</tr>
<tr>
<td>Co-moderator</td>
<td>Ayse Ulusoy (Germany)</td>
<td>Vivek Unni (USA)</td>
<td>Ernesto Arenas (Suecia) &amp; Ariadna Laguna (España)</td>
</tr>
<tr>
<td>Talk 1</td>
<td>Changes in lipid profiles in patients with Parkinson’s disease</td>
<td>Detection and classification of synuclein strains by a seed amplification assay (SAA)</td>
<td>Building resilience and capacity to live well with Parkinson’s disease</td>
</tr>
<tr>
<td>Speaker</td>
<td>Nicolas Dzamko (Australia)</td>
<td>Claudio Soto (USA)</td>
<td>Shantipriya Siva (India)</td>
</tr>
<tr>
<td>Talk 2</td>
<td>Mechanisms of glycolipid-induced α-synuclein aggregation</td>
<td>Assaying misfolded synuclein in fluid and tissue biopsies for the diagnosis of PD</td>
<td>Pre-habilitation: Preventing complications</td>
</tr>
<tr>
<td>Speaker</td>
<td>Joseph Mazzulli (USA)</td>
<td>Brit Mollenhauer (Germany)</td>
<td>Ryan Duncan (USA)</td>
</tr>
<tr>
<td>Talk 3</td>
<td>Molecular mechanisms linking GCase to α-synuclein and the rapeutic strategies targeting the GBA1 pathway</td>
<td>Are we ready for detecting α-synuclein prone to aggregation in patients?</td>
<td>Optimizing care provided in hospital for people with Parkinson’s disease</td>
</tr>
<tr>
<td>Speaker</td>
<td>Pablo Sardi (USA)</td>
<td>Jon B. Toledo (USA)</td>
<td>Richard Genever (UK)</td>
</tr>
</tbody>
</table>

**Learning Objectives:**
1. Describe changes in lipid metabolism associated with PD pathology and potential molecular mechanism behind this relationship; 2. Provide an understanding of the molecular mechanisms linking GBA1 mutations, lipid accumulation, αS and PD pathology; 3. List strategies to prevent/revert the phenotype associated with GBA1 mutations.

**Learning Objectives:**
1. Be able to explain the current status of seed amplification assays to detect with high sensitivity and specificity misfolded alpha-synuclein aggregates in biological fluids; 2. Describe the evidence supporting the use of PMCA and other similar methods in the diagnosis of Parkinson disease and other synucleinopathies; 3. Discuss the potential use of PMCA and related methods in the clinical practice of movement disorders.

**Learning Objectives:**
1. Attendees will be able to describe behaviors that can enhance resilience in patients; 2. Attendees will be able to define pre-rehabilitation (proactivity as opposed reactivity) and give examples of prevention of complications; 3. Attendees will be able to understand the specific difficulties that patients experience when admitted to a hospital setting and the care strategies needed to avoid hospitalization.

---

**Session Levels:**
- Crosstalk – Minimal or no scientific background required
- Moderate-level scientific sessions
- High-level scientific sessions

**Session Type:**
- Basic Science
- Clinical Science
- Comprehensive Care

**Language:**
- Simultaneous interpretation from English to Spanish
- Interpretación simultánea de inglés a español
- Spanish track

---

**Presentation #1:**
**Edad y género en el Parkinson**
**Ponente:** Mayela Rodriguez-Violante (México)

**Presentation #2:**
**Influencia de la genética en el desarrollo del Parkinson**
**Ponente:** Coro Paisan-Ruiz (Estados Unidos)

**Objetivos generales de aprendizaje:**
Influencia de la edad, el sexo y la genética en el desarrollo y progresión del Parkinson.
Parkinson’s disease decrease anxiety in peptidergic system to vaso-intestinal disturbances.

**Talk 1:** Preclinical vs prodromal PD – How can we define them?
**Speaker:** Lana Chahine (USA)

**Talk 2:** Screening for PD risk – Are we ready for population-based approaches?
**Speaker:** Alastair Noyce (UK)

**Talk 3:** Disease-modification trials in prodromal PD – Hopes and barriers
**Speaker:** Michele Hu (UK)

**Learning Objectives:**
1. Explain how chewing and swallowing of food and liquids changes through the course of PD and which treatment, medical and behavioural options are available; 2. Describe why, how and when People with Parkinson’s Disease can take care of healthy nutrition; 3. Describe bowel problems in PD and new insights of adequate management.

---

**Talk 1:** The multiple physiology and pathophysiology of PD
**Moderator:** Eduardo Tolosa (Spain)
**Co-moderator:** Catherine Price (USA)

**Talk 2:** Role of the pedunculopontine nucleus in the pathophysiology of PD
**Speaker:** Juan Mené-Segovia (Spain)

**Talk 3:** Targeting the vaso-intestinal peptidergic system to decrease anxiety in Parkinson’s disease
**Speaker:** François George (France)

**Learning Objectives:**
1. Appraise that the locus coeruleus is a site of neurodegeneration in PD and that the ensuing deficits nonadrenergic neurotransmission contribute to both disease progression and development of several types of symptoms; 2. Describe the amygdala and its anatomically interconnected brain regions, their neurodegenerative changes in PD, and their involvement in neuropsychiatric and emotional dysfunctions such as, apathy, anxiety, and psychotic symptoms; 3. Describe the functions and anatomical connections of the pedunculopontine nucleus, as well as its involvement at different stages of PD (including its possible role in both motor and non-motor disturbances).
<table>
<thead>
<tr>
<th>PARALLEL SESSIONS &gt; 3:30 – 5:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TBP2 – DO KNOWN CAUSES OF PD CONVERGE TO A SHARED MECHANISM?</strong></td>
</tr>
<tr>
<td><strong>Location:</strong> Room 114</td>
</tr>
<tr>
<td>Moderator: Darren Moore (USA)</td>
</tr>
<tr>
<td>Co-moderator: Anne Grünewald (Luxembourg)</td>
</tr>
<tr>
<td>Talk 1: VPS35 and LRRK2 Speaker: Dario Alessi (UK)</td>
</tr>
<tr>
<td>Talk 2: LRRK2 and SNCA Speaker: Laura Volpicelli-Daley (USA)</td>
</tr>
<tr>
<td>Talk 3: GBA1 and LRRK2 Speaker: Matt LaVoie (USA)</td>
</tr>
<tr>
<td>Learning Objectives: 1. Describe the state-of-the-art research investigating molecular mechanisms downstream of etiologic insult; 2. Understand the broad evidence highlighting a particular network/pathway as disease related; 3. Make a case for and against convergence into a single or multiple pathogenic pathways.</td>
</tr>
</tbody>
</table>

| **TCP2 – THE ROLE OF GENETICS AND GENETIC TESTING IN PD**  |
| **Location:** Room 116            |
| Moderator: Andrew Singleton (USA) |
| Co-moderator: A.C. Woolnough (USA) |
| Talk 1: The role of genetics in the pathophysiology of PD Speaker: John Hardy (UK) |
| Talk 2: Genetic testing in PD – What is currently possible? What is useful? Where are the challenges, and what is the future? Speaker: Christine Klein (Germany) |
| Talk 3: How does genetic information impact clinical trial designs? Speaker: Roy Alcalay (Israel) |
| Learning Objectives: 1. Explain the genetic underpinnings of PD and to enhance the understanding of the role of genetics in the pathophysiology of PD, missing heritability, and new methods to disentangle more complex mechanisms; 2. Inform about genetic testing in PD, including current technological challenges; 3. Explain how clinical trials stratify by genetic subtype of PD and to discuss the strengths and limitations of these trials. |

| **TCCP2 – ADDRESSING NON-MOTOR SYMPTOMS: DEBILITATING AND OVERLOOKED**  |
| **Location:** Room 117            |
| Moderator: Daniel Peterson (USA)  |
| Co-moderator: Sue Thomas (UK)     |
| Talk 1: Autonomic Symptoms: Dizziness, urinary urgency, erectile dysfunction, and constipation Speaker: Patricio Millar Vernetti (USA) |
| Talk 2: Emotional and Motivational disorders: Depression, apathy, and anxiety Speaker: Ircema Leroi (Ireland) |
| Talk 3: Fatigue and sleep Speaker: Graham Alec Glass (USA) |
| Learning Objectives: 1. Explain what dysautonomia is and its impact on Parkinson’s; 2. Describe the impact depression and apathy have on an person with PD and preferred treatments for these symptoms; 3. Detail the impact of fatigue on sleep in Parkinson’s and offer two solutions to address this symptom. |

| **TSP2 – SESIÓN 4: SÍNTOMAS NO MOTORES**  |
| **Location:** Room 115            |
| Moderadores: Daniel Martinez-Ramírez (México) & Ana Cámara (España) |
| Presentación #1: Apatía y alteraciones cognitivas Ponente: Jaime Kulisevsky (España) |
| Presentación #2: Disautonomía: estreñimiento y disfunción sexual Ponente: Dolores Vilas Rolán (España) |
| Objetivos generales de aprendizaje: 1. Frecuencia e impacto de la apatía y los trastornos cognitivos e en las distintas etapas del Parkinson; 2. Identificación y manejo de trastornos gastrointestinales y disfunción sexual. |

**Session Levels**
- Crosstalk – Minimal or no scientific background required
- Moderate-level scientific sessions
- High-level scientific sessions

**Session Type**
- Basic Science
- Clinical Science
- Comprehensive Care

**Language**
- Simultaneous interpretation from English to Spanish
- Interpretación simultánea de inglés a español
- Spanish track / Pista española
SCIENTIFIC PROGRAM  
Thursday, July 6, 2023

**WORKSHOPS > 3:30 – 5:00 PM**

**TBSWS2 – LEARNING FROM THE COMPLEX NATURE OF LEWY BODIES**  
Location: Room 113

**Moderator:** Isabel Fariñas (Spain)

**Debate Side 1** – Lewy bodies: It’s not just about α-synuclein

**Moderator:** Roger Barker (UK)
**Co-moderator:** Jeffrey Kordower (USA)

- **Talk 1:** What are the most promising cell transplantation approaches for PD?  
  **Speaker:** Jun Takahashi (Japan)

- **Talk 2:** What are the gene therapy and growth factor approaches for PD?  
  **Speaker:** Krzysztof Bankiewicz (USA)

- **Talk 3:** Reprogramming of cells for neurorestoration  
  **Speaker:** Malin Parmar (Sweden)

**Learning Objectives:** 1. Clarify whether LB are protective or harmful; 2. Describe how interactions between alpha-synuclein and fragmented organelles affect aggregation and toxicity; 3. List consequences of LB-associated disrupted lysosomes in neuronal fate.

**TCCWS2 – WHICH EXERCISE IS THE BEST TIME INVESTMENT?**  
Location: Main Plenary Hall

**Moderator:** Terry Ellis (USA)
**Co-moderator:** Alice Nieuwboer (Belgium)

- **Talk 1:** Exercise for life  
  **Speaker:** Miriam Rafferty (USA)

- **Talk 2:** Enabling people with PD to exercise  
  **Speaker:** Natalie Allen (Australia)

- **Talk 3:** Exercise delivery in an online world  
  **Speaker:** Josefa Domingos (Portugal)

**Learning Objectives:** 1. Give insight into considerations for prescribing exercise to maintain motivation and adherence; 2. Discuss how the range of health professional and community exercise providers can provide/support for safe and appropriate physical activities for People with Parkinson’s along the continuum; 3. Identify safety considerations needed to deliver online exercise activity for People with Parkinson’s.

**TCWS2 – CELL AND GENE THERAPIES FOR PARKINSON’S DISEASE**  
Location: Room 111

**Moderator:** Roger Barker (UK)
**Co-moderator:** Jeffrey Kordower (USA)

- **Talk 1:** What are the most promising cell transplantation approaches for PD?  
  **Speaker:** Jun Takahashi (Japan)

- **Talk 2:** What are the gene therapy and growth factor approaches for PD?  
  **Speaker:** Krzysztof Bankiewicz (USA)

- **Talk 3:** Reprogramming of cells for neurorestoration  
  **Speaker:** Malin Parmar (Sweden)

**Learning Objectives:** 1. Explain the current research on cell transplantation as a treatment for Parkinson’s disease; 2. Discuss the different gene therapy and growth factor approaches that have been tested in PD, and what strategies seem most promising in the future; 3. Discuss the potential for reprogramming cells existing brain cell to achieve neurorestoration in PD and the challenges of this approach.

**TRT2**  
Location: Room 112

- **Table 1:** PD-related psychosis  
  **Host:** Ross Dunne (UK)

- **Table 2:** Women and Parkinson’s  
  **Hosts:** Soania Mathur (Canada) and Indu Subramanian (USA)

- **Table 3:** Swallowing and Parkinson’s  
  **Host:** Yael Manor (Israel)

- **Table 4:** Mobility challenges in PD: Causes and connections  
  **Host:** Kaylena Ehgoetz Martens (Canada)

- **Table 5 (Español):** Mitos y barreras en torno a la participación en la investigación  
  **Host:** Coro Paisan-Ruiz (Estados Unidos)

- **Table 6:** Familial PD: Tips for treating a family vs a single patient  
  **Host:** Leonidas Stefanis (Greece)

- **Table 7:** Parkinson’s Apathy: Why do we care?  
  **Host:** Dawn Bowers (USA)

- **Table 8:** Action observation and motor imagery: From neurophysiology to clinical practice  
  **Host:** Laura Avanzino (Italy)

- **Table 9:** Every person with PD needs a palliative care team  
  **Host:** Ed Richfield (UK)

- **Table 10:** Biological brain changes observed following exercise in Parkinson’s: What do they tell us?  
  **Host:** Mark Hirsch (USA)

- **Table 11:** Assaying misfolded synuclein in tissue biopsies for the diagnosis of PD  
  **Host:** Brit Mollenhauer (Germany)

- **Table 12:** Pre-habilitation: Preventing complications  
  **Host:** Ryan Duncan (USA)

- **Table 13:** Optimizing care provided in hospital for people with Parkinson’s  
  **Host:** Richard Genever (UK)

- **Table 14:** What are the major advances in basic research in PD?  
  **Host:** Tiago Outeiro (Germany)
5:15 – 6:30 PM
Location: Exhibit Hall
See pages 120 to 125 for the list of posters included in each tour. Sign-up required.

**Poster Tour 11:** Pathology  
Host: Michela Deleidi (France)

**Poster Tour 12:** Animal and Cellular models #1  
Host: Yvette Wong (USA)

**Poster Tour 13:** Animal and Cellular models #2  
Host: Cristina Miguelez (Spain)

**Poster Tour 14:** Exercise, Nutrition and Quality of Life  
Host: Alfonso Fasano (Canada)

**Poster Tour 15:** Palliative Care and Advanced Planning  
Host: Dan Weintraub (USA)

**Poster Tour 16:** Health Accessibility, Intimacy, and Non-motor manifestations  
Host: Julia Wood (USA)

**Poster Tour 17:** Biomarkers, neuroimaging and pharmacological therapy  
Host: Jon B Toledo (USA)

**Poster Tour 18:** Public Education & Campaigns  
Host: Laura Volpicelli-Daley (USA)

**Poster Tour 19:** Living well with Parkinson’s  
Host: Hanneke Kalt (Netherlands)

**Poster Tour 20:** Public education & awareness  
Host: Marie Fuzzati (France)

5:15 – 6:30 PM
Location: Main Plenary Hall
Moderator: Vanessa Milanese (Brazil)  
Co-moderator: Miquel Vila (Spain)

Panelists:  
Serge Przedborski (USA)  
Susan Fox (Canada)  
Angela Cenci (Sweden)  
Marina Romero-Ramos (Denmark)

**TEoD – DAILY WRAP-UP PANELS**

5:15 – 6:30 PM
Location: Exhibit Hall Stage
Moderator: Linda Olson (USA)  
Topic: Self-efficacy and Empowerment

Panelists:  
Kat Hill and Nancy Peate (USA)  
**Being Well with Chronic Illness**  
Ingrid Sturkenboom (Netherlands)  
**Detours through the Parkinson’s Brain**  
Larry Linton (Canada) – **Shaken Not Stirred**  
Hiral Shah (USA) – **PD Movers: We Keep Moving**

---

**Session Levels**
- Minimal or no scientific background required
- Moderate-level scientific sessions
- High-level scientific sessions

**Session Type**
- Basic Science
- Clinical Science
- Comprehensive Care

**Language**
- Simultaneous interpretation from English to Spanish
- Pista española
HOT TOPICS > 8:00 – 9:00 AM

Location: Main Plenary Hall
Moderator: Emily Henderson (UK)

Talk 1: Uncovering the interaction between gut microbial factors and GBA1 mutations in the pathogenesis of Parkinson’s disease
Speaker: Christin Weissleder (Germany)

Talk 2: Comprehensive survey data set of women with Parkinson’s by women with Parkinson’s
Speaker: Soania Mathur (Canada)

Talk 3: Modelling human brain-wide pigmentation induces Parkinson-like pathology and transcriptomic alterations in vivo
Speaker: Nuria Peñuelas (Spain)

Talk 4: NLX-112 has favorable safety, tolerability and efficacy against levodopa-induced dyskinesia (LID) in a randomized, double-blind, placebo-controlled, proof-of-concept Ph2A study
Speaker: Adrian Newman-Tancredi (France)

WPC AWARD CEREMONY > 9:00 – 9:15 AM

Recipients for the WPC Robin A Elliott Award for Outstanding Community Service
Honoree: Kabugo Hannington, award presented by Omotola Thomas
Honoree: Richelle Flanagan, award presented by Malú Gámez Tansey

MORNING PLENARY > 9:30 – 11:30 AM

FP3 – PLENARY
Location: Main Plenary Hall

Co-pathologies in Parkinson’s disease
Moderator: Amanda Woerman (USA)
Co-moderator: Nicolas Dzamko (Australia)

Talk 1: Prevalence of co-pathologies in Parkinson’s disease
Speaker: Lauren Walker (UK)

Talk 2: The role of alpha-synuclein and co-pathology in cognitive and non-motor symptoms
Speaker: Georgina Aldridge (USA)

Talk 3: Contributions of co-pathologies in activating the immune response in PD patients
Speaker: Ashley Harms (USA)

Talk 4: Co-pathologies and Parkinson’s: What’s it all mean to those living with PD?
Speaker: Soania Mathur (Canada)

Learning Objectives: 1. Current understanding of co-pathologies in clinical presentation; 2. Current understanding of how a-synuclein interacts with other proteinopathies; 3. Discussion of how to focus research efforts to investigate the contributions of co-pathologies to clinical presentation and disease progression.
## SCIENTIFIC PROGRAM
Friday, July 7, 2023

### LUNCH > 11:30 AM - 1:30 PM

<table>
<thead>
<tr>
<th>CARE PARTNER LOUNGE</th>
<th>CLINICAL RESEARCH VILLAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12:00 - 1:30 PM</strong></td>
<td><strong>12:15 - 12:45 PM</strong></td>
</tr>
<tr>
<td>Location: 212</td>
<td>Location: Exhibit Hall – WPC Theater</td>
</tr>
</tbody>
</table>
| **Activity:** The Poise Project: Partnering with Poise – Caring for Care Partners  
  *Speaker:* Monica Gross (USA) | **Panel:** Challenges, Considerations & Opportunities of Undertaking Research in Africa |

### BOOK NOOK

<table>
<thead>
<tr>
<th>Location: Exhibit Hall – Book Nook booth</th>
</tr>
</thead>
</table>
| **11:45 AM - 12:15 PM**  
  **Mi Parkinson**  
  Meet the Author: Manuel Rojas (Spain)  
| **12:30 - 1:00 PM**  
  **Tiembla**  
  Meet the Author: Ramon Ricart (Spain) |

### SPECIAL PRESENTATIONS

| **FSL1** – 12:00 - 1:00 PM  
  **Location:** 113  
  **Talk:** Parkinson’s: The funny side  
  In 2010 comedy writer Mayhew-Archer was told he had PD and decided to find it funny. If you’re worried or in need of a laugh, come along. This might be just the session you need.  
  **Host:** Roger Barker (UK)  
  **Presenter:** Paul Mayhew-Archer (UK)  |
| **FSL2** – 12:00 - 1:00 PM  
  **Location:** 114  
  **Panel Discussion:** Seed amplification assay – What is it? What does it mean for research? How will it impact people with PD?  
  **Host:** A. Jon Stoessl (Canada)  
  **Panelists:** Leonidas Stefanis (Greece)  
  Lana Chahine (USA)  
  David Standaert (USA) |

### ART WALK

| **12:00 - 12:40 PM**  
  **Location:** Front Lobby – Art Walk Exhibit  
  Meet Matt Eagles, artist, advocate, and more. Hear about his artistic process and the birth of Parky Life. |

### FILM ROOM

| **11:45 AM - 12:30 PM**  
  **Location:** 127  
  **Q&A:** Natasha Fothergill-Misbah (UK), *director* and others  
  **Film:** *Shaking hands with the devil* – 15 min  
  See page 28 for complete schedule. |

---

### Session Levels
- Crosstalk – Minimal or no scientific background required
- Moderate-level scientific sessions
- High-level scientific sessions

### Session Type
- Basic Science
- Clinical Science
- Comprehensive Care

### Language
- Simultaneous interpretation from English to Spanish  
  *Interpretación simultánea de inglés a español*  
- Spanish track  
  *Pista española*
### FBP1 – IMPORTANCE OF THE GUT BRAIN AXIS IN SPREADING ALPHA-SYNUCLEIN PATHOLOGY

**Location:** Room 117

**Moderator:** Per Borghammer (Denmark)  
**Co-moderator:** Michela Deleidi (France)

**Talk 1:** Body-first and brain-first PD animal models mimic human PD subtypes  
**Speaker:** Nathalie Van Den Berge (Denmark)

**Talk 2:** Bidirectionality: Gut-to-brain and brain-to-gut propagation of synucleinopathy  
**Speaker:** Ayse Ulusoy (Germany)

**Talk 3:** The role of microbiota in α-synuclein mediated gut and brain pathology  
**Speaker:** Timothy Sampson (USA)

**Learning Objectives:** 1. To dissect main mechanisms associated to alpha-synuclein aggregation in the ENS paying special attention to the peripheral immune system; 2. Does transport from gut to brain solely involve the vagus nerve? Or are we missing other ways of reaching the brain?; 3. How gut bacteria may trigger alpha-synuclein aggregation; 4. Importance of aging in a potential gut-to-brain spreading of alpha-synuclein pathology.

### FCP1 – THE SCIENCE OF EXERCISE IN PD

**Location:** Main Plenary Hall

**Moderator:** Benzi Kluger (USA)  
**Co-moderator:** Josefa Domingos (Portugal)

**Talk 1:** Biological brain changes observed following exercise in Parkinson’s: What do they tell us?  
**Speaker:** Mark Hirsch (USA)

**Talk 2:** Clinical trials: What is the evidence for the benefit of exercise in PD?  
**Speaker:** Erwin van Wegen (Netherlands)

**Talk 3:** How can we design better exercise trials in PD?  
**Speaker:** Daniel Corcos (USA)

**Learning Objectives:** 1. Outline the clinical effects of exercise in PD; 2. Explain the physiological effects of exercise in PD; what are the non-clinical correlates which may improve the pathophysiology of PD; 3. Discuss the challenges for future clinical trials to explore the effects of the types of exercise for PD and the correlates.

### FCCP1 – CARING FOR PD ACROSS THE AGE AND COGNITIVE SPECTRUM

**Location:** Room 116

**Moderator:** Victor McConvey (Australia)  
**Co-moderator:** Nabila Dahodwala (USA)

**Talk 1:** Aging well with Parkinson  
**Speaker:** Alison Yarnall (UK)

**Talk 2:** Cognitive impairment and dementia  
**Speaker:** Greg Pontone (USA)

**Talk 3:** PD-related psychosis  
**Speaker:** Ross Dunne (UK)

**Learning Objectives:** 1. Highlight the impact of the normal ageing and specific issues that may arise in Parkinson’s; 2. Provide insight from a clinical perspective on identification, treatment and management; 3. Explain how a proactive approach can support understanding and living with cognitive change.

### FSP1 – SESIÓN 5: ESTRATEGIAS EN EL MANEJO DEL PARKINSON (I)

**Location:** Room 115

**Moderadores:** Martilde Calopa (España) & Sabela Avion (Estados Unidos)

**Presentación #1:** Manejo del Parkinson inicial: medicación y estilo de vida  
**Ponente:** María Jose Martí (España)

**Presentación #2:** Fluctuaciones clínicas y discinesias  
**Ponente:** Oriol de Fàbregas-Boixar (España)

**Objetivos generales de aprendizaje:** 1. Conocer las estrategias terapéuticas en las etapas iniciales de la enfermedad; 2. Identificación y manejo de las complicaciones motoras. Descripción general de las terapias avanzadas (asistidas con dispositivos).
SCIENTIFIC PROGRAM
Friday, July 7, 2023

WORKSHOPS > 1:30 – 3:00 PM

FBWS1 – Mitocho-
ondria and
lysosome dysfunc-
tion in PD as therapeu-
tic targets
Location: Room 111

Moderator:
Malú Tansey (USA)
Co-moderator:
Claudio Soto (USA)

Talk 1: Mitochondrial abnormalities underlying PD – What’s on the horizon?
Speaker: Edward Fon (Canada)

Talk 2: Lysosomal abnormalities underlying PD – Beyond genetic data to potential interventions
Speaker: Roy Alcalay (Israel)

Talk 3: Mitochondria-lysosome contact site dynamics in disease
Speaker: Yvette Wong (USA)

Learning Objectives: 1. Discuss the evidence of abnormalities in mitochondrial metabolism underlying PD and treatment which are based on this; 2. Explain the evidence of abnormalities in lysosomal metabolism underlying PD and treatment which are based on this; 3. Outline the evidence of abnormalities in other pathways underlying PD and what treatment compounds may arise from these.

FCWS1 – Infections and Parkinson’s disease
Location: Room 113

Moderator: Wilma Van de Berg (Netherlands)
Co-moderator:
A. Jon Stoessl (Canada)

Talk 1: Infectious agents as a trigger for Parkinson’s
Speaker: Elena Kozina (USA)

Talk 2: Infections and associated medical complications on neuropsychological functions in Parkinson’s
Speaker: Catherine Price (USA)

Talk 3: COVID-19 and Parkinson’s disease
Speaker: Alfonso Fasano (Canada)

Learning Objectives: 1. Explain how infections may contribute to the development of Parkinson’s disease; 2. List how systemic infections can exacerbate cognitive and behavioral problems in Parkinson’s disease; 3. Elaborate on impact of COVID-19 in the Parkinson’s population.

FCCWS1 – Essential communication tools for family, healthcare team, and researcher
Location: Room 114

Moderator: Emily Henderson (UK)
Co-moderator:
Daniel Martinez-Ramirez (Mexico)

Talk 1: Communicating within the family system
Speaker: Angela Roberts (Canada)

Talk 2: Communicating within the care system
Speaker: Neil Archibald (UK)

Talk 3: Communicating within the scientific and research systems
Speaker: Walter Maetzler (Germany)

Learning Objectives: 1. Describe effective communication tools for when working within family networks; 2. Describe key communication tools and tips for working in the care system, particularly around interprofessional care; 3. Explain communication tools for researchers and PwPs to use when communicating around research, technology, and clinical trial engagement.

FRT1 – Location: Room 112

Table 1: Freezing, falling and postural decline: What can be done?
Host: Anat Mirelman (Israel)

Table 2: Role of mindfulness practice in quality of life
Host: Michelle Woerman (USA)

Table 3: The role of breathing exercises in managing Parkinson’s
Host: Amanda Woerman (USA)

Table 4: Subcutaneous L-dopa infusion vs other device-aided therapies – Who shall have what?
Host: Per Odin (Sweden)

Table 5: Alpha-synuclein strain competition
Host: Amanda Woerman (USA)

Table 6: Speak your truth
Host: Miet De Letter (Belgium)

Table 7: Prodromal Parkinson’s: What do we need to do in order to use this?
Host: Alastair Noyce (UK)

Table 8: Screening for PD risk – Are we ready for population-based approaches?
Host: Alastair Noyce (UK)

Table 9: LRRK2 and Parkinson’s
Host: Matt LaVoie (USA)

Table 10: The state of genetics in Parkinson’s
Host: Andrew Singleton (USA)

Table 11: Genetic testing in PD – What is currently possible?
Host: Christine Klein (Germany)

Table 12: Dysautonomia: What is it and how is it related to Parkinson’s?
Host: Patricio Millar Vernetti (USA)

Table 13: Depression, apathy & PD: What do we know and what can we do about these symptoms?
Host: Ira Leroi (Ireland)

Table 14: Synaptic function of α-synuclein
Host: Dragomir Milovanovic (Germany)

COFFEE BREAK > 3:00 – 3:30 PM
### FBP2 - WHAT IS THE FUNCTION OF α-SYNUCLEIN?
**Location:** Room 117

**Moderator:** Tiago Outiero (Germany)
**Co-moderator:** Rosario Moratalla (Spain)

**Talk 1:** Synaptic function of α-synuclein  
**Speaker:** Dragomir Milovanovic (Germany)

**Talk 2:** The role of α-synuclein in the nucleus  
**Speaker:** Vivek Unni (USA)

**Talk 3:** The role of the synuclein in the mitochondria  
**Speaker:** Gabriele Kaminski Schierle (UK)

**Learning Objectives:** 1. Explain the role of α-synuclein in different cell types and compartments with focus on novel concepts in the presynaptic terminal; 2. Identify how loss of α-synuclein function could contribute to disease; 3. List implications for current therapeutic strategies, and potential novel targets.

### FCP2 - THE MANY FACES OF PD - PRODROMAL AND CLINICAL SUBTYPES
**Location:** Room 111

**Moderator:** Per Borghammer (Denmark)
**Co-moderator:** Alastair Noyce (UK)

**Talk 1:** Evolution of phenotypic PD subtypes during the premotor and motor stage  
**Speaker:** Connie Marras (Canada)

**Talk 2:** Evolution of genetic PD subtypes during the premotor and motor stage  
**Speaker:** Susanne Schneider (Germany)

**Talk 3:** Tailored treatment and prevention of different PD subtypes  
**Speaker:** Alberto Espay (USA)

**Learning Objectives:** 1. Define PD subtypes which can be identified during the prodromal stage with respect to etiology, risk factors, pathology, symptomatology and prognosis; 2. List PD subtypes identified during the clinical PD stages; 3. Outline challenges underlying the development of tailored treatment approaches for different PD subtypes.

### FCCP2 - FREEZING AND MOBILITY CHANGES: NOVEL APPROACHES TO THE MAJOR CHALLENGE
**Location:** Main Plenary Hall

**Moderator:** Alice Nieuwboer (Belgium)
**Co-moderator:** Serene Paul (Australia)

**Talk 1:** Mobility challenges in PD: Causes and connections  
**Speaker:** Kaylena Ehgoetz Martens (Canada)

**Talk 2:** Freezing: Assessment, early detection and rehabilitation options  
**Speaker:** Nicholas D’Cruz (Belgium)

**Talk 3:** Treatments for freezing and other gross mobility challenges: Medication and surgical interventions  
**Speaker:** Alfonso Fasano (Canada)

**Learning Objectives:** 1. Explain distinctions between freezing and other mobility challenges; 2. Explain hypothesized underlying causes of these symptoms; 3. Detail the risks and early detection of these symptoms and their development over time; 4. Explain available treatments and future developments for alleviating freezing.

### FSP2 - SESIÓN 6: ESTRATEGIAS EN EL MANEJO DEL PARKINSON (II)
**Location:** Room 115

**Moderadores:** Angel Sesar (España) & Carlos M. Guerra Galicia (México)

**Presentación #1:** Cirugía y otras estrategias terapéuticas complejas  
**Ponente:** Francesc Valdeoriola (España)

**Presentación #2:** Ensayos clínicos en marcha: tratamientos sintomáticos y curativos  
**Ponente:** Pablo Mir (España)

**Objetivos generales de aprendizaje:** 1. Reconocer la fase avanzada (compleja) del Parkinson y las estrategias terapéuticas actuales; 2. Tratamientos experimentales, líneas de investigación en intervenciones avanzadas y sus ventajas potenciales sobre los tratamientos actuales.
Learning Objectives: 1. BETTER understanding of all disease-associated processes and mechanisms by meaningful interpretation of genomic data (omics data), and causal variations; 2. Understanding disease-associated biology through validated gene targets (including all implicated gene targets); 3. Determine accurate analyses/approaches to integrate large amounts of omics data to achieve meaningful con-nections and accurate interpreta-tions between genomic variations and human health and disease.
### Daily > 5:15 - 6:00 PM

**FEOd - Daily Wrap-up Panels**

**5:15 - 6:00 PM**

*Location: Main Plenary Hall*

**Moderator:** Silke Appel-Cresswell (Canada)
**Co-moderator:** Fulvio Capitanio (Spain)

**Panelists:**
- Coro Paisan-Ruiz (USA)
- Ryosuke Takahashi (Japan)
- Darren Moore (USA)
- Nabila Dahodwala (USA)

### Closing Remarks & Reception > 6:00 - 7:00 PM

*Location: Main Plenary Hall*

**Hosts:**
- Marina Romero-Ramos (Denmark)
- Roger Barker (UK)
Basic Science: Etiology, genetics, epidemiology, and toxicants

P01.01  SARS-CoV-2 and the brain: implications for Parkinson’s disease
Eduardo A. Albornoz, Julio Aguado, Alberto Amairilla, Daniel Watterson, Ernst J. Wolvetang, Trent M. Woodruff

P01.02  PROPARK study: Is there an association between PROfessional occupation and PARKinson’s disease?
Elena Natera Villalba, Victoria Ros Castelló, Arantxa Sánchez Sánchez, Ana Gómez López, Paula Pérez Torre, Carlos Estévez Fraga, Isabel Pareés Moreno, Juan Carlos, Martínez Castrillo, Araceli Alonso-Canovas

P01.03  Pathogenic or likely pathogenic GRN variants are present in ~0.2% of patients with Parkinsonism
Christian Ganoza, Ruslan Al-Ali, Ana Westenberger, Tatjana Usnich, Jörg Rennecke, Volha Skrahina, Ilona Csoiti, Christine Klein, Arndt Rolfs, Peter Bauer, Christian Beetz

P01.04  Cytochromes P450 are new potential players in Parkinson’s disease
Rita Bernhardt, Philip Hart, Tobias Fehlmann, Gudrun Wagenpfel, Marcus Unger

P01.05  Identification of suspected familial monogenic cases of Parkinson’s disease in the Australian Parkinson’s genetics study
Svetlana Bivol, Nicholas G. Martin, Kishore R. Kumar, Miguel E. Rentería

P01.06  Larger intracranial and subcortical brain volumes influence a higher Parkinson’s disease risk
Zuriel Ceja, Santiago Diaz-Torres, Luis M. García-Martín, Miguel E. Renteria

P01.07  Contribution of whole exome sequencing in Parkinson’s disease: A review of WES in 929 patients by Guillaume Cogan, France
Guillaume Cogan, Alexis Brice, Thomas Courtin

P01.08  Population fraction of Parkinson’s disease attributed to avoidable risk factors: A case-control study in the Deep South United States
Gwendolyn Cohen, David Standaert, Haydeh Payami

P01.09  Retinal ganglion cell integrity measurements as biomarkers of Parkinson’s disease risk in young adults
Santiago Diaz Torres, Samantha Lee, David A Mackey, Stuart MacGregor, Puya Gharrakhani, Miguel E. Renteria

P01.11  Dry cleaning chemicals and a possible cluster of Parkinson’s disease
Maryam Zafar, Meghan Pawlik, Samantha Lettenberger, Madeleine Coffey, Aayush Sarkar, Peggy Auinger, Caroline Tanner, Samuel Goldman, Briana De Miranda, Karl Kieburtz, Heidi Schwarze, Melanie Braun, Richard Barbano, Jamie Adams, Daniel Kinell, Ray Dorsey

P01.15  Towards a molecular definition of human midbrain dopaminergic neuron subtypes at the single cell level
Ka Wai Lee, Kimberly Silletti, Emelie Braun, MinDan-Gotthold, Rebecca Hodge, Alejandro Mossi Albiach, Lars E. Born, Elin Vinsland, Lijuan Hu, Peter Lönnerberg, Trygve Bakken, Song-Lin Ding, Xiaofei Li, Xiaoling He, Žaneta Andrusiová, Michael Clark, Tamara Casper, Nick Dee, Jessica Goh, C. Dirk Keene, Julie Nyhus, Herman Tung, Anna Marie Yanny, Joakim Lundeberg, Roger A. Barker, Erik Sundström, Ed S. Lein, Sten Linnarsson, Ernst Arenas

P01.19  Update on PD GUT metagenome
Haydeh Payami, Gwendolyn Cohen, Stewart Factor, Eric Molho, Timothy Sampson, David Standaert, Zachary Wallen, Cyrus Zabetian

P01.31  Genetic findings of the Rostock International Parkinson’s Disease (ROPAD) Study

Basic Science: Cell death, neuroprotection and trophic factors

P02.01  Apoptosis-related markers from peripheral blood mononuclear cells as potential biomarkers of Parkinson’s disease
Mária Brodňanová, Michal Cibulka, Milan Grofik, Natália Huňarová, Andrea Ižarik Verešpejová, Egon Kurča, Martin Kolísek
P02.02  The repositioning of pomalidomide as a novel disease-modifying drug: Evidence from the alpha synuclein based rodent model of Parkinson’s disease  
Anna R Carta, Maria Francesca Palmis, Michela Etzi, Augusta Pisanu, Chiara Burgaletto, Maria Antonietta Casu, Alfonso De Simone, Giuseppina Cantarella, Nigel Greig

P02.04  Male sex bias in Parkinson’s disease is linked to an accelerated age-dependent neuromelanin accumulation  
Camille Guillard Sirieix, Jordi Romero-Giménez, Thais Cuadros, Annabelle Parent, Ariadna Laguna, Miquel Vila

P02.07  Function and neuroprotective potential of Fcn knockout in Parkinson’s disease  
Julia Obergasteiger, Owen Fergusen, Cyril Bolduc, Anthony Bilodeau, Thomas Durcan, Flavie Lavoie-Cardinal, Emmanouil Metzakopian, Martin Levesque

Basic Science: Protein misfolding and handling

P03.01  Copper supplementation rescues impaired motor phenotype in a novel mouse model of SOD1 proteinopathy  
Amr Abdeen, Benjamin Rowlands, Connor Karozis, Veronica Cottam, Joel Siciliano, Fabian Kreilaus, Richard Hanwood, Julia Forkgen, Sarah Rosolen, Sara Nikseresht, Benjamin G. Trist, Kai Kyseniou, Michael Gotsbacher, David Bishop, Rachel Codd, Peter J. Crouch, Kay L. Double

P03.02  Lysosomal function and its role in oligodendrocytes in Synucleinopathies  
Denise Balta, Ida Pirkl, Kristina Battis, Philipp Arnold, Jürgen Winkler, Friederike Zunke

P03.03  Proteomic analysis of Parkinson’s patient midbrain neurons reveals a sub-proteome of metastable proteins that are susceptible to aggregation  
Nandkishore Belur, Joseph Mazzulli

P03.04  Assessment of phosphorylated α-synuclein deposits in the skin and GI tract in prodromal Parkinson’s disease  
Martin Ingelsson, Paul de Roos, Vincenzo Donadio, Alex Incensi, Anish Behere, Rocco Liguori, Joakim Bergström, Lars Lannfelt, Per Hellström, Dag Nyholm

P03.05  Discovery of new E3 ligases for alpha-synuclein clearance  
Nur Kocaturk, Zhiyuan Li, Ian Ganley, Gopal P. Sapkota

P03.06  Super-resolution microscopy informs on the molecular architecture of alpha-synuclein inclusions in model systems and in the human brain  
Diana Lazaro, Patrick Welsh, Luís Palmares, Patrícia Santos, Christine Stadelmann, Virginia M-Y. Lee, John Q. Trojanowski, Günter U. Höglinger, Silvio O. Rizzoli

P03.07  Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone mediated-autophagy deficiency, and alpha-synuclein pathology  
Marta Martinez-Vicente, Eddie Pradas-Gracia, Alba Navarro-Romero, Irene Fernandez-Gonzalez, Marta Montpeyo, Jordi Riera, Mercedes Arrue-Gonzalo, Clara Carnicer-Caceres, Laura Castillo-Ribelles, Jose Antonio Arranz-Amos

Basic Science: Mitochondria, oxidative stress, inflammation, pathogenesis

P04.01  Characterizing immune alterations in a rat model of Parkinson’s disease through single-cell RNA sequencing  

P04.02  Monocyte mitochondrial function in Parkinson’s disease  
Fatima Afaar

P04.03  Alpha-synuclein alters the neuronal lipidome and regulates phosphatidylserine synthesis at the Mitochondria-Associated ER Membranes (MAM) in patient-derived neurons modeling Parkinson’s disease  
Peter Barbult, Cristina Guardia-Laguarda, Taekyung Yun, Gérald Cruciani, François Massart, Bruno Santos, Simone Larson, Claire Dording, Nobutaka Hattori, Estela Area-Gomez, Rejko Krüger, Serge Przedborski

P04.04  Impact of chronic stress in Parkinson’s disease pathogenesis: Role of microglial glucocorticoid receptors in the regulation of innate immunity-associated supramolecular organizing centres (SMOCs)  
Pierre Besnault, Sharmilee Antoine, Sheela Vyas, Stephane Hunot
POSTERS – Session 1
Wednesday, July 5, 2023

Basic Science: Pathology

P00.04 Quantification of neurons in the rodent dorsal motor nucleus of the vagus using unbiased stereology
Eugenia Harbachova, Pietro La Vitola, Angela Rollar, Helia Aboutalebi, Ayse Ulusoy, Donato A. Di Monte

P00.05 Blood markers predictive of molecular changes in the brain and clinical outcome in Parkinson’s disease
Krithi Irmady, Caryn Hale, Rizwana Qadri, Sitsandziwe Simelane, John Fak, Thomas Carroll, Serge Przedborski, Robert Darnell

P00.08 Ultrasensitive determination of Ecto-GPR37 in plasma as a potential biomarker for Parkinson’s disease
Marc López Cano, Josep Argerich, Per Svenningsson, Francisco Ciruela

P00.10 Post-mortem quantification of cortical glia cells in patients with Parkinson’s Disease
Mikkel Vestergaard Olesen
Basic Science: Animal and cellular models of Parkinson’s and Parkinsonisms

P06.03  The assessment of VILIP-1 in crosstalk with FAM19A3 as an early biological biomarker in LPS-induced inflammatory model of Parkinson’s disease in rats
Mai M. Anwar, Mohamed H. Fathi

P06.07  NMR-based metabolomic analysis of gut-brain interactions in Parkinson’s disease modeled in Drosophila
Marylène Bertrand, Xiaojing Yue, Céline Landon, Serge Birman

P06.09  G2019S LRRK2 exacerbates inflammation and neurodegeneration in models of PD and colitis
Diego Cabezudo, George Tsafaras, Eva Van Acker, Chris Van den Haute, Veerle Baekelandt

P06.10  Glycated alpha-synuclein modulates the novel receptor for advanced glycation endproducts signaling pathway: A detailed molecular mechanism and it exacerbates on early onset of Parkinson’s disease-like phenotypes
Sayan Chatterjee, Harsh Thakkar, Amit Khairnar, Ravi Shah

P06.12  Delineating neurodegenerative interactions of VPS35 and LRRK2 in rodent models of Parkinson’s disease
Xi Chen, Lindsey Cunningham, Nathan Levine, An Phu Tran Nguyen, Darren Moore

P06.13  Selective manipulation of parvalbumin-expressing neurons in the substantia nigra pars reticulata restores motor behaviors in experimental parkinsonism
Lorena Delgado Zabalza, Nicolas Mallet, Maurice Garret, Christelle Glangetas, Cristina Miguel Palomo, Jérôme Baufreton

P06.14  Characterizing patterns of neural activity in midbrain organoids as a model for studying Parkinson’s disease
Ghislaine Deyab, Nguyen-Vi Mohamed, Rhalena Thomas, Jiarui Ao, Xue Er Ding, Julien Sirols, Carol X-Q Chen, Lenore Beitel, Thomas Durcan, Edward Fon

P06.15  Point of care microfluidic testing of platelets and coagulation using whole blood under hemodynamic conditions
Scott Diamond

P06.16  Non-invasive monitoring of midbrain dopaminergic progenitor cell differentiation
Nicola Drummond, Daniel Tikhomirov, David McNay, Yixi Chen, Maurice Canham, Mio Iwasaki, Mariah Leols, Asuka Morizane, Tilo Kunath

P06.18  DNAJC12 deficiency in Parkinsonism
Jesse Fox

P06.19  DNAJC13 p.N855S in Parkinson’s disease
Jesse Fox

P06.20  Utilising preclinical murine models to investigate sleep and circadian system dysfunction in Parkinson’s disease
Nicholas Garner, Pu Reum Kim, Marco Weiergraeber, Richard Gordon, Katerina Hanton, Henrik Oster, Oliver Rawashdeh

P06.21  Impact of α-Synuclein inclusions on glutamatergic synapses in the amygdala in a PFF mouse model of PD
Nowwali Gcwenisa, Dreson L Russell, Khaliah Long, Charlotte F Brzozowski, Laura Wolpicelli-Daley

P06.22  Involvement of serotonergic descending pathways on pain in a mouse model of parkinsonism
Zoé Grivet, Franck Aby, Rabia Bouali-Benazzouz, Frédéric Naudet, Aude Verboven, Abdelhamid Benazzouz, Pascal Fossat

P06.25  Fluorescence lifetime imaging and immunohistochemical analysis of neuropathological changes related to Parkinson’s disease in murine duodenal tissues
Jana Harsanyiova, Alzbeta Kralova Trancikova, Martin Kolsek

P06.26  Focused ultrasound as a novel therapeutic for depression in Parkinson’s disease
Rachael Herlihy, Francisco Alicandri, Hudy Berger, Huda Rehman, Yifan Kao, Kainat Akhtar, Emily Mahoney-Rafferty, Angela Tawfik, Rachel Skumurski, Damian Shin
**POSTERS – Session 1**
**Wednesday, July 5, 2023**

**Basic Science: Brain physiology and circuitry**

- **P06.27** Reduction in alpha-synuclein levels after antisense oligonucleotides treatment in patient derived midbrain organoids  
  *Javier Jarazo, Isabel Rosety, Mario Richter, Jan Stoehr, Michael Schulz, Peter Reinhardt, Jens Schwamborn*

- **P06.29** Experimental colitis accelerates intragastric rotenone-induced alpha-synuclein pathology and its progression from the gut to the brain  
  *Nishant Sharma, Monika Sharma, Disha Thakkar, Hemant Kumar, Sona Smetanova, Lucie Buresova, Petr Andrla, Amit Khairnar*

- **P06.30** Human α-synuclein-holding familial Parkinson’s disease-linked Ala-53 to Thr mutation causes sleep and circadian dysfunction in transgenic mice  
  *Pureum Kim, Nicholas Garner, Henrik Oster, Oliver Rawashdeh*

- **P06.32** Sub-acute MPTP treatment increases α-synuclein levels and its aggregation in mice  
  *Lucia Lage Pita, Ana Isabel Rodriguez Perez, Jose Luis Labandeira Garcia, Antonio Dominguez Mejide*

- **P06.33** Anatomo-radiological correlations in a Parkinson’s disease animal model  
  *Chirine Katrib, Hector Hladky, Régis Bordet, David Devos, Charlotte Laloux, Nacim Betrouni*

- **P06.34** Characterization of retinal structure and function in the tau knockout mouse model of Parkinson’s disease  
  *Pei Ying Lee, Yolanda Tan, Vickie Wong, Da Zhao, Katie Tran, David Devos, Bang Bui, Christine Nguyen*

- **P06.37** Characterization of a seeding-based model of REM-sleep behavioral disorder in mice  
  *Hansoo Yoo, Russell Luke, Brittany Dugan, Jimmy Fragine, Jonath Lourie, Jefferson Steltz, Yuling Liang, Lauren Torres, John Peever, Kelvin Luk*

- **P06.38** Using patient-derived hiPSC microglia to characterize LRRK2 signaling in Parkinson’s disease  
  *Emma MacDougall, Eric Deneault, Sophie Luo, Edward Fon*

- **P06.39** Heterozygosity of the GBA1 L444P mutation impairs hippocampal-dependent memory tasks, synapse biology, and lysosomal function  
  *Casey Mahoney-Crane, Sumedha Bobba, Eli Berry, Laura Volpicelli-Daley*

- **P06.40** Crosstalk between α-synuclein and neuromelanin exacerbates Parkinson’s disease pathology in melanized tyrosinase-expressing rodents  
  *Alba Nicolau-Vera, Thais Cuadros, Joana M Cladera-Sastre, Jordi Romero-Giménez, Annabelle Parent, Ariadna Laguna, Miquel Vila*

- **P06.44** Interneuronal transfer and brain spreading of synaptic proteins: specific effects of synuclein proteins  
  *Rita Pinto-Costa, Michael Klinkenberg, Michael Helwig, Angela Rollar, Raffaella Rusconi, Donato A Di Monte, Ayse Ulusoy*

- **P06.45** Immunosuppressive tocilizumab prevents astrocyte-induced neurotoxicity in hiPSC-LRRK2 PD by targeting receptor IL-6  
  *Meritxell Pons Espinal, Lucas Blasco-Agell, Valentina Baruffi, Irene Fernandez-Carasa, Pol Andres-Benito, Angelique de Domenico, Yvonne Richaud, Laura Marruecos, Luis Espinosa, Alicia Garrido, Eduardo Tolosa, Michael J. Edel, Manel Juan Otero, Jose Luis Mosquera, Isidre Ferrer, Angel Raya, Antonella Consiglio*

**Basic Science: Dopamine, receptors and other neurotransmitters**

- **P07.01** Impact of α-synuclein pathology on corticostriatal synapses in Parkinson’s disease  
  *Charlotte Brzozowski, Harshita Challa, Douglas Naber, Preston Wagner, Nolwazi Gcwensa, Laura Volpicelli-Daley, Mark Moehle*

- **P07.02** Cortical compensatory mechanisms for adaptive split-belt walking in people with Parkinson’s disease  
  *Femke Hulzinga, Paulo Pelicioni, Nicholas D’Cruz, Veerle de Rond, Pieter Ginis, Moran Gilat, Alice Nieuwboer*

- **P08.02** The mGluR5-A2AR-D2R heteromeric complex: Considerations for Parkinson’s disease treatment  
  *Francisco Ciruela, Wilber Romero-Fernández, Jaume Taura, Rene Crans, Marc López-Can, Ramón Fores-Pons, Manuel Narváez, Jens Carlsson, Kjell Fuxe, Dasiel Borroto-Escuela*

- **P08.03** Spatio-temporal dynamic of DA in the execution of goal-directed movements in rats  
  *Sophie Gauthier, Ana Dorison, Manon Leclerc, Alison McDonald, Nicolas Mallet*

- **P08.04** Physiological functions of aldehyde dehydrogenase 1A1-positive midbrain dopaminergic neuron  
  *Ahsan Habib, Lupeng Wang, Lisa Chang, Lixin Sun, Hualbin Cai*
P08.07  Functional assessment of dopaminergic neurons derived from human lineage-restricted undifferentiated stem cells in a rat Parkinsonian model
Muyesier Maimaitili, Muwan Chen, Fabia Febbraro, Ekin Ücüncü, Johanne Lauritsen, Ida Hyllen Klæstrup, Rachel Kelly, Marina Romero-Ramos, Mark Denham

Basic Science: Neuropharmacology

P09.01  Therapeutic targeting of synaptic vesicle glycoprotein 2C (SV2C) in Parkinson’s disease
Meghan Bucher, Joshua Bradner, Gary Miller

P09.02  Golexanolone, a GABAA receptor-modulating steroid antagonist, improves fatigue, anxiety, depression, and some cognitive and motor alterations in a rat model of Parkinson’s disease
Paula Izquierdo-Altarejos, Yaiza M Arenas, Mar Martinez-Garcia, Gergana Mincheva, Magnus Doverskog, Thomas P Blackburn, Lars Öhman, Marta Liansola, Vicente Felpo

P09.03  Validating a novel therapeutic approach co-targeting immune activation and dopaminergic neuron loss in Parkinson’s disease
Aishwarya Johnson, Sara Jose, Hariharan Saminathan, Richard Gordon

P09.05  Identification of new RXR-Nr4a (Nur) nuclear receptor complex selective compounds for Parkinson’s disease
David Cotnoir-White, Catherine Levesque, Maxime Tremblay, Anne Marinier, Sylvie Mader, Daniel Levesque

Basic Science: Electrophysiology & functional imaging, optogenetics

P10.02  Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment lead to compulsive behaviours and abnormal frontostriatal plasticity
Mélina Decourt, Eric Balado, Maureen Francheteau, Anaïs Bahlous-Gauthier, Pierre-Olivier Fernagut, Marianne Benoit-Marand

P10.05  Globus pallidus contribution to motor behaviour in normal and Parkinson’s disease states: Optogenetic studies in murine models
Abdel-Mouttalib Ouagazzal, Sonia Di Biseglie Caballero, Aurelia Ces, Martine Liberg, Frederic Ambroggi, Marianne Amalric

P10.07  Impact of alpha-synuclein overexpression on electrophysiological properties of the locus coeruleus neurons
Jone Razquin, Laura De las Heras-García, José Angel Ruiz-Ortega, Lorena Delgado, Jérôme Baufreton, Gloria González-Aseguinolaza, Harkaitz Bengoetxea, Cristina Miguelez

Basic Science: Prevention, neuroprotection neuroplasticity

P11.01  Exercise-based rescue strategies in early-stage of PD: From preclinical to clinical studies
Federica Campanelli, Serena Fragapane, Gloria Modica, Gioia Marino, Giuseppina Natale, Elena Marcello, Fabrizio Gardoni, Maria De Carloccio, Federica Servillo, Anna Picca, Maria Rita Lo Monaco, Maria Teresa Viscomi, Anna Rita Bentivoglio, Veronica Ghiglieri, Paolo Calabresi

P11.02  Novel noninvasive gene therapy for Parkinson’s disease using viral encoded single-chain antibody treatment
Anne-Marie Castonguay, Béatrice Morin, Thomas Durcan, Claude Gravel, Martin Lévesque

P11.03  “Silver Snow Flake”: Una iniciativa de prevención de caídas de Parkinson, “Silver Snowflake” Parkinson’s Fall Prevention Initiative
Klaudia Cwikala-Lewis, Brandon Parkyn, Ileana Feistritzer

P11.07  Regenerating dopaminergic neural circuits in Parkinson’s disease through transplantation of super-resistant human neurons
Beatrice Morin, Anne-Marie Castonguay, Julia Obergasteiger, Tiago Cardoso, Valérie Watters, Claude Gravel, Samer Hussein, Thomas Durcan, Martin Lévesque

Comprehensive Care: Caregiving, relationships, respite care, families

P12.01  Time critical medication on time every time: A right for all people with Parkinson’s
Clare Addison, Jonny Acheson, Garth Ravenhill, Tincy Jose, Cormac Mehigan, Claire Leman, Ed Kirkham, Andrew Perkins
Comprehensive Care: Exercise and physical activity

P13.01 Mobile health technology, exercise adherence and optimal nutrition post rehabilitation among people with Parkinson’s disease (mHEXANUT) – A randomized controlled trial
Sigrid Ryeng Alnes, Ellisiv Lærum-Onsager, Asta Bye, Annette Vistven, Erika Franzén, Mette Holst, Therese Broyold

P13.03 Exercise = delay Parkinosons + keep mental health in check
Isaac Jose Alvarez Torres

P13.04 Modulation of neural activity in response to dance training in Parkinson’s: A case study
Judith Bek, Royze Simon, Katayoun Ghanai, Karolina Bearss, Rebecca Barnstaple, Rachel Bar, Joseph DeSouza

P13.05 The effects of table tennis training on dual task performance in Parkinson’s disease: Protocol for a pilot study
Pere Bosch-Barceló, María Masbernat-Almenara, Filip Bellon, Francisco José Verdejo-Amengual, Ares Alcaina, Helena Fernández-Lago

P13.06 The effectiveness of ‘motor-motor’ and ‘motor-cognitive’ dual-task training interventions on balance in people with Parkinson’s disease: A feasibility study
Nesibe Cakmak, Jenny Freeman, Camille Carroll, Lisa Bunn

P13.07 Immersive virtual reality exergame for patients with Parkinson’s disease: Feasibility and potential benefits
Pablo Campo Prieto, Jose Maria Cancela Carral, Gustavo Rodriguez Fuentes

P13.08 Outdoor Adventure Program (OAP) for people with Parkinson’s (PWP): Increasing activity through fun and salient community classes
Joy Cochran

P13.09 Impact of active gait training programs on gait under daily life conditions and quality of life in Parkinson’s disease
Bettina Debù, Pierre Pelissier, Nicolas Vuillerme, Matthias Chardon, Valérie Fraix, Elena Moro

P13.10 Step variability is decreased during ice skating approach to a door amongst people living with Parkinson disease
Jon Doan, Brittany Mercier, Claudia Steinke, Natalie de Bruin, Lesley Brown

P13.11 Effectiveness of trampoline training in people with Parkinson’s: preliminary study results
Josefa Domingos, Joao Gomes, Julio Belo Fernandes, John Dean, Joao R Vaz, Catarina Godinho

P13.12 Online zumba gold for people with Parkinson’s disease: Acceptability study
Josefa Domingos, Sonia Gow, John Dean, Catarina Godinho, Julio Fernandes, Drew Falconer

P13.13 U-Turn Parkinson’s: Empowering the pursuit of wellness … for free
Tim Hague
**Comprehensive Care: Alternative & complementary therapies/ Creativity**

**P14.01** CANNABAPA: CANNAbis-BAsed medicine for Parkinson’s disease: patients’ and health workers’ points of view to pave the way
Tanguy Barré, Christelle Baunez, Camelia Protopopescu, Fabienne Marcellin, Morgane Bureau, Géraldine Cazorla, Patrizia Carrieri

**P14.02** Patients with Parkinson’s disease able of postural adaptation to the task performed but not as much as healthy controls
Cédrick Bonnet, Yann-Romain Kecharia, Arnaud Delval, Luc Delèvre

**P14.03** Why the fascia system needs to be addressed to manage and potentially reverse the effects of Parkinson’s disease
Florence Cerruti, Deanna Hansen, Gary Sharpe

**P14.04** Music and the native american flute – A tool for slowing Parkinson’s disease progression
William Clugston

**P14.05** Holistic complementary therapies for people with Parkinson’s and their families in the open air in synergy with the nature
Francesca De Bartolomeis

**P14.06** Improv for Parkinson’s: Creative skills for cognitive health
Daniel Dumsha, Peter Jarvis, Lucia Forward, Quinn Contini

**P14.07** Social work student knowledge and attitudes about medical cannabis use for Parkinson’s disease
Offer Emanuel Edelstein, Alexander Reznik, Richard Isralowitz

**P14.08** ES - Park: Evaluation of the effectiveness of the Parkinson’s Specialized Teams intervention on the quality of life of Parkinson’s patients in the territory of the Nouvelle-Aquitaine: ES-Park pilot study
Alexandra Foubert-Samier, Isabelle Benatru, Jean-Luc Houeto

**P14.09** “Those movements weren’t moving anything to me”: Investigating experiences and opinions about using motor imagery in people with Parkinson’s
Charlotte Growcott, Ellen Poliakoff, Emma Gowen

**P14.10** Rhythmic flow taiko – Therapeutic drumming for people with Parkinson’s
Vivian Lee, Yeeman Mui, Galen Rogers

**P14.11** Dance for Parkinson in Iberian: Portugal and Spain methodologies
Anjos L. Macedo, Rafael Alvarez, Annabel Barnes, Luísa Bento, Leonor Tavares, Cesar Casares, Paloma Alfonsel, Guillermina Bedoya, Sara Mora, Aurora Rodríguez del Barrio, Juvenal García

**Comprehensive Care: Lay/professional health literacy & public thought**

**P15.01** The early treatment phase in Parkinson’s disease: Not a honeymoon for all, not a honeymoon at all?
Araceli Alonso-Canovas, Jos Voeten, Larry Gifford, Omotola Thomas, Andrew J Lees, Bastiaan R Bloem

**P15.02** Precision needed in Parkinson’s advocacy: Healthy land and affordable food for people is always in desperate need
Grant Burchnall
P15.03 Teaching nursing students about Parkinson’s disease using conversation mapping
Marjorie Getz

P15.04 Piece of mind: Bridging scientific research and the lived experience of Parkinson’s with the performing arts
Naila Kuhlmann, Aliki Thomas, Natalia Incio-Serra, Stefanie Blain-Moraes

Comprehensive Care: Disability and quality of life outcome measures

P16.01 Impact of sexual dysfunction in quality of life amongst Mexican population living with Parkinson’s disease

P16.02 Introducing Project “Parkinson & Well”: A study by Slovak Health Spa Piestany and Comenius University in Bratislava, Jessenius Faculty of medicine in Martin, Slovakia
Alena Korencikova, Milan Grofik, Martin Kollisek, Boris Banovsky, Ivona Hrdinova, Michal Verchola

P16.03 Flourishing in the face of Parkinson’s: The question of well-being as it relates to Parkinson’s disease
Neil Arvin Bretana, Edward Shepherd, Dominic Rowe

P16.04 Quality of life in Parkinson’s disease hypokinetic dysarthria and acoustic features in dialogical speech
Barbara Gili Fivela, Anna Chiara Pagliaro, Sonia d’Apolito

P16.05 Understanding the circumstances and consequences of falls and near-falls in people with Parkinson’s disease
Dale Harris, Wei-Peng Teo, Gavin Abbott, Robin Daly

Comprehensive Care: PwP - Clinician partnership: Shared decision-making

P17.01 Why doctors should be talking about DBS with their YOPD patients early in their Parkinson’s journey
Christy Daniels

P17.02 The complexity of Parkinson disease medication regimens may factor into treatment decisions: Results of a PMD alliance survey
Jill Farmer, Clarisse Goas, Jason Rivera, Anissa Mitchell, Andrea Merriam, Nikkilina Crouse, Andrea Formella

Comprehensive Care: Palliative care/ advance planning/ end of life care

P18.06 Status report on palliative care in Parkinson’s patients: Dark reality in resource poor nations
Shankh Pal, Ranjit Sharma, Tillotma Roy, Kaul Meghna

P18.07 The role of telemedicine to support care in advanced Parkinson’s disease
Robin van den Bergh, Pauline van Barschot, Bauke W. Dijkstra, Herma H. Lennaerts-Kats, Catharina Muente, Marjan J. Meinders

Comprehensive Care: Health accessibility/ underserved populations

P19.01 What can applicable Hoehn and Yahr five assessment measures tell us about people in advanced Parkinson’s disease?
Pâmela Barbosa, Maria Elisa Pimentel Piemonte

P19.03 Towards inclusion: Using integrated knowledge translation to design and implement a community-based assessment service for young people with Parkinson’s disease
Sarah Davies, Donna Rooney, Miguel Diaz

P19.04 Increasing Hispanic/Latino recruitment into Parkinson’s genetics research
Priscila Delgado Hodges, Rebeca DeLeon, Anna Naito, Roy N Alcalay, Juan Ramirez-Castaneda, Ruby Rendon, Claudia Martinez, Camila Gadala-Maria, Adriana Jimenez, Rossy Cruz-Vicioso, Henry Moore, Paulina Gonzalez Latapi, Valentina Caceres, Anny Coral, Ignacio F Mata
P19.05  Academic-community partnership to develop a Parkinson resource center in the rural southern U.S.
Donna Hood, Denise Pyles

P19.06  Gaps in the literature for women with young onset Parkinson’s disease
Kristi LaMonica, Katherine Florian, Diandra Hennessy, Alexandra Iglesia, Britney Merwin, Eliza Whitman, Kate Murphy

Comprehensive Care: Sexuality & intimacy

P20.02  LGBTQ, intimacy, sexuality and Parkinson’s Disease (PD): Planning an observational pilot study
Gila Bronner, Tanya Gurevich

P20.03  The cultural imaginary of disease: How those with Young-Onset Parkinson’s disease are restricted in their relationships
Lewis Johnstone

P20.04  Biopsychosocial factors associated with the sexual health of women living Parkinson’s disease
Katia Nobrega, Maria Elisa Piemonte, Thalyta Martins, Geovanna Santos

Comprehensive Care: Daily life activities including working & driving

P21.01  Impact of laser shoes on activities of daily living in people with Parkinson’s and freezing of gait
Laurelei Dirks, Katie Plesher, Paige Rupiper, Sarah Moskowitz, Daniel Peterson, Linda Denney, Cindy Ivy

Comprehensive Care: Self-management, empowerment, coping strategies

P22.02  Behaviour change techniques to reduce sedentary behaviour and increase physical activity in people with Parkinson’s disease: A scoping review
Ghazi Alnajdi, Natalie Allen, Dr Serene Paul, Dr Sonia Cheng, A/Prof Zoe McKeough

P22.03  Salutogenesis among people living with diagnosed Parkinson’s disease
Alannah Beston, Edward Shepherd, Terry Boyle, Neil Arvin Bretaña

P22.04  Examining leadership of Parkinson’s disease support groups in rural and regional New South Wales: A qualitative descriptive case study
Vincent Carroll, Rachel Rossiter, Marguerite Bramble

P22.05  Lifestyle medicine for Parkinson’s disease: Diet as a treatment tool
Rachel Dolhun, Erin Presant

P22.06  Possible explanations for unexpectedly high functional mobility despite the presence of postural instability and gait disturbances. A longitudinal mixed-models analysis
Anne-Marie Hanff, Christopher McCrum, Armin Rauschenberger, Gloria A. Aguayo, Maurice Zeegers, Anja K. Leist, Rejko Krüger

P22.10  Gaitkeeping: A Parkinson’s telehealth training program
Pamela Quinn, Jeff Friedman, Colin O’Connor, Natalie Schultz-Kahway, Lauren St. Hill, Roseanne D. Dobkin

P22.16  Patient experience and treatment satisfaction with continuous subcutaneous infusion of foslevodopa/foscarbidopa for treatment of advanced Parkinson’s disease
Rajeev Kumar, Michael Soileau, Connie H. Yan, Triza Brion, Alex Bellenger, Christina O'Donnell, Pavnit Kukreja, Maurizio F. Facheris, Anand Shewale, Jason Aldred

P22.18  Investigating pain catastrophizing to improve treatment of pain and psychological distress in Parkinson’s disease
Léonore Robieux, Sylvia Zimmers, Catherine Bungener

Comprehensive Care: Multidisciplinary/interdisciplinary teams

P23.01  Parkinson’s care clinic: “Outside the pill box” interdisciplinary rehab and wellness care: Improving access and efficiency of care for people with Parkinson’s disease (PWP) and their care partner(s) in underserved areas of North Alabama, USA
Erin Edmundson, Arantxia Wijngaarde, Rebecca Rodgers
**P23.02** A missing piece of the Parkinson’s puzzle: The critical role of the dietitian in the care of people living with Parkinson’s disease (PD)
Richelle Flanagan, Indu Subramanian, Carley Rusch

**P23.03** Feasibility and efficacy of a multidisciplinary telemedicine intervention program to reduce falls and improve quality of life in Parkinson’s disease (NCT04694443)
Álvaro García-Bustillo, Florita Valiñas-Sieiro, Marta Allende-Rio, Alicia Olivares-Gil, José Miguel Ramírez-Sanz, José Luis Garrido-Labrador, álvar Arnaiz-González, José Francisco Díez-Pastor, Maha Jahouh, Josefa González-Santos, Jerónimo Javier González-Bernal, José María Trejo-Gabriel-Galán, Esther Cubo

**P23.04** Advanced practice providers central to managing patients with Parkinson disease and other movement disorders
Sherrie Gould, Kelly Papesh, Bruce Jones, Anissa Mitchell

**P23.05** ParkinsonNet Luxembourg – A multidisciplinary network adjusted to the healthcare environment in Luxembourg
Mariella Graziano, Nicole Colson, Joëlle V. Fritz, Sylvia Herbrink, Anne Kaysen, Carole Simon, Jochen Klucken, Alexandre Bisdorff, Sanne Bouwman, Bastiaan R. Bloem, Rejko Krüger

**P23.06** Temporal trends in the coverage of specialized allied health services for Parkinson’s disease: 10 years of experience with the Dutch ParkinsonNet
Sanne Bouwman, Judith van Erkelens, Anja van Baardewijk-Joosten, Bastiaan Bloem, Johanna Kalf

**P23.07** All hands on deck! Development and implementation of a nurse-driven, rehab-focused, in-person or telehealth interdisciplinary team (IDT) clinic for Veterans with PD and other movement disorders
Jessica Kaplan, Jessica Lehosit, Erin Buckley, Hall Emily, Serio Karissa, Brittany Reed, Lauren Sharpe-Payne, Abu Qutubuddin, Debbie Lindsey, Mark Baron, Cameron Jennings, Melissa Oliver, Alicia Sullivan, Hope Kumme, Mark Flores, Leslee Hudgins, Kayla Thompson, Julie Thompson, Lesa Beatty, Christina Kausek, Mary Hammt, Miriam Hirsch, Michael Shapiro

**Comprehensive Care: Digital health, E-health and technology**

**P24.02** Adherence and satisfaction of telemedicine in patients with Parkinson’s disease. A longitudinal, randomized, multidisciplinary-based intervention (NCT04694443)
Marta Allende-Rio, Florita Valiñas-Sieiro, Álvaro García-Bustillo, José Luis Garrido-Labrador, José Miguel Ramírez-Sanz, Alicia Olivares-Gil, Álvar Arnaiz-González, José Francisco Díez-Pastor, Maha Jahouh, Josefa González-Santos, Jerónimo Javier González-Bernal, José María Trejo-Gabriel-Galán, Esther Cubo

**P24.03** Use of a single inertial sensor on the thigh to assess gait quality during the 6-minute walk test in persons with Parkinson Disease
Dheepak Arumukhom Revi, Franchino Porciuncula, Nick Wendel, Jenna Zajac, James Cavanaugh, Terry Ellis, Louis Awad

**P24.04** Methods to quantify skin conductance in people with Parkinson’s disease: A systematic review of observational studies
Mercedes Barrachina, Laura Valenzuela-López, Marcos Moreno-Verdú, Yeray González-Zamorano, Juan Pablo Romero, Carmen Sánchez-Ávila

**P24.05** Ability of electrodermal activity measures to detect non-motor fluctuations in Parkinson’s disease
Mercedes Barrachina, Laura Valenzuela-López, Marcos Moreno-Verdú, Yeray González-Zamorano, Francisco José Sánchez-Cuesta, Juan Pablo Romero, Carmen Sánchez-Ávila

**P24.06** Measuring rest-activity patterns using wearable devices in inpatients with Parkinson’s and delirium: A nested feasibility study
Gemma L Bate, Sarah J Richardson, John-Paul Taylor, David J Burn, Louise M Allan, Alison J Yarnall, Silvia Del Din, Rachael A Lawson

**P24.07** From research to home: Deployment of three web-based interventions types developed with people living with Parkinson disease and their caregivers in Quebec, Canada
Line Beaudet, Auriane Haegeman, Caroline Champeau, Dora Rodriguez, Marie-Neige Filteau, Renée Coulombe

**P24.08** Video-assisted telenursing in patients with advanced Parkinson’s disease treated with LCIG: Results from the Facilitate-Care study
Lars Bergmann, Tanya Gurevich, Andrew Evans, Georg Kägi, Dariusz Koziorowski, Juan Carlos Parra Riaza, Olga Sanchez-Soliño, Jaroslaw Slawek
P24.10 Digitised home-based care for people with Parkinson’s disease
Katie Bounsall, Sue Whippes, John Whippes, Edward Meinert, Camille Carroll

P24.11 Evaluation of the Parkinson’s Remote Interactive Monitoring System (PRIMS): Beta testing
Bronwyn Bridges, John Weber, Jake Taylor

P24.12 Accelerating research on Parkinson’s disease and empowering patients through digital health technologies
Yun-Hsuan Chang, Matt Wilson, Alastair J Noyce

P24.14 Making my moves matter
Richelle Flanagan

P24.15 Digital mobility outcomes derived from different wearable sensors and their link to clinically relevant scores in Parkinson’s disease
Heiko Gassner, Sarah Selferth, Teresa Greinwalder, Sabine Stallforth, Jelena Jukic, Patrick Süß, Alexander German, Franz Marxreiter, Martin Regensburger, Jochen Klucken, Alison Yamnal, Clemens Becker, Walter Mätzler, Lynn Rochester, Jürgen Winkler

P24.16 Validation of mobility biomarkers in the assessment of Parkinsonian bradykinesia: Experience from a large real world data set
Tiffany Jansen, Aiden Arnold, Witney Chen, Ro’ee Gilron

P24.17 Usability and acceptability of a cognitive training application in Parkinson’s
Julia Das, Gill Barry, Rodrigo Vitório, Lisa Graham, Claire McDonald, Brony Storey, Richard Walker, Samuel Stuart, Rosie Morris

Comprehensive Care: Rehabilitation sciences (PT, OT, SLP)

P25.01 Fisior sequential squares mat as a stable environment to reeducate gait in patients with Parkinson disease
José Alegre Tamariz, Nuria Toledo Martel, Leticia Martínez Caro, Alberto Bermejo Franco

P25.02 Fisior® sequential square mat as a stable environment to improve the risk of falls in patients with Parkinson’s disease
José Alegre Tamariz, Asier Arizabalaga Otaegui, Leticia Martínez Caro, Alberto Bermejo Franco

P25.03 Visual perturbation training to reduce fall risk in people with Parkinson’s disease
Remco Baggen, Anke Van Bladel, Maarten Prins, Katie Bouche, Leen Maes, Miet De Letter, Dirk Cambier, Patrick Santens

P25.04 Relationship between self-efficacy and real world walking activity in persons with Parkinson’s disease
Teresa Baker, Kerri Rawson, Jaimie Girnis, Ryan Duncan, James Cavanaugh, Tamara R. DeAngelis, Daniel Fulford, Martha Hessler, Michael Lavally, Timothy Nordahl, Marie Saint-Hilaire, Cathi Thomas, Jenna Zajac, Gammon Earhart, Terry Ellis, Franchi Porciuncula

P25.05 Can augmented feedback facilitate learning in serious games in People with Parkinson’s Disease? A single-blind randomized clinical trial
Pâmela Barbosa, Amarilis Falconi, Matheus D’Alencar, Erika Okamoto, Maria Elisa Pimentel Piemonte

P25.06 Differences in gait between clinical subtypes in Parkinson disease
Sidney Baudendistel, Scout Hizer, Allison Haussler, Kerri Rawson, Meghan Campbell, Gammon Earhart

P25.07 Assessment of upper limbs impairments in Parkinson’s disease: A systematic review
Tamine Capato, Rubia Rodrigues, Beatriz Santos, Manoel Teixeira, Rubens Cury, Egberto Barbosa

P25.08 Use of a novel comprehensive balance assessment to measure fall risk in people with Parkinson’s disease
Patricia Carlson-Kuhta, Carla Silva-Batista, Anjanibhargavi Ragothaman, Jacqueline Ellison, Graham Harker, Giorgia Marchesi, Alice De Luca, Valentina Squeri, Fay B. Horak, Martina Mancini

P25.09 The eyes have it: Persons with Parkinson Disease demonstrate poor performance on the King-Devick test
Valerie Carter, John Heick, Robert Gorman, Tarang Jain

P25.10 Talk the Walk: Dual tasking with walking and visual-verbal processing is more difficult for persons with Parkinson than for young and older adults
Valerie Carter, John Heick, Tarang Jain

P25.11 Effectiveness of a virtual physiotherapy for Parkinson’s course using a mixed on-demand and live model: Lessons learned from Malta
Veronica Clark, Josefa Domingos, Victoria Masalha
P25.12 BeatMove: A personalized music-based gait auto-rehabilitation for persons with Parkinson’s disease
Valérie Cochen De Cock, Loïc Damm, Dobri Dotov, Simone Dalla Bella, Benoit Bardy

P25.13 Voice self-assessment in Parkinson’s disease: A comparison with different types of dysphonias
Francisco Contreras-Ruston, Jordi Navarra, Adrian Castillo-Allende, Jorge Saavedra-Garrido, Andrés Ochoa-Muñoz, Sonja Kotz

P25.14 The priority goals and underlying symptomology related to goal-related performance of people with Parkinson’s disease receiving a community-based rehabilitation program
Sarah Davies, Hannah Gullo, Emmah Doig

P25.15 CO-OP feasible and promising for facilitating goal attainment in adults with Parkinson’s disease: findings of a randomised controlled feasibility trial
Sarah Davies, Hannah Gullo, Emmah Doig

P25.16 “I didn’t know I had executive functioning problems, but now I do… And there’s something I can do about it” – Perspectives of people with Parkinson’s disease about the Cognitive Orientation to daily Occupational Performance approach
Sarah Davies, Hannah Gullo, Emmah Doig

P25.17 The effect of rehabilitation interventions on freezing of gait in people with Parkinson’s disease: A systematic review and meta-analyses
Lina Goh, Colleen G Canning, Jooeun Song, Lindy Clemson, Natalie E Allen

P25.18 Immediate effects of music therapy on gait disturbance in Parkinson’s disease, and possibility to reduce the risk of freezing by analyzing the trajectory of center of body
Emiri Gondo

P25.19 Effectiveness of transcranial direct current stimulation (tDCS) on clinical perceived pain and pain processing features in Parkinson’s disease (PD) patients
Yeray González Zamorano, Francisco José Sánchez Cuesta, Aida Arroyo Ferrer, Marcos Moreno Verdú, Laura Valenzuela López, José Fernández Camero, Juan Pablo Romero Muñoz

P25.20 Voice changes following deep brain stimulation in persons with Parkinson disease
Nicole Herndon, Karen Hegland

P25.21 Speech and swallow trends following bilateral deep brain stimulation in persons with Parkinson disease: A retrospective chart review
Nicole Herndon, Karen Hegland, May Smith-Hublou

P25.22 Effects of motor-cognitive training on dual task performance in people with Parkinson’s disease: A systematic review and meta-analysis
Hanna Johansson, Ann-Kristin Folkerts, Ida Hammarström, Elke Kaibe, Breiffni Leavy

P25.23 Long-term effects of a 6-month brisk walking and balance program on physical performance and health-related quality of life in people with Parkinson disease: A randomized controlled trial
Margaret KY Mak, Irene SK Wong-Yu

P25.31 Gait impairments in Parkinson’s disease
Anat Mirelman, Richard Camicioli, Terry Ellis, Jochen Klucken, Larry Gilford, Jeffrey Hausdorff, Elisa Pelosin, Paolo Bonato, Alfonso Fasano, Alice Nieuwboer

P25.36 Clinical practice guideline for the physical therapist management of Parkinson disease: An American physical therapy association and academy of neurologic physical therapy collaboration for quality improvement
Miriam Rafferty, Beth Crowner, Jacqueline Osborne, Terry Ellis

Comprehensive Care: Nutrition and gastrointestinal issues

P26.01 Case studies documenting the interaction of antibiotics, photobiomodulation and Parkinson’s disease
Brian Bicknell, Ann Liebert, Anita Saltmarche, Orla Hares, Hosen Kiat

P26.03 The mealtime of people with Parkinson’s disease: A qualitative descriptive pilot study
Muriel Gabas, Estelle Harroche, Jean Paul Poulain, Virginie Woizard, Margherita Fabбри
P26.04 The unmet nutritional needs of people living with Parkinson’s Disease
Richelle Flanagan

Clinical Science: Symptoms, signs, features & non-motor manifestations

P27.01 The novel p.A30G SNCA mutation in Greek Parkinson’s disease patients and asymptomatic family members
Ioanna Alefanti, Christos Koros, Chrisoula Kartanou, Athina Maria Simitsi, Maria Bozi, Stefanos Varvarellos, Athina Zachou, Roubina Antonelou, Matina Maniati, Sokratis Papageorgiou, Georgios Paraskevas, Constantín Potagas, Marios Panas, Konstantinos Youmournakis, Georgia Karadima, Georgios Koutris, Leonidas Stefanis

P27.02 Nature, degree of frequency and importance of the motor and non-motor disorders in 39 patients with Parkinson’s disease
Etienne Baldayrou, Etoile Baroux-Petiperrin, Camille Beauger, Geneviève Merelle, Elise Maugras, Serge Merelle

P27.03 Compassionate mind training for people with Parkinson: A pilot study
Elena Berti, Silvia Della Morte, Carolina Lalli, Francesca Morgante, Nicola Modugno, Luca Ricciardi

P27.04 Personality dimensions in Parkinson’s disease patients with or without chronic pain
Mathilde Boussac, Fleur Lerebours, Nathalie Cantagrel, Margherita Fabbri, Clémence Leung, Fabienne Ory-Magne, Olivier Rascol, Estelle Harroch, Emeline Descamps, Christine Brefel-Courbon

P27.05 Validation and replication of Parkinson disease behavioral subtypes
Christina Lessov-Schlaggar, Peter Myers, Joshua Jackson, Baijayanta Maiti, Paul Kotzbauer, Joel Perlmutter, Meghan Campbell

P27.09 Exploring prediction of freezing of gait using sensor-based probability of freezing
Allison M Haussler, Lauren E Tueth, David S May, Gammon M Earhart, Pietro Mazzoni

P27.11 Impulsiveness: A clinical aspect in Parkinson’s disease with freezing of gait
Karina Yumi Tashima Honda, Nathalia de Britto Pereira, Maria Elisa Pimentel Piemonte, Isaila Almeida Pereira da Silva Nascimento, Katia Cirilo Costa Nobrega, Thayane Habache Barolli

P27.12 Parkinson’s disease duration and motor symptom severity at baseline: An analysis of the Parkinson Progression Markers Initiative (PPMI) dataset
Emily Houston

P27.13 Patterns and consistency of speech changes in a diverse national sample of people with parkinson disease in the United States
Jessica Huber, Andrew Exner, Sandy Snyder, Hardik Kothare, Jackson Liscombe, Renee Kohlmeier, Shreyu Sridhar, Brianna Coster, Kaylee Patterson, Helen Willis, Vikram Ramanarayan

P27.14 Women and Parkinson’s disease: The impact of hormonal fluctuations during the menstrual cycle on parkinson symptoms
Willanka Kapelle, Esra Stuart, Hein Bogers, Bastiaan Bloem, Marjan Meinders, Annelien Oosterbaan, Bart Post

P27.15 Measurement of dyskinesia in Parkinson’s disease using a lower back sensor

P27.16 Clinical parameters associated with impaired self-awareness of levodopa-induced dyskinesias in Parkinson’s disease

P27.17 Discrepancy between self-awareness and objective measurements of olfactory function In patients with Parkinson’s disease
Do-Young Kwon, Hwa Been Yang, Minyoung Seo

P27.18 Association between dizziness and clinical features in patients with de novo Parkinson’s disease?
Kyum-Yil Kwon, Jiwhan You, Rae On Kim, Eun Ji Lee
P27.19  Sex differences in motor and non-motor symptoms among Spanish patients with Parkinson’s disease

P27.20  Cardiac perception task demonstrates interoceptive precision is impaired in Parkinson’s disease
Senegal Alfred Mabry, Samantha Moss, Jeffery Bauer, Eve De Rosa, Adam Anderson

P27.21  Observational study to investigate the relationship between stress related disorders and dysautonomic symptoms in Parkinson’s disease
Esrom Jared Acosta Espinoza, Ilse Alejandra Ortiz Marroquin, Daniela Itzel Salinas Leal, Adriana Salinas Blancas, Hannia Mariana Macías Cruz, Daniel Martinez-Ramirez

Clinical Science: Progression & prognosis
P28.01  The neuro genomics partnership: A new consortium dedicated to a fully open patient to patient (P2P) integrative R&D approach
Clotilde Degroot, Kirsten Taylor, Sandor Szalma, Vincent Mooser, Ziv Gan-Or, Madeleine Sharp, Thomas Durcan, Caitlin Taylor, Marc Lussier, Edward Fon

P28.02  Parkinson’s: One disease or several? The fallacy of subtypes
Jodie Forbes

P28.07  Machine learning-based prediction of cognitive decline in early Parkinson’s disease using multimodal features
Hannes Almgren, Milton Camacho, Alexandru Hangau, Mekale Kibreab, Richard Camiciaoli, Zahirou Ismail, Nils D. Forkert, Oury Monchi

Clinical Science: Behavioral disorders
P29.01  Cognitive behavioral therapy for anxiety in Parkinson’s disease induces functional brain changes
Guillaume Carey, Renaud Lopes, Anja Moonen, Anne Mulders, Joost de Jong, Gregory Kuchcinski, Defevre Luc, Mark Kuijf, Kathy Dujardin, Leentjens Albert

P29.02  Jumping to conclusions (JtC) and its association with psychosis and impulsivity in early stages of Parkinson’s disease
Ioanna Pachi, Vasilis Papadopoulos, Christos Koros, Athina-Maria Simitsi, Anastasia Bougea, Maria Bozi, Nikos Papagiannakis, Rigas-Filippos Soldatos, Dimitra Kolovou, George Pantes, Nikolaos Scarmeas, Georgios Paraskevas, Konstantinos Vourmourakis, Sokraitis Papageorgiou, Konstantinos Kollias, Nikos Stefanis, Leonidas Stefanis

P29.03  Multidisciplinary approach as key to successful management of functional disorders in patients treated with deep brain stimulation – A report of two patients
Marijan Masic, Valentino Racki, Elisa Papic, Ines Toric, Vladimir Vuletic

Clinical Science: Cognition/ mood/ memory
P30.01  Investigating the effects of COVID-19 and the first UK lockdown on anxiety and mood in people with Parkinson’s
Moudhi Al Twaijri

P30.02  Imitation of object-directed hand movements in Parkinson’s
Judith Bek, Eamon Brockenbrough, Emma Gowen, Stefan Vogt, Trevor Crawford, Ellen Poliakoff

P30.03  Impact of cognitive impairment on quality of life in Mexican persons living with Parkinson’s disease
Gloria Itzel Cerda Hernández, María Alejandra Ruiz Mafud, Anna Paola Bazán Rodríguez, Etienne Reséndez Henríquez, Eduardo Ichikawa Escamilla, Daniela Renee Aquila Godínez, Axel Antonio Herrera Ruiz, Ana Jimena Hernández Medrano, Amin Cervantes Arriaga, Mayela Rodríguez-Violante

P30.04  NeuroOrb: An accessible co-designed “Serious Games” system for targeted cognitive training in Parkinson’s disease
Lyndsey Collins-Praino, Bianca Guglietti, Simon Drum, Angus McNamara, Benjamin Ellul, Bradley Wesson, David Hobbs
POSTERS – Session 1
Wednesday, July 5, 2023

P30.05  Moderating effects of uric acid and sex on non-motor symptoms in asymmetric Parkinson’s disease
         Ioana Medeleine Constantin, Philippe Voruz, Julie Anne Péron

P30.06  Differential effects of motor task and executive demand on cognitive dual-task performance in people with Parkinson’s disease and freezing of gait
         Nicholas D’Cruz, Jana Seuthe, Femke Hulzinga, Pieter Ginis, Christian Schlenstedt, Alice Nieuwboer

P30.07  The impact of antidepressant treatment on disease-related disability: Preliminary findings from the Parkinson’s progression markers initiative
         Roseanne Dobkin, Nabila Dahodwala, Catherine Kulick, Meredith Bock, Ryan Cho, Chelsea Caspell-Garcia, Ethan Brown, Dag Aarsland, Daniel Weintraub

P30.08  Is the ability to create motor images related to functionality and quality of life in people with Parkinson’s disease and healthy control?
         María del Rosario Ferreira-Sánchez, Marcos Moreno-Verdú, Yeray González-Zamorano

P30.09  Cognitive performance and depression in Parkinson’s disease: A cross sectional analysis
         Emily Houston

P30.10  The neuropsychological profile and other clinical characteristics in non-affected GBA-carriers versus non-carriers
         Sonja R. Jónsdóttir, Claire Pauly, Valerie E. Schröder, Laure Pauly, Olena Tsurkalenko, Rejko Krüger

P30.23  Extending the BRAIN keyboard tapping test: To detect cognitive decline in a large community cohort of older Australians
         Xinyi Wang, Rebecca J. St George, Aidan Bindoff, Alastair J Noyce, Katherine Lawler, Eddy Roccati, Larissa Bartlett, Son Tran, James Vickers, Quan Bai, Jane Alty

P30.24  Using keyboard motor tests in a cognitive clinic may help identify stages of the dementia continuum
         Xinyi Wang, Aidan Bindoff, Rebecca J. St Geroge, Son Tran, Kaylee Rudd, Quan Bai, James Vickers, Jane Alty

Clinical Science: Sleep disorders/ fatigue

P31.01  Continuous dopaminergic stimulation to improve sleep disorders in Parkinson’s disease with insomnia: Results from the Apomorphine study on subcutaneous night-time only apomorphine infusion
         Valérie Cochen De Cock, Pauline Dodet, Smaranda Leu, Cecile Aerts, Giovanni Castelnovo, Beatriz Abril, Sophie Drapier, Laurene Leclair-Visonneau, Marie Vidalhil, Isabelle Arnulf, Mohamed Doulazmi, Emmanuel Roze

P31.05  Keyboard tapping performance in people with subjective REM sleep behaviour disorder
         Cristina Simonet, Harneek Chohan, Teresa Perinan Tocino, Laura Perez-Carbonell, Guy Leschziner, Aneet Gill, Jonathan Bestwick, Anette Schrag, Alastair Noyce

Clinical Science: Diagnosis (differential, accuracy)

P32.01  Acute onset secondary Parkinsonism due to extrapontine myelinolysis
         Cintia Margoth Armas Puente, Carlos Cosentino Esquerre

P32.02  Tacrolimus-induced Parkinsonism: A case report
         Cintia Margoth Armas Puente, Carlos Cosentino Esquerre

P32.03  Parkinson’s disease: A new metabolic biomarker for early diagnosis and development of potential therapeutic target
         Sabrina Boulet, David Mallet, Raphael Goutaudier, Thibault Dufourd, Sebastien Carnicella, Emmanuel Barbier, Florence Fauvelle, Véronique Sgambato, Pierre-Olivier Fernagut, Jerry Colca

Clinical Science: Co-morbidities

P33.01  PD and spine surgery: The importance of less-invasive surgery and potential of knowledge mobilizatil
         Christian Carrwik, Anna Clareborn
P33.02 The prevalence of sarcopenia in an international Parkinson’s disease cohort

P33.03 A systematic review of the prevalence of sarcopenia in Parkinson’s disease and related disorders
Laura Cordova Rivera, Ashley Hart, Fred Barker, Avan A. Sayer, Antoneta Granic, Alison J Yarnall

Clinical Science: Biomarkers and neuroimaging

P34.01 Plasma ptau181 helps to identify amyloid-β co-pathology in Lewy body disease patients
Carla Abdelnour, Melanie J. Piastini, Marian Shahid, Alena Smith, Edward N. Wilson, Katrin Andreasson, Victor Henderson, Geoffrey Kerchner, Kathleen L. Poston

P34.03 Dopaminergic dysfunction is more symmetric in dementia with Lewy bodies compared to Parkinson’s disease
Tatyana Fedorova, Karoline Knudsen, Jacob Horsager, Allan K Hansen, Niels Okkels, Hanne Gottrup, Kim Vang, Per Borghammer

P34.05 Ocular microtremor in Parkinson’s disease: Protocol for an observational pilot study
Lisa Graham, Rodrigo Vitorio, Claire McDonald, Richard Walker, Alan Godfrey, Rosie Morris, Samuel Stuart

P34.07 Differential prognostic implications of cerebral hypo- and hyperperfusion in Parkinson’s disease: Early-phase 18F-FP-CIT PET study
Seong Ho Jeong, Jong Sam Baik, Phil Hyu Lee, Young H. Sohn, Seok Jong Chung

P34.08 Adaptive closed loop deep brain stimulation in advanced idiopathic Parkinson’s disease patients: A study with neuroengineering perspective
Neerati Lavanya

P34.10 Characterizing Parkinson’s clinical features in black americans and measuring the effect of non-impact lower body exercise on neuroimaging biomarkers and motor and gait function
Senegal Alfred Mabry, Samantha Moss, Jeffery Bauer, Eve De Rosa, Adam Anderson

P34.11 Predicting progression of Parkinson’s disease motor outcomes using a multimodal combination of baseline clinical measures, neuroimaging and biofluid markers
Angus McNamara, Benjamin Ellul, Dr Irina Baetu, Dr Stephan Lau, Professor Mark Jenkinson, Assoc/Professor Lyndsey Collins-Praino

P34.12 Local field potentials in Parkinson’s disease: Effect of lead type and target, peak detection, and contact selection
Alfonso Fasano, Thomas Witt, Sara Bick, Mya Schiess, Hideo Mure, Genko Oyama, Katsuo Kimura, Alexa Singer, Claudia Sannelli, Nathan Morelli

P34.13 Real-world local field potential dynamics in patients with Parkinson’s disease
Alfonso Fasano, Hideo Mure, Genko Oyama, Thomas Witt, Alexa Singer, Claudia Sannelli, Nathan Morelli

Clinical Science: Pharmacological therapy

P35.03 Effect of cannabis on motor and non-motor symptoms of Parkinson’s disease: A behavioral and pharmacological study in rats
Elodie Giorla, Christelle Baunez

P35.04 Deciphering cross talks of dopamine/insulin/NLRP3-Inflammasome signaling (DA/IN/NLRP3), metabolic syndrome(MeS) and cardiovascular risk (CVR) in drug-(antipsychotic)-induced Parkinsonism (DIP) and tardive dyskinesia (TD) mimicking Parkinson’s disease (PD) motor/cognition symptoms: Neuroprotective effects of Panax ginseng: The prototypal NLRP3 regulator
Autumn Carriere, Simon Chiu, Jerry Hou, Edmund Lui, Mariwan Husni, John Copen, Robin Campbell, Allison foskett, Shad Muejeeb, Michel Woodbury-Farina, Ram Mishra, Yves Bureau, Amresh Srivastava

P35.05 Drivers of treatment decisions in advanced Parkinson’s disease: A qualitative study among people with Parkinson’s and caregivers
Josefa Domingos, Rajesh Pahwa, Angelo Antonini, Irene Malaty, Susanna Lindvall, Francesco De Renzis, Connie Yan, Kryshalla Pantiri, Nancy Toubia, Emily Evans, Ali Alobaidi, Anand Shewale, Pavnrit Kukreja, Jorge Zamudio, K Ray Chaudhuri

P35.06 Apomorphine hydrochloride injection (Apokyn®) treatment initiations in the presence and absence of an antiemetic in people with Parkinson disease
Mindy Grall, Cindy Happel, Andrea Formella
P35.08 Personalized dopaminergic treatment in a cohort of Parkinson’s disease patients carrying autosomal recessive gene variants
Christos Koros, Athina-Maria Simitsi, Anastasia Bougea, Nikolaos Papagiannakis, Roubina Antonelou, Ioanna Pachi, Athina Zachou, Constantin Potagas, Leonidas Stefanis

P35.09 Summative human factors validation of the foslevodopa/foscarbidopa (ABBV-951) continuous subcutaneous infusion drug delivery system by Parkinson's disease patients, caregivers, and healthcare professionals
Pavnit Kukreja, Ed Halpern, Jill M. Giordano Farmer, Michael J. Soileau, Ji Zhou, Amy M. Spiegel

P35.10 A comparative study for selecting the proper Parkinson’s disease medication with Fuzzy PROMETHEE
Ilker Ozsahin, Efe Precious Onakpojeruo, Berna Uzun, Diller Uzun Ozsahin, Tracy Butler

P35.11 6 years of safinamide in the treatment of Parkinson’s disease: Low rate of discontinuation and sparing of dopamine agonists
Anna Planas Ballvé, Nuria Caballol Pons, Isabel Gómez-Ruiz, Marta Balagüé Marmaña, Alex Velazquez, Xavier Cardona, Asunción Ávila Rivera

Clinical Science: Surgical therapy, including cell and gene therapy

P36.02 Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson’s disease patients: Five-year follow-up
Sun Ju Chung, Sungyang Jo, Seung Hyun Lee, Mi-Sun Kf, Yun Su Hwang

P36.03 Accuracy of the Guide™ XT to determine the electrodes position according to the clinical outcome after subthalamic nucleus deep brain stimulation in patients with Parkinson’s disease
Kirysys Del Giudice, Almudensa Sánchez-Gómez, Pedro Roldán, Jordi Rumià, Esteban Muñoz, Ana Cámara, Francesc Valdeoriola

P36.04 Enhanced differentiation of human induced pluripotent stem cells towards the midbrain dopaminergic neuron lineage both in vitro and in vivo through GLYPICAN-4 down regulation
Serena Corti, Remi Bonjean, Thomas Legier, Diane Rattier, Christophe Melon, Pascal Salin, Lydia Kerkerian-Le Goff, Rosanna Dono

P36.05 Improvement in quality-of-life and motor function during daily clinical practice using a directional DBS system
Jan Vesper, Helene Scholtes, Roshini Jain, Lilly Chen, Michael Barbe, Steffen Paschen, Andrea Kühn, Chong Sik Lee, Jens Volkmann, Günther Deuschl

P36.06 Real-world outcomes in USA using DBS systems with directionality and multiple independent current control

P36.07 Motor function and quality-of-life improvement following asleep versus awake deep brain stimulation (DBS) procedures
Jan Vesper, Günther Deuschl, Lilly Chen, Roshini Jain

Clinical Science: Complications of therapies

P37.01 Protocol to help neurologists manage subcutaneous apomorphine therapy skin nodules: Expert roundtable recommendations
Stu Isaacson, Mindy Grall, Fiona Gupta, Daniel Kremens, Cuong Nguyen, Rajesh Pahwa, Marc Serota, Matthew Zirwas, Steven Feldman

P37.02 Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson’s disease: A systematic review
Jean-François Houvenaghel, Virginie Czenecki, Kathy Dujardin, Emmanuelle Schmitt, Alexia Arifi, Eve BENCHETRIT, Céline Dillier, Elodie Lemercier, Cécile Cau, Amélie Bichon, Laura Lavigne, Mylène Meyer

Clinical Science: Clinical trials: Design, outcomes, recruiting, etc.

P38.02 Phenotyping REM sleep behaviour disorder in a large community cohort in Tasmania, Australia: Baseline characteristics of the ISLAND Sleep Study
Samantha Bramich, Alastair Noyce, Anna King, Aidan Bindoff, Maneesh Kuruvilla, Sharon Naismith, Larissa Bartlett, James Vickers, Jane Alty
Onset of efficacy with continuous, subcutaneous levodopa/carbidopa infusion in patients with PD experiencing motor fluctuations
C. Warren Olanow, Fabrizio Stocchi, Aaron L. Ellenbogen, Liat Adar, Ryan Case, Tami Yardeni, Alberto J Espay

Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Alberto J. Espay, Tanya Gurevich, David Arkadir, Sophia Sopromadze, Liat Adar, Ryan Case, Tami Yardeni

Efficacy of 24-hour subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Subgroup-analysis from the open-label BeyoND study
Werner Poewe, Stuart Isaacson, Fabrizio Stocchi, Liat Adar, Nelson Lopes, Ryan Case, Tami Yardeni, Nir Giladi

Enrollment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612

Utilizing a variation of the train the trainer model to create best practice guidelines and to build a culturally sensitive and community educated team of ambassadors to increase diverse enrollment in clinical trial research studies
R Bernard Coley, Denise Coley

Targeted touchscreen training in people with Parkinson’s disease: A pilot study
Joni De Vleeschauwer, Evelien Nackaerts, Yifeng Zhang, Luc Janssens, Wim Vandenbergh, Alice Nieuwboer

An entirely home-based phase 3 clinical trial of specialized light therapy for Parkinson’s disease – Rationale and design
Ray Dorsey, Dan Adams, Suzanne Hendrix, Bradley Wyman, Jamie Adams, Meghan Pawlik, Melissa Kostrzebski, Karl Kieburtz

Key factors affecting participation in Parkinson’s clinical trials
Rosie Fuest, Gary Rafaloff, Kevin McFarthing, Lyndsay Isaacs, Helen Bracher, Tim Bracher, Alison Anderson, Michelle Bartlett, Zia Mursaleen, Georgia Mills, Marie-Louise Zeissler, Camille Carroll, Leah Mursaleen, Soania Mathur, Helen Matthews, Emma Lane

The current experience of participating in Parkinson’s clinical trials
Rosie Fuest, Gary Rafaloff, Kevin McFarthing, Lyndsay Isaacs, Helen Bracher, Tim Bracher, Alison Anderson, Michele Bartlett, Zia Mursaleen, Georgia Mills, Marie-Louise Zeissler, Camille Carroll, Leah Mursaleen, Soania Mathur, Helen Matthews, Emma Lane

Building a coalition to advance engagement of black and African American communities in Parkinson’s disease (PD) research using best practices in diversity, equity and inclusion (DEI), and patient engagement: A multidisciplinary approach

Outcomes and impact of capacity building for patient engagement in research on staff at academic research centers through a patient advisory board model
Casey Gallagher, Karlin Schroeder, Melissa Armstrong, Martie Carne, Megan Dini, Megan Feneey, Benzi Kluger, Sandhya Seshadri, Lance Wilson, Jori Fleisher, Patricia Davies

An outcome measure set for disease-modifying multi-arm multi-stage Parkinson’s disease trials within the EJS ACT-PD initiative: Selection process and preliminary results
Cristina Gonzalez-Robles, Rebecca Chapman, Sally Collins, David T Dexter, Susan Duty, Romy Ellis-Doyle, Edwin Jabbari, Keith Martin, Kevin McFarthing, Georgia Mills, Heather Mortiboy, Esther Sammler, Paula Scurfeld, Simon Stott, George Tofaris, Li Wei, Alan Wong, Marie-Louise Zeissler, Camille B Carroll, Thomas Foltynie, Rimona Weil, Anette Schrag

Disease-modifying drug selection in multi-arm multi-stage Parkinson’s disease trials within the EJS ACT-PD initiative
Cristina Gonzalez-Robles, Rebecca Chapman, Shona Clegg, Sally Collins, Eric Deeson, Romy Ellis-Doyle, Maryanne Graham, Vince Greaves, Joel Handley, Emily J Henderson, Karen Matthews, Laurel Miller, Georgia Mills, Marie-Louise Zeissler, Camille B Carroll, Thomas Foltynie, Sonia Gandhi, Joy Duffen

Funding and sustainability of a multi-arm multi-stage Parkinson’s disease clinical trial: Challenges and progress within the EJS ACT-PD initiative
Cristina Gonzalez-Robles, Rebecca Chapman, Shona Clegg, Sally Collins, Eric Deeson, Romy Ellis-Doyle, Maryanne Graham, Vince Greaves, Joel Handley, Emily J Henderson, Karen Matthews, Laurel Miller, Georgia Mills, Marie-Louise Zeissler, Camille B Carroll, Thomas Foltynie, Sonia Gandhi, Joy Duffen
P38.20  Piloting the PREDIGT score in a movement disorders clinic to distinguish Parkinson’s patients from subjects with other diagnoses without a neurological examination  
Kelsey Grimes, Juan Li, Joseph Saade, Julianna Tomlinson, Douglas Manuel, Tiago Mestre, Michael Schlossmacher

P38.21  LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson’s disease patients with and without LRRK2 mutations (LIGHTHOUSE and LUMA)  
Julia Shirvan, Danna Jennings, Pan Wang, Romeo Maciuca, Sowmya Chary, Katie Harrison, Angela Kay, Kyle Fraser, Sarah Huntwork-Rodriguez, Minhua Yang, Mathieu Levee, Peter Chin, Tien Dam

P38.30  Characterizing the frequency of clinically reportable variants in major genes established in Parkinson’s disease (PD) in a large American cohort  

P38.38  Parkinson’s disease drug therapies in the clinical trial pipeline: 2020-2022  
Kevin McFarthing, Sue Buff, Gary Rafaloff, Leah Mursaleen, Rosie Fuest, Marco Baptista, Brian Fiske, Richard Wyse, Simon Stott

P38.39  Ten years of drug repurposing for Parkinson’s: The international linked clinical trials project  

Clinical Science: Rating scales

P39.01  Virtual low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson’s disease  

P39.02  Remote scoring of a low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson’s disease  

P39.03  The Ziegler test is a reliable and valid measure of freezing of gait in people with Parkinson’s disease  
Lina Goh, Serene S Paul, Colleen G Canning, Kaylena A Ehgoetz Martens, Jooeun Song, Stephanie L Campoy, Natalie E Allen

Clinical Science: E-health and technology

P40.01  TAS Test automatic hand movement analysis – Validation of a new self-assessment tool designed for home use  
Jane Alty, Quan Bai, Xinyi Wang, Renjie Li, Guan Huang, Katharine Lawler, Rebecca St. George, Kaylee Rudd, Eddy Roccati, Aidan Bindoff, Larissa Bartlett, Saurabh Garg, Mark Hinder, Anna King, James Vickers

P40.02  A 20-second home-based test helps detect prodromal Parkinson’s in a community sample of older Australians  
Jane Alty, Samantha Bramich, Xinyi Wang, Renjie Li, Alastair Noyce, Guan Huang, Maneesh Kuruvilla, Rebecca St. George, Katherine Lawler, Mark Hinder, Eddy Roccati, Larissa Bartlett, Saurabh Garg, Quan Bai, Sharon Naismith, Anna King, James Vickers

P40.03  Evaluation of the Parkinson’s Remote Interactive Monitoring System (PRIMS): A usability study  
Bronwyn Bridges, John Weber, Jake Taylor

P40.04  Screening risk of falls in people with Parkinson’s disease using a digital App: A feasibility study  
Tamine Capato, Johnny Miranda, Venicio Graboi, Francielle Santos, Fabiana Almeida, Rafael Carra, Rubens Cury, Manoel Teixeira, Egberto Barbosa

P40.06  Acceptability of a hybrid dual-task exercise program for Parkinson’s delivered online to an in-person group, facilitated by an on-site physical therapist  
John Dean, Josefa Domingos, Emily Moncheski, Catarina Godinho
P40.07 A preliminary feasibility study of online motor assessments of people with Parkinson’s disease and related conditions
Menna Eltaras, Abdelwahab Eshourbagy, Hassan Abdelshafy, Samrah Javed, Ahmed Sadaney, Timothy Harrigan, Kelly Mills, Manuel Hernandez, James Brasic

P40.08 Design and development of a digital therapeutics (DTx) delivering personalized medication optimization for people with Parkinson’s disease
Giovanni Gentile, Maria Teresa Pellecchia, Pier Paolo Iagulli, Raffaele Aulisio, Maria Frediani, Silja-Riin Voolma, Gerry Chilè

Clinical Science: Neuroimaging

P41.01 Cerebral glucose consumption and synaptic density in patients with Lewy body diseases, as measured with [18F]FDG and [11C]UCB-J PET
Katrine B. Andersen, Allan K. Hansen, Anna Christina Schacht, Jacob Horsager, David J. Brooks, Per Borghammer

P41.05 Dancing modifies activations in brain regions associated with movement, mood and reward in people with Parkinson’s
Rebecca Barnstaple, Judith Bek, J Royze Simon, Rachel Bar, Karolina Bearss, Katayoun Ghanaeei, Ashkan Karimi, Joseph FX DeSouza

P41.06 Image-guided programming tool for DBS programming used with a multiple-source, constant-current system reduces initial programming time
Jason Aldred, Theresa Zesiewicz, Michael Okun, Juan Ramirez-Castaneda, Leo Verhagen-Metman, Corneliu Luca, Ritesh Ramdhani, Jennifer Durphy, Yarema Bezhchibnyk, Jonathan Carlson, Kelly Foote, Sepehr Sani, Alexander Papunastassioi, Jonathan Jagid, David Weintraub, Julie Pilisius, Lilly Chen, Roshini Jain

P41.07 The effect of nonimpact eccentric lower body exercise on Parkinson’s symptoms and substantia nigra structure and function
Senegal Alfred Mabry, Samantha Moss, Jeff Bauer, Eve De Rosa, Adam Anderson

P41.10 Neuroinflammation is elevated in people with Parkinson’s disease with higher risk of developing dementia: Baseline findings from the NET-PDD (NEuroinflammation and Tau aggregation in Parkinson’s Disease Dementia) study
Lennart R B Spindler, Antonina Kouli, Tim D Fryer, Young T Hong, Franklin I Algbrhio, Simon R White, Maura Malpetti, Marta Camacho, Caroline H Williams-Gray

Clinical Science: Prodromal

P42.01 Isolated REM sleep behaviour disorder (prodromal Parkinson’s disease) is associated with poor sleep quality in Tasmanian ISLAND sleep study
Samantha Bramich, Aidan Bindoff, Anna King, Alastair Noyce, Jane Alty

P42.02 Detecting early symptoms of parkinsonism and isolated REM sleep behaviour disorder in the Tasmanian ISLAND sleep study using a quick online screening questionnaire
Samantha Bramich, Aidan Bindoff, Anna King, Alastair Noyce, Jane Alty

Living with Parkinson’s: Public education or awareness programs

P43.02 Subjective evaluation of “painfulness” and its variation factors in working generation PwPs (Parson with Parkinson’s)
Yojiro Ashina, Yuki Furumoto, Junya Ogawa, Mikitaka Matsuno, Masashi Hiraoka, Satoshi Akiyama

P43.04 Maintaining social insertions while facing varying symptoms: Experiences of working-age patients with Parkinson disease
Myriam Borel

P43.05 “Surely, you are too young”
Sheenagh Bottrell

P43.07 Development of a patient journey map for people living with Parkinson’s disease
Alberto Albanese, Ryan Case, Anat Amit, Shmuel Ben-Hamo

P43.08 Exploring public perceptions and awareness of Parkinson’s disease: A scoping review of the international literature
Sophie Crooks, Gillian Carter, Christine Brown Wilson, Lisa Wynne, Gary Mitchell
P43.10  **Stand up to Parkinson’s: A global awareness campaign for exercise in Parkinson’s on WPD 2022**  
Laura Douglas

P43.17  **A call to action for community-based exercise classes: Building a team of healthcare providers, students, and fitness instructors**  
Robert Hand

P43.21  **Piece of mind: Parkinson’s screening and interactive workshop**  
Naila Kuhlmann, Anne Molsaac, Jeremie Robert, Alice Masson, Rebecca Barnstaple, Louise Campbell

P43.22  **Friends of Parkinson’s: Involving youth in raising public awareness about Parkinson’s disease in India**  
Deepshikha Mathur, Maria Barretto

P43.25  **A Parkinson’s manifesto for Europe**  
Fiona Montague, Joseta Domingos, Amelia Hursey

P43.26  **What I didn’t say – A journey through Parkinson’s: An original play about life with Parkinson’s, authored and produced by Matthew Moore, Ohio, United States**  
Matthew Moore

P43.27  **The Barcelona Parkinson’s Ready Program**  
Selma Pelaez

P43.28  **A study on social media strategies employed by the PDMDS to create awareness on Parkinson’s Disease in India**  
Neha Rane, Maria Barretto

P43.29  **Faces of Parkinson’s**  
Travis Robinson

**Living with Parkinson’s: Government advocacy/campaigns/public policy**

P44.02  **Anti-antiparkinsonian drug use after diagnosis of Parkinson’s disease**  
Woong-Woo (Woody) Lee, Beomseok Jeon

P44.03  **Assessing access to medications and other health-related barriers for people living with Parkinson’s: A pmd alliance policy panel survey**  
Andrea Merriam, Greg Chesmore, Maria Cristina Ospina, Jill Farmer, Lori DePorter, Julia Pitcher, Kelly Papesh, Jason Rivera

P44.04  **Networking of NGOs with World Parkinson Coalition: Approach in public health policy evolution**  
Shankh Pal, Toshni Roy, Jyothi Kumari

**Living with Parkinson’s: Living well with PD**

P45.01  **Living well with Parkinson’s disease**  
Chinyere Rachel Agwu

P45.02  **PARK&SUN: An intergenerational discussion**  
Jean Andresen, Hannah Nizet, Lily Nizet

P45.03  **What patients themselves can do to make DBS a success**  
Yojiro Ashina

P45.07  **Live well with Parkinson’s through connective dance/movement practices that promote changing flow states: A study by Dr Melanie Brierley, independent dance and health artist and researcher, United Kingdom**  
Melanie Brierley

P45.08  **4 simple tips for full-time workers with Parkinson’s**  
Luis Castellanos

P45.09  **Restore your power and control your present with a health education channel you can truly rely on**  
Begoña Cirera Perez
P45.10  Parkinson Society BC bridges the gap between clinical care and social care: Social prescription initiatives  
Alana Dhillon

P45.11  Young Parkies Portugal: Empowered to improve care in young-onset Parkinson’s disease  
Josefa Domingos, Maria do Carmo Teixeira Bastos, Rui Couto, Ana Rita Carneira, Ana Leal Cardoso, Alexandre Reffóios, Susana Magalhães, João Massano, Tiago Fleming Outeiro

P45.12  Walking in a group using urban walking poles to improve physical and mental health  
Sandra Elms

P45.17  Happiness with Haiku; ZOOM Haiku meeting for PwP  
Nobuko Haneji

P45.18  Caring for the carepartner: Gatekeepers and guardians  
Celeste Harris, Kathleen Crist

P45.20  PD&ME: Leveraging technology to increase access to wellness and support groups  
Rebecca Korduner, Anissa Mitchell

P45.21  Sunday mornings with Twitchy Woman: Learn together, play together and thrive together. A response to the pandemic shutdown  
Sharon Krischer

P45.22  Decades-long fight against PD: A scientist’s experience and perspectives  
Prabhakaran Kuniyiyi

P45.25  A novel peer mentoring support system for persons with Parkinson’s disease  
Tsao-Wei Liang, S. Kenneth Thurman, Lance Wilson, Kimberly Stoveld

P45.28  Parkinson can’t steal my heart, love, thoughts and poetry: Writings by Lil Saint Laurent  
Alice Masson

P45.29  Parkinson’s wellness professionals needs assessment  
Bradley McDaniels, Gabriella Dimotsantos, Davis Phinney Foundation, National Engagement Advisory Team

P45.30  Impact of socioeconomic status on severity of symptoms and quality of life in Mexican people living with Parkinson’s disease  
Maria Fernanda Medina-Pérez, Diana Paulina Romero-Terán, Andrea García-Hernández, Ana Jimena Hernández-Medrano, Rodolfo Arturo Abundes-Corona, Amin Cervantes-Ariaga, Mayela Rodriguez-Violante

P45.31  Parkinson’s Europe’s don’t lose sleep over Parkinson’s campaign  
Tara Nabili, Dominic Graham, Jennifer Stratten, Adrien Moyroud

P45.32  ‘Exchanges’: A visual resource to inspire and support deeper conversations in the Parkinson’s community  

Living with Parkinson’s: Advancing research: collaborations, capacity building, fundraising, trials, campaigns

P46.01  Including patients and care partners in clinical trial design: The EJS ACT-PD experience  
Michele Bartlett, Eric Deeson, Jodie Forbes, Anna Jewell, Keith Martin, Laurel Miller, Kuhun Pushparatnam, Dorothy Salathiel, Paula Scurfield, Carroll Sia, Sue Whipps, Sheila Wonncott, Kevin McFarthing

P46.03  The Canadian Open Parkinson Network (C-OPN): A multimodal biorepository connecting the Canadian Parkinson’s community around the world  
Marisa Cressatti, Catherine Normandeau, Clotilde Degroot, Iris Kathol, A. Jon Stoessl, Martin McKeown, Janis Miyasaki, Richard Camicioli, David Grimes, Lorraine Kalia, Antonio Strafella, Penny MacDonald, Nicolas Dupré, Edward Fon, Oury Monchi
P46.04 Parkinson community plays a critical role in new brain health initiative
Roseanne Dobkin, Maggie McGuire Kuhl, Lynell Lemon, Christina Destro, Caitlin Kelliher, Laura Heathers, Michelle Totten, Erin Bryan, Craig Stanley, Chris Hobbick, Bridget McMahon, Kim Fabrizio, Ken Marek

P46.05 A call to action: Including people with Parkinson’s in clinical study design and execution
Anne Donnelly, Margaret Sheehan

P46.06 Informing a multi-country Parkinson’s research grant in Africa through community engagement and involvement
Jared Okeno, Natasha Fothergill-Misbah, Richard Walker, Njideka Okubadejo, Tania Park, Omotola Thomas

P46.07 Transforming Parkinson’s Care in Africa (TraPCAF): A newly funded research grant
Natasha Fothergill-Misbah, Njideka Okubadejo, Catherine Dotchin, Tania Park, Richard Walker

Living with Parkinson’s: Other

P47.02 A neurologist with PD: What I’ve learnt about being a patient and person with PD
David Blacker

P47.05 Medication experiences of people with Parkinson’s disease
Sneha Mantri, Kristin Richards, Steven Arcona, Rahul Sasane

Late-Breaking

LBP01.18 Genome-wide association identifies novel etiological insights associated with Parkinson’s disease in African and African admixed populations
Mie Rizig, Sara Bandres Ciga, Mary Makarious, Oluwadamilola Ojo, Kristin Levine, Olaitan Okunoye, Ellen Sidransky, Nahid Tayebi, John Hardy, Andrew Singleton, Njideka Okubadejo

LBP01.23 Association of diet with gut microbiome in patients with Parkinson’s disease
Dayoon Kwon, Keren Zhang, Kimberly Paul, Irish Del Rosario, Jonathan Jacobs, Adrienne Keener, Jeff Bronstein, Beate Ritz

LBP01.24 A low-quality diet is associated with Parkinson’s disease in central California
Dayoon Kwon, Aline Folle, Irish Del Rosario, Keren Zhang, Kimberly Paul, Adrienne Keener, Jeff Bronstein, Beate Ritz

LBP03.08 G51D, a rare and aggressive form of Parkinson’s disease
Noelia Pelegrina-Hidalgo

LBP05.02 The effect of gut microbiome dysbiosis on tyrosine and cholesterol sex hormone metabolism in Parkinson’s disease
Natalia Birch, Nanthini Jayabalal, Kerry Roper, Helen Woodhouse, John O’Sullivan, Robert Adam, Richard Gordon

LBP05.06 Spatial transcriptomics identifies molecular signatures of prodromal and advanced alpha-synuclein pathology
Asad Jan, Xiaoying Zhao, Poul H. Jensen, Yongjun Luo, Marina Romero-Ramos, Lin Lin, Jens R. Nyengaard

LBP06.04 Establishing a Progenitor Cell Bank of iPSC-derived cells poised for neural differentiation for the Parkinson’s research community
Michela Ilaria Barbatò, Nicola J. Drummond, Yixi Chen, Karamjit Singh Dolt, Maurice A. Canham, Peter Kilbride, G. John Morris, Andrew Chai, Zhijun Wang, Tilo Kunath

LBP06.05 Diverging progression of synucleinopathy in mouse models of Parkinson’s disease and multiple system atrophy
Anna Barber Janer, Eline Vonck, Chris Van den Haute, Ariel Louwrier, Vicky Marie Myhre, Jacob Alec McPhail, Veerle Baekelandt, Wouter Peelaerts

LBP06.17 Functional and neuropathological changes induced by injection of distinct alpha-synuclein strains: A pilot study in non-human primates
Audrey Fayard, Alexis Fenyi, Sonia Lavisse, Sandra Dovero, Luc Bousset, Tracy Bellande, Sophie Lecourtois, Christophe Jouy, Martine Guillermier, Caroline Jan, Pauline Gipchtein, Benjamin Dehay, Erwan Bezd, Ronald Melki, Philippe Hantraye, Romina Aron Badin
LBP06.24  Early-life Parkinson’s-related behavioural changes in neonatal Lrrk2 knock-in mice  
David J Harrison, Fatima M Sheikh, Dayne A Beccano-Kelly

LBP06.31  Characterization of the GBA1 E326K mutation in Parkinson’s disease progression and its impact on neuroinflammation and α-synucleinopathy  
Sangjune Kim, Sin Ho Kwoen, Hye Guk Ryu, Hyeonwoo Park, Saebom Lee, Namshik Kim, Han Seok Ko

LBP08.01  Imaging the noradrenergic system in Parkinson’s disease: A [11C]Yohimbine PET and neuromelanin MRI study  
Chloé Laurencin, Sophie Lancelot, Marine Huddleston, Sarah Brosse, Inès Merida, Nicolas Costes, Jéréôme Redouté, Didier Le Bars, Stéphane Thobois, Philippe Boulinguez, Bénédicte Ballanger

LBP09.04  A pilot study about the effectiveness of the high-dose donepezil in the cognitive function and neuropsychiatric symptoms in Parkinson disease with cognitive impairment  
Sang Jin Kim

LBP10.01  The modulation of subthalamic beta bursts during task execution underlies deep brain stimulation related motor improvement in Parkinson’s disease  
Manuel Bange, Gabriel Gonzalez-Escamilla, Damian Marc Herz, Gerd Tinkhauser, Alek Pogosyan, Martin Glaser, Dumitru Ciolac, Christian Dresel, Hulling Tan, Peter Brown, Sergiu Groppa

LBP13.02  Exercise and physical activity promotion after a Parkinson’s diagnosis: a UK survey of healthcare professionals  
Ledia Alushi, Peter Hartley, Louise Lafortune

LBP19.02  Transforming Parkinson’s disease education & care: Engaging & addressing American Indian & Alaskan Native communities  
Somil Bhushan, Peery White, Sarah Osborne

LBP22.01  “It’s such a basic instinct to walk, but...” People with Parkinson’s experience using compensation strategies to improve walking  
Sheemah Alenezi, Sarah Morgan-Trimmer, Sophia Huibert, William Young, Victoria A Goodwin

LBP24.01  Exploring people with Parkinson’s disease’s experiences of online exercise groups in the UK – a qualitative study  
James Alexander, Caroline Appel, Yiota Constantinou, Anette Schrag

LBP24.07  Different speech biomarkers for tremor and motor coordination in Parkinson’s disease — Implications for remote disease severity monitoring  
Ebru Baykara, Louisa Schwed, Johannes Tröger, Nicklas Linz, Juan Rafael Orozco-Arroyave

LBP24.13  Patient experiences and working alliance in a decentralized, online trial of cognitive behavioral therapy for depression in PD.  
Aleksander H. Erga, Guido Alves, Albert Leentjens

LBP27.07  Alopecia in females with young onset Parkinson’s disease: An exploratory survey  
Kelsey Fisher, Erin Clifford, Nicholas Piniella, Dr. Rosemary Gallagher, Dr. Adena Leder

LBP28.03  The prevalence of delirium and risk of mortality in hospital inpatients with Parkinson’s disease  
Florence Gerakios, Gemma Bate, Laura Wright, Daniel Davis, Blossom CM Stephan, Louise Robinson, Carol Brayne, Linda Barnes, Glenn Stebbins, John-Paul Taylor, David J Burn, Louise M Allan, Alison J Yarnall, Sarah J Richardson, Rachael A Lawson

LBP32.04  Which tests? Evaluation of bedside tests to identify delirium in Parkinson’s disease  
Rachael A Lawson, Sarah J Richardson, Florence Gerakios, Gemma Bate, Alison J Yarnall, Laura Wright, John-Paul Taylor, David J Burn, Louise M Allan, Glenn Stebbins

LBP34.04  Prospective role of PAK6 and 14-3-3γ as biomarkers for Parkinson’s disease  
Elena Giusto, Lorenzo Maistrello, Lucia Iannotta, Veronica Giusti, Ludovica Ivoino, Rina Bandopadhyay, Angelo Antonini, Luigi Bubacco, Rita Barresi, Nicoletta Plotheger, Elisa Greggio, Laura Civiero

LBP34.09  The Synuclein-One study: Detection of cutaneous phosphorylated alpha-synuclein for the diagnosis of the synucleinopathies  
Todd Levine, Christopher Gibbons, Jade Stohl, Bailey Béliaire, Roy Freeman

LBP36.01  Preclinical safety and efficacy of dopamine neuron progenitor cells derived from PD donor induced pluripotent stem cells  
Derren Barken, Rachel Hills, Jim Mossman, Ha Tran, Ai Zhang, Roy Williams, Emma Lane, Mariah Lelos, Xiaokui Zhang, Andres Bratt-Leal
LBP38.01 Effects of asymmetric vs symmetric dosing of IPX203 during a Phase 3 trial on the occurrence of drug-related adverse events
Robert Hauser, Zachary Grieb, Ghazal Banisadr, Stanley Fisher

LBP38.09 Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease
David Devo

LBP38.11 The Norwegian Parkinson’s Registry and Biobank
Eldbjørg Fiske, Johannes Lange, Kenn Freddy Pedersen

LBP38.16 A novel technological functional movement Parkinson test. A preliminary study
Marco Gidoni, Giuseppe Sarcinella, Milena Guizzetti, Marco Esposito, Cecilia Gatti

LBP38.27 Redesigning Parkinson’s disease care: rationale, methods and baseline data from the PRIME-UK Parkinson’s randomised controlled trial
Katherine Lloyd, Emma Tenison, Matthew Smith, Rebecca Heath, Charlotte McDonald, Nicola Giles, Alexandru Stan, Chloé Thomas, Michele O Breasall, Yoav Ben-Shlomo, Emily J Henderson

LBP38.31 NLX-112 has favorable safety, tolerability and efficacy against levodopa-induced dyskinesia (LID) in a randomized, double-blind, placebo-controlled, proof-of-concept Ph2A study
Per Svenningsson, Per Odin, Filip Berquist, Karin Wirdefeldt, Dag Nyholm, Måns Jergil, Christopher Jankosky, Mark Varney, Fabienne Herbrecht, Steven Johnson, Adrian Newman-Tancred

LBP40.05 DigiPark: First results of a medical device based on digital neuromarkers monitoring for better individualized care of patients with Parkinson’s disease
Djamchid Dalili, Caroline Atlani

LBP40.09 Support groups are empowering the Parkinson’s community
Lori DePorter

LBP43.20 Parkinson’s is not witchcraft: A report by Kabugo Hannington Tamale, Parkinson’s Si Buku Uganda, Parkinson’s Si Buku USA Hannington Kabugo Tamale, Sherryl Klingelhofer

LBP45.04 Constitution of the Argentinian Parkinson’s Network Civil Association – RaPark
Adrián Borches, Daniel Merino, Andrea Cuellar, Natalia Lardieri, Beatriz Navarro, María de los Angeles Bacigalupe, Fernanda López, Graciela Orostizaga

LBP45.19 Scaling heights: Climbing Mount Kilimanjaro with Parkinson’s
Michael High

LBP45.19 SParky Samba – Exploring the benefits of Samba percussion
Eirwen Malin, Emma Lane

LBP46.08 A framework to facilitate access to medicines for people with Parkinson’s disease in Africa
Kabugo Hannington

LBP47.06 In their own words: Fears of people with Parkinson disease
Sneha Mantri, Jennifer Purks, Daniel Kinel, Allison Allen, Connie Marras
Basic Science: Etiology, genetics, epidemiology, and toxicants

P01.12 Do Parkinson’s susceptibility risk factors also influence age of onset? 
Amali S. Fernando, Santiago Díaz-Torres, Nicholas G. Martin, Miguel E. Renteria

P01.13 Shared molecular pathways underlie the relationship between Parkinson’s disease and chronic pain
Luis Marín, Freddy Chafota, Miguel Renteria

P01.16 Parkinson’s disease is associated with large-scale microbial dysbiosis which may promote disease progression
Avril Metcalfe-Roach, Mihai Cirstea, Adam Yu, Hena Ramay, Davide Martino, Laura Sycuro, Silke Appel-Cresswell, B. Brett Finlay

P01.17 β-adrenoreceptor drugs and incidence of Parkinson’s disease in women from the French E3N cohort study
Thi Thu Ha Nguyen, Agnès Fournier, Émeline Courtois, Fanny Artaud, Sylvie Escolano, Pascale Tubert-Bitter, Isabelle Degaey, Emmanuel Roze, Ismail Ahmed, Anne C.M. Thiébaut, Alexis Elbaz

P01.20 Genome wide association studies using SNP1 reveals new associated genes with Parkinson Disease in a Latino Cohort

P01.21 Differences in cytochrome P450s genes between genetically predisposed Parkinson’s disease individuals with and without disease signs
Polina Petkova-Kirova, Stephan Baas, Gudrun Wagenpfell, Marcus Unger, Rita Bernhardt

P01.22 High-throughput proteomics in the study of Parkinson’s disease progression
Raquel Real, Laura Winchester, Alejandro Martinez-Carrasco, Michael A Lawton, Yoav Ben-Shlomo, John Hardy, Alejo Nevada-Holgado, Donald G Gross, Huw R Morris

P01.25 Parkinson Disease in women: How does sex affect motor and non-motor symptoms? 
Francisca Ruiz Gonzalez, Silvia Enriquez Calzada, Daniela Samaniego Toro, Helena Xicoy, Sara Belmonte, Miquel Vila, Jorge Hernandez-Vara, Ariadna Laguna

P01.26 Persistent microgliosis and neurodegenerative processes in a SARS-CoV-2-model
Cara Schreiber, Christopher Käuper, Anna-Sophia Hartke, Ivo Wiesseg, Stephanie Stanelle-Bertram, Sebastian Beck, Nancy Mounougou Kouassi, Berfin Schaumburg, Gülsah Gabriel, Franziska Richter

P01.27 What causes Parkinson’s Disease? 
Jennifer Thornton

P01.28 The DRD4 gene polymorphism is associated with the severity of impulse control disorder using dopamine agonists in Parkinson’s disease
Viviana Torres Ballesteros, Mario Ezquerra, Jessica Perez, Ruben Fernandez-Santiago, Manel Fernandez, Francesca Valideoriola

P01.29 Nuclear functions of alpha-synuclein in DNA double-strand break repair
Moriah Arnold, Dörthe Payne-Larsen, Pamela Cassidy, Stephan Witt, Vivek Unni

P01.30 Non-motor symptoms of Parkinson’s disease in Mexico: Case series
Xavier Vilchis, Jose Eduardo Solórzano Quiroz, Jose Antonio Fernandez, Alejandro Medardo Gonzalez

P01.32 Elevated trimethylamine (TMA) from the gut microbiota drives synuclein pathology and immune activation in Parkinson’s disease
Zizheng Xian, Nanthini Jayabalan, Katherine Roper, Helen Woodhouse, John O’Sullivan, Robert Adam, Anumanta Kanthasamy, Gene Tyson, Richard Gordon
Basic Science: Cell death, neuroprotection and trophic factors

P02.03 Identification of new neuroprotective molecules
Joanna Fombonne, Kristina Radkova, Erika Cosset, Merja Voutilainen, Catherine Guix, Mart Saarma, Patrick Mehlen

P02.05 SARS-CoV-2 induces dopaminergic neuron loss in midbrain organoids
Javier Jarazo, Eveline Santos da Silva, Enrico Glaab, Danielle Perez Bercoff, Jens Schwamborn

P02.06 The neuroprotective effect of NLX-112 in MPTP-treated mice is mediated through upregulation of astrocytic GDNF
William H. Powell, Lucy E. Annett, Ronan Y. Depoortere, Adrian Newman-Tancredi, Mahmoud M. Iravani

P02.08 Therapeutic role of MicroRNA 34a in Parkinson’s disease via inhibiting expression of colony-stimulating factor 1 and subsequent anti-neuroinflammation and neuroprotection
Ming Yew, Ping Heng Tan

Basic Science: Protein misfolding and handling

P03.09 Aged periventricular microglia contribute to CSF-borne aggregated αSyn spreading
Salomé Sirerol-Piquer, Ana Pérez-Villalba, Pere Duart-Abadia, Laura Blasco-Chamarro, Pau Garrillo- Barberà, Ulises Gomez-Pinedo, Victoria Navarro, Benjamin Dehay, Javier Vitorica, Azucena Pérez-Cañamá, Francisco Pérez-Sánchez, Miquel Vila, Isabel Farfías

P03.10 Impaired autophagic-lysosomal fusion in Parkinson’s patient midbrain neurons occurs through ykt6 and is rescued by farnesyltransferase inhibition
Caleb Pitcairn, Naomi Murata, Annie Zalon, Iva Stojkovska, Joseph Mazzulli

P03.11 SUMO system changes in PD and SUMOylation inhibitor promotion of autophagy subtypes as a novel therapy
Matthew K. Boag, Shamini Vijayakumaran, Jacob Clark, Angus Roberts, Ruth E. Carmichael, Kevin A. Wilkinson, Stephen Wood, George D. Mellick, Jeremy M. Henley, Dean L. Pountney

P03.12 Combination of fluorescence lifetime and anisotropy imaging microscopy to measure intracellular microenvironment as early diagnosis of neurodegenerative diseases
Soheila Sabouri, Hamid Soleimaninejad, Yuning Hong

P03.14 Directed evolution of the human molecular chaperone DNAJB1 towards the alpha-synuclein protein
Come Stellio, Marie-Pierre Castanié-Cornet, Axel Mogk, Bernd Bukau, Pierre Genevaux

P03.15 Interplay of α-synuclein aggregation and mitochondrial function in PD
Carmen Venegas, Patrycja Mulica, Thais Arns, Dimitrios Kyriakis, Sylvie Delcambre, Sandro L Pereira, Paul MA Antony, Rejko Krüger, Alexander Skupin, Anne Grünewald

P03.16 Uncovering secretory mechanisms underlying the spreading of alpha-synuclein
Aurore Filaquier, Marie-Laure Parmentier, Julien Villeneuve

Basic Science: Mitochondria, oxidative stress, inflammation, pathogenesis

P04.12 Peripheral and central immune changes in early PD: Baseline analysis of the AZA-PD trial cohort
Julia Greenland, Jonathan Holbrook, Caroline Williams-Gray

P04.13 The ubiquitin E3 ligase Parkin regulates CaV1.3 channel functional expression with a prospective role in Parkinson’s disease pathogenesis
Lizbeth Grimaldo, Alejandro Sandoval, Paz Duran, Liliana Gómez-Flores-Ramos, Ricardo Félix

P04.16 The influence of vagus-mediated immune modulation in the progression of Parkinson’s disease and its hypothesized subtypes
An 80% improvement in UPDRS was followed by no progression in the last seven years in one Parkinson’s patient. Here are the five lifestyle changes made, and how they might work
Patrick Bradshaw, William M Curtis, Jeffrey Bohnen, William Seeds

Immunoproteasome PSMB8 subunit increased in in Parkinson’s disease
Hyeol-II Ma, Huu Dat Nguyen, Linh Nhat Nguyen, In Hee Kwak, Young Eun Kim

The intranigral infusion of alpha synuclein oligomers induces a cognitive decline underpinned by altered neuronal firing and neuroinflammation in cognition-related areas
Maria Francesca Palmas, Michela Etzi, Claudia Sagheddou, Maria Francesca Manchinu, Michele Santoni, Chiara Camoglio, Giuliana Fusco, Alfonso De Simone, Paola Fadda, Marco Pistis, Nicola Simola, Ezio Carboni, Augusta Pisanu, Anna Rosa Carta

Elucidating the link between mitochondrial stress responses and cellular senescence using human induced pluripotent stem cell-derived neurons and glia
Maria Jose Perez Jimenez, Mariella Bosch, Stefanie Kalb, Hariam Raji, Michela Deleidi

The CaV3.2 T-type calcium channel is a novel target dysregulating miro1-dependent mitophagy and driving Parkinson’s disease pathology
Sean Pintchovski, Chung-Han Hsieh, Atossa Shaltouki, Eric Beattle, Ashley Gonzalez, Bill Shrader

High levels of cell-Free mitochondrial DNA deletions in cerebrospinal fluid from patients with idiopathic, but not LRRK2, Parkinson’s disease
Margalida Puigros, Anna Calderon, Alexandra Pérez-Soriano, Cristina de Dios, Manel Fernández, Anna Colell, Maria-Jose Martí, Eduard Tolosa, Ramon Trullas

Blocking the angiotensin type-1 receptor reduces NLRP3 inflammasome upregulation in the substantia nigra of aging and PD animal models
Aloia Quijano Ocampo, Carmen Díaz Ruiz, Andrea López López, Begoña Villar Cheda, Ana Muñoz Patiño, Ana Isabel Rodríguez Pérez, José Luis Labandeira García

Non-cell autonomous effects of neuromelanin on Parkinson’s disease pathogenesis
Gerard Roch, Maria Sellés, Joan Compte, Marta Gonzalez-Sepulveda, David Ramos-Vicente, Thais Cuadros, Joana M Cladera-Sastre, Annabelle Parent, Ariadna Laguna, Jordi Bové, Miquel Vila

Viscosity sensitive AIE probes: Solid fluorescent tools for mapping mitochondria viscosity in proteostasis disordered in neurodegenerative cells
Soheila Sabouri, Hamid Soleimani Nejad, Tze Cin Owyoung, Yuning Hong

Acetylation of intestinal proteins: A potential mediator of systemic inflammation in Parkinson’s disease
Verena Schmitt, Ippei Miyagawa, Birthe Gercke, Martin Regensburger, Franz Marxreiter, Franziska Richter, Mario M. Zaiss, Jürgen Winkler, Wei Xiang

PINK1-PD neurons display altered tyrosine hydroxylase phosphorylation
Karan Sharma, Katharina Zittlau, Boris Macek, Julia Fitzgerald

Systemic inflammation activates coagulation and immune cell infiltration pathways in brains with propagating α-synuclein fibril aggregates
Anne-Line S. Laursen, Mikkel V. Olesen, Jonas Folke, Tomasz Brudek, Florence Sotty, Kate L. Lambertsen, Karina Fog, Louise T. Dalgaard, Susana Aznar

Investigating the mechanisms by which progranulin deficits contribute to Parkinson’s disease pathology
Oihane Uriarte Huarte, Jake S. Boles, Rebecca L. Wallings, Noelle K. Neighbarger, Cassandra L. Cole, Malú Gámez Tansey

Mitochondrial DNA copy number inferred from whole genome sequencing data is lower in individuals with Parkinson’s disease
Longfei Wang, Liam Fearnly, Haloom Rafhei, Jiiru Han, Melanie Bahlo

Validation of clinical stage NLRP3 inflammasome inhibitor RRx-001 for disease modification in Parkinson’s disease
Madeleine Yule, Natalia Birch, Katerina Hanton, Nanthini Jayabalain, Rob Adams, John O’Sullivan, Brian Oronsky, Tony Reid, Richard Gordon
Basic Science: Pathology

P05.01 Novel antibodies against oligomeric alpha synuclein
Johanne Aarup Lauritsen, Janni Nielsen, Sanne Simone Kaalund, Susana Aznar, Daniel Otzen, Marina Romero-Ramos

P05.03 Activating beta-glucocerebrosidase by exploiting its transporter LIMP-2
Jan Philipp Dobert, Simon Bub, Rebecca Mächtel, Alice Drobny, Dovile Januliene, Arne Möller, Philipp Arnold, Friederike Zunke

P05.07 Heterozygous GBA N370S mutation does not uniformly reduce GCase activity or cause lysosomal dysfunction in iPSC-derived neurons
Adahir Labrador-Garrido, Katherine Moruzi, Siying Zhong, Shikara Keshiya, Glenda Halliday, Nicolas Dzamko

P05.09 Neuropathological alterations in subjects initially diagnosed by polysomnography with isolated REM sleep behavior disorder
Gerard Mayà, Alex Iranzo, Carles Gaig, Joan Santamaria, Mónica Serradell, Laura Molina-Porcel, Ellen Gelpi, Iban Aldecoa

P05.12 Single molecule array assay for phosphorylated alpha-synuclein detection in cerebrospinal fluid
Camilla Pedersen, Guido Alves, Jodi Maple-Grødem, Johannes Lange

P05.14 Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models
Alice Drobny, Fanni Boros, Caleb Pitcairn, Joseph Mazzulli, Friederike Zunke

Basic Science: Animal and cellular models of Parkinson’s and Parkinsonisms

P06.06 Establishment of a 3D iPSC-based neurovascular model to investigate Parkinson’s disease pathophysiology
Valentina Baruffi, Veronica Testa, Meritxell Pons Espinal, Livia Piatti, François Korbmacher, Ivonne Richaud, Alicia Garrido, Eduardo Tolosa, Angel Raya, Maria Bernabéu Aznar, Antonella Consiglio

P06.08 Exacerbation of alpha-synuclein pathology by B-lymphocyte depletion
Tomasz Brudek

P06.11 A high-content analysis pipeline for quantifying the autophagy-lysosomal pathway in IPSC-derived cortical neurons carrying Parkinson’s disease associated mutations
Jessica Chedid, Adahir-Labrador Garrido, Gautam Wall, Dad Abubonsarah, Lachlan Thomson, Carolyn Sue, Deniz Kirik, Clare Parish, Glenda Halliday, Nicolas Dzamko

P06.22 Modeling PRKN/PARK2-associated Parkinson’s disease
Christopher J. Griffey, Alf H. Lystad, Anne Simonsen, Robert E. Burke, Ai Yamamoto

P06.28 Cell autonomous role of leucine-rich repeat kinase in dopaminergic neuron survival
Jongkyun Kang, Guodong Huang, Long Ma, Youren Tong, Phoenix Chen, Jie Shen

P06.35 Modulation of the gut microbiota modifies Parkinson’s disease-like pathology in transgenic neuromelanin-producing mice
Marina Lorente-Picon, Núria Perluelas, Marta Gonzalez-Sepulveda, Marc Veililla, Gisela Besa, Annabelle Parent, Josep A. Villena, Miquel Vila, Ariadna Laguna

P06.36 IPSC-derived human midbrain-striatal assembloid for Parkinson’s disease modeling
Beatriz Elena Lucumi Villegas, Julia Obergasteiger, Valerie Clavet-Fournier, Flavie Lavoie Cardinal, Samer Hussein, Martin Lévesque

P06.41 Healthy human IPSC-derived astrocytes rescue the degenerative phenotype of p.A53T-αSyn IPSC-derived neurons generated from Parkinson’s disease patients
Olympia Apokotou, Christina Paschou, Anastasios Kollias, Era Taoufik, Rebecca Matsas, Florentia Papastefanaki

P06.42 A novel autoimmune alpha-synuclein-induced model of Parkinson’s disease
Rebekah Parkinson, Jessica Petitt, Alexandre Rcom-H’cheo-Forgues, Rebecca Buckland, Christopher Parish, Anne Bruestle, Nathalie Dehorter

P06.43 Modelling human brain-wide pigmentation induces Parkinson-like pathology and transcriptomic alterations in vivo
P06.47  Nuclear α-Synuclein detection and α-Synuclein-histones interactions  
Angela Rollar, Shirley S. L. Lee, Ayse Ulusoy, Donato A. Di Monte

P06.48  Exploring the role of the lysosomal lipid flippase ATP10B in the nigrostriatal dopaminergic pathway of rats  
Maria Sanchiz-Calvo, Eduard Bentea, Christopher Cawthorne, Mirte De Ceuninck, Teresa Torre-Muruzabal, Chris Van den Haute, Peter Vangheluwe, Veerle Baekelandt

P06.49  Ketamine as a modulator of endoplasmic reticulum stress in a cross-sex mouse model of Parkinson’s disease with depressive phenotype  
Unai Sarritx-Serrano, Lluis Miquel-Rio, Verónica Paz, Jose Javier Meana, Analia Bortolozzi

P06.51  Unveiling the impact of glial autophagic dysfunction in the initiation and progression of Parkinson’s disease  
Aurora Scrivo, Veronica Testa, Valentina Baruffi, Merixtell Pons Espinals, Irene Fernandez Carasa, Eduardo Tolosa, Angel Raya, Antonella Consiglio

P06.54  Investigating the role of astrocytes and microglia in driving neurodegeneration in Parkinson’s disease using an hiPSC-based in vitro model  
Veronica Testa, Valentina Baruffi, Merixtell Pons Espinal, Franz Arnold Ake, Marieke Alzeer, Irene Fernandez Carasa, Yvonne Richaud-Patin, Eduardo Tolosa, Angel Raya, Mireya Plass, Antonella Consiglio

P06.55  Ca2+-calmodulin–calcineurin signaling modulates α-synuclein transmission  
Jun Ueda, Norihito Uemura, Tomoyuki Ishimoto, Tomoyuki Taguchi, Masanori Sawamura, Etsoo Nakanishi, Masashi Ikuno, Shuichi Matsuzawa, Hodaka Yamakado, Ryosuke Takahashi

P06.57  Age-related elevations in type-I interferon signalling control brain-gut transmission in the α-synuclein pre-formed fibril model of Parkinson’s disease  
Harrison Waters, Shuyan Chen, Peter Crack, Juliet Taylor

P06.58  TLR2 mediated α-synuclein pathology development and the contribution of astrocytes in a midbrain model of Parkinson’s disease  
Fiona Weiss, Glenda Halliday, Nicolas Dzamko

P06.60  Modelling of axonal degeneration in Parkinson’s disease using hiPSC-derived midbrain dopaminergic neurons carrying SNCA gene duplication  
Wei Xiang, Yanni Schneider, Aron Koller, Marie Andert, Lukas Seebauer, Katharina Pieger, Johannes Schlachetzki, Johann Helmut Brandstätter, Jürgen Winkler

P06.61  A novel mouse model to investigate the formation of oligodendroglial α-synuclein aggregates in multiple system atrophy (MSA)  
Hodaka Yamakado, Tomoyuki Ishimoto, Miki Oono, Takashi Ayaki, Katsuya Nishida, Itaru Funakawa, Seiji Kaji, Takakuni Maki, Shu-ichi Matsuzawa, Ryosuke Takahashi

P06.62  Single cell transcriptomic analysis of peripheral blood immune cells from people with Parkinson disease: Subtypes and sex  
Ankita Singh

Basic Science: Brain physiology and circuitry

P07.03  Overexpression of human α-synuclein in serotonin neurons drives brain functional disconnection in a PD-like mouse model with depressive phenotype  
Lluis Miquel-Rio, Maria Torres-López, Verónica Paz, Carme Casal, Emma Muñoz-Moreno, Xavier López-Gil, Analia Bortolozzi

P07.04  Advancing adaptive subthalamic deep brain stimulation for gait disturbances and freezing of gait in Parkinson’s disease  
Marie-Laure Welter, Brian Lau, Ludovic Saint-Bauzel, Carine Karachi, Mathieu Yeche, Sinan Hailyo, Alexandre Guerre, He Shenghong, Huiling Tan

Basic Science: Dopamine, receptors and other neurotransmitters

P08.05  PD antibodies without side effects: Dr. Mehmet Oz, probably the most famous medical doctor of our time, has said, “The next big frontier in medicine is energy medicine.”  
Jeffrey Harsh
P08.06 70 years of historical brain life cell therapy for PD, and thank God it is not created from aborted human fetus!
Jeffrey Harsh

P08.09 Calcium-sensor linkage of N-methyl-D-aspartate receptors to the MAP kinase pathway is blockade by α-synuclein in cortical and hippocampal neurons and microglia
Gemma Navarro Brugal, Irene Reyes, Jaume Lillo, Iu Raich, Rafael Rivas-Santisteban, Joan Biel Rebassa, Rafael Franco

P08.10 Adora1 mutation linked to early-onset Parkinson’s disease alters adenosine A1-A2A receptor heteromers formation and function
Laura Isabel Sarasola, Claudia Llinas del Torrent, Victor Fernandez-Dueñas, Sergi Ferré, Leonardo Pardo, Francisco Ciruela

Basic Science: Neuropharmacology

P09.06 Epigenetic deregulation in striatal neurons during impulse control disorders related to dopamine agonists in Parkinson’s disease: towards the identification of therapeutic target
Louise-Laure Mariani, Jean-Antoine Girault, Denis Herve, Olga Corti, Jean-Christophe Corvol

P09.07 A model to test novel therapeutic interventions for Parkinson’s disease: The Thy1-aSyn (“line 61”) mice
Franziska Richter Assencio, Christopher Kaefer, Birthe Gericke, Malte Feja

P09.08 Uncovering the interaction between the cannabinoid CB1 receptor and the angiotensin AT2 receptor. Overexpression of AT2-CB1 receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.
Rafael Rivas-Santisteban, Jaume Lillo, Iu Raich, Ana Muñoz, Alejandro Lillo, Ana I. Rodríguez-Pérez, José L. Labandeira-Garcia, Gemma Navarro, Rafael Franco

P09.09 Clemizole hydrochloride reduces alpha-synuclein toxicity in Parkinson’s disease models: A behavioural and mechanistic study
Bhupesh Vaidya, Pankaj Gupta, Joydev K. Laha, Ipsita Roy, Shyam Sunder Sharma

Basic Science: Electrophysiology & functional imaging, optogenetics

P10.03 Parkinsonian beta oscillations in the cortico-basal ganglia network during movement: Beyond the frequency range
Marc Deffains

P10.04 LRRK2 G2019S mutation causes hyperexcitability of iPSC-derived cortical neurons
Shiva Nag Kompella, Dayne Becanno-Kelly

P10.06 Analysis of Parkinson’s neuronal disease using microelectrode recording and simulation data with subthalamic-nucleus deep brain stimulation
Venkateshwarla Rama Raju, Lavanya Neerati

P10.08 A spectrotemporal analysis of local field potentials in the subthalamic nucleus during language processing
Patrick Santens, Emma Depuydt, Elissa-Marie Cocquyt, Arnout Bruggeman, Dirk Van Roost, Pieter Van Mierlo, Miet De Letter

Basic Science: Prevention, neuroprotection neuroplasticity

P11.04 Potential of exercise to modify the progression of prodromal Parkinson’s disease
Malte Feja, Leonie Baldauf, Milos Stanojlovic, Julia Hankel, Christian Visscher, Eva Schläffer, Daniela Berg, Franziska Richter

P11.05 Systematic balance exercise affects the level of Sirt1 and Sirt3 in older adults and persons with Parkinson’s disease – pilot study
Jadwiga Kubicza, Joanna Pera, Magdalena Wiecek, Justyna Kusmierczyk, Jadwiga Szymura

P11.06 Case series of PD patients with and without immobility symptoms and gait function – Three-dimensional motion analysis
Tadamitsu Matsuda, Kazunori Sato, Erito Kitahara, Yuji Fujino, Toshiyuki Fujiwara, Nobutaka Hattori

P11.08 Effects of magnetic stimulation in the rat brain plasticity: New insight in the astrocytes function in experimental parkinsonism
Giuseppina Natale, Maria De Carluccio, Maria Teresa Visconti, Veronica Ghiglieri
Comprehensive Care: Caregiving, relationships, respite care, families

P12.07  A call for more comprehensive approaches to Parkinson’s, taking into account the voice of Uruguayan PwP and their families
Paula Dodera

P12.08  Partnering with poise: Retention of cognitive, emotional, and physical benefits for care partners of people living with Parkinson’s disease at 6 and 12 months after completion of an in-person Alexander-based group course
Monika Gross, Jaime Bellingham, Pepper Brisset, Rajal G. Cohen

P12.09  Supporting the journey to empowerment for people with Parkinson’s through the person-centred lens of those living with Parkinson’s
Julie Jones, Alison Williams

P12.10  Getting Real!*: Addressing the educational, support and planning needs of Parkinson’s caregivers through virtual formats
Anissa Mitchell

P12.11  Relationship of psychological, financial and societal factors to Parkinson’s disease
Elpida Panagiotounakou, Anastasia Bougea, Nikolaos Papagiannakis, Athina-Maria Simitsi, Chrysa Chrysoyitsanou, Christos Koros, Leonidas Stefanis

P12.12  Close contact for couples with Parkinsons
Judith Sachs

Comprehensive Care: Exercise and physical activity

P13.14  Utilizing the Parkinson’s foundation five domains of exercise professional competencies to map five criteria for exercise education: A pilot study
Lisa Hoffman, Miriam Rafferty, Lauren Krusucki

P13.16  An exploration of service users perceptions of the Parkinson’s beat program
Julie Jones, Yoon Iorns, Alison Williams, Jo Holland

P13.20  Physical exercise interventions on balance and postural stability in Parkinson’s disease: A network meta-analysis
Patricia Lorenzo-Garcia, Iván Cavero-Redondo, Sergio Nuñez de Arenas-Arroyo, María José Guzmán-Pavón, Susana Priego-Jiménez, Celia Álvarez-Bueno

P13.21  Immediate effects of forced exercise cycling on core outcomes in individuals with Parkinson’s disease
Daniel Miner, Kenny Harrah, Kevin Chui

P13.22  Expanding on the brain-body connection through free, symptom-driven Parkinson’s fitness programming
Nina Mosier

P13.23  Evaluation of functional capacity, body composition and VO2max in Parkinson’s disease: Pre and post physical activity practice
Marcos Moura, Dirce Sanches Rodrigues, Miguel Soares Conceição, Katia Lousada Gouveia, Luiz Arthur Moreira Nunes

P13.24  Does exercise attenuate indicators of disease progression in Parkinson’s disease? A systematic review with meta-analysis
Jiecheng Alex Li, Marte Loevaas, Catherine Guan, Lina Goh, Natalie Allen, Margaret Mak, Jinglei Lv, Serene Paul

P13.25  Use of inertial sensors to measure the impact of a therapeutic boxing program in people with PD in Chile.
Miguel Pino, Pablo Burgos, Lorena Bernales, Pablo Roa

P13.26  Relationship between habit strength of walking-related exercise behavior and real-world walking in persons with Parkinson disease
Franchino Porciuncula, Jenna Zajac, Nicholas Wendel, Dheepak Arumukhom Revi, Jaimie Girmis, Louis Awad, James Cavanaugh, Terry Ellis

P13.27  A retrospective evaluation of the brain and body fitness studio service on functional capacity and quality of life in people with neurological disorders
Joyce Ramos, Ranjay Chakraborty, Lance Dalleck, Kristina Sarunic, Jyoti Khadka, Tayla Haslam, Olivia Nassar
P13.28 Evaluating dancing with Parkinson’s (DWP) online dance classes
Sarah Robichaud

P13.29 Physical exercise and its impact on caregivers burden of people living with Parkinson’s disease in a National Institute of Neurology and Neurosurgery from Mexico City
Diana Paulina Romero-Terán, Ana Jimena Hernandez-Medrano, María Fernanda Medina-Pérez, Andrea García-Hernández, Rodolfo Arturo Abundes-Corona, Amin Cervantes-Anliaga, Mayela Rodriguez-Violante

P13.30 Case report: A dual tasking intervention for Parkinson’s disease
Darbe Schlosser

P13.32 Establishing the impact of aerobic exercise on biomarkers, mobility, and cognitive functioning of Parkinson’s disease: A translational study
Isabel Soto, Vicki Nejetek, Gary Boehm, Paige Braden, Kelly Brice, Eila Kasanga, Robert McManus, Walter Navarrete-Barahona, Michael Salvatore

P13.33 Post pandemic motor performance recovery among people with Parkinson’s disease in a community-based wellness center
Elizabeth Stiles, Karen Jaffe, Cathe Schwartz, David Riley, Ben Rossi, Patrick Houlahan

P13.34 Paradoxical relationship between handgrip strength performance and gait in subjects with Parkinson’s disease
Eduardo Villamil-Cabello, Alfonso Jimenez-Gutierrez, Miguel Angel Fernandez-del-Olmo

P13.35 Pass to Pass: Outdoor adventures with Parkinson’s
A.C. Woolnough, Sarah Eltzman, John Cunniff, William Clugston, Sandy Knudson

Comprehensive Care: Alternative & complementary therapies/ Creativity

P14.12 Mucuna: The power of nature
Patricia Maldonado, Veronica Ruscio, Felix Jozsa

P14.13 Dance and Parkinson’s: The effects on selected functional parameters during the 180 turning phase of the timed up & go test in people with Parkinson’s
Aline Nogueira Haas, Leonardo Alexandre Peyré-Tartaruga, Marcela Dos Santos Delabary, Tina Smith, Yiannis Koutedakis, Matthew Wyon

P14.14 Effect of vocal-dance program on speech, voice quality, and quality of life in persons with Parkinson’s disease
Eunsun Park, Frank Boutsen, Betty Kollia, Justin Dvorak

P14.15 Systematic review of the efficacy of traditional Chinese medicine in Parkinson’s disease
Catarina Pereira, Jorge Rodrigues, Natália Oliveira, Jorge Machado, Maria Criad, Henri Greten6

P14.16 Moving mindfully: A mindfulness-based walking therapy program for people with freezing of gait
Kerri Rawson, Tueth Lauren, Jeanne Kloeckner, Raina Foreman, Ryan Duncan, Allison Haussler, Sidney Baudenstiel, Keith Lohse, Gammon Earhart

P14.17 The use of music in every day life among people with Parkinson’s: A mixed methods study
Dawn Rose, Ellen Poliakoff, William Young, Michelle Phillips

P14.18 Songlines for Parkinson’s: A new approach to co-developing a group-based music and movement intervention for and with people with Parkinson’s, practitioners, medical professionals, and scientists
Dawn Rose, Marietta Ungerer, Sabrina Koechli

P14.19 Sing a new song: Results from research on group therapeutic singing for people with Parkinson’s disease
Elizabeth Stegemoller

P14.20 Music therapy improves strength and gait in Parkinson’s disease patients: A pilot study and clinical case analysis
Cristina Tinajas Arrontes, Manuel García San Emeterio, Marta Méndez Olavide, Vanessa Bayo Tallón, Carlos Llobregat Delgado, Jordi Esquirol Caussa

P14.21 Can musical sonification improve motor control in Parkinson’s disease? Results from a rehabilitation protocol
Lauriane Veron-Delor, Serge Pinto, Alexandre Eusebio, Jean-Philippe Azulay, Tatiana Witjas, Bruno Nazarian, Jean-Luc Anton, Julien Sein, Marieke Longcamp, Jérémy Danna
P14.22  Can action observation and/or motor imagery improve computer-based actions in Parkinson’s?
Camilla Woodrow-Hill, Emma Gowen, Stefan Vogt, Matthew Sullivan, Ellen Poliakoff

Comprehensive Care: Lay/professional health literacy & public thought

P15.05  Supporting Parkinson’s disease medication safety for nurses in the acute care setting through an educational intervention study

P15.06  Certified Parkinson disease care (CPDC™): Improving the care of Parkinson’s patients in long-term care
Anissa Mitchell, Andrea Merriam-Crespo

P15.07  Doing DBS: Social considerations
David Shea

P15.08  The Edmond J Safra visiting nurse faculty program at the Parkinson foundation
Gwyn Vernon

Comprehensive Care: Disability and quality of life outcome measures

P16.06  Comparing the benefits of cognitive mapping and motivational interviewing with the Canadian occupational performance measure to provide better person-centered care
Mary Grace Lagasca

P16.07  Correlation between functionality, motor and non-motor aspects of daily life experiences and the evolution of Parkinson’s disease
Isaíra Nascimento, Kátia Nobrega, Isabela Barone, Giovanna Checchio, Vitória Ponciano, Clara Paula, Natália Cardoso, Arieni Possani, Maria Elisa Piemonte

P16.08  Tracing quality of life in Parkinson’s
Fiona Navilly

P16.09  Falls and quality of life in patients with Parkinson’s disease
Kumar M Prakash, Ee Chien Lim, Siew Lian Voon

P16.10  Quality of life neurological disorders (Neuro-QoL) differences among individuals with Parkinson disease with and without freezing of gait
Lauren Tuelth, Raina Foreman, Ryan Duncan, Teresa Baker, James Cavanaugh, Tamara DeAngelis, Daniel Fulford, Jaimie Girnis, Michael Lavalley, Timothy Nordahl, Marie Saint-Hilaire, Cathi Thomas, Terry Ellis, Gammon Earhart, Kerri Rawson

P16.11  Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease – Use of the screening visual complaints questionnaire
Iris Van der Lijn, Gera de Haan, Fleur Van der Feen, Joost Heutink, Teus Van Laar

Comprehensive Care: PwP – Clinician partnership: Shared decision-making

P17.03  What’s your style? How personas can support personalized information provision for people with Parkinson’s disease
Angelika Geerlings, Sanne Van den Berg

P17.04  The 55-word story to improve patient-provider communication
Esme Trahair, Allison Allen, Sneha Mantri

Comprehensive Care: Palliative care/ advance planning/ end of life care

P18.01  Parkinson’s and palliative care – Are there different needs for women?
Kathleen Armstrong
P18.02 Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life
Matthieu Bereau, Mathilde Giffard, Anne-Laure Clairet, Marc Verin, Manon Auffret

P18.03 Terminal care for parkinsonian residents in French nursing homes: A 10-year longitudinal retrospective study
Mathilde Giffard, Corentin Geoffroy, Manon Auffret, Matthieu Béreau

P18.04 The effect of a multidisciplinary blended learning program on palliative care knowledge for health care professionals involved in the care for people with Parkinson’s disease
Herma Lennart, Anne Ebenau, Silvia Kanter, Bas Bloem, Kris Vissers, Bauke Dijkstra, Marjan Meinders, Marieke Groot

P18.05 Feasibility of a nurse-led advance care planning and care coordination intervention in Parkinson’s disease – Results of a multicenter European study
Catharina Muente, Bauke W. Dijkstra, Marieke Groot, Marjan J. Meinders

P18.08 Symptoms at the end of life in patients with Parkinson’s disease
Elisabeth Wilson, Emily King-Oakley, Edward Richfield

Comprehensive Care: Health accessibility/ underserved populations

P19.08 The role of community neurology clinic
Iku Moroo

P19.09 Leveraging design thinking to increase the accessibility of power for Parkinson’s programming for underserved populations in Austin, Texas
Nina Mosier, Elena Eddington

P19.10 www.PregSpark.com, introducing the International PregnancieS and Parkinson’s Registry, an initiative of the Radboud UMC in co-creation with PWP
Annelien Oosterbaan, Wilanka Kapelle, Bastiaan Bloem, Bart Post

P19.11 Novel initiative project for Parkinson’s care by community contribution
Shankh Pal, Tillotma Roy, Bhindu Gupta

P19.12 Improving equitable access to care through Parkinson Society BC (PSBC)’s innovative new programs of physiotherapy and healthcare navigation
Shelly Yu

Comprehensive Care: Sexuality & intimacy

P20.01 Approach to the management of sexual and intimate problems in patients with motor and non-motor manifestations of Parkinson’s disease
Gila Bronner, Tanya Gurevich

P20.05 Association between motor, non-motor and sexual function in women living with Parkinson’s disease in Brazil
Katia Nobrega, Maria Elisa Piemonte, Thalyta Martins, Geovanna Santos

P20.06 Development of a scale assessing sexual dysfunctions specifically experienced by patients with Parkinson’s disease: “Parkinson’s disease sexual experience scale” (PD-SES)
Emilie Wawrziczny, Kathy Dujardin, Luc Defebvre, Bérengère Finois, Virginie Herlin, Nicolas Carrière, Clara De Groote

Comprehensive Care: Daily life activities including working & driving

P21.02 Grip strength, motor symptoms, and ADL function pre-versus post-deep brain stimulation surgery
Nicole Tester, Samantha Witte, Ori Shechtman, Justin Mason, Lisa Warren, Charles Jacobson, Michael Okun, Kelly Foote, Justin Hilliard

P21.03 Reading difficulties in Parkinson’s disease – Guidance for assessment and rehabilitation
Iris Van Der Lijn, Gera de Haan, Pia Langenberg, Fleur Van der Feen, Joost Heutink, Teus Van Laar
Comprehensive Care: Self-management, empowerment, coping strategies

P22.07 Influence of neuropsychological care for the empowerment of patients with Parkinson’s disease in managing their continuous subcutaneous apomorphine infusion
Jean-François Houvenaghel, Marie Delliaux, Sophie Drapier

P22.08 Unique methods to alleviate freezing of gait that people with Parkinson’s developed
Yasuuki Okuma

P22.09 Impower: Developing home-based digital training for people with Parkinson’s to manage impulse control behaviours
Ellen Poliakoff, Jade Pickering, Judith Bek, Chris Kobylicki, Aansha Priyam, Jacob Hadfield, Jennifer McBride

P22.11 Exercise with C.A.R.E.
William Richard

P22.12 A qualitative analysis of coping strategy patterns in Parkinson’s disease
Caroline Seton, Aileen K. Ho

P22.13 Detours of persons affected by Parkinson’s disease in circumventing cognitive obstacles in daily life: The COPIED study
Ingrid Sturkenboom, Edwin Barentsen

P22.14 Empowerment of people with Parkinson’s disease: development, testing and evaluation of a cross-sectoral, intervention-based self-management program
Trine Thomsen, Sara Lyngby Skovbelling, Morten Møller, Vibeke W. Grønlund, Maria Branden, Bo Biering-Sørensen

P22.15 Registry of patients living with Parkinson: Active patient role in co-creating data-driven tools and solutions
Lucia Wang, Lucila Falcone

P22.17 P.D. PowerUp: A Comprehensive virtual program for managing pain in Parkinson’s disease
Apurva Zawar

Comprehensive Care: Multidisciplinary/interdisciplinary teams

P23.10 CENPAR: Rehabilitation area to 12 months
Paola Alicia Riveros Cortés

P23.11 Integrative treatment of Parkinson’s disease including photobiomodulation: A case series
Anita Saltmarche, Ann Liebert, Orla Hares, Brian Bicknell

P23.12 Six month evaluation of a one year post graduate nurse practitioner (NP) fellowship focused on care for persons with movement disorders: An interdisciplinary approach
Kristen Matulis, Patrick Walker, Abigail Corriveau, Christopher Hess, Christine Kim, Eli Pollard, Serge Przedborski, Janice Smolowitz

P23.13 Multidisciplinary education transforming Parkinson’s services
Susan Thomas, Sarah Gillett, Charlie Peel

P23.14 Home-based titration with duodenal infusion of levodopa in People with Parkinson’s disease: An observational feasibility study
Trine Thomsen, Bo Biering-Sørensen, Nick Schou Nielsen, Asher Lou Isenberg, Michael Møller, Jesper Boje Clausen, Louise Olsen, Mahsa Javidi, Marc Klee Olsen, Jeanet Roger Vilhelmsen

P23.15 Frailty and risk for falling in Parkinson’s disease. A longitudinal, randomized, multidisciplinary-based telemedicine intervention (NCT04694443)
Florita Valiñas-Sieiro, Marta Allende-Rio, Álvaro García-Bustillo, José Miguel Ramírez-Sanz, Alicia Olivares-Gil, José Luis Garrido-Labrador, Álvar Arnáiz-González, José Francisco Diez-Pastor, Maha Jahouh, Josefina González-Santos, Jerónimo Javier González-Bernal, José María Trejo-Gabriel-Galán, Esther Cubo

P23.16 Improving Parkinson’s care in senior living communities and home care agencies in the US
Rose Wichmann, Joan Gardner
Comprehensive Care: Digital health, E-health and technology

P24.18 Investigating usability, understandability, and acceptance of the MY PD-CARE digital tool for tracking and communicating symptoms of Parkinson’s: The self-aware study
Angelo Antonini, Tove Henriksen, Amelia Hursey, Lars Bergmann, Juan Carlos Parra, Per Odin

P24.19 Mobilising patient and public involvement in the development of real-world digital technology solutions: Lessons learned from the Mobilise-D consortium

P24.20 Individualized smartphone-based exercise as a telemedical approach to reduce motor symptoms in Parkinson’s disease
Lisa Lützow, Isabelle Teckenburg, Veronica Koch, Martin Regensburger, Franz Marxreiter, Jelena Jukic, Sabine Stallforth, Jürgen Winkler, Jochen Klucken, Heiko Gaßer

P24.21 Integration of a conversational agent in a mHealth solution to increase exercise adherence in Parkinson’s disease
Patricia Macedo, Pedro Mota, Ana Beatriz Rebola, Rui Neves Madeira, Carla Pereira

P24.22 Suppocial – Connect. Support. Inspire
Blake Mackey

P24.23 Development of an evaluation framework for digitally enabled integrated care: Connected care PD
Ivana Paccoud, Liyousew Borga, Joëlle V. Fritz, Jochen Klucken

P24.24 Compliance and satisfaction of Parkinson’s disease patients from a pilot smart devices-enabled study
Nikolaos Papagiannakis, Anastasia Bougea, Athina-Maria Simitsi, Elpida Panagiotounakou, Chrysa Chryssovitsanou, Minas Badounas, Ioannis Ladakis, Hara Stefanou, Panos Tsakanikas, Christos Keros, Leonidas Stefanis

P24.25 Alameda study protocol: Bridging the early diagnosis and treatment gap of brain diseases via smart, connected, proactive and evidence-based technological interventions for Parkinson’s disease

P24.27 MoveONParkinson: Development of an innovative motivational solution for personalized exercise through the ONParkinson platform
Carla Pereira, Ana Beatriz Rebola, Daniela Sinieiro, Pedro Alburquerque Santos, Ricardo Carmo, João Carreira, Patricia Macedo, Rui Neves Madeira

P24.28 Stepping outside the clinic: Gait detection using wrist-worn sensors for remote arm swing analysis in Parkinson’s disease
Erik Post, Twan Van Laarhoven, Yordan Raykov, Max Little, Peter Kok, Pablo Rodriguez-Sánchez, Tom Heskes, Bastiaan Bloem, Luc Evers

P24.30 A system for measuring akinesia via handheld momentum sensors
Venkateshwarla Rama Raju

P24.31 Consultation preparation: A pilot study to improve Parkinson’s disease patients’ perception of their doctor visit
Laura Carrasco, Damaris Alvarez, Manuel Perez, Chiara Capra, Daniel Rodriguez-Martín, Marina Mata, Monica M. Kurtis, Carmen Borrej, Lydia Lopez-Manzanares

P24.32 Co-designing digital medical devices for living well with Parkinson’s disease
Isabel Schwaninger, Alexandre Kloos, Fozia Noor, Sandrine Lavalle, Anne Kayes, Jochen Klucken

P24.33 A 26-week case study of long-term adherence to a smartphone-based patient reported outcomes (PRO) platform: Enhancing measurement and improving outcomes for an individual living with Parkinson’s
Benoit Tas, Benoit Duvivier, Heiko Mueller, John M Dean

P24.34 Patient-centered recommendations for Parkinson’s clinical trials using digital health technologies
Kimberly Ward Barowicz, Marjan Meinders, Mark Frasier, Johan Hellsten, Taïrmae Kangarlo, Matthew Sullivan, Cindy Zadikoff, Martijn Müller, Diane Stephenson
POSTERS – Session 2
Thursday, July 6, 2023

P24.35 Soft robotic apparel and freezing of gait: A targeted approach
Nick Wendel, Jinsoo Kim, Franchino Porciuncula, Teresa Baker, Hee Doo Yang, Sungwoo Park, Conor Walsh, Terry Ellis

Comprehensive Care: Rehabilitation sciences (PT, OT, SLP)

P25.23 Occupational outcomes in individuals with Parkinson’s disease using a small group functional skill training approach
Noelle Joyner, Heather Simpson, Alison Kraus, Becky Farley

P25.24 Use of constraint induced goggles to manage dystonia and axial rigidity in Parkinsonism
Aison Kraus, Paul Auth, Nicole Tester, Michael Okun

P25.25 The application of PD specific functional training in group rehabilitative sessions – Physical performance outcomes
Aison Kraus, Heather Simpson, Noelle Joyner

P25.26 Defining the components of an occupation-based intervention for people with Parkinson’s with anxiety using Group Concept Mapping
Chris Lovegrove, Jon Marsden, Ingrid Sturkenboom, Katrina Bannigan

P25.27 Developing an occupation-based complex intervention for living well with anxiety and Parkinson’s (OBtAIN-PD): A logic modelling approach
Chris Lovegrove, Jon Marsden, Ingrid Sturkenboom, Katrina Bannigan

P25.28 Evaluating the occupation-based complex intervention for living well with anxiety and Parkinson’s disease (OBtAIN-PD): A feasibility cluster randomised controlled trial protocol
Chris Lovegrove, Jon Marsden, Chris Hayward, Joanne Hosking, Ingrid Sturkenboom, Katrina Bannigan

P25.30 Does hand exercise and training improve dexterity and function in people with Parkinson’s disease? A systematic review and meta-analysis
Jennifer McGinley, Elizabeth Proud, Kimberly Miller, Meg Morris, Jannette Blennerhassett

P25.32 Effectiveness of balanceHOME program in functional mobility and cognitive performance in Parkinson’s disease: A case study with mild cognitive impairment
Sara Monléon Guinot, José M. Tomás, Joan Sánchez-Orti, Vivina Aranda Asensi, Concepción de Salazar Antón, Manuel Villanueva Navarro, Constanza San Martin Valenzuela

P25.33 Crowdsourced perceptual ratings of voice quality in people with Parkinson’s disease before and after intensive voice and articulation therapies: Secondary outcome of a randomized controlled trial
Tara McAllister, Christopher Nightingale, Gemma Moya-Galé, Ava Kawamura, Lorraine Ramig

P25.34 Clinicians’ self-perceptions of LSVT LOUD Globally: Data from Germany, France, and Japan
Gemma Moya Galé, Thomas Brauer, Catherine Airiau, Masako Fujiu-Kurachi, Cynthia Fox, Heike Penner, Petra Benecke, Lorraine Ramig

P25.37 Do dual-tasks affect gait asymmetry in people with Parkinson’s disease?
Constanza San Martin Valenzuela, Lirios Dueñas Moscardó

P25.38 Comprehensive communication care for people with Parkinson’s disease and their care partners
Lisa Sommers, Sara Mamo

P25.39 Developing an integrated guideline for allied health care in Parkinson’s disease with decision support: Lessons learned
Ingrid Sturkenboom, Anneli Langbroek-Amersfoort, Marten Munneke, Bastiaan Bloem

P25.40 Feasibility of a combined intermittent theta-burst stimulation and video game-based dexterity training in Parkinson’s disease
Manuela Pastore-Wapp, Brigitte C. Kaufmann, Thomas Nyffeler, Simona Wapp, Stephan Bohihalter, Tim Vanbellingen

P25.41 No added effect of transcranial direct current stimulation on motor sequence learning in older adults
Britt Vandendooren, Sanne Broeder, Moran Giliat, Evelien Nackaerts, Jean-Jacques Orban de Xivry, Alice Nieuwboer

P25.42 Effects of a 6-month community-based Nordic walking program on alleviating motor and non-motor symptoms and improving balance performance in people with Parkinson’s disease
Irene SK Wong-Yu, Ken CK Poon, Margaret KY Mak
P25.43 Experiences and future perspectives with two patterns of intensive online exercise training in early-stage Parkinson’s disease  
Yuya Yamaguchi, Junya Ogawa, Hiromi Masumori, Tadamitsu Matsuda

P25.44 Effect of transcranial direct current stimulation depending on stimulation sites to improve dual-task performance in Parkinson’s disease  
Seo Jung Yun, Sung Eun Hyun, Woo Hyung Lee, Byung-Mo Oh, Han Gil Seo

Comprehensive Care: Nutrition and gastrointestinal issues

P26.02 Objective measures of gut dysfunction in Parkinson’s disease  
Marta Camacho

P26.05 Comprehensive personalized nutrition approach for people with Parkinson’s: A case study  
Sally Hillis

P26.06 The relationship between diet and Parkinson symptoms over time  
Laurie Mischley, Joshua Farahnik

Clinical Science: Symptoms, signs, features & non-motor manifestations

P27.06 Does musculoskeletal pain impact physical activity in people with Parkinson’s disease?  
Ryan Duncan, Timothy Nordahl, Teresa Baker, James Cavanaugh, Tamara DeAngelis, Daniel Fulford, Jaimie Girnis, Martha Hessler, Michael Lavallee, Marie Saint-Hilaire, Cathi Thomas, Jenna Zajac, Terry Ellis, Gammon Earhart, Kerri Rawson

P27.08 The hormonal impact on symptoms in women with Parkinson’s  
Richelle Flanagan, Kat Hill, Sree Sripathy, Sabela Avion

P27.10 Apathy, gender and quality of life among Mexican people living with Parkinson’s disease: An underrecognized non-motor symptom  
Ana Jimena Hernández-Medrano, Diana Paulina Romero-Terán, María Fernanda Medina-Pérez, Andrea García-Hernández, Rodolfo Arturo Abundes-Corona, Daniela Renee Águla-Godínez, Axel Antonio Herrera-Ruiz, Amin Cervantes-Arriaga, Mayela Rodríguez-Violante

P27.22 Respiratory dysfunction in Parkinson’s Disease: Prevalence and determinants  
Maarten J. Nijkrae, Veerle A. van de Wetering-van Dongen, Philip J. van der Wees, Joanna IntHout, Sirwan K.L Darweesh, Bastiaan R. Bloem, Johanna G. Kalf

P27.23 Clinical and cognitive characteristics in Parkinson’s: The role of white matter injuries is decisive?  
Daniela Ortiz Zacarias, Ingrid Eloisa Estrada Bellmann, Christopher Cerda, Roberto Estrella Silva, Juan Roberto Trejo Ayala, Beatriz Chavez Luevano, Fernando Góngora Rivera

P27.24 Association between anxiety and freezing of gait in Parkinson’s disease  
Nathalia de Brito Pereira, Karina Yumi Tashima Honda, Isaira Almeida Pereira da Silva Nascimento, Katia Cirilo Costa Nobrega, Thayane Habache Barolli, María Elisa Pimentel Piemonte

P27.25 Atypical Parkinsonism and psychiatric disorder in hereditary diffuse leukoencephalopathy with spheroids: A novel variant in the CSF1R gene  
Neus Rabaneda Lombarte, Belén Flores Pina, Dolores Vilas Rolán, Ana Castillo Gandía, Cristina Carrato Moñino, Katrin Beyer, Martí Paré Curell, Anna Massuet, Lourdes Ispierto González, Mireia Gea Rispal

P27.26 Compliance with national and international guidelines in treatment of non-motor symptoms in late stage Parkinson’s disease  
Kristina Rosqvist

P27.27 Correlation of olfactory dysfunction in total and selective smell factors with cardiac sympathetic degeneration  
Dong-Woo Ryu, Sang-Won Yoo, Ko-Eun Choi, Joong-Seok Kim

P27.28 The impact of freezing of gait on daily life mobility  
Christian Schlenstedt, Jennifer Kudelka, Jonas Müller, Paul Fritz, Pia Reisdorf, Katharina Dirksen, Heiko Gassner, Clemens Becker, Anat Mirelman, Jeff Hausdorff, Lynn Rochester, Pieter Ginis, Alice Nieuwboer, Walter Maetzler
P27.29 Visual dysfunction and performance in activities of daily living among persons with Parkinson’s disease
Nicole Tester, Chiung-ju Liu, Yun Chan Shin, Aparna Wagle-Shukla

P27.30 Relationship between cognitive functions and motor performance in patients with Parkinson’s disease
Olena Tsurkalenko, Patricia Martins Conde, Claire Pauly, Sonja Jonsdottir, Stefano Sapienza, Laure Pauly, Anne-Marie Haniff, Jochen Klucken, Rejko Kruger

P27.31 Applications of acoustic analysis in the evaluation of the prosody in people with Parkinson
Alejandro Cano Villagrasa, Beatriz Valles-González, Cristina Agudo, Leticia Moreno

P27.32 The impact of faecal microbiome transplantation (FMT) on gut physiology in Parkinson’s disease patients with abnormal gut microbiota composition
Nora Vetkas, Lotta Luiskari, Tatyana D Fedorova, Reeta Levo, Berta Bosch, Riitta Korpela, Perttu Lahtinen, Rebekka Ortiz, Valtteri Kaasinen, Reetta Satokari, Perttu Arkkila, Filip Scheperjans

P27.33 Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with Parkinson’s: A randomised sham-controlled pilot trial
Alison Yarnall, Hilmar Sigurdsson, Heather Hunter, Lisa Alcock, Ross Wilson, Ilse Pienaar, Elizabeth Want, Mark Baker, John-Paul Taylor, Lynn Rochester

P27.34 The natural history of orthostatic blood pressure instability in early Parkinson’s disease
Sang-Won Yoo, Joong-Seok Kim

P27.35 Striatal dopaminergic depletion is related with cardiovascular non-motor symptom in drug-naïve patients with Parkinson’s disease
Minkyeong Kim, Eugene Jeong, Jong Hyeon Ahn, Jin Whan Cho, Kyung-Han Lee, Seunghwan Moon, Jong Kyu Park, Jinyoung Youn

P27.36 The experience of pain in people diagnosed with Parkinson’s disease at an early age: An interpretive phenomenological analysis
Sylvia Zimmers, Catherine Burgener

Clinical Science: Progression & prognosis

P28.04 Pure autonomic failure developed parkinsonism without changes in 18F-FP-CIT PET: A case study
Oh Dae Kwon

P28.05 Larger ventricle may predict the development of freezing of gait in Parkinson’s disease
Jae-Jung Lee, Young Bok Yong, Jong Sam Baik

P28.06 Development and validation of a 7-year prognostic model for institutionalisation in Parkinson’s disease: An individual-participant-data meta-analysis
Yan Li, David McLemon, Rachael Lawson, Alison Yarnall, David Bäckström, Lars Forsgren, Marta Camacho, Caroline Williams-Gray, Jodi Maple-Grødem, Guido Alves, Ole-Bjørn Tysnes, Carl Counsell, Angus Macleod

P28.08 Effects of dihydropyridines on the motor and cognitive outcomes of patients with Parkinson’s disease
Jin Ho Jung, Han Kyu Na, Seong Ho Jeong, Seok Jong Chung, Han Soo Yoo, Yang Hyun Lee, Kyoungwon Baik, Sang Jin Kim, Young H Sohn, Phil Hyu Lee

P28.09 Clinical evidence and upcoming neuroprotective strategies for Parkinson’s disease: An update
Olivier Uwishema

Clinical Science: Behavioral disorders

P29.04 Mindfulness-based cognitive therapy for anxiety and depression in people with PD
Andreea Seritan, Ana-Maria Iosif, Prarthana Prakash, Sarah Wang, Stuart Eisdendrath

P29.05 Minds & movement: Evidence-based guidance for psychological interventions for people with Huntington’s disease, Parkinson’s disease, motor neuron disease, and multiple sclerosis
Jane Simpson, Fiona Eccles, Nicolò Zarotti

P29.06 Psychosocial interventions affecting global perceptions of control in people with Parkinson’s disease: A scoping review
Nicolò Zarotti, Katherine Deane, Catherine Ford, Jane Simpson
Clinical Science: Cognition/ mood/ memory

P30.11 Impairment in the behavioral synergic control of postural sway, gaze shift, and mental workload in Parkinson’s disease
Yann Kechabia, Arnaud Delval, Luc Defebvre, Cédrick Bonnet

P30.12 In the direction of quantifiable objective psychopathology via cognitive neuropsychiatry: A fusion oriented hybrid-study
Neerati Lavanya

P30.13 The effect of the social evaluative threat on substantia nigra functional connections to stress processing system regions of interest
Senegal Alfred Mabry, Marlen Gonzalez, Eve De Rosa, Adam Anderson

P30.14 Psychotic features in early PD: Prevalence, phenomenology and clinical correlates
Ioanna Pachi, Vasillis Papadopoulos, Christos Koros, Athina-María Simitsi, Anastasia Bougea, Maria Bozi, Nikos Papagiannakis, Rigas-Filippos Soldatos, Dimitra Kolovou, George Pantes, Nikolaos Scarmeas, Georgios Paraskyas, Konstantinos Voumavourakis, Sokratis Papageorgiou, Konstantinos Koliass, Nikos Stefanis, Leonidas Stefanis

P30.15 Cognitive profile in prodromal Parkinson’s disease – Cross-sectional and case-control study in an at-risk cohort of people with REM-sleep-behavior-disorder and hyposmia
Laure Pauly, Claire Pauly, Armin Rauschenberger, Valerie E. Schröder, Gilles Van Cutsem, Anja K. Leist, Rejko Krüger

P30.16 Facial emotion recognition is associated with MoCA score in patients with Parkinson’s disease
Claire Pauly, Anne-Marie Hanff, Sonja R. Jónsdóttir, Olena Tsurkalenko, Nico J. Diederich, Rejko Krüger

P30.17 Cognition and freezing of gait in Parkinson’s disease: A systematic review and meta-analysis
Andrew Monaghan, Elise Gordon, Lisa Graham, Daniel Peterson, Rosie Morris

P30.18 Screening for anxiety symptoms in Parkinson’s disease in a Mexican cohort
Paula Reyes-Pérez, Alejandra Medina-Rivera, Alejandra Ruiz-Contreras, Sarael Alcauter-Solórzano, Miguel Rentería, Luis García-Marín, Alejandra Lázaro-Figueroa, Eugenia Morelos-Figaredo, Damaris Vazquez-Guevara

P30.19 Agents and phases of stress and coping strategies in Parkinson’s disease
Dirce Sanches Rodrigues, Marcos Antônio Moura, Adriana Aparecida Ferreira de Souza, Kátia Lousada Gouveia, Luiz Arthur Moreira Nunes, Miguel Soares Conceição

P30.20 Association between thyroid dysfunction and severity of cognitive impairment in de novo patients with Parkinson’s disease
Iva Sarac, Helena Sarac, Fran Borovecki, Neven Henigsberg, Ida Ivec, Lucija Bagarić Krakan, Mateja Iveta, Tea Sukobljevic, Zdravko Kresic

P30.21 The effects of computerised cognitive training of executive functioning on emotion regulation in Parkinson’s disease
Caroline Seton, Carien M. van Reekum, Aileen K. Ho

P30.22 Motor symptom asymmetry predicts emotional and cognitive theory of mind outcome following STN DBS in Parkinson’s disease
Philippe Voruz, Julie Péron

P30.23 Perceived control as a predictor of medication adherence in people with Parkinson’s: A large-scale cross-sectional study
Nicolò Zarotti, Katherine Deane, Catherine Ford, Jane Simpson

P30.24 Gait initiation in Parkinson’s disease: Investigating the role of proactive and reactive inhibition with EEG
Déborah Ziri, Laurent Hugueville, Claire Olivier, Marie-Laure Welter, Nathalie George

Clinical Science: Sleep disorders/ fatigue

P31.02 Do motor symptoms worsen Parkinson’s disease insomnia? A videopolysomnographic study
Sarah Joanny, Smaranda Leu-Semenescu, Isabelle Arnulf

P31.04 Examining the impact of sleep disturbances on lived experiences of persons with Parkinson’s disease (PwPD)
Adriana Omelas, Karen Aranha, Angela Blackwell, Nina Mosier
Clinical Science: Diagnosis (differential, accuracy)

P32.05 Correlation between olfactory dysfunction and severity of tremor: New hypothesis
Denis Pokhabov, Vladislav Abramov, Michael Sadovsky, Dmitrii Pokhabov

P32.06 Transcranial sonography as a tool for the differential diagnosis of early stages of synucleinopathies
Neus Rabaneda Lombarte, Anna Planas Balvé, Belén Flores Pina, Mireia Gea Rispal, Lourdes Ispierto González, Laia Grau, Ramiro Álvarez, Pau Pastor, Dolores Vilas Rolán

P32.07 Whole-exome sequencing for Parkinson’s disease: Tertiary single-center experience
Valentino Racki, Elisa Papic, Mario Hero, Anja Kovanda, Borut Peterlin, Vladimira Vuletic

P32.08 Impact of educational level on delayed diagnosis in people living with Parkinson’s disease (PD): Treated at the National Institute of Neurology and Neurosurgery (INNN) during the year 2022

Clinical Science: Co-morbidities

P33.04 Association between history of SARS-CoV-2 infection and worsening of non-motor symptoms and non-motor fluctuations in Mexican people living with Parkinson’s disease
Ana Jimena Hernández-Medrano, Diana Paulina Romero-Terán, María Fernanda Medina-Pérez, Andrea García-Hernández, Rodolfo Arturo Abundes-Corona, María Alejandra Ruiz-Mafud, Daniela Renee Aguila-Godínez, Axel Antonio Herrera-Ruiz, Amin Cervantes-Arriaga, Mayela Rodríguez-Violante

P33.05 Association between type 2 diabetes mellitus with Parkinson’s disease and the increase of the severity of neuropsychiatric symptoms in a Mexican institute

P33.06 Pain and moods disorders as determinants of quality of life in Parkinson
Daniela Ortiz Zacarias, Ingrid Eloísa Estrada Bellman, Roberto Estrella Silva, Juan Roberto Trejo Ayala

Clinical Science: Biomarkers and neuroimaging

P34.02 The influence of gut microbiota as a potential regulator of amino acid metabolism and its novel correlations in Parkinson’s pathogenesis
Yasunthara Balalle-Deo, Nanthini Jayabalal, Kerry Rooper, Helen Woodhouse, John O’Sullivan, Robert Adam, Richard Gordon

P34.06 Assessing the biomarker potential of LRRK2 and GCase in Parkinson’s disease monocytes
Laura Hughes, Nicolas Dzamko, Rebecca Wallings, Roy Alcalay, Alicia Garrido, Malú Gámez Tansey

P34.14 Cortical microstructural changes in Parkinson’s disease and its correlation with clinical and neuropsychological performance
Jéssica Pardo, Víctor Montal, Ana Campabadal, Javier Oltra, Ignacio Roura, Carme Uribe, Gemma Monté-Rubio, María J. Martí, Yaroslau Compta, Juan Fortea, Carme Junqué, Bárbara Segura

P34.15 Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB
Mee Y Park, Dong S Shin

P34.16 Evaluation of a clinically validated digital platform to provide diffusion MRI biomarkers in Parkinsonian syndromes
Vincent Perlbarg, Lydia Chougar, Jean-Baptiste Martin, Arthur Bezie, Julie Rachline, David Grabli, Florence Cormier, Marie Vidalhét, Jean-Christophe Corvol, Bertrand Degos, Stéphane Lehérix
P34.17  Multi-modal prognostic biomarkers for Parkinson’s disease  
Anne-Sophie Rolland, Ophélie Simonin, Romain Viard, Julien Labreuche, Jessica Carpenter, Petr Dušek, Markus Otto, Marie-Odile Habert, Stéphane Lehericy, Gregory Kuchcinski, Renaud Lopes, Jean-Pierre Pruvo, Christophe Scherfler, Jean-François Mangin, Marie Chapin, Caroline Moreau, David Devos, For the FAIRPARK-II study group For the FAIRPARK-II study group

P34.18  Peripheral retinal and microbial biomarkers for the early diagnosis of Parkinson’s disease  
Victoria de los Angeles Soto Linan, C. Gora, M. Peralta, F-A. Guevara Aguadelo, N. Dupré, M. Hébert, F. Raymond, M. Lévesque

P34.19  Imaging presynaptic terminal integrity in parkinsonism: New findings from the 18F-SynVesT-1 tracer  
Carme Uribe, Sarah Martin, Kelly Smart, Kimberly Desmond, Anthony Lang, Neil Vasdev, Antonio Strafella

P34.20  Peripheral immunophenotype and inflammation changes in PD upon αSyn treatment  
Ana Florencia Vega Benedetti, Clara Porcedda, Tommaso Ercoli, Chiara Burgaletto, Giovanni Defazio, Alfonso De Simone, Giuseppe Cantarella, Valeria Sogos, Anarosa Carta

P34.21  Characterisation of blood-derived extracellular vesicles in Parkinson’s disease patients  
Alexander Weiss, Fanni Annamaria Boros, Philipp Arnold, Andreu Matamos-Angles, Verena Taudte, Friederike Zunke

P34.22  Delayed cardiac sympathetic denervation in Parkinson’s disease: An intermediate gradient between CNS- and PNS-dominant subtypes  
Sang-Won Yoo, Joong-Seok Kim

P34.23  Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson’s disease biomarkers  
Priscilla Youssef, Laura Hughes, Wookin Kim, Glenda Halliday, Simon Lewis, Antony Cooper, Nicolas Dzamko

Clinical Science: Pharmacological therapy

P35.02  May apomorphine be helpful for the axial symptoms of Parkinson’s disease?  
Araceli Alonso-Canovas, Paula Pérez-Torre, Gema Sánchez, Angeles Patiño Paton, Nieves Monterde Fernández, Isabel Pareés Moreno, Juan Carlos Martínez Castrillo

P35.07  Astrocytic networks as a novel therapeutic target in Parkinson’s disease  
Nataly Hastings, Saifur Rahman, Przemyslaw Aleksandr Stempor, Wei-Li Kuan, Maha Alfaidi, Matthew Wayland, Aleksandr Zakirov, Michael Whitehead, Mark Kotter

P35.12  May safinamide have a role in atypical Parkinsonism? A retrospective study in clinical practice  
Fernando Rodríguez Jorge, Paula Pérez Torre, Isabel Pareés Moreno, Jose Luis López Sendón, Samira Fanjul Arbós, Juan Carlos Martínez Castrillo, Araceli Alonso Cánovas

P35.13  The impact of RAS inhibition on Parkinson’s disease risk in hypertensive patients: A meta-analysis  
Youssef Soulman, Mostafa Hossam, Basma Ehab Amer, Hadeer Elsaed AboElfah, Motasem Ayoub, Maged Elsayed Mohamed, Ahmed Nasr, Eman T. Salah, Omar Ahmed Abdelwahab, Mostafa Meshref

P35.14  Improvements in neuronal health by N-cyano pyrrolidine USP30 inhibitors in Parkinson’s disease  
Elizabeth Stephen, Fernanda Martins Lopes, Emma Green, Emma Murphey, Franziska Gunther, Katherine England, John Davis, Michael Clague, Sylvie Urbé, Laura Ferraiuolo, Heath Moritboys

P35.15  Passive immunization reduces propagation of alpha-synuclein pathology along gut-brain axis  
Vasilios Theologidis, Jonas Folke, Tomasz Brudek, Richard Dodel, Alexander Ross, Hjalte Gram, Poul Henning Jensen, Per Borghammer, Nathalie Van Den Berge

Clinical Science: Surgical therapy, including cell and gene therapy

P36.08  Evidence-based correlates and predictors of medication reduction after DBS in PD  
Jim Kirk, Arthur Berg, Michele York, Jason Schwalb, Mustafa Siddiqui, Jim McNerney, Joohi Jimenez-Shahed

P36.09  Effectiveness of lead-point using combined imaging driven by computed axial tomography and mer for targeting stn-dbs in Parkinson’s  
Neerati Lavanya
P36.10 Acceptability of adaptive deep brain stimulation for Parkinson’s disease
Asuka Nakajima, Genko Oyama, Yasushi Shimo, Hikaru Kamo, Atsushi Umemura, Hirokazu Iwamuro, Yuta Sekiguchi, Ayumi Tsuchiya, Thomas C. Brionne, Kate Noel, Nobutaka Hattori

P36.11 High-density noninvasive wired and wireless EEG electrodes and minimally invasive DBS in Parkinson’s: A study with microelectrode recording
Venkateshwarla Rama Raju

P36.12 Refined cutting-edge adaptive closed loop smart deep brain stimulation in Parkinson’s: A study with progressive machine learning decryption techniques
Venkateshwarla Rama Raju

P36.13 Functional analysis of Parkinson’s disease using computational simulation models and systems control theory
Venkateshwarla Rama Raju

P36.14 Computational simulation prototype-model of adaptive closed-loop deep brain stimulation (ACL-DBS) for curbing the low frequency β-oscillations in Parkinson’s
Venkateshwarla Rama Raju, Lavanya Neerati

Clinical Science: Complications of therapies

P37.03 Can Abilify cause disability?: A case series providing insight into parkinsonian symptoms experienced by Abilify users
Kristin Richey, Jacob Golforth, Paul Brill

P37.04 Apathy and impulse control disorders are not exclusionary behavioral conditions: Challenging a classical model in Parkinson’s disease
Marta Vales Montero, Francisco Ferre Navarrete, Javier Conejo Galindo, Pablo Andrés Camazón, José Suárez Campayo, Rubén Reyes Marrero, José Ramón López-Trabada Gómez, M Bayta Díaz Rodríguez, Pedro José Melgarejo Otálora, Francisco Grandas

Clinical Science: Clinical trials: Design, outcomes, recruiting, etc.

P38.22 Listening to the experience of participants on neurosurgical trials: Outcomes of the LEARN-GDNF and LEARN-transeuro studies
Cheney Drew, Kim Smallman, Suzette Shahmoon, Emma Lane

P38.23 The LEARN study: Tools to aid participant and support partner experience in clinical trials for Parkinson’s disease
Cheney Drew, Kim Smallman, Lesley Gosden, Colin Gosden, Darren Calder, Jayne Calde, Helen Matthews, Emma Lane

P38.25 Case studies of a 3-year follow-up of abdominal photobiomodulation treatment for Parkinson’s disease
Ann Liebert, Brian Bicknell, Vincent Pang, Geoffrey Herkes, Hosen Kiat

P38.26 A triple-blinded, sham controlled study of transcranial photobiomodulation (PBM) in Parkinson’s disease
Claire McGee, Ann Liebert, Brian Bicknell, Vincent Pang, Craig McLachlan, Hosen Kiat, Geoffrey Herkes

P38.29 Exploring the disease-modifying potential of the probiotic Bacillus subtilis in Parkinson disease
Jodi Maple-Grødem, Veslemøy Hamre Frantzen, Conni McCarthy, Johannes Lange, Rachel Dakin, Guido Alves, Maria Doitsidou, David Breen

P38.32 APGS-ShakeItUp Australia Parkinson’s registry: A catalyst for rapid testing of new therapies in clinical trials
Michael Katz, Clyde Campbell, Vicki Miller, Richard Balansan, Nicholas G. Martin, Miguel E. Renteria

P38.33 Randomized, double-blind, sham-controlled study to evaluate effectiveness of photobiomodulation plus exercise to enhance motor, cognition and quality of life in those with Parkinson’s disease
Anita Saltmarche, Orla Hares, Ann Liebert, Brian Bicknell, Margaret Naeser, Geoff Herkes

P38.34 The Vall d’Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal and observational study enrolling de novo Parkinson’s disease (PD) patients and carriers of PD-linked mutations for biomarker and pathophysiologo studies
Daniela Samengo, Laura Domingo, Maria Camprodon, Silvia Enriquez, Mar Armengol, Victoria Gonzalez, Sara Lucas, Helena Xicoy, Jordi Riera-Heredia, David Montpey, Marta Martinez-Vicente, Ariadna Laguna, Jorge Hernandez-Vara
P38.36 Development and validation of the Parkinson’s Disease-Health Index (PD-HI): A disease-specific, patient-reported outcome measure for use in clinical trials
Jamison Seabury, Jennifer Weinstein, Spencer Rosero, Anika Varma, Charlotte Engebrecht, Nuran Dilek, John Heatwole, Michael McDermott, Abigail Arky, E. Ray Dorsey, Christine Zizzi, Chad Heatwole

P38.37 Worldwide collaborative framework for optimizing new Parkinson’s treatment trials with patient centric outcome measures
Diane Stephenson, Yuge Xiao, Catherine Kopil, Karen Lee, David T. Dexter, Martijn Müller, Klaas Romero, Helen Matthews, Gary Rafaloff, Jodie Forbes, Sarah Zenner, Carroll Sui, Johan Hellsten, Mark Maybank, Tanya Simuni

P38.40 Patient engagement in early drug development: Building target product profiles with patient experts and organisations, from validation to co-creation
Kate Trenam, Kevin Kwock, Paula Scurfeld, Nikul Bakshi, James Beck, Carl Vandeloo, Isabelle Wilputte

P38.41 Designing a protocol to evaluate feasibility, acceptability and impact of patient and care partner engagement in the EJS ACT-PD initiative
Marie-Louise Zeissler, Nikul Bakshi, Michèle Bartlett, Amit Batla, Rebecca Chapman, Eric Deeson, Romy Ellis-Doyle, Jodie Forbes, Cristina Gonzalez-Robles, Anna Jewell, Emma Lane, Keith Martin, Helen Matthews, Laurel Miller, Georgia Mills, Miriam Parry, Kuhun PushparanNam, Dorothy Salathie, Paula Scurfeld, Carroll Sui, Sue Whipp, Sheila Wonncott, Thomas Foltynie, Camille B Carroll, Kevin McFarthing

P38.42 Towards a preliminary protocol for a multi-arm multi-stage trial of disease modify therapies in Parkinson’s disease: the EJS ACT-PD initiative
Marie-Louise Zeissler, Matthew Burnell, Tom Barber, Yoav Ben-Shlomo, Rebecca Chapman, Caroline Clarke, Sally Collins, Carl Counsell, Mark Edwards, Romy Ellis-Doyle, Cristina Gonzalez-Robles, Anna Jewell, Georgia Mills, Dorothy Salathie, Sue Whipp, Alan Whone, Thomas Foltynie, Camille B Carroll, Roger Barker, James Carpenter

P38.43 Understanding site capability to inform the delivery of an inclusive multi-arm multi-stage trial for disease modifying therapies in Parkinson’s as part of the EJS ACT-PD initiative
Marie-Louise Zeissler, Jennifer Allison, Dilan Athauda, Sandra Bartolomeu-Pires, Gareth Baxendale, Kailash Bhatia, David Breen, Rebecca Chapman, Helen Collins, Rebecca Croucher, Romy Ellis-Doyle, Jodie Forbes, Cristina Gonzalez-Robles, Fleur Hudson, Rajeshree Khengar, Prasad Korlippur, Christian Lambert, Georgia Mills, Huw Morris, Monty Silverdale, Sheila Wonncott, Alison Yarnall, Thomas Foltynie, Camille B Carroll, Stephen Mullin

P38.45 The effects of an on-demand auditory cueing device used in the home for freezing of gait in people with Parkinson’s disease
Demi Zoetewei, Pieter Ginis, Taila Herman, Marina Brogol, Pablo Cornejo Thumm, Luca Palmerini, Alberto Ferrari, Jeffrey Hausdorff, Alice Nieuwoerboer

Clinical Science: Rating scales

P39.04 Test-retest reliability of a low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson’s disease
Samrah Javed, Abdelwahab Elshourbagy, James Brasic

P39.05 Validation of the UCLA Loneliness Scale 8- and 3-item versions in a cohort of people living with Parkinson’s disease and correlation with quality of life
Indu Subramanian, Bradley McDaniels, Devon Fox, Laurie Mischley

Clinical Science: E-health and technology

P40.09 Moving towards the clinic: Validation of computer vision motor function analysis in clinical-based videos of people with Parkinson’s disease
Kathrin Heye, Renjie Li, Quan Bai, Rebecca J. St. George, Kaylee Rudd, Guan Huang, Marjan J. Meinders, Bastiaan R. Bloem, Jane E. Alty
P40.10 Wearables for Parkinson’s disease monitoring – The kuranos project
Lars Jorgensen, Manuel Gonzalez Berges, Emiliano Piselli, Anna Ferrari, Samuel Simko

P40.11 Data managing for Parkinson’s disease monitoring using wearable devices
Lars Jorgensen, Manuel Gonzalez Berges, Emiliano Piselli, Anna Ferrari, Samuel Simko

P40.13 Design of theSTEPS trial: A phase II double blind randomized controlled trial evaluating motor-cognitive home training for people with Parkinson’s disease
Breiffni Leavy, Jenny Sedhed Sedhed, Elisabet Åkesson, Elke Kalbe, Erika Franzen, Hanna Johansson

P40.14 Computer vision, a promising artificial intelligence tool to detect bradykinesia in Parkinson’s disease
Alicia Olivares-Gil, José Miguel Ramírez-Sanz, José Luis Garrido-Labrador, Álvaro García-Bustillo, Alvar Arnaiz-González, José Francisco Díez-Pastor, Florita Valiñas, Marta Allende, Maha Jahouth, Josefa González-Santos, Jerónimo Javier González-Bernal, José Trejo-Gabriel-Galán, Esther Cubo

P40.15 Developing automated video assessment of Parkinson’s disease: What happens when the training clinician makes errors?
Kye Won Park, Mohsen Gholami, Tianze Yu, Maryam S. Mirian, Ravneet Mahal, Z. Jane Wang, Martin J. McKeown

P40.16 Feasibility of a community-based walking program using autonomous rhythmic auditory stimulation in persons with Parkinson disease
Franchino Porciuncula, Jenna Zajac, James Cavanaugh, Colin McGregor, Jaimie Girnis, Louis Awad, Brian Harris, Alexander Pantelyat, Terry Ellis

P40.17 Real-world effects of autonomous rhythmic auditory stimulation on walking speed modulation in persons with Parkinson disease
Franchino Porciuncula, Jenna Zajac, James Cavanaugh, Colin McGregor, Jaimie Girnis, Louis Awad, Brian Harris, Alexander Pantelyat, Terry Ellis

Clinical Science: Neuroimaging

P41.02 An interpretable radiomics model of basal ganglia for prediction of dementia conversion in Parkinson’s disease
Seok Jong Chung, Yun Joong Kim, Chae Jung Park, Yae Won Park

P41.03 Cingulate island sign is not associated with early dementia conversion in Parkinson’s disease
Seok Jong Chung, Young H. Sohn, Su Hong Kim, Phil Hyu Lee, Yong Jeong

P41.04 Patterns of regional cerebral hypoperfusion and risk for dementia conversion in early Parkinson’s disease
Seok Jong Chung, Phil Hyu Lee, Su Hong Kim, Young H. Sohn, Yong Jeong

P41.08 Microstructural underpinnings of mild behavioral impairment in early-to-mid stage Parkinson’s disease
Hannes Almgren, Maxime Descoteaux, Maryam Ghahremani, Zahinoor Ismail, Oury Monchi

P41.09 When freezing causes a shutdown! A functional near-infrared spectroscopy study on complex stepping in people with Parkinson’s disease
Paulo Pelicioni, Stephen Lord, Yoshiro Okubo, Jasmine Menant

P41.11 Pattern of cortical atrophy and its association with motor and cognitive symptoms in Parkinson’s disease
Han Soo Yoo, Sung Woo Kang, Han-Kyeol Kim, Chul Hyoun Lyoo

Clinical Science: Prodromal

P42.03 Parkinson’s disease prodromal features and motor symptom progression over five years in the Parkinson’s Progression Markers Initiative (PPMI) dataset
Emily Houston

P42.04 Grow the prodromal Parkinson’s cohort to speed the development of neuroprotective and disease modifying therapies:
Five strategies
Sarah Winter
Living with Parkinson’s: Public education or awareness programs

P43.01  Parkinson’s disease emergency care (PDEC)
        Eric Aquino

P43.03  Onda PK: A radio show in Spanish about women and PD
        Paqui Ruiz, Sonia Soriano, Inma García, Rosa Blázquez, Sabela Avion

P43.06  Optimizing hospital care for people with Parkinson’s: A new professional education course detailing best practices in inpatient hospitalizations, emergency department visits, and outpatient procedures
        Anne Brooks, Lisa Hoffman, Indhira Blackwood

P43.11  Raising the voices of women with Parkinson’s
        Richelle Flanagan, Kat Hill, Sree Sripathy

P43.12  WPC partner series with Womens Parkinson’s Project - Unmet needs of women living with Parkinson’s disease: The gaps & controversies
        Richelle Flanagan, Kat Hill, Sree Sripathy, Sabela Avion

P43.13  Adapting and replicating a multidisciplinary model of Parkinson’s care, rehabilitation and support developed in India to the Kenyan context
        Peter Masese, Natasha Fothergill-Misbah, Neha Rane, Jared Okeno, Krupa Ovalekar, Hellen Mwithiga, Maria Barretto

P43.14  APDA trains first responders and fitness professionals to address the unique needs of people with Parkinson’s disease
        Elvin Yao, Allan Bleich, Tamara R. DeAngelis, Lee Dibble, Terry Ellis, Robin Kornhaber, Merrill R. Landers, Cathi A. Thomas, Rebecca Gilbert

P43.15  Eradicating neurophobia through expert patient tutors: The Parkinson’s perspective
        Gina Hadley, Sally Bromley, Gabriele C. DeLuca

P43.16  Global mentor/mentee program for Organizations: A pilot project of allied health education for community volunteers in Africa
        Angela Halpern, Cynthia Fox, Hellen Mwithiga, Margarita Makoutonina, Building Global Alliances Working Group

P43.18  Results from a multi-country survey on advanced Parkinson’s treatment knowledge, experience and information
        Amelia Hursey, Francesco De Renzis

P43.22  The development of a girl scout topic action patch for Parkinson’s awareness: T.A.P. – P.D.
        Margaret McCormick, Gwyn Vernon

P43.23  Providing authentic learning experiences about Parkinson’s disease: Bringing humanity into the classroom-phase II
        Margaret McCormick, Gwyn Vernon

P43.30  Parkinson’s experience at school: “Viu el Parkinson a l’escola”
        Jordi Santandreu Esteve, Sofia Malagón Gutiérrez, Pepa Martín Barceló, Núria Langa Beltrán, Paula Artigues Martinez, Montse Gabaldà Torrente

P43.31  Using story to raise awareness, reach and connect African American and black individuals affected by Parkinson’s disease
        Hiral Shah, Denise Coley, Bernard Coley, Sandra Coplin, Elizabeth Delaney, Victoria Dillard, Lorraine Haye, Angela Huckabee, Richard Huckabee, Danielle Kipnis, Michele Lin, Chelsea Macpherson, Nia Mensah, Alissa Pacheco, Anita Parker, Terrie Peachey-Ransom, Randell Pearson, Don Ransom, Kermit Smith, Lori Quinn

P43.32  Improving care and reducing professional isolation: Developing a community of practice for occupational therapists treating people with Parkinson’s
        Victoria Tull

P43.33  Parkinson’s survey: How much do we know about our disease
        Lucia Wang, Lucila Falcone, Monica Giuliano

P43.34  3-part book study of “Ending Parkinson’s disease: A prescription for action" Book author: Ray Dorsey, MD, ET, AL
        Jane Rice Williams
Living with Parkinson’s: Government advocacy/ campaigns/ public policy

P44.01  The PD avengers: A patient-led, global alliance demanding change in how the disease is seen and treated, adding urgency to the cause of ending Parkinson’s
Larry Gifford, Tim Hague, Soania Mathur, MD

P44.05  CENPAR: Covid-19
Paola Alicia Riveros Cortés

P44.06  Cenpar and the integral health care model (MAIS)
Paola Alicia Riveros Cortés

P44.07  A patient survey: What does the Fahr’s community need?
Adam Tate, Amit Batla

Living with Parkinson’s: Living well with PD

P45.05  BC brain wellness program ... Brain wellness beyond all boundaries: From idea to implementation
Elaine Book, Amanda Cammalleri, Emily Gerson, Katy Chen, Alex Barber-Cross

P45.06  Everybody has a story: The impact of intergenerational storytelling on wellness
Elaine Book, Rifad Bhuyia, Serena Woo, Tiffany Chang, Julia Handra, Jiayi Li, Jennifer Lim

P45.13  Education and exercise support for individuals newly diagnosed with Parkinson disease and their care partners
Alicia Flach, Reed Handlery, Myriam Sollman, Travis Gawler, Emily Delany, Madeline East, Rebecca Schmidt, Elizabeth Regan

P45.14  Evaluating a cross-national multisectoral OPTIM-PARK intervention for people with Parkinson’s disease and their family carers in the community: A feasibility study
Ellen Gabrielsen Hjelle, Tove Lise Nielsen, Jacob Callesen, Naja Benigna Kruse, Louise Buus Vester, Line Kildal Bragstad, Silje Bjernsen Haavaag, Eline Aas, Anita Haahr, Maria Victoria Navarta-Sánchez, Azucena Pedraz-Marcos, Ana Palmar Santos, Leire Gutierrez Ambrosio, Dorit Kunkel, Mari Carmen Portillo

P45.15  Coordinated care and individualised communication in Parkinson’s disease: Four perspectives on the meaningfulness of a cross-sectoral intervention

P45.16  Do you dance? Profile of people participating in dance for Parkinson’s in Denmark - before Covid-19
Anita Haahr, Kristian Winge

P45.23  The importance of single peer support relationships for women with Parkinson’s
Susan Lehman, Sharon Krischer

P45.24  Healthcare professionals with Parkinson’s: Insights from a support group in the UK National Health Service (NHS)
Claire Lehman, Jonny Acheson, Clare Addison, Tiny Binu, Ed Kirkham, Cormac Mehigan, Andrew Perkins, Garth Ravenhill

P45.27  HerStory: An opera film showcasing the creative talents of people living with Parkinson’s
Amy Mallett

P45.33  Deep brain stimulation – What are you getting yourself in for?
Todd Murfitt

P45.34  Eur -up - jan 2023 - A personal endurance event across Europe to raise awareness of YOPD, fundraise for dedicated charity and make long term Europe wide YOPD connections
Ian O’Brien

P45.35  Developing the Parkinson’s disease support group network in Massachusetts, USA
Rosemary Owen, Raymond James, Michael T Stevenson, Marie Saint-Hilaire, Cathi A Thomas
All in summit: Convening support group and community leaders to connect, learn, collaborate and expand Parkinson’s community resources  
Clemie Pizzillo, Anissa Mitchell

Art as an avenue for participation in the Spanish-speaking Parkinson’s community  
Ruby Rendon, Claudia Martinez, Gregory Pearce

Podcasting as a way to create a global PD community  
Travis Robinson

“Help me card” for off periods  
Jordi Santandreu Esteve

Parkinson’s disease and the use of technology for the management of symptoms: A qualitative study  
Richard Walker, Francesca Hookway, Kyle Montague, Lorelle Dismore

The power to give Parkinson’s to another  
Lucia Wang

Pivoting to a virtual world: How Parkinson Society BC increased impact and reach to the Parkinson’s community during the 2020 pandemic and beyond  
Jean Blake, Alana Dhillon, Shelly Yu, Liz Janze

Living with Parkinson’s: Advancing research: collaborations, capacity building, fundraising, trials, campaigns

The OPTIM-PARK project: A feasibility study assessing acceptability and feasibility of a cross-national multisectoral intervention for people affected by Parkinson’s disease  

Optimism in the research-based graphic medicine novel “Moving Along”: Generating hope for people with Parkinson’s and their caregivers through research communication about Parkinson’s dance  
Lisbeth Frelund, Grethe Lundin

A vital piece in a giant jigsaw: A lived experience of participating in an international Parkinson’s study  
Heather Hunter, John Vasey, Philip Brown, Lisa Alcock, Walter Maetzler, Alice Nieuwboer, Pieter Ginis, Heiko Gassner, Mark Gordon, Alison Keogh, Anat Mirelman, Jeff Hausdorff, Clemens Becker, Lynn Rochester, Alison Yarnall

Movement as methodology for individual and collective wellbeing: Overcoming persistent disparities in Parkinson’s research and care through dance, qualitative research, and community  
Jhia Jackson, Richard Jackson

Parkinson’s with altitude: A case study  
Claire Lehman, Jules Janssen Daalen

Sparks of experience – Enhancing serendipity – An initiative by PD avengers research committee  
Eirwen Malin

Experience in action: Using art-science activities to explore experiences of movement and the body in Parkinson’s and autism  
Ellen Poliakoff, Antony Hall, Eve Edmonds, Peter Baimbridge, Garry Copitch, Graham Hanks, Matthew Sullivan, Emma Gowen

A patient engagement council for Parkinson’s research: Methods of meaningfully incorporating the perspectives of people with Parkinson’s into clinical research and decision making  
Kate Trenam, Karlin Schroeder, Nikul Bakshi, Marc van Grieken, Carol Schulte, Harold de Wit

Accelerate research gains and improve service delivery by streamlining the Parkinson’s non-governmental organization (NGO) sector in the United States  
Sarah Winter, Melissa Tribelhorn
Living with Parkinson’s: Other

P47.01 Promoting “custom” Parkinson’s medication orders in the hospital improves timely administration
Hooman Azmi, Francis Ruzicka, Lisa Cocoziello, Elana Clar, Anthony Rocco, Florian Thomas

P47.03 Quebec Parkinson network: a collaborative approach to research in Parkinson’s disease and related disorders
Sarah Bogard

P47.04 Sorting the sock drawer: A performance provocation for changing pan-Parkinson perceptions
Eirwen Malin

P47.07 APDA Parkinson’s Symptom Tracker App, New York, USA
Rosa Pena, Rebecca Gilbert, Eloise Caggiano, Vicky Chan

Late-Breaking

LBP01.14 The pesticide chlordecone promotes Parkinsonism-like neurodegeneration with tau lesions in midbrain cultures and C. elegans worms
Annie Lannuzel, Valeria Parrales, Patrick P. Michel, Aurore Tourville, Rita Raisman-Vozari, Stéphane Haik, Stéphane Hunot, Nicolas Bizat

LBP03.13 The role of karyopherin abnormalities in the onset and progression of synucleinopathies
Daulet Sharipov, Erika Bereczki, Richard Killick, Tibor Hortobagyi, Claire Troake, Dag Aarsland, Frank Hirth

LBP05.13 Exploring LRRK2-Clusterin pathway in astrocytes: implication for a-synuclein clearance and spreading
Alice Filippini, Giulia Carini, Veronica Mutti, Massimo Gennarelli, Isabella Russo

LBP06.01 Alpha-synuclein miRNA-based AAV gene therapy leads to target engagement and phenotypic correction in an in vivo rat model of Parkinson’s disease
Seyda Acar Broekmans, Rhodé Erbrink, Charlotte van Rooijen, Lodewijk Toonen, Mercedes Valls, Astrid Vallès

LBP06.02 Combining vectorized antibody and miRNA lowering strategies for synucleinopathies
Seyda Acar Broekmans, Rhode Erbrink, Nikki Timmer, Charlotte van Rooijen, Sebastian Kieper, Verena Hehle, Astrid Vallès

LBP06.46 Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson’s disease
Karina Henrique Binda, Anne Marlene Landau, Marucia Chacur, David J Brooks, Caroline Real Gregorio

LBP06.50 Alpha-synuclein aggregate pathology in the cranial sensorimotor system in a mouse model of Parkinson’s disease
Allison Schaser, Brooke Rodgers, Vivek Unni

LBP06.52 Use of in-vitro cell-models and fluorescent protein markers for understanding amyloid-related diseases
Priyanka Swaminathan, Marikken Sundnes, Benedikte Emilie Vindstad, Odrun A.Gederaas, Mikael Lindgren, Therése Klingstedt, Ebba Hellsstrand, Per Hammarström, Sofie Nyström, K Peter R Nilsson, Nathalie Van Den Berge

LBP06.53 Vaccination with a modified fungal prion mimicking conformational epitopes on alpha-synuclein fibrils extends survival in mouse models of Parkinson’s disease
Verena Pesch, Sara Reithofer, Liang Ma, José Miguel Flores-Fernandez, Benedikt Frieg, Yannick Busch, Pelin Özdüzenciler, Gunnar Schröder, Holger Wille, Erdem Gültekin Tamgüney

LBP06.56 Super high resolution metagenomic identified novel targets associated with pathogenic changes in microbiome composition in a Parkinson’s disease mouse model
Connor Wadsworth, Zizheng Xian, Nanthini Jayabalans, Kathrein (Kerry) Roper, Helen Woodhouse, Robert Adam, John O’Sullivan, Gene Tyson, Richard Gordon

LBP06.59 Development of an alpha-synuclein targeting vectorized antibody strategy: First in vivo proof of mechanism in wild type mice
Seyda Açar Broekmans, Rhode Erbrink, Charlotte van Rooijen, Lukas Schwarz, Meriem Bourajaj, Kim Wolzak, Verena Hehle, Astrid Vallès

LBP08.08 Pathway dysfunction in dopamine transporter associated parkinsonism and comorbid psychiatric disease
Jamila Lilja, Ulrik Gether, Freja Herborg
LBP12.13 The meaning of caregiving for people with Parkinson’s Disease: A hermeneutic study of non-family Muslim caregiver in New Zealand
Martyarini Budi Setyawati, Bobbi Laing, Chistantie Effendy, Andrew Lynch, John Parson

LBP13.31 Do people with Parkinson’s disease in daily life do, what they can do in the clinic? Exploring the “can do, do do” conceptual framework
Sabine Schootemeijer, Kirsten de Laat, Nienke de Vries

LBP19.07 Comprehensive survey data set of women with Parkinson’s by women with Parkinson’s
Soania Mathur, Kristi Lamonica, Kat Hill, Helen Matthews

LBP23.09 Integrated care for Parkinson’s disease: An international practice survey
Jennifer L. McGinley, Jennifer G. Goldman, Nabila Dahodwala, Laura Brennan, Joan Gardner, David Grimes, Robert Iansek, Addie Patterson, Norbert Kovacs, Ariela Hilel, Sotrios Parashos, Maria Elsa Piemonte, Bastiaan R. Bloem, Carsten Eggers, Roopa Rajan

LBP24.26 How can I help you? - Iterative design process of a chatbot for people with Parkinson’s
Tessa Femke Peerbolte, Rozanne van Diggelen, Jacqueline Deenen, Pieter van den Haak, Bas Bloem, Nienke de Vries, Sanne van den Berg

LBP24.29 Accelerating physical therapy exercise monitoring through digital health technology for people with Parkinson’s
Kevin Smaller, Bridget Fowler King, Kristen Hohl, Monica Hendrickson, Jillian MacDonald, Miriam Rafferty

LBP25.35 Proprioceptive training for upper limb deficits in people with Parkinson’s disease: A systematic review with meta-analyses of randomised controlled trials
Kavinda Malwanage, Thusharika Dissanayaka, Natalie Allen, Serene Paul

LBP26.07 Food for brain diseases; The development of the Brain Anti-Inflammatory Nutrition (BrAIN) Diet
Ellen van den Oever

LBP31.03 Prediction of treatment response and effect on clinical manifestations for Normal Pressure Hydrocephalus of sleep disorders
Ho-Won Lee, Ji-Hee Jeon

LBP35.01 Discovery and development of a small molecule inhibitor targeting alpha-synuclein pathology
Nadine Ait-Bouziad, Nicolas Dreyfus, Coralie Vallet, Leonida Maliqi, Lorene Aeschbach, Sylvain Pautet, Sebastien Menant, Johannes Brune, Irina Borovko, Alexis Fenyi, Clarisse Schumer, Thomas Jaquier, Nicolas Fournier, Heiko Kroth, Sonia Poli, Andrea Pfeifer, Marie Kosco-Vilbois, Elpida Tsika

LBP35.16 Enhancing lysosomal function and autophagy via TRPML1 as a potential therapeutic strategy for Parkinson’s disease

LBP38.24 Effect of acupuncture stimulation on cognitive reserve in normal aging and neurodegenerative disease: A study design of clinical trial using a functional-near infrared spectroscopy
Dong Hyuk Lee, Joo-Hee Kim

LBP38.28 Motor, non-motor, and cognitive trajectories from 4 to 6 years after diagnosis in the AT-HOME PD cohort

LBP38.35 Double-blind placebo-controlled multicenter trial of fecal microbiota transplantation in Parkinson’s disease
Filip Scheperjans, Reeta Levo, Berta Bosch, Mitja Lääpäri, Perttu Lahtinen, Rebekka Ortiz,Valteri Kaasinen, Reetta Satokari, Perttu Arkkila

LBP39.06 Extraction of the pull force from inertial sensors during the pull test in Parkinson’s disease: An inter- and intra-rater reliability study
Ryoma Taniiuchi, Shusaku Kanai, Amane Hara, Kazuya Monden, Hiroaki Nagatani, Tsuyoshi Torii, Toshihide Harada

LBP40.12 Lexico-semantic differences between people with PD and healthy controls observed in a story retell task
Hardik Kothare, Andrew Exner, Sandy Snyder, Jessica Huber, Vikram Ramanarayanan

LBP45.39 Mime as a therapeutic tool for people with Parkinson’s Disease
Barbara Salsberg Mathews, Muhammad Kathia

LBP45.43 Utility in nutritional guidance for patients with Parkinson’s disease
Misa Yamaguchi, Yasunao Baba, Makoto Shiraiishi, Kenji Isahaya, Yuri Kintaka
The *Journal of Parkinson’s Disease* (JPD) is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease.

The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment of Parkinson’s disease.

It publishes research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication (the average turn-around time to first decision is 18 days). The journal has transformed to open access in 2023 with a publication charge of EUR2000/US$2000 (excl. VAT): All published articles are freely accessible immediately upon publication.

JPD is committed to serving the PwP community, and publishes sections such as “Clinical Trial Highlights”, which is run jointly by a PwP and a researcher. PwP are represented on the Editorial Board and the journal features PwP blogs on the website. More initiatives are in the works.

The abstract book for the WPC 2023 is available at:
https://content.iospress.com/journals/journal-of-parkinsons-disease/13/s1
5:15 PM - 6:30 PM

Presenters of featured posters will be present during poster tours to explain their work. Tour sign up is required (see sheets in back of Exhibit Hall).

**Poster Tour 1: Etiology, genetic and epidemiology**
*Host: Mike Nalls (USA)*

- **P01.07** Contribution of whole exome sequencing in Parkinson’s disease: A review of WES in 929 patients by Guillaume Cogan, France
- **P01.15** Towards a molecular definition of human midbrain dopaminergic neuron subtypes at the single cell level
- **P01.19** Update on PD GUT metagenome
- **P01.31** Genetic findings of the Rostock International Parkinson’s Disease (ROPAD) Study
- **LBP01.18** Genome-wide association identifies novel etiological insights associated with Parkinson’s disease in African and African admixed populations
- **LBP01.23** Association of diet with gut microbiome in patients with Parkinson’s disease

**Poster Tour 2: Electrophysiology, brain physiology, dopamine receptors**
*Host: Nathalie Van Den Berge (Denmark)*

- **P07.01** Impact of α-synuclein pathology on corticostriatal synapses in Parkinson’s disease
- **P08.07** Functional assessment of dopaminergic neurons derived from human lineage-restricted undifferentiated stem cells in a rat Parkinsonian model
- **P09.05** Identification of new RXR-Nr4a (Nur) nuclear receptor complex selective compounds for Parkinson’s disease
- **P10.02** Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment lead to compulsive behaviours and abnormal frontostriatal plasticity
- **P10.05** Globus pallidus contribution to motor behaviour in normal and Parkinson’s disease states: Optogenetic studies in murine models
- **P10.07** Impact of alpha-synuclein overexpression on electrophysiological properties of the locus coeruleus neurons

**Poster Tour 3: Neuroprotection, cell death and protein misfolding**
*Host: Mark Cookson (USA)*

- **P02.04** Male sex bias in Parkinson’s disease is linked to an accelerated age-dependent neuromelanin accumulation
- **P02.07** Function and neuroprotective potential of Flcn knockout in Parkinson’s disease
- **P03.04** Assessment of phosphorylated α-synuclein deposits in the skin and GI tract in prodromal Parkinson’s disease
- **P03.06** Super-resolution microscopy informs on the molecular architecture of alpha-synuclein inclusions in model systems and in the human brain
- **P11.02** Novel noninvasive gene therapy for Parkinson’s disease using viral encoded single-chain antibody treatment
- **P11.07** Regenerating dopaminergic neural circuits in Parkinson’s disease through transplantation of super-resistant human neurons

**Poster Tour 4: Mitochondria, oxidative stress, inflammation, pathogenesis**
*Host: Kim Tieu (USA)*

- **P04.05** Stratifying people with sporadic Parkinson’s disease by pathological mechanism in patient-derived fibroblasts
- **P04.08** Investigating the role of alpha-synuclein in neuronal innate immunity and its role in the interferon response pathway
- **P04.14** Bruton’s Tyrosine Kinase (BTK) is a druggable therapeutic target for neuroprotection in Parkinson’s disease
Poster Tour 5: Self-management, empowerment and Inter professional teams  
*Host: Anjan Chatterjee (USA)*

- **P22.03** Salutogenesis among people living with diagnosed Parkinson’s disease
- **P22.10** Gaitkeeping: A Parkinson’s telehealth training program
- **P22.16** Patient experience and treatment satisfaction with continuous subcutaneous infusion of foslevodopa/foscarbidopa for treatment of advanced Parkinson’s disease
- **P22.18** Investigating pain catastrophizing to improve treatment of pain and psychological distress in Parkinson’s disease
- **P23.02** A missing piece of the Parkinson’s puzzle: The critical role of the dietitian in the care of people living with Parkinson’s disease (PD)
- **P23.05** ParkinsonNet Luxembourg – A multidisciplinary network adjusted to the healthcare environment in Luxembourg
- **P23.07** All hands on deck! Development and implementation of a nurse-driven, rehab-focused, in-person or telehealth interdisciplinary team (IDT) clinic for Veterans with PD and other movement disorders

Poster Tour 6: Rehabilitation sciences  
*Host: Indu Subramanian (USA)*

- **P25.10** Talk the Walk: Dual tasking with walking and visual-verbal processing is more difficult for persons with Parkinson than for young and older adults
- **P25.15** CO-OP feasible and promising for facilitating goal attainment in adults with Parkinson’s disease: findings of a randomised controlled feasibility trial
- **P25.19** Effectiveness of transcranial direct current stimulation (tDCS) on clinical perceived pain and pain processing features in Parkinson’s disease (PD) patients
- **P25.29** Long-term effects of a 6-month brisk walking and balance program on physical performance and health-related quality of life in people with Parkinson disease: A randomized controlled trial
- **P25.31** Gait impairments in Parkinson’s disease
- **P25.36** Clinical practice guideline for the physical therapist management of Parkinson disease: An American physical therapy association and academy of neurologic physical therapy collaboration for quality improvement

Poster Tour 7: Surgical therapy and Neuroimaging  
*Host: Daniel Martinez (Mexico)*

- **P36.05** Improvement in quality-of-life and motor function during daily clinical practice using a directional DBS system
- **P36.06** Real-world outcomes in USA using DBS systems with directionality and multiple independent current control
- **P41.01** Cerebral glucose consumption and synaptic density in patients with Lewy body diseases, as measured with [18F]FDG and [11C]UCB-J PET
P41.10 Neuroinflammation is elevated in people with Parkinson’s disease with higher risk of developing dementia: Baseline findings from the NET-PDD (NEuroinflammation and Tau aggregation in Parkinson’s Disease Dementia) study

LBP36.01 Preclinical safety and efficacy of dopamine neuron progenitor cells derived from PD donor induced pluripotent stem cells

**Poster Tour 8: Clinical trials: Design, outcomes**
*Host: Richard Gordon (Australia)*

P38.30 Characterizing the frequency of clinically reportable variants in major genes established in Parkinson’s disease (PD) in a large American cohort

P38.38 Parkinson’s disease drug therapies in the clinical trial pipeline: 2020-2022

P38.39 Ten years of drug repurposing for Parkinson’s: The international linked clinical trials project

LBP38.09 Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease

LBP38.27 Redesigning Parkinson’s disease care: rationale, methods and baseline data from the PRIME-UK Parkinson’s randomised controlled trial

LBP38.31 NLX-112 has favorable safety, tolerability and efficacy against levodopa-induced dyskinesia (LID) in a randomized, double-blind, placebo-controlled, proof-of-concept Ph2A study

**Poster Tour 9: E-health, Progression, Cognition, and Sleep disorders**
*Host: Dawn Bowers (USA)*

P28.07 Machine learning-based prediction of cognitive decline in early Parkinson’s disease using multimodal features

P29.01 Cognitive behavioral therapy for anxiety in Parkinson’s disease induces functional brain changes

P29.02 Jumping to conclusions (JtC) and its association with psychosis and impulsivity in early stages of Parkinson’s disease

P30.23 Extending the BRAIN keyboard tapping test: To detect cognitive decline in a large community cohort of older Australians

P31.01 Continuous dopaminergic stimulation to improve sleep disorders in Parkinson’s disease with insomnia: Results from the Apomorphee study on subcutaneous night-time only apomorphine infusion

P31.05 Keyboard tapping performance in people with subjective REM sleep behaviour disorder

P40.02 A 20-second home-based test helps detect prodromal Parkinson’s in a community sample of older Australians

**Poster Tour 10: Advancing Research via collaboration and capacity building**
*Host: Dayne Beccano-Kelly (UK)*

P46.03 The Canadian Open Parkinson Network (C-OPN): A multimodal biorepository connecting the Canadian Parkinson’s community around the world

P46.04 Parkinson community plays a critical role in new brain health initiative

P46.07 Transforming Parkinson’s Care in Africa (TraPCAF): A newly funded research grant

P47.05 Medication experiences of people with Parkinson’s disease

LBP47.06 In their own words: Fears of people with Parkinson disease
5:15 PM - 6:30 PM

Presenters of featured posters will be present during poster tours to explain their work. Tour sign up is required (see sheets in back of Exhibit Hall).

**Poster Tour 11: Pathology**
*Host: Michela Deleidi (France)*

- P05.01 Novel antibodies against oligomeric alpha synuclein
- P05.03 Activating beta-glucocerebrosidase by exploiting its transporter LIMP-2
- P05.07 Heterozygous GBA N370S mutation does not uniformly reduce GCase activity or cause lysosomal dysfunction in iPSC-derived neurons
- P05.09 Neuropathological alterations in subjects initially diagnosed by polysomnography with isolated REM sleep behavior disorder
- P05.12 Single molecule array assay for phosphorylated alpha-synuclein detection in cerebrospinal fluid
- P05.14 Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models

**Poster Tour 12: Animal and Cellular models #1**
*Host: Yvette Wong (USA)*

- P06.11 A high-content analysis pipeline for quantifying the autophagy-lysosomal pathway in IPSC-derived cortical neurons carrying Parkinson’s disease associated mutations
- P06.22 Modeling PRKN/PARK2-associated Parkinson’s disease
- P06.41 Healthy human iPSC-derived astrocytes rescue the degenerative phenotype of p.A53T-αSyn iPSC-derived neurons generated from Parkinson’s disease patients
- P06.42 A novel autoimmune alpha-synuclein-induced model of Parkinson’s disease
- P06.43 Modelling human brain-wide pigmentation induces Parkinson-like pathology and transcriptomic alterations in vivo
- P06.48 Exploring the role of the lysosomal lipid flippase ATP10B in the nigrostriatal dopaminergic pathway of rats
- P06.54 Investigating the role of astrocytes and microglia in driving neurodegeneration in Parkinson’s disease using an hiPSC-based in vitro model

**Poster Tour 13: Animal and Cellular models #2**
*Host: Cristina Miguelez (Spain)*

- P06.06 Establishment of a 3D iPSC-based neurovascular model to investigate Parkinson’s disease pathophysiology
- P06.08 Exacerbation of alpha-synuclein pathology by B-lymphocyte depletion
- P06.28 Cell autonomous role of leucine-rich repeat kinase in dopaminergic neuron survival
- P06.35 Modulation of the gut microbiota modifies Parkinson’s disease-like pathology in transgenic neuromelanin-producing mice
- P06.36 IPSC-derived human midbrain-striatal assembloid for Parkinson’s disease modeling
- P06.57 Age-related elevations in type-I interferon signalling control brain-gut transmission in the α-synuclein pre-formed fibril model of Parkinson’s disease
- LBP06.02 Combining vectorized antibody and miRNA lowering strategies for synucleinopathies
Poster Tour 14: Exercise, Nutrition and Quality of Life
Host: Alfonso Fasano (Canada)

P13.14 Utilizing the Parkinson’s foundation five domains of exercise professional competencies to map five criteria for exercise education: A pilot study
P13.16 An exploration of service users perceptions of the Parkinson’s beat program
P16.11 Prevalence and nature of self-reported visual complaints in people with Parkinson’s disease – Use of the screening visual complaints questionnaire
P26.02 Objective measures of gut dysfunction in Parkinson’s disease
P27.06 Does musculoskeletal pain impact physical activity in people with Parkinson disease?

Poster Tour 15: Palliative Care and Advanced Planning
Host: Dan Weintraub (USA)

P18.01 Parkinson’s and palliative care – Are there different needs for women?
P18.02 Continuous subcutaneous apomorphine infusion for the management of Parkinson’s disease at the end-of-life
P18.03 Terminal care for parkinsonian residents in French nursing homes: A 10-year longitudinal retrospective study
P18.04 The effect of a multidisciplinary blended learning program on palliative care knowledge for health care professionals involved in the care for people with Parkinson’s disease
P18.05 Feasibility of a nurse-led advance care planning and care coordination intervention in Parkinson’s disease – Results of a multicenter European study
P18.08 Symptoms at the end of life in patients with Parkinson’s disease

Poster Tour 16: Health Accessibility, Intimacy, and Non-motor manifestations
Host: Julia Wood (USA)

P19.10 www.PregSpark.com, introducing the International PregnancyS and Parkinson’s Registry, an initiative of the Radboud UMC in co-creation with PWP
P20.01 Approach to the management of sexual and intimate problems in patients with motor and non-motor manifestations of Parkinson’s disease
P27.08 The hormonal impact on symptoms in women with Parkinson’s
P27.10 Apathy, gender and quality of life among Mexican people living with Parkinson’s disease: An underrecognized non-motor symptom
LBP19.07 Comprehensive survey data set of women with Parkinson’s by women with Parkinson’s

Poster Tour 17: Biomarkers, neuroimaging and pharmacological therapy
Host: Jon B Toledo (USA)

P34.02 The influence of gut microbiota as a potential regulator of amino acid metabolism and its’ novel correlations in Parkinson’s pathogenesis
P34.06 Assessing the biomarker potential of LRRK2 and GCase in Parkinson’s disease monocytes
P34.19 Imaging presynaptic terminal integrity in parkinsonism: New findings from the 18F-SynVesT-1 tracer
P35.02 May apomorphine be helpful for the axial symptoms of Parkinson’s disease?
P35.07 Astrocytic networks as a novel therapeutic target in Parkinson’s disease
P35.15 Passive immunization reduces propagation of alpha-synuclein pathology along gut-brain axis
LBP35.01 Discovery and development of a small molecule inhibitor targeting alpha-synuclein pathology
Poster Tour 18: Public Education & Campaigns

Host: Laura Volpicelli-Daley (USA)

P43.03 Onda PK: A radio show in Spanish about women and PD
P43.12 WPC partner series with Womens Parkinson’s Project - Unmet needs of women living with Parkinson’s disease: The gaps & controversies
P43.13 Adapting and replicating a multidisciplinary model of Parkinson’s care, rehabilitation and support developed in India to the Kenyan context
P43.16 Global mentor/mentee program for Organizations: A pilot project of allied health education for community volunteers in Africa
P43.24 Providing authentic learning experiences about Parkinson’s disease: Bringing humanity into the classroom-phase II
P44.01 The PD avengers: A patient-led, global alliance demanding change in how the disease is seen and treated, adding urgency to the cause of ending Parkinson’s

Poster Tour 19: Living well with Parkinson’s

Host: Hanneke Kalf (Netherlands)

P45.05 BC brain wellness program ... Brain wellness beyond all boundaries: From idea to implementation
P45.13 Education and exercise support for individuals newly diagnosed with Parkinson disease and their care partners
P45.14 Evaluating a cross-national multisectoral OPTIM-PARK intervention for people with Parkinson’s disease and their family carers in the community: A feasibility study
P45.15 Coordinated care and individualised communication in Parkinson’s disease: Four perspectives on the meaningfulness of a cross-sectoral intervention
P45.23 The importance of single peer support relationships for women with Parkinson’s
P45.27 HerStory: An opera film showcasing the creative talents of people living with Parkinson’s

Poster Tour 20: Public education & awareness

Host: Marie Fuzzati (France)

P43.01 Parkinson’s disease emergency care (PDEC)
P43.06 Optimizing hospital care for people with Parkinson’s: A new professional education course detailing best practices in inpatient hospitalizations, emergency department visits, and outpatient procedures
P43.11 Raising the voices of women with Parkinson’s
P43.15 Eradicating neurophobia through expert patient tutors: The Parkinson’s perspective
P43.18 Results from a multi-country survey on advanced Parkinson’s treatment knowledge, experience and information
P47.01 Promoting “custom” Parkinson’s medication orders in the hospital improves timely administration
# Faculty List

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonny Acheson</td>
<td>12, 29, 44, 45, 47, 72, 115</td>
</tr>
<tr>
<td>Aguzzl Adriano</td>
<td>47</td>
</tr>
<tr>
<td>Chinyere Rachel Agwu</td>
<td>15, 53, 88</td>
</tr>
<tr>
<td>Roy Alcalay</td>
<td>12, 33, 44, 56, 63, 86, 109</td>
</tr>
<tr>
<td>Georgina Aldridge</td>
<td>16, 60, 65</td>
</tr>
<tr>
<td>Dario Alessi</td>
<td>56, 65</td>
</tr>
<tr>
<td>Natalie Allen</td>
<td>38, 49, 57, 76, 99, 118</td>
</tr>
<tr>
<td>Alison Anderson</td>
<td>5, 6, 37, 41, 47, 85</td>
</tr>
<tr>
<td>Silke Appel-Cresswell</td>
<td>11, 17, 33, 39, 55, 66, 93</td>
</tr>
<tr>
<td>Neil Archibald</td>
<td>55, 63</td>
</tr>
<tr>
<td>Raven Belachiel</td>
<td>6, 46, 49, 50, 70, 90, 97</td>
</tr>
<tr>
<td>Krzysztof Bankiewicz</td>
<td>57, 65</td>
</tr>
<tr>
<td>Roger Barker</td>
<td>3, 6, 11, 17, 37, 39, 57, 61, 65, 66, 112</td>
</tr>
<tr>
<td>Angela Bayés</td>
<td>13, 48</td>
</tr>
<tr>
<td>Dayne Beccano-Kelly</td>
<td>5, 6, 50, 65, 122</td>
</tr>
<tr>
<td>Bastiaan R. Bloem</td>
<td>14, 52, 77, 106, 112, 118</td>
</tr>
<tr>
<td>Elaine Book</td>
<td>6, 24, 33, 38, 73, 77, 115</td>
</tr>
<tr>
<td>Per Borghammer</td>
<td>6, 12, 44, 49, 62, 64, 83, 87, 110</td>
</tr>
<tr>
<td>Dawn Bowers</td>
<td>48, 50, 57, 122</td>
</tr>
<tr>
<td>Martlde Calopa</td>
<td>17, 62</td>
</tr>
<tr>
<td>Ana Cámara</td>
<td>6, 15, 56, 84</td>
</tr>
<tr>
<td>Fulvio Capitanio</td>
<td>6, 12, 17, 33, 40, 42, 44, 66</td>
</tr>
<tr>
<td>Jesse Cederbaum</td>
<td>47, 55</td>
</tr>
<tr>
<td>Angela Cenci</td>
<td>6, 15, 55, 58</td>
</tr>
<tr>
<td>Lana Chahine</td>
<td>55, 61, 63</td>
</tr>
<tr>
<td>Anjan Chatterjee</td>
<td>11, 39, 47, 49, 50, 121</td>
</tr>
<tr>
<td>Marie-Françoise Chesselet</td>
<td>3, 6, 33</td>
</tr>
<tr>
<td>Gerhard (Gerry) Coetzee</td>
<td>65</td>
</tr>
<tr>
<td>Yaroslau Compta</td>
<td>13, 48, 109</td>
</tr>
<tr>
<td>Geoffrey Costable</td>
<td>15, 53</td>
</tr>
<tr>
<td>Mark Cookson</td>
<td>11, 39, 47, 50, 120</td>
</tr>
<tr>
<td>Daniel Corcos</td>
<td>62, 65</td>
</tr>
<tr>
<td>Esther Cubo</td>
<td>13, 38, 46, 48, 77, 103, 113</td>
</tr>
<tr>
<td>Nicholas D’Cruz</td>
<td>64, 71, 82</td>
</tr>
<tr>
<td>Nabila Dahdowala</td>
<td>6, 11, 17, 38, 39, 62, 66, 82, 118</td>
</tr>
<tr>
<td>Oriol de Fábregas-Boixar</td>
<td>17, 62</td>
</tr>
<tr>
<td>María De Leon</td>
<td>6, 15, 25, 40, 55</td>
</tr>
<tr>
<td>Miet De Letter</td>
<td>63, 65, 78, 98</td>
</tr>
<tr>
<td>Briana De Miranda</td>
<td>46, 55, 67</td>
</tr>
<tr>
<td>Nienke de Vries</td>
<td>6, 47, 48, 118</td>
</tr>
<tr>
<td>Michel Deleidi</td>
<td>6, 55, 58, 62, 69, 95, 123</td>
</tr>
<tr>
<td>Josefa Domingos</td>
<td>23, 57, 62, 73, 78, 83, 86, 88, 89</td>
</tr>
<tr>
<td>Ray Dorsey</td>
<td>45, 46, 49, 67, 85, 112, 114, 118</td>
</tr>
<tr>
<td>Jacques Doumbe</td>
<td>38</td>
</tr>
<tr>
<td>Kathy Dujardin</td>
<td>38, 47, 48, 81, 84, 102</td>
</tr>
<tr>
<td>Ryan Duncan</td>
<td>54, 57, 78, 100, 101, 106</td>
</tr>
<tr>
<td>Ross Dunne</td>
<td>57, 62</td>
</tr>
<tr>
<td>Nicolas Dzamko</td>
<td>16, 54, 60, 96, 97, 109, 110</td>
</tr>
<tr>
<td>Matt Eagles</td>
<td>29, 33, 41, 61</td>
</tr>
<tr>
<td>Louise Ebenezer</td>
<td>49, 55</td>
</tr>
<tr>
<td>Kaylena Ehgoetz Martens</td>
<td>57, 64</td>
</tr>
<tr>
<td>Alberto Espay</td>
<td>49, 64, 118</td>
</tr>
<tr>
<td>Isabel Fairíñas</td>
<td>13, 46, 57, 94</td>
</tr>
<tr>
<td>Alfonso Fasano</td>
<td>58, 63, 64, 79, 83, 124</td>
</tr>
<tr>
<td>Richelle Flanagan</td>
<td>5, 6, 12, 15, 16, 30, 33, 40, 41, 44, 49, 53, 55, 60, 77, 78, 80, 106, 114</td>
</tr>
<tr>
<td>Edward Fon</td>
<td>63, 65, 70, 71, 81, 89</td>
</tr>
<tr>
<td>Susan Fox</td>
<td>6, 15, 47, 58, 86</td>
</tr>
<tr>
<td>Darla Freeman</td>
<td>11, 39, 55, 65</td>
</tr>
<tr>
<td>Victor Fung</td>
<td>6, 37</td>
</tr>
<tr>
<td>Celine Galvagnion</td>
<td>6, 54, 65</td>
</tr>
<tr>
<td>Richard Genever</td>
<td>54, 57</td>
</tr>
<tr>
<td>François George</td>
<td>55</td>
</tr>
<tr>
<td>Larry Gifford</td>
<td>5, 6, 25, 33, 40, 49, 55, 74, 79, 115</td>
</tr>
<tr>
<td>Rebecca Gifford</td>
<td>24, 41, 47, 49</td>
</tr>
<tr>
<td>Tomas Gisby</td>
<td>47</td>
</tr>
<tr>
<td>Graham Alec Glass</td>
<td>48, 56</td>
</tr>
<tr>
<td>Adriana Gonzalez-Aguinaha</td>
<td>38</td>
</tr>
<tr>
<td>Richard Gordon</td>
<td>5, 6, 49, 50, 69, 70, 72, 90, 93, 95, 109, 117, 122</td>
</tr>
<tr>
<td>Francisco Grandas</td>
<td>6, 13, 46, 111</td>
</tr>
<tr>
<td>Monica Gross</td>
<td>23, 61</td>
</tr>
<tr>
<td>Anne Grünewald</td>
<td>49, 56, 69, 94</td>
</tr>
<tr>
<td>Carlos Guerra-Galicia</td>
<td>17, 64</td>
</tr>
<tr>
<td>Tim Hague</td>
<td>33, 40, 41, 73, 115</td>
</tr>
<tr>
<td>John Hardy</td>
<td>37, 55, 56, 90, 93</td>
</tr>
<tr>
<td>Ashley Harms</td>
<td>6, 16, 48, 60</td>
</tr>
<tr>
<td>Emily J. Henderson</td>
<td>4, 6, 16, 38, 40, 60, 83, 95</td>
</tr>
<tr>
<td>Christopher Hess</td>
<td>47, 49, 103</td>
</tr>
<tr>
<td>Kat Hill</td>
<td>6, 33, 47, 54, 58, 92, 106, 114, 118</td>
</tr>
<tr>
<td>Etienne Hirsch</td>
<td>13, 37, 47, 50</td>
</tr>
<tr>
<td>Mark Hirsch</td>
<td>57, 62</td>
</tr>
<tr>
<td>Michele Hu</td>
<td>55, 65, 85</td>
</tr>
<tr>
<td>Malcolm Irving</td>
<td>42</td>
</tr>
<tr>
<td>Hanneke Kalf</td>
<td>6, 55, 58, 125</td>
</tr>
<tr>
<td>Lorraine Kalia</td>
<td>47, 49, 89</td>
</tr>
<tr>
<td>Gabrielle Kaminski Schierie</td>
<td>64</td>
</tr>
<tr>
<td>Dina Katabi</td>
<td>49</td>
</tr>
<tr>
<td>Suketu Khandhar</td>
<td>6, 38, 49</td>
</tr>
<tr>
<td>Agnete Kirkeby</td>
<td>37</td>
</tr>
<tr>
<td>Christine Klein</td>
<td>56, 63, 67, 69</td>
</tr>
<tr>
<td>Jochen Klucken</td>
<td>46, 55, 77, 78, 79, 83, 104, 107, 112</td>
</tr>
<tr>
<td>Benzi Kluger</td>
<td>6, 49, 62, 85</td>
</tr>
<tr>
<td>Jeffrey Kordower</td>
<td>57</td>
</tr>
<tr>
<td>Elena Kozina</td>
<td>63, 65</td>
</tr>
<tr>
<td>Sharon Krischer</td>
<td>40, 89, 115</td>
</tr>
<tr>
<td>Jaime Kulisevsky</td>
<td>15, 56</td>
</tr>
<tr>
<td>Ariadna Laguna</td>
<td>5, 6, 13, 15, 47, 54, 68, 71, 81, 93, 95, 96, 111</td>
</tr>
<tr>
<td>Hilal Lashuel</td>
<td>46, 57</td>
</tr>
<tr>
<td>Matt LaVoie</td>
<td>56, 63</td>
</tr>
<tr>
<td>Iracema Leroi</td>
<td>11, 39, 56, 63</td>
</tr>
<tr>
<td>Walter Maetzler</td>
<td>47, 63, 80, 83, 106, 112, 116</td>
</tr>
<tr>
<td>Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Yael Manor</td>
<td>55, 57</td>
</tr>
<tr>
<td>Connie Marras</td>
<td>13, 50, 64, 92</td>
</tr>
<tr>
<td>María Jose Martí</td>
<td>6, 17, 62, 95</td>
</tr>
<tr>
<td>Daniel Martinez-Ramirez</td>
<td>15, 56, 63, 81</td>
</tr>
<tr>
<td>Raul Martinez Fernandez</td>
<td>37</td>
</tr>
<tr>
<td>Ignacio Mata</td>
<td>15, 65, 86</td>
</tr>
<tr>
<td>Diana Matheoud</td>
<td>47, 48</td>
</tr>
<tr>
<td>Soania Mathur</td>
<td>6, 16, 41, 57, 60, 85, 86, 92, 115, 118</td>
</tr>
<tr>
<td>Joseph Mazzulli</td>
<td>49, 54, 68, 94, 96</td>
</tr>
<tr>
<td>Victor McConvey</td>
<td>6, 62</td>
</tr>
<tr>
<td>Kevin McFarthing</td>
<td>6, 12, 44, 47, 85, 86, 89, 112</td>
</tr>
<tr>
<td>Juan Mena-Segovia</td>
<td>55</td>
</tr>
<tr>
<td>Cristina Miguez</td>
<td>55, 58, 70, 72, 123</td>
</tr>
<tr>
<td>Vanessa Milanese</td>
<td>6, 11, 15, 37, 39, 58, 65</td>
</tr>
<tr>
<td>Patricio Millar Vernetti</td>
<td>37, 56, 63</td>
</tr>
<tr>
<td>Becca Miller</td>
<td>33, 41</td>
</tr>
<tr>
<td>Dragomir Miloanovic</td>
<td>63, 64</td>
</tr>
<tr>
<td>Pablo Mir</td>
<td>6, 17, 64, 81</td>
</tr>
<tr>
<td>Anat Mirelman</td>
<td>6, 46, 63, 79, 80, 83, 106, 112, 116</td>
</tr>
<tr>
<td>Brit Mollenhauer</td>
<td>54, 57</td>
</tr>
<tr>
<td>Darren Moore</td>
<td>6, 17, 56, 66, 70, 86</td>
</tr>
<tr>
<td>Rosario Morallta</td>
<td>13, 15, 45, 55, 64</td>
</tr>
<tr>
<td>Esteban Muñoz</td>
<td>46</td>
</tr>
<tr>
<td>Mike Nails</td>
<td>50, 65, 120</td>
</tr>
<tr>
<td>Alice Nieuwboer</td>
<td>4, 6, 13, 50, 57, 64, 71, 79, 80, 82, 83, 85, 105, 106, 112, 116</td>
</tr>
<tr>
<td>Alastair Noyce</td>
<td>55, 63, 64, 82, 84, 85, 86, 87</td>
</tr>
<tr>
<td>Jose Obeso</td>
<td>6, 13, 45</td>
</tr>
<tr>
<td>Per Odin</td>
<td>6, 46, 63, 92, 104</td>
</tr>
<tr>
<td>Michael Okun</td>
<td>4, 6, 37, 45, 46, 65, 84, 87, 102, 105</td>
</tr>
<tr>
<td>Linda Olson</td>
<td>6, 11, 14, 15, 39, 52, 53, 58</td>
</tr>
<tr>
<td>Jill Ostrem</td>
<td>65</td>
</tr>
<tr>
<td>Tiago Outeiro</td>
<td>57</td>
</tr>
<tr>
<td>Genko Oyama</td>
<td>6, 49, 55, 83, 111</td>
</tr>
<tr>
<td>Rajesh Pahwa</td>
<td>83, 84, 85</td>
</tr>
<tr>
<td>Coro Paisan-Ruiz</td>
<td>15, 17, 54, 57, 65, 66</td>
</tr>
<tr>
<td>Malin Parmar</td>
<td>57</td>
</tr>
<tr>
<td>Serene Paul</td>
<td>6, 46, 49, 64, 76, 99, 118</td>
</tr>
<tr>
<td>Elisa Pelosin</td>
<td>6, 48, 55, 79</td>
</tr>
<tr>
<td>Cecilia Peralta</td>
<td>6, 13, 14, 37, 48, 52</td>
</tr>
<tr>
<td>Selma Pelaez Hervas</td>
<td>39</td>
</tr>
<tr>
<td>Daniel Peterson</td>
<td>6, 47, 56, 76, 108</td>
</tr>
<tr>
<td>Greg Pontone</td>
<td>26, 41, 62, 65</td>
</tr>
<tr>
<td>Catherine Price</td>
<td>55, 63</td>
</tr>
<tr>
<td>Serge Przedborowski</td>
<td>15, 47, 58, 68, 69, 103</td>
</tr>
<tr>
<td>Pamela Quinn</td>
<td>11, 23, 33, 39, 47, 76</td>
</tr>
<tr>
<td>Miriam Rafferty</td>
<td>41, 57, 65, 74, 79, 99, 118</td>
</tr>
<tr>
<td>Ed Richfield</td>
<td>49, 57</td>
</tr>
<tr>
<td>Sara Riggare</td>
<td>6, 14, 33, 40, 52</td>
</tr>
<tr>
<td>Beate Ritz</td>
<td>46, 49, 90</td>
</tr>
<tr>
<td>Angela Roberts</td>
<td>24, 38, 49, 63</td>
</tr>
<tr>
<td>Lynn Rochester</td>
<td>46, 49, 78, 80, 83, 85, 104, 106, 107, 112, 116</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayela Rodriguez-Violante</td>
<td>6, 15, 17, 24, 48, 54, 65, 75, 81, 89, 100, 106, 109</td>
</tr>
<tr>
<td>Marina Romero-Ramos</td>
<td>4, 6, 14, 15, 17, 49, 52, 58, 66, 68, 72, 90, 94, 96</td>
</tr>
<tr>
<td>Timothy Sampson</td>
<td>48, 62, 67</td>
</tr>
<tr>
<td>Cynthia Sandor</td>
<td>65</td>
</tr>
<tr>
<td>Pablo Sardi</td>
<td>54</td>
</tr>
<tr>
<td>Susanne Schneider</td>
<td>6, 64</td>
</tr>
<tr>
<td>Sonja Scholz</td>
<td>12, 44, 47</td>
</tr>
<tr>
<td>Angel Sesar</td>
<td>6, 17, 64</td>
</tr>
<tr>
<td>Binit Shah</td>
<td>33, 37, 65</td>
</tr>
<tr>
<td>Hyunsoo Shawn Je</td>
<td>47</td>
</tr>
<tr>
<td>Andrew Siderowf</td>
<td>37</td>
</tr>
<tr>
<td>Michael Simpson</td>
<td>47, 48</td>
</tr>
<tr>
<td>Andrew Singleton</td>
<td>4, 6, 56, 63, 90</td>
</tr>
<tr>
<td>Shanthipriya Siva</td>
<td>5, 6</td>
</tr>
<tr>
<td>Claudio Soto</td>
<td>54, 63</td>
</tr>
<tr>
<td>David Standaert</td>
<td>4, 6, 12, 14, 37, 44, 52, 54, 61, 67</td>
</tr>
<tr>
<td>Leonidas Stefanis</td>
<td>6, 12, 44, 57, 61, 80, 81, 84, 99, 104, 108</td>
</tr>
<tr>
<td>A. Jon Stoessl</td>
<td>6, 37, 61, 63, 89</td>
</tr>
<tr>
<td>Indu Subramanian</td>
<td>25, 49, 50, 57, 63, 65, 77, 112, 121</td>
</tr>
<tr>
<td>Jun Takahashi</td>
<td>6, 55, 57</td>
</tr>
<tr>
<td>Ryosuke Takahashi</td>
<td>6, 17, 33, 37, 66, 97</td>
</tr>
<tr>
<td>Maü Tansey</td>
<td>37, 48, 63</td>
</tr>
<tr>
<td>Omotola Thomas</td>
<td>5, 6, 13, 16, 33, 40, 47, 50, 60, 74, 90</td>
</tr>
<tr>
<td>Susan Thomas</td>
<td>103</td>
</tr>
<tr>
<td>Kim Tieu</td>
<td>49, 50, 120</td>
</tr>
<tr>
<td>Jon B. Toledo</td>
<td>54</td>
</tr>
<tr>
<td>Eduardo Tolosa</td>
<td>6, 13, 37, 45, 55, 71, 96, 97</td>
</tr>
<tr>
<td>Claudia Trenkwalder</td>
<td>6, 13, 50</td>
</tr>
<tr>
<td>Michelle Troche</td>
<td>63, 65</td>
</tr>
<tr>
<td>Ayse Ulusoy</td>
<td>54, 62, 69, 71, 97</td>
</tr>
<tr>
<td>Vivek Unnii</td>
<td>54, 64, 93, 117</td>
</tr>
<tr>
<td>Francesc Valideorola</td>
<td>17, 64, 84, 93</td>
</tr>
<tr>
<td>Nathalie Van Den Berge</td>
<td>50, 62, 94, 110, 117, 120</td>
</tr>
<tr>
<td>Anke Van der Perren</td>
<td>46</td>
</tr>
<tr>
<td>Thilo van Eimeren</td>
<td>14, 33, 49, 52</td>
</tr>
<tr>
<td>Erwin Van Wegen</td>
<td>33, 49, 62</td>
</tr>
<tr>
<td>Rune Vethe</td>
<td>6, 33, 41, 65</td>
</tr>
<tr>
<td>Miquel Vila</td>
<td>6, 13, 15, 37, 46, 55, 58, 68, 69, 71, 93, 94, 95, 96</td>
</tr>
<tr>
<td>Dolores Vilas Rolán</td>
<td>15, 56, 106, 109</td>
</tr>
<tr>
<td>Laura Volpicielli-Daley</td>
<td>56, 58, 70, 71, 125</td>
</tr>
<tr>
<td>Lauren Walker</td>
<td>16, 60, 65</td>
</tr>
<tr>
<td>Lisa Warren</td>
<td>6, 47, 49, 102</td>
</tr>
<tr>
<td>Daniel Weintraub</td>
<td>6, 37, 48, 82</td>
</tr>
<tr>
<td>Caroline Williams-Gray</td>
<td>6, 47, 48, 85, 94, 107</td>
</tr>
<tr>
<td>Amanda Woerman</td>
<td>6, 13, 16, 46, 60, 63</td>
</tr>
<tr>
<td>Yvette Wong</td>
<td>58, 63, 123</td>
</tr>
<tr>
<td>Julia Wood</td>
<td>6, 27, 47, 58, 124</td>
</tr>
<tr>
<td>A.C. Woolnough</td>
<td>5, 6, 33, 41, 56, 100</td>
</tr>
<tr>
<td>Alison Yarnall</td>
<td>54, 62, 78, 80, 83, 107, 112, 116</td>
</tr>
<tr>
<td>Zhenyu Yue</td>
<td>47, 49</td>
</tr>
<tr>
<td>Markus Zweckstetter</td>
<td>12, 44, 47</td>
</tr>
</tbody>
</table>
launched first Tour de Parkinson program supporting cyclists in their journey to Barcelona!

The World Parkinson Coalition, together with Parkinson advocates from around the world launched its first Tour de Parkinson program this year. Nearly 60 cyclists, from 7 countries who live with PD or care for someone with PD, cycled a collective 3,000 km from across Europe to reach Barcelona in time to attend the 6th World Parkinson Congress.

We honor these Parkinson’s champions for their hard work and perseverance for this physical feat, but also in raising awareness about Parkinson’s, exercise, and the WPC. We tip our hats to them and look to them for inspiration for our next adventure.

Bike to Barcelona was made possible with support from Esteve, Charco Neurotech, Davis Phinney Foundation, Abbvie, Supernus, Bial, Barcelona Turisme and Convention Bureau, Reftec, Rock Steady Boxing, Reftec, CoFounder Management AS, Rune Labs, Boston Scientific, Vestfold Parkinson Foreningen, Orbit Health, Parkinson and Sport, Cure Parkinson Trust, Associació Catalana per al Parkinson, and the World Parkinson Coalition.
We have everything you need to live better with Parkinson’s.

Our Helpline can help by answering questions and providing educational resources.

Email Helpline@Parkinson.org
In English and Español

Interact with us and the Parkinson’s community at
www.PDConversations.org
www.PDConversations.org/Espanol

www.Parkinson.org
www.Parkinson.org/Espanol

Visit us at Booth 601 in the Exhibit Hall
### Exhibitors

<table>
<thead>
<tr>
<th>EXHIBITOR NAME</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbvie</td>
<td>1000</td>
</tr>
<tr>
<td>American Parkinson Disease Association (APDA)</td>
<td>1101</td>
</tr>
<tr>
<td>Amneal</td>
<td>1004</td>
</tr>
<tr>
<td>BeatHealth</td>
<td>1401</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>1200</td>
</tr>
<tr>
<td>Charco Neurotech Ltd</td>
<td>600</td>
</tr>
<tr>
<td>Comfort Linen</td>
<td>1504</td>
</tr>
<tr>
<td>Convatec</td>
<td>1201</td>
</tr>
<tr>
<td>Cue2Walk International B.V.</td>
<td>1501</td>
</tr>
<tr>
<td>Cure Parkinson’s</td>
<td>604</td>
</tr>
<tr>
<td>Davis Phinney Foundation for Parkinson’s</td>
<td>801</td>
</tr>
<tr>
<td>Fuerte es la Vida Parkinson No Limits</td>
<td>603</td>
</tr>
<tr>
<td>Gyrogear Ltd.</td>
<td>1502</td>
</tr>
<tr>
<td>International Parkinson and Movement Disorder Society (MDS)</td>
<td>1402</td>
</tr>
<tr>
<td>IOS Press: Journal of Parkinson’s Disease</td>
<td>704</td>
</tr>
<tr>
<td>Japan Selfcare Institute®</td>
<td>402</td>
</tr>
<tr>
<td>LSVT Global</td>
<td>902</td>
</tr>
<tr>
<td>Medtronic</td>
<td>901</td>
</tr>
<tr>
<td>NeuroMo</td>
<td>1301</td>
</tr>
<tr>
<td>Orbit Health</td>
<td>501</td>
</tr>
<tr>
<td>Parkinson &amp; Movement Disorder Alliance</td>
<td>1204</td>
</tr>
<tr>
<td>Parkinson’s Association Mentor Program</td>
<td>1104</td>
</tr>
<tr>
<td>Parkinson’s Europe</td>
<td>703</td>
</tr>
<tr>
<td>Parkinson’s Foundation</td>
<td>601</td>
</tr>
<tr>
<td>Parkinson’s UK</td>
<td>1001</td>
</tr>
<tr>
<td>PD Avengers</td>
<td>1302</td>
</tr>
<tr>
<td>Portables HealthCare Technologies</td>
<td>1103</td>
</tr>
<tr>
<td>Rock Steady Boxing</td>
<td>401</td>
</tr>
<tr>
<td>Rune Labs</td>
<td>1304</td>
</tr>
<tr>
<td>Sense4care</td>
<td>502</td>
</tr>
<tr>
<td>Strolli Ltd</td>
<td>1003</td>
</tr>
<tr>
<td>Symbyx Biome</td>
<td>1203</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation for Parkinson’s Research</td>
<td>803</td>
</tr>
<tr>
<td>UCB Pharma / Novartis</td>
<td>1403</td>
</tr>
<tr>
<td>UPI – Activator Walking Poles</td>
<td>1303</td>
</tr>
<tr>
<td>Walk With Path</td>
<td>1503</td>
</tr>
<tr>
<td>World Parkinson Coalition®</td>
<td>605</td>
</tr>
</tbody>
</table>

### Partners Table

<table>
<thead>
<tr>
<th>ORGANIZATIONAL PARTNER TABLES</th>
<th>TABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Grant Foundation</td>
<td>3</td>
</tr>
<tr>
<td>Dance for PD®, a program of Mark Morris Dance Group</td>
<td>2</td>
</tr>
<tr>
<td>Federación Española de Parkinson</td>
<td>4</td>
</tr>
<tr>
<td>International Table Tennis Federation Foundation</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ORGANIZATIONAL PARTNER TABLES</th>
<th>TABLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPO U60 Challenged Supporters</td>
<td>5</td>
</tr>
<tr>
<td>Parkinson’s Disease Nurse Specialist Association</td>
<td>6</td>
</tr>
<tr>
<td>Ping Pong Parkinson</td>
<td>1</td>
</tr>
<tr>
<td>Power for Parkinson’s®</td>
<td>7</td>
</tr>
</tbody>
</table>
EXHIBIT FLOOR PLAN

WPC-THEATRE

CLINICAL RESEARCH VILLAGE

5-7-6

8

5-4-3-2-1

PARTNERS AREA

WPC BOOTH

TULIP GARDEN

YOPD VILLAGE

LUNCH BOXES

604 704

603 703

BOOK NOOK

LUNCH BOXES

601

801 902 901

1001 1101

BUDDIES CORNER

LUNCH BOXES

402 502

401 501

600

1000 1200

POSTER AREA

1004 1104

1003 1103

1204 1304

1203 1303

1403 1503

1402 1502

1401 1501

ENTRANCE /EXIT
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth</th>
<th>Address Details</th>
<th>Phone Number</th>
<th>Website</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABBVIE</strong></td>
<td>#1000</td>
<td>1 North Waukegan Road, North Chicago, Illinois 60064 USA</td>
<td>+1 224-221-6346</td>
<td><a href="http://www.abbie.com">www.abbie.com</a></td>
<td>AbbVie is a global, research-driven biopharmaceutical company committed to developing advanced therapies for some of the world’s most complex and critical conditions. AbbVie’s mission is to use its expertise and unique approach to innovation to improve treatments across four therapeutic areas: immunology, oncology, virology and neuroscience.</td>
</tr>
<tr>
<td><strong>AMNEAL</strong></td>
<td>#1404</td>
<td>400 Crossing Blvd, 3rd Floor, Bridgewater, New Jersey 08807 USA</td>
<td>+1 908-332-2743</td>
<td><a href="http://www.amneal.com">www.amneal.com</a></td>
<td>At Amneal, we are committed to people living with Parkinson’s disease. We believe that every dose and every detail makes a difference—and that together, with patients, care partners, healthcare providers, and advocacy, we can achieve so much more.</td>
</tr>
<tr>
<td><strong>AMERICAN PARKINSON DISEASE ASSOCIATION (APDA)</strong></td>
<td>#1101</td>
<td>PO Box 61420, Staten Island, NY 10306 USA</td>
<td>+1 718-737-8151</td>
<td><a href="http://www.apdaparkinson.org">www.apdaparkinson.org</a></td>
<td>Founded in 1961, the American Parkinson Disease Association (APDA) works tirelessly every day to provide the support, education, and research to help everyone impacted by Parkinson’s disease live life to the fullest through a nationwide grassroots network of Chapters and Information &amp; Referral Centers.</td>
</tr>
<tr>
<td><strong>BOSTON SCIENTIFIC</strong></td>
<td>#1200</td>
<td>25155 Rye Canyon Loop, Valencia, California 91355 USA</td>
<td>+1 661-949-4345</td>
<td><a href="http://www.dbsandme.com">www.dbsandme.com</a></td>
<td>Boston Scientific is dedicated to advancing Deep Brain Stimulation (DBS) technology by developing meaningful, industry-leading solutions and partnering with healthcare providers to improve the quality of life for patients.</td>
</tr>
<tr>
<td><strong>BEATHEALTH</strong></td>
<td>#1401</td>
<td>630 Avenue du Professeur Emile Jeanbrau, Montpellier 34090, France</td>
<td>+33 61 73 72 242</td>
<td><a href="http://www.beathealth.eu">www.beathealth.eu</a></td>
<td>BeatMove is a patented and clinically validated walking aid which records the walk cadency and plays music that is synchronized to it. This allows a stabilization of the walk, a reduction in the number of falls, fear of falling, apathy, pain and more generally an improvement in quality of life.</td>
</tr>
<tr>
<td><strong>CHARCO NEUROTECH LTD</strong></td>
<td>#600</td>
<td>Wellington House, East Rd, Petersfield, Cambridge CB1 1BH, UK</td>
<td>+44 20 8164 0844</td>
<td>charconeuromechtech.com</td>
<td></td>
</tr>
</tbody>
</table>
**EXHIBITORS**

**CUE2WALK INTERNATIONAL B.V.**
Booth #1501

Lulofsstraat 55 Unit 26
The Hague 2521 AL
Netherlands
Tel: +31 64 405-8059
www.cue2walk.nl

Cue2Walk offers a Smart Cueing device to help people with Parkinson’s overcome Freeze of Gait. A simple wearable that allows patients to stay active by application of Smart Technology. The award-winning Medical Device was developed in close cooperation with researchers, medical professionals, and people with Parkinson.

**COMFORT LINEN**
Booth #1504

632 Robson Drive
Kamloops, British Columbia V2E 2B7
Canada
Tel: +1 403-389-6226
www.comfortlinen.com

Comfort Linen is a global online retailer of a friction-reducing sleep system comprised of a garment and bed sheet. Re-positioning becomes smooth and easy thereby allowing a more restful sleep. It is especially helpful to people coping with pain, mobility issues, Parkinson’s Disease, stroke, post surgery and other conditions.

**CONVATEC**
Booth #1201

Unomedical A/S, Aaholmvej 1-3
Osted 4320 Lejre
Denmark
Tel: +45 819-47135
www.convatec.com/infusion-care

Convatec Infusion Care specializes in manufacturing subcutaneous infusion sets since the 1980s and is the world’s largest manufacturer of subcutaneous infusion sets today. Each year, we provide patients with millions of sets for subcutaneous drug delivery. These are used in treatment areas including Diabetes, Parkinson’s Disease, Pain Management and more.

**CURE PARKINSON’S**
Booth #604

120 New Cavendish Street
London W1W 6XX
UK
Tel: +44 0207-487-3892
www.cureparkinsons.org.uk

We’re here for the cure. Cure Parkinson’s is working with urgency to investigate new treatments to slow, stop or reverse Parkinson’s. Our funding and innovative approach has created a dynamic programme of clinical trials of drugs each with the potential to modify the progression of the disease.

**DAVIS PHINNEY FOUNDATION FOR PARKINSON’S**
Booth #801

357 S McCaslin Blvd #105
Louisville, Colorado 80027
USA
Tel: +1 866-358-0285
www.davisphinneyfoundation.org

The Davis Phinney Foundation creates programs, tools, resources, and experiences that provide inspiration and information aimed at changing how people live with Parkinson’s. Their living well programs include the Every Victory Counts® suite of resources, Ambassador Leadership Program, Healthy Parkinson’s Communities™ initiative, extensive online educational content, and quality-of-life research.

**FUERTE ES LA VIDA PARKINSON NO LIMITS**
Booth #603

Calle Cardón 34
Corralejo 38770
Spain
Tel: +34 696-980-220
www.parkinsonnolimits.com

The nonprofit association Fuerte es la Vida Parkinson No Limits, organizes therapeutic and wellness vacations for People with Parkinson’s and their family (or friends) in Fuerteventura, Canary Islands. The activities offered during the vacation are personalized and are part of the Parkinson No Limits Method. They are all done outdoors.

**COMFORT LINEN**
Booth #1504

632 Robson Drive
Kamloops, British Columbia V2E 2B7
Canada
Tel: +1 403-389-6226
www.comfortlinen.com

Comfort Linen is a global online retailer of a friction-reducing sleep system comprised of a garment and bed sheet. Re-positioning becomes smooth and easy thereby allowing a more restful sleep. It is especially helpful to people coping with pain, mobility issues, Parkinson’s Disease, stroke, post surgery and other conditions.

**CONVATEC**
Booth #1201

Unomedical A/S, Aaholmvej 1-3
Osted 4320 Lejre
Denmark
Tel: +45 819-47135
www.convatec.com/infusion-care

Convatec Infusion Care specializes in manufacturing subcutaneous infusion sets since the 1980s and is the world’s largest manufacturer of subcutaneous infusion sets today. Each year, we provide patients with millions of sets for subcutaneous drug delivery. These are used in treatment areas including Diabetes, Parkinson’s Disease, Pain Management and more.

**CURE PARKINSON’S**
Booth #604

120 New Cavendish Street
London W1W 6XX
UK
Tel: +44 0207-487-3892
www.cureparkinsons.org.uk

We’re here for the cure. Cure Parkinson’s is working with urgency to investigate new treatments to slow, stop or reverse Parkinson’s. Our funding and innovative approach has created a dynamic programme of clinical trials of drugs each with the potential to modify the progression of the disease.

**DAVIS PHINNEY FOUNDATION FOR PARKINSON’S**
Booth #801

357 S McCaslin Blvd #105
Louisville, Colorado 80027
USA
Tel: +1 866-358-0285
www.davisphinneyfoundation.org

The Davis Phinney Foundation creates programs, tools, resources, and experiences that provide inspiration and information aimed at changing how people live with Parkinson’s. Their living well programs include the Every Victory Counts® suite of resources, Ambassador Leadership Program, Healthy Parkinson’s Communities™ initiative, extensive online educational content, and quality-of-life research.

**FUERTE ES LA VIDA PARKINSON NO LIMITS**
Booth #603

Calle Cardón 34
Corralejo 38770
Spain
Tel: +34 696-980-220
www.parkinsonnolimits.com

The nonprofit association Fuerte es la Vida Parkinson No Limits, organizes therapeutic and wellness vacations for People with Parkinson’s and their family (or friends) in Fuerteventura, Canary Islands. The activities offered during the vacation are personalized and are part of the Parkinson No Limits Method. They are all done outdoors.
GyroGear has developed the most advanced hand tremor stabilizer globally, the GyroGlove. This intelligent glove can provide instantaneous relief to the 200 million people globally with Parkinson’s Disease and Essential Tremor. Wear it, turn it on and regain that magical stability in your life.

IOS Press: Journal of Parkinson’s Disease is a dedicated forum for original research in basic and translational study and clinical medicine, to expedite our understanding and treatment of PD. The journal is international, multidisciplinary and aims to promote progress in epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis and treatment.

LSVT Global pioneered innovative, scientifically-validated therapies that restore and maintain voice (LSVT LOUD®) and movement (LSVT BIG®) in people with Parkinson’s. We have trained over 60,000 therapists from 83 countries who positively impact the lives of people they treat. We provide exercise videos and virtual exercise classes supporting treatment gains.

More than 11,000 clinicians, scientists and other healthcare professionals dedicated to improving care for some of the most challenging disorders through education and research.

Exhibited at WPC 2019 as the sole distributor of the ultrasound head stimulator “Ultra-Ma”. It is used in specified clinical trial of Lewy body dementia in Japan. The reported data shows improvement in Parkinson’s disease related motor functions. Ultra-Ma has been introduced in Japan for treatment in clinics.

We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us.
**NEUROMO**  
Booth #1301  
Carrer d’Osi  
Barcelona 08034  
Spain  
Tel: +1 003 466-416-1933  
www.a-champs.com

Empowering lives with innovative home-based training. Our interactive system enhances cognitive and motor skills simultaneously, empowering individuals with neurological impairments to actively participate in life. Join us on our mission to unlock potential and foster independence.

---

**ORBIT HEALTH**  
Booth #501  
Am Kartoffelgarten 14  
Munich N/A  
Germany  
Tel: +49 1607-564836  
orbit.health

Orbit Health’s mission is to empower people living with Parkinson’s (PwP) to lead a quality life. Its AI-powered solution Neptune automatically tracks symptoms and enables PwP and their healthcare teams to learn about how daily activities and treatments may affect motor states to ultimately personalize care.

---

**PARKINSON & MOVEMENT DISORDER ALLIANCE**  
Booth #1204  
7739 E Broadway, #352  
Tucson, Arizona 85710  
USA  
Tel: +1 800-256-0966  
www.pmdalliance.org

PMD Alliance is a nonprofit organization on a mission to empower people impacted by movement disorders with tools, inspiration, and meaningful connections. We create and deliver free resources across the Movement Disorder Care & Support Ecosystem—to people living with the disease, their families, support group leaders, and healthcare providers.

---

**PARKINSON’S EUROPE**  
Booth #703  
Lynwood House, Crofton Road  
Orpington, Kent BR6 8QE  
UK  
Tel: +1 796-206-2978  
www.epda.eu.com

Parkinson’s Europe is the leading voice for Parkinson’s in Europe. We provide trusted information, share good practices, raise awareness and improve understanding of the condition, as well as facilitate research collaboration. Our vision is that people with Parkinson’s have access to the highest standards of treatment, support, and care.

---

**PARKINSON’S ASSOCIATION MENTOR PROGRAM**  
Booth #1104  
PO Box 1633  
Solana Beach, California 92075  
USA  
Tel: +1 619-373-5476  
mentors.parkinsonsassociation.org

If you are living with or are struggling with Parkinson’s, or you are a care partner, and need someone to talk to, the Parkinson’s Association Mentor Program is the place for you. Find a mentor, and get guidance from someone who has walked in your shoes.

---

**PARKINSON’S FOUNDATION**  
Booth #601  
200 SE 1st Street  
Miami, Florida 33131  
USA  
Tel: +1 800-473-4636  
parkinson.org

The Parkinson’s Foundation makes life better for people with Parkinson’s disease (PD) by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community.
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PARKINSON’S UK</strong></td>
<td>#1001</td>
</tr>
<tr>
<td>215 Vauxhall Bridge Road</td>
<td></td>
</tr>
<tr>
<td>London SW1V 1EJ</td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td></td>
</tr>
<tr>
<td>Tel: +44 790-424-5146</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a></td>
<td></td>
</tr>
</tbody>
</table>

Parkinson’s UK is here for everyone affected by Parkinson’s. It’s the largest European charitable funder of Parkinson’s research. Driven by people with Parkinson’s, scientists and supporters, fundraisers and families, carers and clinicians. Working together to improve lives and find a cure.

<table>
<thead>
<tr>
<th><strong>PORTABLES HEALTHCARE TECHNOLOGIES</strong></th>
<th>Booth #1103</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henkestr. 91</td>
<td></td>
</tr>
<tr>
<td>Erlangen 91052</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Tel: +49 9131-974991</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.portables-hct.de">www.portables-hct.de</a></td>
<td></td>
</tr>
</tbody>
</table>

Portables HealthCare Technologies — medical apps made in Germany. Our patented, CE-labeled medical devices facilitate remote patient monitoring for therapy planning and clinical trials with a combination of wearable sensors and a smartphone-app. For patients the solutions allow an individualized coaching based on physiotherapeutic exercises and tips for daily living.

<table>
<thead>
<tr>
<th><strong>RUNE LABS</strong></th>
<th>Booth #1304</th>
</tr>
</thead>
<tbody>
<tr>
<td>649 Irving St</td>
<td></td>
</tr>
<tr>
<td>San Francisco, California 94122</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Tel: +1 860-305-5926</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.runelabs.io">www.runelabs.io</a></td>
<td></td>
</tr>
</tbody>
</table>

Rune Labs is a software and data analytics company for precision neurology. StrivePD is the company’s care delivery ecosystem for Parkinson’s disease, enabling patients and clinicians to better manage Parkinson’s by providing access to dashboards summarizing a range of patient-data, and by connecting patients to clinical trials.

<table>
<thead>
<tr>
<th><strong>PD AVENGERS</strong></th>
<th>Booth #1302</th>
</tr>
</thead>
<tbody>
<tr>
<td>2593 Grant Street</td>
<td></td>
</tr>
<tr>
<td>Vancouver, British Columbia V5K 3G6</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td></td>
</tr>
<tr>
<td>Tel: +1 778-233-6173</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.pdavengers.com">www.pdavengers.com</a></td>
<td></td>
</tr>
</tbody>
</table>

PD Avengers is a non-profit, global alliance of people with Parkinson’s, our partners and friends, standing together demanding change in how the disease is seen and treated. We add urgency to research, wellness and advocacy by uniting people and organizations to the cause of ending Parkinson’s.

<table>
<thead>
<tr>
<th><strong>ROCK STEADY BOXING</strong></th>
<th>Booth #401</th>
</tr>
</thead>
<tbody>
<tr>
<td>6847 Hillsdale Ct</td>
<td></td>
</tr>
<tr>
<td>Indianapolis, Indiana 46250</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>Tel: +1 317-676-6606</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.rocksteadyboxing.org">www.rocksteadyboxing.org</a></td>
<td></td>
</tr>
</tbody>
</table>

Rock Steady Boxing is an international non-profit organization that trains fitness and rehab professionals to lead boxing-based exercise specifically for people with Parkinson disease.

<table>
<thead>
<tr>
<th><strong>SENSE4CARE</strong></th>
<th>Booth #502</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tirso De Molina, 36 OF18</td>
<td></td>
</tr>
<tr>
<td>Cornellà de Llobregat 8940</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Tel: +34 942-3959</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.sense4care.com">www.sense4care.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Sense4Care is a leader MedTech company developing and producing wearable medical devices based on the identification of human movement patterns, especially in Parkinson’s Disease. The solution for Parkinson STAT-ON™ can replace evaluating methods used to date for digital medical reports automatically generated by our device.
Strolll’s Reality DTx® is a digital therapeutics software solution for commercially available AR glasses that can transform physio and rehabilitation for people living with neurological disorders.

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.

UCB and Novartis have partnered on a Parkinson’s research project, combining our expertise and aiming to bring disease-modifying therapies to people living with Parkinson’s Disease.

Urban Poling is an international education center and distributor of the high-performance ACTIVATOR® Poles; an evidence-based, patented tool that is revolutionizing rehabilitation. The award-winning ACTIVATOR® Program has been called a game changer for those living with Parkinson’s Disease; improving posture, balance and gait re-training.

Walk With Path is a mobility company dedicated to providing simple solutions to solve daily mobility challenges. Path Finder is a laser cueing shoe attachment that provides step synchronized cueing to alleviate and prevent freezing of gait. See walkwithpath.com for more details.
The World Parkinson Coalition® works with nearly 200 organizations globally to connect and inspire members of the Parkinson’s community. Its main focus is organizing and hosting the triennial World Parkinson Congress where it brings together some of the world’s most respected movement disorder specialists, neuroscientists, nurses, rehab specialists, people with Parkinson’s and care partners to learn about the latest scientific discoveries, medical practices, and care initiatives for PD.
### BRIAN GRANT FOUNDATION

Table #3

650 NE Holladay Street  
Portland, Oregon  97232  
USA  
Tel: +1 503-274-9382  
briangrant.org

The Brian Grant Foundation empowers people impacted by Parkinson’s to lead active and fulfilling lives.

---

### INTERNATIONAL TABLE TENNIS FEDERATION FOUNDATION (ITTF FOUNDATION)

Table #8

Richard-Wagner-Str. 10  
Leipzig  4109  
Germany  
Tel: +49 34199-992944  
ittffoundation.org/home

Table tennis 4all.4a better life, used as tool to promote development, health, peace, connecting people, implementing/supporting projects and empowering as models; for people with Parkinson and other diseases, to do it universal, inclusive, as a healthy activity with multiple benefits for physical-mental-social health, 2improve their daily life.

---

### DANCE FOR PD®, A PROGRAM OF MARK MORRIS DANCE GROUP

Table #2

3 Lafayette Ave  
Brooklyn, NY  11217  
USA  
Tel: +1 718-624-8400  
danceforparkinsons.org

Dance for PD® offers internationally-acclaimed in-person and online dance classes for people with Parkinson’s through a network of partners in 28 countries. Dance for PD®, a program of Mark Morris Dance Group, empowers participants to build confidence, community and physical skills while experiencing the joys and research-backed benefits of dance.

---

### FEDERACIÓN ESPAÑOLA DE PÁRKINSON

Table #4

Paseo de la Ermita del Santo, 5  
Madrid  28011  
Spain  
Tel: +34 914-345-371  
www.esparkinson.es

Federación Española de Párkinson is the only national umbrella organization about Parkinson’s in Spain. With more than 25 years of experience, we have been able to bring together nearly 70 members, which are local Parkinson’s associations located all around Spain. All together, they represent around 13.000 people living with Parkinson’s.

---

### PARKINSON’S DISEASE NURSE SPECIALIST ASSOCIATION (PDNSA)

Table #6

Bronlyys Hospital  
Powys  LD3 0LU  
UK  
Tel: +44 187-471-2595  
www.pdnsa.org

The PDNSA is a national organisation for nurses who care for people living with Parkinson’s disease. We raise awareness to improve quality of life through education. We are based in the UK with international membership including supporting mentorship in sub Saharan Africa.

---

### NPO U60 CHALLENGED SUPPORTERS

Table #5

5-1-205, 2-Chou  
Sakai, Osaka  N/A  
Japon  
Tel: +81 090-4496-3010

We provide assistance to younger PD patients under 60. We start a new challenge with NPO TENBII.N. Goal is a society where everyone has appropriate knowledge about PD and can respect and cooperate with each other. We challenge to use puppet shows and movies as a means to do so.
### Ping Pong Parkinson

**Table #1**

175 Tompkins Avenue  
Pleasantville, NY 10520-3413  
USA  
Tel: +1 914-557-6092  
[pingpongparkinson.org](http://pingpongparkinson.org)

We didn’t conquer Parkinson, but we conquered the fear of Parkinson. Mission to create a global sports movement that is inclusive and supportive of people with a Parkinson diagnosis. The first and only world table tennis championship organizers dedicated to raising awareness of the benefits.

### Power for Parkinson’s

**Table #7**

5555 N Lamar St. L121  
Austin, Texas 78751  
USA  
Tel: +1 512-815-3324  
[www.powerforparkinsons.org](http://www.powerforparkinsons.org)

Our mission is to provide free fitness, dance, and singing classes for people with Parkinson’s Disease and their care partners in the Austin, Texas area and around the world.

---

The **WPC Buddies Program** is an initiative to strengthen the global Parkinson’s community by connecting **World Parkinson Congress** registrants with each other before the Congress even begins!

This is an opportunity for community members to engage in meaningful conversation with someone on the other side of the world, or just next door.
The 6th World Parkinson Congress will be held in the Barcelona International Convention Centre located at Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain. To find out more about the Congress location, please visit https://ccib.es.
M1 FLOOR

P0 FLOOR

- **TERRACE**
- **VIP ROOM**
- **MULTI-PURPOSE ROOM TOTAL**
- **AREA 1**
- **AREA 2**
- **AREA 3**
- **AREA 4**
- **AREA 5**
- **AREA 6**
- **AREA 7**
- **AREA 8**
- **ENTRANCE HALL**
- **FOYER 0**
Be Inspired.

WPC 2023 video competition

WATCH THE VIDEOS FROM THE COMPETITION AT

WORLDPDCONGRESS
Neptune Care offers symptom tracking and monitoring right at your fingertips. It is designed to empower people living with Parkinson’s to learn and take back control.

- **Treatment Response**: Receive personalised insights into your PD treatment response
- **Symptom Tracking**: Gain a better understanding of your overall symptoms and see how lifestyle and other factors impact them
- **Customised Report**: Identify trends using our easy-to-understand motor graph

Come see us at **Booth 501**!

We are opening up **free early access** to Neptune Care for qualified WPC participants*.

*Currently available in Austria, Germany, Ireland, Singapore & UK

To win our WPC **daily raffles** come to our Booth today.

Visit www.orbit.health to learn more.

---

**Book Nook**

Visit the WPC **BOOK NOOK** in the Exhibit Hall.

This space gives delegates a chance to learn about, connect with, and be inspired by authors and new publications.
**Acetylcholine**: One of the chemical neurotransmitters in the brain and other areas of the central and peripheral nervous system. It is highly concentrated in the basal ganglia, where it influences movement. It is located in other regions of the brain as well, and plays a role in memory. Drugs that block acetylcholine receptors (so-called anticholinergics) are utilized in the treatment of PD.

**Agonist**: A chemical or drug that can activate a neurotransmitter receptor. Dopamine agonists, such as pramipexole, ropinirole, bromocriptine and apomorphine, are used in the treatment of PD.

**Aggregate**: A whole formed by the combination of several elements. In Parkinson’s disease, there is a clumping of many proteins inside neurons, including α-synuclein. Levy bodies are a kind of aggregate found in PD.

**Akinesia**: Literally, means loss of movement also described as a difficulty with initiating voluntary movements. It is commonly used interchangeably with bradykinesia, however bradykinesia means slow movement.

**Alpha-synuclein (α-synuclein)**: A protein present in nerve cells where it can be found in their cell body, their nucleus and their terminals. The accumulation and aggregation of this protein is a pathologic finding in PD. The first genetic mutation found in PD was discovered in the gene for α-synuclein (SNCA), and was called PARK1. α-synuclein also accumulates in multiple system atrophy (MSA) and in Lewy Body Disease. α-synuclein appears to play a key role in the pathogenesis of PD.

**Alexander Technique**: This technique is a form of complementary therapy, pioneered at the turn of the century by FM Alexander. The principal aim is to help improve health by teaching people to stand and move more efficiently.

**Amygdala**: An almond-shaped nucleus located deep in the brain’s medial temporal lobe in animals. It is involved in fear and anxiety responses, and in the formation of memories involving emotion.

**Anticholinergics**: A type of medication that interferes with the action of acetylcholine. It is sometimes used in PD to restore the balance between dopamine and acetylcholine in the striatum. They are not recommended for use in the elderly because they can cause confusion. Examples include:
- benztropine mesylate
- biperiden hydrochloride
- orphenadrine citrate
- procyclidine hydrochloride
- trihexyphenidyl hydrochloride

**Apathy**: Lack of interest, enthusiasm, or concern.

**Axon**: A nerve fiber that carries electrical impulses from the nerve cell body to other neurons. Thick axons tend to be through the brain and spinal cord; they are surrounded by a protective fatty sheath called myelin (in multiple sclerosis the myelin is damaged). Thin axons tend to be unmyelinated. In PD, α-synuclein is deposited in long, thin axons, and these are called Lewy neurites.

**Autonomic Nervous System (ANS)**: Part of the peripheral nervous system, consisting of sympathetic and parasympathetic nerves that control involuntary actions, in particular the heartbeat, smooth muscle (such as bladder and blood vessels), the digestive system, and glands.

**Autonomic Dysfunction**: Any abnormal functioning of the autonomic nervous system resulting in problems with bodily functions such as bowel and bladder control, blood pressure control, sweating, drooling, and so forth.

**Autophagy**: The segregation and disposal of damaged organelles within a cell. This is a normal physiological process in the body. It maintains normal functioning by protein degradation and turnover of the destroyed cell organelles for new cell formation. During cellular stress the process of Autophagy is increased. Cellular stress is caused when there is deprivation of nutrients and/or growth factors. Thus autophagy may provide an alternate source of intracellular building blocks and substrates that may generate energy to enable continuous cell survival. Dysfunctional autophagy can lead to the building of damaged organelles and misfolded proteins in the cell.

**Autosomal recessive**: A mode of inheritance of genetic traits located on the autosomes that only manifests when two copies of a mutated gene (two alleles) are present. In order for a particular trait to be expressed, both parents must have the particular mutated allele or gene, and both must pass it to the offspring who then manifests the genetic disease. Some genetic forms of PD are autosomal recessive, such as from the genes known as parkin, PINK1 and DJ1. In some cases, the gene of interest is missing. In others, there are abnormalities and if two different abnormalities of the same gene are inherited, that can result in recessive inheritance.

**Astrocytes**: They are a major support cells in the brain. Among other things, they secrete growth factors that help neurons grow and communicate. They can also pump glutamate, a neurotransmitter that, in excess, can cause neurotoxicity.

**Ataxia**: Inability to coordinate voluntary muscle movements; unsteady movements and staggering gait.

**Axon**: A nerve fiber that carries electrical impulses from the nerve cell body to other neurons. Thick axons tend to be through the brain and spinal cord; they are surrounded by a protective fatty sheath called myelin (in multiple sclerosis the myelin is damaged). Thin axons tend to be unmyelinated. In PD, α-synuclein is deposited in long, thin axons, and these are called Lewy neurites.
**Basal Ganglia:** Clusters of neurons that include the caudate nucleus, putamen, globus pallidus and substantia nigra which are located deep in the brain and play an important role in movement. Cell death in the substantia nigra contributes to Parkinsonian signs. The subthalamic nucleus is now also often considered part of the basal ganglia because it connects with other regions of the basal ganglia.

**Blood brain barrier:** The separating membrane between the blood and the brain; a tight physical barrier that normally keeps immune cells, and some chemicals and drugs out of the brain.

**Bradykinesia:** Literally, means slowness of movement. It is commonly (but erroneously) used synonymously with akinesia and hypokinesia. Bradykinesia is a clinical hallmark of Parkinsonism.

**Brain stem:** The part of the brain between the cerebral hemispheres and the spinal cord. The three parts of the brain stem are the medulla oblongata, pons, and midbrain. The brain stem is a vital structure that is a passageway between the brain and spinal cord, and it contains neurons involved in sleep and wakefulness, as well as the main centers that command vital functions such as respiration and heart function. The substantia nigra, which is damaged in Parkinson’s, is located in the midbrain of the brain stem.

**Calcium:** An essential mineral. Calcium is important for neurological “signaling” and is involved in many chemical reactions within neurons and in mitochondria function. Calcium overload in substantia nigra has been postulated as one mechanism that could contribute to death of these neurons.

**Carbidopa:** A drug given with levodopa. Carbidopa blocks the enzyme dopa decarboxylase, thereby preventing levodopa from being metabolized to dopamine. Because carbidopa does not penetrate the blood brain barrier, it only blocks levodopa metabolism in the peripheral tissues and not in the brain, thereby reducing side effects, but increasing the effectiveness of levodopa.

**Cerebrospinal fluid (CSF):** A watery fluid generated within the brain’s ventricles. CSF circulates to bathe the brain and spinal cord to cushion these from physical impact. Small amounts can be harvested in humans by lumbar puncture to measure chemicals coming from the brain.

**Chronic:** (opposite: acute) Chronic diseases are of long duration. Chronic diseases are typically of subtle onset and slow worsening over time. The term does not imply anything about the severity of a disease.

**Clinical Trials:** Refers to those research studies that involve human volunteers and are conducted to add to our understanding of certain diseases or to determine whether a drug may be effective in treating a disease.

**Central Nervous System (CNS):** consists of the brain, brain stem and spinal cord.

**Cognition:** Mental processes including attention, remembering, producing and understanding language, solving problems and making decisions.

**Complementary therapies:** These are non-medical treatments, which many people use in addition to conventional medical treatments, such as the Alexander technique, acupuncture, aromatherapy, music and art therapies, reflexology, and osteopathy.

**Computed tomography (CT):** A medical imaging method employing computer processing to produce images seen as slices through the tissue. This presentation of images is known as tomography.

**Continuous Dopaminergic Stimulation (CDS):** A therapeutic concept for the management of Parkinson’s disease that proposes that continuous (as opposed to discontinuous or pulsatile) stimulation of striatal dopamine receptors will delay or prevent the onset of levodopa-related motor complications.

**Deep Brain Stimulation (DBS):** A surgical treatment that involves the implantation of a medical device (electrical stimulator) that acts as a brain pacemaker sending electrical impulses to the specific area in which the electrode was inserted. In Parkinson’s patients, the device is typically inserted in either the subthalamic nucleus or the globus pallidus, less often in the thalamus or pedunculopontine nucleus, depending upon the specific problem.

**Cerebellum:** Part of the hindbrain; controls smooth movements. When damaged, it results in ataxia.
Dendrites: (from Greek meaning, “tree”) Nerve fibers that project from the nerve cell body. Branches of dendrites are the receiving fibers of signals coming to the neuron from other neurons and convert these chemical signals into electrical ones to the nerve cell body.

Depression: Causes feelings of sadness and/or a loss of interest in activities once enjoyed. It can decrease one’s ability to function in daily activities. Depression can be a clinical symptom of PD.

Disease modification: Treatments or interventions that affect the underlying pathophysiology of the disease and have a beneficial outcome on the course of a disease, for example Parkinson’s.

Dopa decarboxylase inhibitors: Drugs (such as carbidopa) that inhibit the metabolism of levodopa to form dopamine. By inhibiting dopa decarboxylase only in the peripheral organs (not the Central Nervous System), levodopa concentration is increased and more can enter the brain. These drugs are particularly useful in Parkinson’s when used with levodopa.

Dopamine: A small chemical molecule that is one of the brain’s neurotransmitters. Among other brain regions, it is found in cells within the substantia nigra. These cells project to the striatum in the basal ganglia. Deficiency of dopamine in the striatum due to the death of cells in the substantia nigra causes symptoms of Parkinsonism.

Dopamine agonist: A compound that activates dopamine receptors, other than dopamine. Examples include, bromocriptine mesylate (Parlodol), pergolide (Permax), pramipexole (Mirapex), ropinirole hydrochloride (Requip), piribedil, apomorphine (Apokyn), rotigotine (Neupro patch) and lisuride. These act like dopamine, but are not actually dopamine. They can be used in both the early and late stages of Parkinson’s disease. They are the second most powerful type of anti-Parkinson medication after levodopa. They can cause side effects such as sleepiness, sleep attacks, ankle swelling, hallucinations and impulse control problems, more commonly than levodopa does.

Dopaminergic pathways: Neural pathways in the brain which utilize dopamine as their neurotransmitter. There are four major groups: the nigrostriatal, mesocortical, mesolimbic and tuberoinfundibular pathways.

- Nigrostriatal: Connects the substantia nigra to the striatum. Involved heavily in Parkinson’s.
- Mesocortical: Connects the ventral tegmental area (adjacent to the substantia nigra) to the cerebral cortex. Closely associated with the mesolimbic pathway. Can cause hallucinations and schizophrenia if not functioning properly.
- Mesolimbic: Connects ventral tegmental area to nucleus accumbens, amygdala & hippocampus and prefrontal cortex. Along with the mesocortical pathway, is involved in memory, motivation, emotional response, reward and addiction.
- Tuberoinfundibular: from hypothalamus to pituitary gland involved in hormonal regulation, maternal behavior (nurturing), pregnancy and sensory processes.

Drug Repurposing: Repurposing generally refers to studying drugs that are already approved to treat one disease or condition to see if they are safe and effective for treating other diseases.

Dyskinesia: Abnormal involuntary movements; also sometimes called hyperkinesia.

Dystonia: Characterized by persistent or intermittent contractions of opposing muscles causing abnormal movements or postures. It should not be confused with dyskinesia.

Freezing of Gait (FOG): The sudden brief inability to walk or to continue walking.

GABA (gamma amino butyric acid): The principal inhibitory neurotransmitter in human brain. GABA neurons are rich in the striatum, globus pallidus, substantia nigra and cerebellum.

GABA (Glucocerebrosidase): An enzyme found within the lysosome of cells. Mutations in the GBA gene are associated with Parkinson’s disease.
GDNF: Glial Cell line derived nerve growth factor. See growth factors.

Gene therapy: The insertion of genes into an individual’s cells and tissues to treat hereditary diseases where deleterious mutant alleles can be replaced with functional ones. The genes are usually placed within a non-pathogenic virus, which serves as the vector to penetrate the cells. Gene therapy can also be used to correct non-genetic deficiencies such as the loss of dopamine in Parkinson’s, to modify the function of a group of cells (e.g. convert an excitatory structure to one that is inhibitory) or to provide a source of growth factors.

Genotype: The collection of genetic material in an organism that gives rise to its characteristics.

Glia (Glial cells): Non-neural cells, commonly called neuroglia or simply glia (Greek for “glue”), that maintain homeostasis, form myelin, and provide support and protection for the brain’s neurons. Astrocytes are one kind of glial cells.

Globus pallidus: A major part of the basal ganglia involved in movement control. It is split into two main parts: the internal globus pallidus (GPI), and the external globus pallidus (GPe). Deep brain stimulation of the GPI causes an increase in motor function in Parkinson’s patients. Often patients also show a reduction in dyskinesia, probably because they require less levodopa.

Glucose: A simple sugar that is an important energy source in living organisms and is a component of many carbohydrates.

Glutamate: An amino acid and the main excitatory neurotransmitter in the human brain. The major input to the striatum is from the cerebral cortex and uses glutamate as a neurotransmitter. Excess glutamate can occur if the neurotransmitter is not well regulated and may cause cell death.

Glycation: The bonding of a sugar molecule to a protein or lipid molecule without enzymatic regulation.

Growth factors: Naturally occurring substances (usually proteins) that help maintain the health of neurons and encourage cell growth, proliferation and differentiation. Some growth factors are being looked at to try to promote the survival of the neural cells that are degenerating in Parkinson’s.

• Glial cell line derived nerve growth factor (GDNF): Thought to promote the health of dopamine neurons.
• Brain-derived nerve growth factor (BDNF): Also supports dopamine neurons.
• Fibroblast growth factor (FGF): Studies have found a possible genetic link to Parkinson’s disease on the FGF20 gene.
• Vascular endothelial growth factor-B (VEGF-B): May have neuroprotective affects in Parkinson’s disease.

Gut microbiome: The complex community of microorganisms that live in the digestive tracts of humans and other animals.

Heterogeneity: Lacking uniformity in composition or character (as opposed to homogeneity, which is uniformity in composition or character).

Hippocampus: A complex neural structure (shaped like a sea horse) located in the temporal lobes of the brain; involved in memory storage, motivation and emotion as part of the limbic system.

Hoehn and Yahr scale: A commonly used system for describing how the symptoms of Parkinson’s disease progress. The higher the stage, the more advanced the disease.

• Stage 0: No signs of disease.
• Stage 1: Unilateral symptoms only.
• Stage 1.5: Unilateral and axial (midline) involvement.
• Stage 2: Bilateral symptoms. No impairment of balance.
• Stage 2.5: Mild bilateral disease with recovery on pull test.
• Stage 3: Balance impairment. Mild to moderate disease. Physically independent.
• Stage 4: Severe disability, but still able to walk or stand unassisted.
• Stage 5: Needing a wheelchair or bedridden unless assisted.

Hyperkinesia: An abnormal increase in movement and/or muscle activity; sometimes used synonymously with dyskinesia.

Idiopathic: Arising from an unknown cause.

Idiopathic Parkinson’s disease: This term is used to describe the common type of Parkinson’s disease to distinguish it from other forms of Parkinsonism (also termed “Sporadic PD”).

Impulse control disorder (ICD): A set of psychiatric disorders characterized by an inability to control one’s actions, in particular those that might bring harm to oneself or others. Common ICDs in patients receiving dopamine agonists are pathologic gambling, compulsive eating, compulsive shopping and hypersexuality.

Interdisciplinary care: Multiple healthcare professionals collaborating to provide care with a common perspective, often involving joint consultations.

Leucine rich repeat kinase 2 (LRRK2): A protein created by the LRRK2 gene which when mutated can lead to Parkinson’s. Several different mutations in the LRRK2 gene have been found to cause Parkinson’s disease, but there may also be variants within the general population that do not necessarily cause disease.
Levodopa (L-DOPA): A chemical that is the precursor to dopamine. It can pass through the blood-brain barrier (whereas dopamine cannot). Once it has entered the central nervous system, L-dopa is converted into dopamine by aromatic L-amino acid decarboxylase (DOPA decarboxylase/DDC). L-DOPA is also converted into dopamine within the peripheral nervous system, but this is usually blocked by employing peripherally-active dopa decarboxylase inhibitors to avoid unwanted effects.

Lewy bodies: A pathologic hallmark of Parkinson’s disease and dementia with Lewy bodies. First described by Frederic Lewy, Lewy bodies are seen microscopically as inclusions in neurons in several brain regions, including the substantia nigra and locus ceruleus. One protein seen is α-synuclein in an aggregated form. Aggregates of this protein in axons are called Lewy neurites.

Magnetic resonance imaging (MRI): A noninvasive medical imaging technique to visualize detailed internal structure and limited function of the body. MRI provides much greater contrast between the different soft tissues of the body than computed tomography (CT), making it especially useful in neurological (brain), musculoskeletal, cardiovascular and oncological (cancer-related) imaging.

MAO (monoamine oxidase): A family of enzymes with two subtypes: MAO-A and MAO-B. These catalyze the oxidation of amine molecules (replacing the amine group with an oxygen molecule.)
- MAO A inhibitors: Drugs that inhibit the MAO-A enzyme, which is responsible for the metabolism of dietary tyramine. MAO-A inhibitors can cause tyramine-induced hypertension, the so-called “cheese effect” because tyramine can be found in high concentrations in some soft cultured cheeses.
- MAO B inhibitors: These drugs (e.g. selegiline, rasagiline) inhibit the breakdown of dopamine via MAO-B enzyme and do not cause the “cheese effect” of hypertension.

MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine): A neurotoxin precursor of MPP+ that is taken up in dopamine nerve terminals. MPP+ damages the dopamine cells. MPTP is catalyzed to MPP+ by MAO-B. MPTP has been widely used to create an animal model of Parkinsonism by depleting substantia nigra dopamine neurons.

Microbiome: The collection of microbes (bacteria, viruses, fungi) and their genetic material that live outside an area of the human body. See gut microbiome.

Microglia: A type of glial cell; it provides the first immune defense mechanism in the brain and central nervous system.

Micrographia: The tendency to have very small handwriting due to difficulty with fine motor movements in Parkinson’s disease.

Mild Cognitive Impairment (MCI): A decline in memory or intellectual functioning that is not as severe as that found in dementia.

Mitochondria: A spherical or elongated organelle in the cytoplasm of nearly all eukaryotic cells, containing genetic material and many enzymes important for cell metabolism, including those responsible for the conversion of food to usable energy. It consists of two membranes: an outer smooth membrane and an inner membrane arranged to form cristae.

Mitophagy: The selective degradation of mitochondria by autophagy. See Mitochondria and Autophagy.

Motor skills: The degree of control or coordination provided by brain control of the skeletal muscles.

Motor symptoms: Symptoms that involve movement, coordination, physical tasks or mobility. These include, among others: resting tremor, bradykinesia, rigidity, postural instability, freezing, micrographia, mask-like expression, unwanted accelerations, stooped posture, dystonia, impaired motor dexterity and coordination, speech problems, difficulty swallowing, muscle cramping, and drooling of saliva. See non-motor symptoms.

Movement Disorder Specialist (MDS): A neurologist that has special interest in and extra training and experience with movement disorders such as Parkinson’s disease.

Multiple System Atrophy (MSA): A less common degenerative neurological disorder that causes symptoms similar to Parkinson’s disease but with more widespread damage to the central nervous system. Other systems involved besides the basal ganglia include the cerebellum and autonomic systems.

Neuroinflammation: The swelling of the tissue in the nervous system. It could be initiated in response to a number of things including infection, traumatic brain injury, toxic metabolites, or autoimmunity. Microglia are the immune cells activated in response to these cues.

Neurology: A branch of medicine dealing with the diagnosis and treatment of disorders of the nervous system.

Neuromelanin: The dark pigment made from oxidized metabolites of monoamine neurotransmitters including dopamine and norepinephrine, found in neurons enriched with these amines, namely the substantia nigra and locus ceruleus, respectively. Neuromelanin gives the substantia nigra (Latin for “black substance”) its black appearance.

Neuromodulator: A chemical substance other than a neurotransmitter, released by a neuron at a synapse and either enhances or dampens their activities.
**Neurologist:** A doctor who specializes in the diagnosis, care and treatment of disorders of the brain or nervous system.

**Neuroplasticity:** The ability of the brain to change and form new connections even with aging. It involves neurons regenerating anatomically or functionally after partial injury, or changing (such as by making more numerous or more effective connections) in response to training and experience.

**Neuron:** A nerve cell that is the fundamental unit of the brain and nervous system. Neurons transmit information through electro-chemical signals.

**Neuroprotection:** Mechanisms within the nervous system that would protect neurons from dying due to a degenerative disease or from other types of injury.

**Neuroprotective:** Serving to protect neurons from injury or degeneration or an effect that may result in salvage, recovery or regeneration of the nervous system, its cells, structure and function.

**Neuroscience:** The scientific study of the nervous system that deals with the anatomy, biochemistry, molecular biology, and physiology of neurons and neural circuits.

**Neurotransmitter:** A chemical messenger in the nervous system that permits communication between two neuronal cells, often but not always across a synapse. The neurotransmitter is usually released from the nerve terminals on the axons. Examples of neurotransmitters include dopamine, acetylcholine, adrenaline, noradrenaline, serotonin, glutamate, and GABA.

**Objective measurements:** The repetition of a unit amount that maintains its size, within an allowable range of error, no matter which instrument, intended to measure the variable of interest, is used and no matter who or what relevant person or thing is measured.

**Occupational therapist:** Occupational therapists are concerned with assessing a person’s home or work situation and then devising ways to make them more manageable and less hazardous. They can also advise on aids and equipment and leisure activities.

**Olfactory dysfunction:** An impaired ability to detect odors, impaired sense of smell. Thought to be an early sign of Parkinson’s disease but can occur in many situations not related to Parkinson’s.

**Organoid:** A miniature, simplified version of an organ that shows realistic micro-anatomy. They are derived from tissue, embryonic stem cells, or induced pluripotent stem cells.

**Oxidative stress:** See Reactive Oxidative Species.

**Parkin:** A protein that is generated by the Parkin gene. With homozygous (both alleles affected) Parkin mutations (PARK2 gene), Parkinson’s disease develops. It is the most common cause of juvenile onset PD.

**Parkinsonism:** A group of neurological diseases whose features include slowness and paucity of spontaneous movement (bradykinesia), rest tremors, rigidity of the muscles, loss of postural reflexes, flexed posture and freezing of gait.

**Pathogenesis:** The underlying biologic mechanism responsible for a disease.

**Peripheral Nervous System:** The nervous system outside the brain and spinal cord.

**Phenotype:** The observable characteristics of an organism or person, such as appearance, development and behavior. Determined by the interaction between the genotype and the environment.

**Phosphorylation:** A process that modifies proteins by adding one or more phosphates. For proteins that function as enzymes, this results in activating or deactivating their function.

**PINK-1:** An abbreviation for the name of a gene that encodes a particular serine/threonine kinase found in mitochondria that stops stress related cell destruction. With homozygous (both alleles affected) PINK-1 mutations, juvenile or early onset Parkinson’s disease can develop. Lack of PINK-1 causes an overload of calcium in mitochondria and indirectly cell death. The substantia nigra is particularly sensitive to PINK-1 mutations.

**Physiotherapist:** Physiotherapists use physical means such as exercise and manipulation to help prevent or reduce stiffness in joints and restore muscle strength. They can also advise on aids and equipment to help with movement problems.

**Placebo:** A simulated or inert form of treatment without known proven benefit on a symptom or a disease. A pill serving as a placebo is colloquially called a “sugar pill.” Placebos are employed in controlled clinical trials along with the active drug being tested; patients and health professionals involved in the trial do not know who receives the placebo or the drug. The difference in responses between the two drugs is considered the true effect of the active drug. Surgical trials can also utilize a placebo arm in which sham or simulated surgery is performed in the control group. Sometimes placebos provide benefit; it is called a placebo effect. The mechanism of how placebos provide benefit may be associated with release of dopamine in the brain when patients believe that they receive an effective drug.
Positron emission tomography (PET): A medical imaging technique in which radioactive isotopes that emit gamma rays are used. The radioactive substance is incorporated into a chemically active compound (a radiotracer, which could be a substrate for an enzyme or a ligand that binds to neurotransmitter receptors) utilized by an organ in the body. The emitted gamma rays are detected by a special camera/scanner. These radioactive strikes on the camera are analyzed by a computer to produce an image to localize where that ligand is located in the organ being studied. Fluorodeoxyglucose (FDG) measures regional metabolism of glucose (sugar); fluorodopa (F-DOPA) is taken up in dopamine nerve terminals. The amount of uptake serves as a measure of the integrity of these nerve terminals. Other radiotracers may bind to neurotransmitter receptors (including those for dopamine) or to inflammatory cells, etc.

Postural instability: Difficulty with balance.

PPMI — Parkinson’s Progression Markers Initiative: a study launched in 2010 by Michael J Fox Foundation to find biomarkers for PD; a landmark observational clinical study to comprehensively evaluate people with Parkinson’s disease and those at greater risk of developing the disease, as well as healthy controls.

Prodromal: Referring to the period before the classic manifestation of a disease leading to diagnosis.

Protein: 1. A class of food necessary for the growth and repair of the body tissues—sources of proteins include fish, meat, eggs and milk. 2. Large biomolecules or macromolecules consisting of long chains of amino acid residues. Within organisms, proteins catalyze metabolic reactions (enzymes), replicate DNA, and transport molecules.

PwP: Person with Parkinson’s.

Receptor: A protein structure typically embedded in the cell membrane with which neurotransmitters and drugs interact.

REM (rapid eye movement) sleep behavior disorder (RBD): A sleep disorder that involves movement and abnormal behavior during the sleep phase with rapid eye movements — the stage of sleep in which dreaming occurs. In normal sleep, muscles are paralyzed during dreaming, except for the eye movements. In RBD, muscles are not paralyzed so that the dreamer acts out his or her dreams. RBD is common in people with Parkinson’s disease or Multiple System Atrophy.

Rigidity: A special type of muscle stiffness, which is one of the main symptoms of Parkinson’s disease. The muscles tend to pull against each other instead of working smoothly together.

Schwab and England Activities of Daily Living (ADL) Scale: An estimation of the abilities of a person’s degree of independence. The person (or a family member) can self-assess this as:

- 100% — Completely independent. Able to do all chores without slowness, difficulty or impairment.
- 90% — Completely independent. Able to do all chores with some slowness, difficulty or impairment. May take twice as long to complete.
- 80% — Independent in most chores. Takes twice as long. Conscious of difficulty and slowing.
- 70% — Not completely independent. More difficulty with chores. 3 to 4 times longer to complete chores for some. May take large part of day for chores.
- 60% — Some dependency. Can do most chores, but very slowly and with much effort. Errors, some impossible.
- 40% — Very dependent. Can assist with all chores but few alone.
- 30% — With effort, now and then does a few chores alone or begins alone. Much help needed.
- 20% — Nothing alone. Can do some slight help with some chores. Severe invalid state
- 10% — Totally dependent, helpless.
- 0% — Vegetative functions such as swallowing, bladder/bowel function are not functioning. Bedridden.

Seed amplification assays: Can detect teeny amounts of misfolded protein. A synuclein SAA pegs sporadic Parkinson’s disease with high sensitivity. Its sensitivity is lower in familial PD, or if sense of smell is normal. The assay also detects mixed pathology in people with Alzheimer’s.

Serotonin: A neurotransmitter that regulates mood, appetite, and sleep. It also has some cognitive functions, including memory and learning. The serotonin-containing neurons are in the brain stem. Serotonin is reduced in PD.

Shaking palsy: Prior term for Parkinson’s disease.

Side effects: A reaction to drugs, which is additional to the intended therapeutic actions. These unwanted extra effects are called side effects. Side effects vary in their severity from person to person, and often disappear when the body becomes used to a particular drug.

Stem cells: Biological cells found in all multicellular organisms, that can divide (through mitosis) and differentiate into diverse specialized cell types and can self-renew to produce more
PARKINSON’S DISEASE GLOSSARY

stem cells. They are a potential line of treatment in Parkinson’s, either by directly replacing the old nigrostriatal neuronal cells or by creating growth factor releasing cells. Problems have arisen due to the inability to stop growth, which may cause tumor growth.

**Striatum:** A large cluster of nerve cells that are part of the basal ganglia. The striatum consists of two sectors: the caudate nucleus and the putamen. It controls movement, balance, and walking; the striatum receives nerve inputs from many parts of the brain including dopamine neurons from the substantia nigra and glutamate neurons from the cerebral cortex. Acetylcholine and GABA neurons are located within the striatum. GABA neurons also send signals outside the striatum. The striatum contains the largest concentration of dopamine and acetylcholine in the brain.

**Substantia nigra:** (Latin for black substance). A brain structure located in the midbrain that plays an important role in movement. Parts of the substantia nigra appear darker than neighboring areas due to high levels of neuromelanin in dopaminergic neurons. The substantia nigra is the site of the brain’s major collection of dopamine neurons, which project their axons to the striatum, the so-called nigrostriatal pathway. These neurons slowly die in PD. The substantia nigra is part of the basal ganglia; the other parts of the basal ganglia include the striatum (caudate nucleus, putamen), globus pallidus, and subthalamic nucleus. The substantia nigra is made up of two parts: the pars compacta and the pars reticulata.

- **Pars compacta:** The part of the substantia nigra primarily involved in Parkinson’s. It contains dopamine neurons, and it is black due to the high concentration of neuromelanin within these neurons. (Parkinson’s disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta.)

- **Pars reticulata:** Part of the substantia nigra that serves both as the location of dendrites from the pars compacta, receiving nerve signals to the substantia nigra and also as an output, conveying signals to numerous other brain structures. These output neurons are mainly GABAergic neurons.

**Subthalamic nucleus (STN):** A small lens-shaped nucleus involved in movement control. As suggested by its name, the subthalamic nucleus is located below the thalamus. It is part of the basal ganglia. It receives input from the cerebral cortex and from the globus pallidus interna. It sends its output mainly to the globus pallidus externa and substantia nigra pars reticulata. It is a component of the “indirect pathway” within the basal ganglia. It is “overactive” in PD due to loss of inhibitory incoming fibers. It is a common target in deep brain stimulation for PD.

**Synapse:** The narrow space between two neurons (axon to dendrite) or between a neuron and a muscle. Axons release neurotransmitters at the nerve terminal. The neurotransmitter crosses the synapse to activate or inhibit another nerve cell by acting on a receptor on the dendrite.

**Syndrome:** A group of symptoms that tend to occur together and which reflect the presence of a specific disorders or diseases. Parkinson syndrome, also called Parkinsonism, comprise a group of disorders with symptoms and signs in common, such as bradykinesia, rigidity, tremor, loss of postural reflexes, flexed posture and freezing of gait. A person with Parkinsonism does not need to have all of these but must have bradykinesia according to one diagnostic criterion. Disorders that fall within Parkinson syndrome include Parkinson’s disease, atypical Parkinsonism, Parkinson Plus Syndromes, drug-induced Parkinsonism, and normal pressure hydrocephalus.

**Synucleinopathy:** A class of neurodegenerative disease resulting from pathological accumulation of α-synuclein in neurons (Parkinson’s, Lewy Body Dementia) or a kind of glia cells called oligodendrocytes (Multiple System Atrophy).

**Thalamus:** A midline paired symmetrical structure situated between the cerebral cortex and brain stem, both in terms of location and neurological connections. It is composed of many regions with distinct functions. For example, some thalamic regions relays sensory signals to the cerebral cortex, other relay signals from the basal ganglia to the cerebral cortex, and others relay motor signals from the cortex to the spinal cord and brain stem.

**Toxicity:** The degree to which a chemical substance or a particular mixture of substances can damage an organism.

**T.R.A.P.:** Acronym for four primary Parkinson’s disease symptoms:

- **Tremor:** Shaking of limb (usually hands) while they are at rest.
- **Rigidity:** Muscle stiffness and resistance to movement.
- **Akinesia/bradykinesia:** Difficulty initiating voluntary body movements/Slowed ability to start and continue movements.
- **Postural instability:** Loss of postural stability can cause falls and produce a feeling of unsteadiness.

**Transcranial Magnetic Stimulation:** A method in which a changing magnetic field is used to cause electric current to flow to a small region of the brain.
Translation: A step in protein biosynthesis wherein the genetic code transferred from DNA to messenger RNA (mRNA) is decoded to allow the formation of a protein molecule. The process is preceded by transcription of the DNA into the mRNA.

Tyrosine: An amino acid used by cells to synthesize proteins. It is also the precursor of dopamine.

Ubiquitin: A small regulatory protein that is composed of 76 amino acids. It is involved in the degradation of damaged proteins. In Parkinson’s disease, it is believed that accumulation of damaged proteins “choke” the cell, leading to the eventual death of the cell.

Unified Parkinson’s Disease Rating Scale (UPDRS): A rating scale used to measure the severity of Parkinson’s disease. The UPDRS can follow a person’s worsening over time and also measure improvement with various treatments. The UPDRS is made up of the following sections:
- Part I: Evaluation of mentation, behavior, motivation and mood
- Part II: Self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, cutting food
- Part III: Clinician-scored motor evaluation
- Part IV: Measures some of the adverse effects (such as motor complications of “off” states and dyskinesias) of levodopa therapy in Parkinson’s disease

The UPDRS has been modified by the Movement Disorder Society to include more non-motor features of PD. This new version is called MDS-UPDRS.

Ventral Tegmental Area (VTA): A group neurons located in the midbrain next to the substantia nigra and involved in cognition and motivation, including reward and addiction.

Vesicle: An organelle in a cell that separates some molecules from the rest of the cell. In nerve terminals, the vesicles are called synaptic vesicles. They store neurotransmitters, which are released into the synapse when the nerve fires.

Wearable devices: Devices worn on the body, incorporating computers, electronics, software and/or sensors, often used to measure some aspect of function or physical manifestation, for example: activity trackers, accelerometers, gyroscopes, etc.
WPC 2023 SUPPORTERS

WPC is grateful to the supporters who help make the World Parkinson Congress possible.

PLATINUM

abbvie  
Supernus Pharmaceuticals

BRONZE

amneal  
Boston Scientific  
Advancing science for life™

FRIENDS

cerevel  
ESTEVE  
UCB

NOVARTIS  
Medtronic  
Further, Together
WPC INTERNATIONAL PARTNERS

WPC is grateful to its international partners in the nonprofit space that help the WPC find innovative and impactful ways to bring the Parkinson’s community together.

**GOLD**

- Parkinson’s Foundation

**SILVER**

- American Parkinson Disease Association
- Edmond J. Safra Philanthropic Foundation
- PMD Alliance
- The Michael J. Fox Foundation for Parkinson’s Research
- Share IT UP Foundation

**FRIENDS**

- Davis Phinney Foundation for Parkinson’s
- International Parkinson and Movement Disorder Society
- Cure Parkinson’s
WORLD PARKINSON COALITION PARTNERS

EUROPE

Albanian Society of Neurology (ALBANIA)
Antiparkinson Association (ROMANIA)
Association of Physiotherapists in Parkinson’s Disease Europe (BELGIUM)
Associazione Italiana Giovani Parkinsoniani (ITALY)
British Association of Neuroscience Nurses (UK)
British Geriatrics Society (UK)
Bulgarian Neurological Society (BULGARIA)
Con P de Parkinson (SPAIN)
Delta Hungarian Parkinson Association (HUNGARY)
Dutch Movement Disorders Study Group (NETHERLANDS)
Early Onset Parkinson’s Disease (IRELAND)
Edmond J. Safra Philanthropic Foundation (SWITZERLAND)
European Foundation for Health and Exercise (NETHERLANDS)
European Parkinson’s Disease Association (UK)
Federación Española de Parkinson (SPAIN)
Finnish Parkinson Association (Suomen Parkinson-liitto ry) (FINLAND)
Fuerte Es La Vida, Parkinson No Limits (SPAIN)
International Association of Parkinsonism and Related Disorders (NETHERLANDS)
Internationale Parkinson Fonds Nederland (NETHERLANDS)
Italian Association of Young Parkinsonians (ITALY)
Move4Parkinsons Foundation Limited (IRELAND)
Norges Parkinsonforbund (Norwegian Parkinsons Disease Association) (NORWAY)
Parkinson Fonds (OSTERREICH)
Parkinson Fonds Deutschland (GERMANY)
Parkinson Selbsthilfe österreich Dachverband (AUSTRIA)
Parkinson Switzerland (SWITZERLAND)
Parkinson Vereniging (NETHERLANDS)
Parkinson’s Association of Ireland (IRELAND)
Parkinson’s Concierge Ltd (UK)
Parkinson’s People Inc. (UK)
Parkinson’s UK (UK)
ParkinsonForbundet (Swedish Parkinson’s Disease Association) (SWEDEN)
Parkinsonline (PON) Österreich (AUSTRIA)
ParkinsonNet (LUXEMBOURG)
Radio Parkies (BELGIUM)
Spotlight YOPD (UK)
Społeczność Parkinson, z. s. (CZECH REPUBLIC)
Swedish Parkinson Research Foundation (SWEDEN)
Stichting Parkinson’s On the Move (NETHERLANDS)
The Cure Parkinson’s Trust (UK)
Unidos contra el Parkinson (SPAIN)
Valencia Parkinson Association (SPAIN)
Yuvedo Foundation (GERMANY)

SOUTH AMERICA

Agrupacion Amigos de Parkinson (CHILE)
Alianza Parkinson Cali Fundacion Valle Del Cauca (COLOMBIA)
Brazilian Movement Disorders Group, Brazilian Academy of Neurology (BRAZIL)
Fundación Valle del Lili (COLOMBIA)
Parkinson Foundation of Columbia (COLOMBIA)

ASIA

Hong Kong Parkinson’s Disease Association (PRC)
Hong Kong Parkinson’s Disease Foundation (HONG KONG)
Japan Parkinson Disease Association (JAPAN)
Korean Movement Disorder Society (SOUTH KOREA)
Korean Parkinson’s Disease Association (SOUTH KOREA)
Malaysian Parkinson’s Disease Association (MALAYSIA)
Negeri Sembilan Parkinson’s Society, Malaysia (MALAYSIA)
Nepalese Parkinson Disease Association (NEPAL)
Nutrition Support Association (JAPAN)
Parkinson Alliance of Taiwan (TAIWAN)
Parkinson’s Awareness Association of Central Indiana (USA)
Parkinson’s Disease and Movement Disorder Society (INDIA)
Parkinson’s Disease Society Singapore (SINGAPORE)
Parkinson’s Society Singapore (SINGAPORE)
Perak Parkinson’s Association (MALAYSIA)
SAAR Foundation (INDIA)
Society of Indian Neurosciences Nurses (INDIA)
U60 Challenged Supporter Association (JAPAN)

OCEANIA

Australasian Neuroscience Nurses Association (AUSTRALIA)
BMRI Parkinson’s Disease Research Clinic University of Sydney (AUSTRALIA)
Fight Parkinson’s (AUSTRALIA)
It’s Not Funny (AUSTRALIA)
Multiple Sclerosis and Parkinson’s Canterbury (NEW ZEALAND)
ParkiLife Australia Pty Ltd (AUSTRALIA)
Parkinson’s New South Wales Inc. (AUSTRALIA)
Parkinson’s New Zealand (NEW ZEALAND)
Parkinson’s Queensland Inc (AUSTRALIA)
Parkinson’s South Australia, Inc (AUSTRALIA)
Parkinson’s Western Australia (AUSTRALIA)
People with Parkinson’s Inc (NEW ZEALAND)
Shake It Up Australia Foundation (AUSTRALIA)
Southland Multiple Sclerosis Society Inc. (NEW ZEALAND)
Victorian Comprehensive Parkinson Program (AUSTRALIA)
AFRICA/ MIDDLE EAST
Adewunmi Desalu Parkinsons Foundation (NIGERIA)
Africa Parkinson’s Disease Foundation (KENYA)
Israel Parkinson Association (ISRAEL)
Parkinson’s Africa (AFRICA)
Parkinson Patients Support Organization (ETHIOPIA)
Parkinson’s si buko Uganda (UGANDA)
Parkinson’s ZA (SOUTH AFRICA)
Tikvah for Parkinson’s (ISRAEL)

NORTH AMERICA
Alliance for Aging Research (USA)
American Association of Neuroscience Nurses (USA)
American Parkinson Disease Association, Inc. (USA)
Brain Support Network (USA)
Canadian Movement Disorders Group (CANADA)
Caregiver Action Network (USA)
Community Transcultural Support Services (CANADA)
Critical Path Institute (USA)
Dallas Area Parkinsonism Society (USA)
Dance for PD (USA)
Davis Phinney Foundation (USA)
Entraidons-nous (CANADA)
GZ Sobol’s Parkinson’s Network (USA)
Houston Area Parkinson Society (USA)
InMotion (USA)
Inova Parkinson’s & Movement Disorders Center (USA)
International Parkinson and Movement Disorder Society (MDS) (USA)
Kaiser Permanente Northern California Neuroscience Movement Disorders Program (USA)
LSVT Global (USA)
Medowlark Hills Parkinson’s Program (USA)
Michigan Parkinson Foundation (USA)
Movers & Shakers Inc. (USA)
Muhammad Ali Parkinson Center (USA)
New Mexico Parkinson’s Disease Coalition (USA)
Neuro Challenge Foundation (USA)
NIH National Institutes of Neurological Disorders and Stroke (USA)
Northwest Parkinson’s Foundation (USA)
Parkinson & Movement Disorder Alliance (USA)
Parkinson Association of the Carolinas (USA)
Parkinson Association of the Rockies (USA)
Parkinson Canada (CANADA)
Parkinson Educational Program of Greater Cleveland (USA)
Parkinson Place (USA)
Parkinson Society British Columbia (CANADA)
Parkinson Society Nova Scotia (CANADA)
Parkinson Study Group (USA)
Parkinson Research Consortium (CANADA)
Parkinson Wellness Recovery (USA)
Parkinson Voice Project (USA)
Parkinson’s Association Alberta (CANADA)
Parkinson’s Association of San Diego (USA)
Parkinson’s Association of West Michigan (USA)
Parkinson’s Disease and Voice Clinic (PUERTO RICO)
Parkinson’s Disease Nutrition (USA)
Parkinson’s Disease Nurse Specialist Association (USA)
Parkinson’s Foundation (USA)
Parkinson’s Resources of Oregon (USA)
Parkinson’s Resource Organization (USA)
PD Avengers | Global Alliance to End Parkinson’s Disease Assn. (USA)
Ping Pong Parkinson (USA)
PJ Parkinson’s Support Group (USA)
Power for Parkinson’s (USA)
Project Spark Foundation (USA)
Rock Steady Boxing Inc. (USA)
Summit for Stem Cell (USA)
Struthers Parkinson’s Center (USA)
The Barbados Parkinson’s Trust & Support Group (BARBADOS)
The Brian Grant Foundation (USA)
The International Parkinson and Movement Disorder Society (USA)
The Michael J. Fox Foundation (USA)
The Parkinson Council (USA)
U Turn Parkinsons (CANADA)
VA Parkinson’s Disease Research, Education and Clinical Centers and National VA PD Consortium (USA)
Well Spouse Association (USA)
Wilkins Parkinson’s Foundation (USA)
Wisconsin Parkinson Association (USA)
World Federation of Neuroscience Nurses (USA)
World Parkinson’s Education Program (USA)
Young Onset Parkinson’s Network (USA)
BRINGING THE WHOLE PARKINSON’S COMMUNITY TOGETHER SINCE 2006!

WPC Congress Secretariat – JPdL
1555 Peel Street, Suite 500 | Montréal QC H3A 3L8 | Canada
Tel: +1 514-287-9898 ext: 335
WPC_Secretariat@jpdl.com

WPC 2023 CONFERENCE WEBSITE
http://www.wpc2023.org

WORLD PARKINSON COALITION WEBSITE
https://www.worldpdcoalition.org